2019-nCoV Outbreak and Cardiovascular Diseases

A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
Virus negative conversion rate in the first week

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
Clinical improvement based on the 7-point scale;Lower Murray lung injury score;Lower Murray lung injury score

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
The incidence of composite adverse outcome

Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)
duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;

A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)
inhospital length;inhospital mortality;ECMO treatment length;28th day mortality after admission;

A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)

A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)

A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)

A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)

Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients
clinical features and risk factors;validity and reliability of the model;

A medical records based study of novel coronavirus pneumonia (COVID-19) and influenza virus co-infection

Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)
Conversion rate of mild and common type patients to severe type;Mortality Rate;

A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR

Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)
Positive/Negtive;SEN, SPE, ACC, AUC of ROC;

A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy
14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;

The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial
Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate;

A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)
TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;

A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pulmonary imaging improvement;time and rate of change to negative COVID-19 nucleic acid test;time and rate of improvement of oxygenation measurement;improvement time and rate of CD4 count;rate of mild/modorate type to severe type, rate of severe type to critical type;length of hospitalization;mortality;

Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)

Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)

An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)

A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection

Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation

Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients
Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;

Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)
Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;

Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)
Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;

Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
Time of viral nucleic acid turns negative;Antipyretic time;

Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein

Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)
Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;

Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)

Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)

Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)

Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)

Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial
Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;

Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)

Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging
Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;

Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)
Length of hospital stay;fever clearance time;

A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy
14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;

A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)

Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)

A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency

A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study

The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial
Rate of conversion to severe or critical illness;

Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients
length of stay;length of stay in ICU;Antibiotic use;Hospital costs;Organ function support measures;Organ function;

Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)
vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;

Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People

Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)
blood routine examination;CRP;PCT;Chest CT;Liver and kidney function;Etiology test;

Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)
Chest CT;Routine blood test;liver and renal function;TCM syndrome;

A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)

Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study
Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL-6, IL-10, TNF-a, etc.);Lymphocyte subsets and complement;Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count);Virus nucleic acid;

A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)
the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;

Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)

Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)
Epidemiological history;haematological;First symptom;blood glucose;blood glucose;prognosis;Blood gas analysis;complication;

Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19)

Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Exhaled Breath
Sensitivity of detection of NCP;Specificity of detection of NCP;

A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)

Study for Mental health and psychological status of doctors, nurses and patients in novel coronavirus pneumonia (COVID-19) designated hospital and effect of interventions

An observational study for Xin-Guan-1 formula in the treatment of novel coronavirus pneumonia (COVID-19)
Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;

Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial
2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;

A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)
Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;

Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)

Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)
Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;

A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)
Time for body temperature recovery;Chest CT absorption;Time of nucleic acid test turning negative;

Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)
Virus negative conversion rate in the first week;

A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)

Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)
The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2<= 93% without oxygen supplementation, PaO2/FiO2 <= 300mmHg or RR <=30 breaths per minute.;

Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population
Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;days of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;

Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population
the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;

Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)
Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;

Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial
Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;

Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial

Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial

Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)
The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;

Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province
blood routine;urine blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;

Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients
Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2<2 for 24 hours.;

A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy
Time to viral negativity by RT-PCR;Time to clinical improvement;

Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)

A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)
Time to conversion of 2019-nCoV RNA result from RI sample;

A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)
The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;

Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial
Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;

Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial
Relief of clinical symptoms and duration;

Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period
Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;

Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial
pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;

Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children
body temperature;Whole blood count and five classifications;C-reactive protein;

A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)

Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)

A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)
pulmonary function;Antipyretic time;Time of virus turning negative;

The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period
pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;

The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period
pulmonary function;St Georges respiratory questionnaire, SGRQ;

Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)
Antipyretic time;Time of virus turning negative;

A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)
CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;

A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)

A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)
Duration of PCR normalization;Clinical symptom score;

Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population
Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;

A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)
Time for body temperature recovery;Chest X-ray absorption;

Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)

Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)

Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial

Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)

A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)

Immunoregulatory Therapy for 2019-nCoV

Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)
TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;

The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)

Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)

Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration
pulmonary function;Novel coronavirus pneumonic nucleic acid test;

Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)
Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;

Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;

Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)
CT scan of the lungs;Nucleic acid detection of throat secretion;

Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)
Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;

A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU

Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)

Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)

Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)

A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)
Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;

A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)

Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)
Time to leave ventilator on day 28 after receiving MSCs infusion;

A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients

Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir
Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;

A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)
Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Blood oxygen saturation;Time to 2019-nCoV RT-PCR negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day);Liver, renal and heart function;

Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)

Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages

Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)

Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques
M mode echocardiography;two-dimensional echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;

A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students

A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)

Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)
The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;

Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)
Three-dimensional ultrasound;Two-dimensional ultrasound;Respiration related parameters;Doppler ultrasound;

Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae
CT image of lung of close contact medical staff;Human body temperature of close contact medical staff;Anxiety Scale of of close contact medical staff;

A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression
the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;

A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)
The days from positive to negative for viral nucleic acid testing;

Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients

A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)

A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)
The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine aminotransferase) and ALT(aspartate aminotransferase);Neutralization antibody level;

Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial
pneumonia severity index (PSI);Incidence of new organ dysfunction;

A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)
The novel coronavirus nucleic acid negative rate;

Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)
SARS-CoV-2 DNA;SARS-CoV-2 antibody levels;thoracic spiral CT;

Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial
Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;

A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)
Proportion of COVID-19 close contacts who have developed as confirmed cases;

Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions
Distribution of 'B' line around lungs of both lungs;Whether there is peripulmonary focus;

A medical records based study for acute kidney injury in novel coronavirus pneumonia (COVID-19)

A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)
clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;

Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial
Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;

A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients

The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)
Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);

The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp

Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)

Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)
viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme);

Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women

Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)

A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)
Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);

Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak
psychological scale;Intestinal flora abundance, etc;Upper respiratory flora abundance, etc;

Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)
Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;

A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)

Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students

Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19)
hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;

Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)

The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial

An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)
Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;

A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)
gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;ß CT;abdominal CT;ECG;Weight;height;body temperature;respiratory rate;Heart Rate;Blood Pressure;Defecate frequency;Bristol grading;

A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)

Study on anxiety of different populations under novel coronavirus (COVID-19) infection
Self-Rating Anxiety Scale;Self-Rating Depression Scale;Posttraumatic stress disorder checklist,;Questionnaire for Simple Responses;

Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial

A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)
Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;

Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)
Improved respiratory system function (blood oxygen saturation) recovery time;

A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)
Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;

Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)

Study for mental health status and influencing factors of nurses during epidemic prevention of novel coronavirus pneumonia (COVID-19)

Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions
SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;

A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)

A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)
Time to Clinical recovery;Butyrate in feces;

A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)
the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;

Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province

Clinical observation and research of Severe acute respiratory syndrome coronavirus 2(COVID-19) infection in perinatal newborns

Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)
Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;

Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial

Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics
Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;

Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients
blood cell count;C-reactive protein (CRP);arterial blood-gas analysis;markers of myocardial injury;coagulation profile;serum biochemical test;brain natriuretic peptide(BNP);blood lipid;fibrinogen(FIB), D-Dimer.;

A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)

A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)
Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;

A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)

A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)

Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)
oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;

Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
The cure rate of 2019-nCoV.;The improvement rate of 2019-nCoV.;The incidence of long-term adverse outcomes.

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia
Time to Clinical recoveryTime to Clinical Recovery (TTCR)

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19

Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

The COVID-19 Mobile Health Study (CMHS)
Accuracy of nCapp COVID-19 risk diagnostic model

Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
High-resolution computed tomography (HRCT) score;Lung function including FVC, FVC as a percentage of projected value and DLco

Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection

Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations
Positive rate of 2019 Novel Coronavirus RNA

The Investigation of the Neonates With or With Risk of COVID-19
The death of newborns with COVID-19;The SARS-CoV-2 infection of neonates born to mothers with COVID-19

Fingolimod in COVID-19
The change of pneumonia severity on X-ray images

Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)

Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)

Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic

A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;

A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform
Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;

Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)
Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;

A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).
Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;

A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients
cure rate;virus negative rate;time of virus negative;

Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology

A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)

Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)

Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)

Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet

Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome

microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)

A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus pneumonia (COVID-19)
K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;

Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)
Blood Routine;Liver function;Blood electrolyte;Anticoagulation index;Lung CT;Viral RNA;

A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang

Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)

Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients

Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period
During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;

Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)

Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)

Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)

Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients

Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China
Quality of Life;Epidemic Prevention Medical Protective Equipment related Skin Lesion and Management Scale;

Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)

Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)

ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)

Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic

A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)

Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau
NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;

Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial
Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;

A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients
temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;

The coagulation function of novel coronavirus pneumonia (COVID-19) patients

Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome
Clearance rate and time of main symptoms (fever, fatigue, cough);

Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid

The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study

Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)
Length of hospital stay;Discharge time of general type;Discharge time of severe type;

Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey

Cancelled due to lack of participants Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People

Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)
Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;

Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)
Clinical recovery time;Pneumonia Severity Index (PSI) score;

Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)
Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node imaging;Chest CT;Infectious disease test;

A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)

A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)

Cancelled due to lack of patient A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive&

A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)
COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;

A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.
Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;

A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)

Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)
viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;

Cancelled due to lack of patient Medical records based study for epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing

Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial Prevention and Control Strategy

Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial

Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial

Cancelled due to lack of patient Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)
Worsening condition;Death;Heart fatty acid binding protein;

Cancelled due to lack of patient Clinical study for the effect and
Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;

Cancelled due to lack of patient Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)
Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;

Cancelled due to lack of patient A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases

Retracted due to lack of patient A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm

A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)

A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)
The proportion of patients diagnosed with 2019-ncov viral pneumonia;

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia
The time to 2019-nCoV RNA negativity in patients;

Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial

A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia
Adverse reaction (AE) and severe adverse reaction (SAE);Time to clinical improvement (TTIC)

A New Screening Strategy for 2019 Novel Coronavirus Infection

A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection

CT Scores Predict Mortality in 2019-nCoV Pneumonia

The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Fever to normal time (day);Pulmonary inflammation resolution time (HRCT) (day);Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment

Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases

Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study

The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope

Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)

Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)
Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;

Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)

Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)
Child Stress Disorders Checklist evaluation;Achenbach children's behavior checklist evaluation;children's severe emotional disorder and psychological crisis during inpatient treatment;

A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19)

A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)

Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)
Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;

Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)
Lung ultrasound index;Right ventricular function ultrasound index;Left ventricular function ultrasound index;

Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)

Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)

A clinical study about the diagnosis and prognosis evaluation of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.
Pulmonary image findings;Relevant clinical manifestations of COVID-19;Oxygen saturation in resting state;Arterial partial pressure of oxygen/ Oxygen absorption concentration;Length of hospital stay;Viral genome information;Host genome information;Expression level of host cytokines;Conventional laboratory testing index;

Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country

Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy
Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;

Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine
Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);

Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)

Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial
Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs);Time to clinical improvement;Change in size of lesion area by chest CT;Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours;

Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient

Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)

Retrospective study for integrate Chinese and conventional medicine treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province

A medical records based study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City
length of stay;length of stay in ICU;Hospital costs;Hospital costs;Antibiotic use;Organ function support measures;

To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)

Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases
Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;

A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;

Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study

HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)
PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or absent;Time for dyspnea to become mild or no dyspnea;Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation;Inflammatory cytokines (CRP / PCT / SAA, etc.);Frequency of serious adverse events;

A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19)
Cardiac injury;Death in hospital and/or Endotracheal Intubation Deaths during hospitalization;Admitted to the ICU;Composite end points of cardiovascular events( nonfatal heart failure, nonfatal myocardial infarction, nonfatal stroke or cardiovascular death);Stroke;Heart failure;Myocardial infarction;Other cardiovascular health related endpoints;

The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;

Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)

Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)
lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;

oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)

Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)

An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)
Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;

Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)
Progression rate from mild to critical/severe;

A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)
fever clearance time;Effective rate of TCM symptoms;

Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation
disease incidence;Duration of PCR normalization;Distribution pattern of TCM syndromes;

A Randomized Controlled Trial for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform

Cancelled by the investigator Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)
SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 < 90%;

Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)

Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)

Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)

Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&
Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;

Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)

A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)
cure rate;duration of hospitalization;days of treatment;

Cancelled due to lack of patient Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients

A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19)

A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department

Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
the number of days between randomised grouping and clinical improvement;

Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial

The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance

Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)

Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)
Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;

A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)
Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospitalization for oxygen therapy;3 points: Hospitalization does not require oxygen therapy;2 points: discharged but not restored to normal functional status;1 point: discharged to normal function;

Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus
Mortality;The time interval of Nucleic acid detection become negative

Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;Numbers of participants with different Clinical outcomes

Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients
The incidence of side effects;The incidence of side effects;The incidence of side effects

Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)

Medical Masks vs N95 Respirators for COVID-19

Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia
Success rate of intubation;Infection rate of Anesthesiologist

Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019
The prevalence and incidence changes of common mental disorders

Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors
mental health status and influence factors;

Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong
Transmission dynamics of COVID-19 in Hong Kong;Characteristics of super-spreading events;Effectiveness of public health measures;

Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)

Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)

Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)

Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period

Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial

Study for effects of crisis intervention based on positive psychology for medical staffs working in the novel coronavirus pneumonia (COVID-19) field

Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study

Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)
temperature;Systemic symptom;Respiratory symptoms;Chest imaging changes;Detection of novel coronavirus nucleic acid two consecutive negative time;

Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)
Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients;

Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection

Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)
2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;

Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter Cohort Study

Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study
Laboratory inspection index;Oxygen therapy case;Film degree exam;

Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling

A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients

A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital

Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital

Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)

An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT

Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19)
Length of stay in ICU;Diaphragm movement;

A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)

Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)

Factors associated with death in patients with novel coronavirus pneumonia (COVID-19)

Study for the physical and mental health status of medical workers under the novel coronavirus pneumonia (COVID-19) epidemic
Chinese health status scale;Self-rating Anxiety Scale;Self-rating Depression Scale;

Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies

Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)

Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery
SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;

Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images

Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy
14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;

Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)

Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area
Epidemiological characteristics;SARS-CoV-2 IgM, IgG antibody titer test result;

Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit
RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;

Study for the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)

The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single center and descriptive study in Wuhan
Laboratory inspection index;Imaging examination results(chest CT);performance of intubation;therapeutic schedule;prognosis;

Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning
Abnormalities on chest CT;Exposure to source of transmission within past 14 days;

Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan

A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19)

Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients

A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route

Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients

Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine
Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;

A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients

Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19)

Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)
blood RT;ABG;blood clotting function;liver and kidney function;

Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19)

Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial

Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19)
age;sex;comorbidities;chest-CT examination;standard blood counts;albumin;pre-albumin;hemoglobin;alanine transaminase;aspartate protein;coagulation function;nutritional risk screening;body weight;body height;prognosis;

A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19)
time and rate of cure; proportion and time of patients who progressed to severe disease;

Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center retrospective observational study

Cancelled by the investigator Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value

Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19)
cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;

A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19)

clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients

Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)

A multicenter retrospective study of rheumatic patients with novel coronavirus pneumonia (COVID-19)

A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi

The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia (COVID-19)

A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)

A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital

Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)
death;Number of failure organs;Length of hospital stay;

Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19)

Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations

A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)

Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''

Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study

A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China
the clinical, laboratory and the radiologic characteristics;

Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)
The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;

A medical records based study for sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)
Dose of analgesic and sedative drugs;28-day mortality rate;

Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers

Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)

A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area

Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19)
false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;

A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)
ICU hospitalization days;The recurrence rate of infection;

A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)

Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)
nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;

A prospective cohort study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)

Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)

Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19)

Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)

Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19).
mortality;ICU hospital stay;mechanical ventilation time;mortality of 28 days;

Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS
Tempreture;cough;dyspnea;Blood Routine;Aterial Blood Gas;Chest CT Scan;

Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)

A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)
detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;

Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management
Medical imaging improvement rate in patients during recovery period;

A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan
Mortality rate;Common-severe conversion rate;Length of hospital stay.;

Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)

A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients

Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of novel coronavirus pneumonia (COVID-19) male patients

Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China
Levels of anxiety, stress and depression;

Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau

Cancelled by the investigator Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19)

A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)

Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial
Time to clinical recovery after randomization;

A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19)

Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients

A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals

Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19)

Novel coronavirus pneumonia (COVID-19) associated kidney injury in children
temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine analysis;microalbuminuria;COVID-19 nucleic acid;COVID-19 antibody;renal ultrasound;24-hour urine protein;Tc-DTPA renal dynamic imaging;eGFR;

The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak
impact on the treatment of tumor patients;

The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study

An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room

Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children

A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19)

Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)

Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19)
chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;

Cancelled by the investigator Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital
CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;

Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)

Cancelled by the investigator Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
Time and rate of novel coronavirus become negative.;

Cancelled by the investigator A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)

Cancelled by the investigator Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)
lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;

Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)
Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;

Cancelled due to lack of patients Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)

Cancelled by the investigator Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)
Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sampling interval at least 1 day);

Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)
The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;

Cancelled by investigator A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient
Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;

Cancelled by the investigator Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)
Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;

Cancelled by the investigator Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development
Time to disease recovery;Time and rate of coronavirus become negative;

Cancelled by the investigator Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)
sleep status and related factors of insomnia;

Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)
Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;

Cancelled by the investigator A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients

Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia (COVID-19)
Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);

Cancelled by the investigator Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients

Cancelled by the investigator Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)
The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;

Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)
Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;

Cancelled by the investigator A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COV
Time of conversion to be negative of novel coronavirus nucleic acid;

Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test
detection of SARS-Cov-2 nucleic acid;SEN, ACC;

Cancelled by the investigator Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)
IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);

Cancelled by the investigator An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)

Cancelled by investigator Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)
The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;

Cancelled by the investigator A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)
Time of conversion to be negative of novel coronavirus nucleic acid;

Cancelled by the investigator A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)

Cancelled by investigator A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)

Cancelled by the investigator Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Cancelled by the investigator Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Cancelled by the investigator Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Cancelled by the investigator Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)

Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)
Patients’ general information: epidemiological indicators such as age, gender, address, telephone, exposure history, past medical history, and BMI;Clinical symptoms;Patients' signs;blood routine examination;Urine routine test;stool routine examination;Blood biochemistry;myocardial enzyme spectrum;full set of coagulation;blood gas analysis;cytokine profile;T lymphocyte subsets;ESR;CRP;PCT;complete set of self-immunity test;Etiology related inspections;Chest X-ray;lung CT;Patients' treatment history;Patients' Prognosis;the cause of death;Others;

Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff

Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia

Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study

Safety and Immunity of Covid-19 aAPC Vaccine
Frequency of vaccine events;Frequency of serious vaccine events;Proportion of subjects with positive T cell response

Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
Disppear time of ground-glass shadow in the lungs

Accurate Classification System for Patients With COVID-19 Pneumonitis

Influence of the COvid-19 Epidemic on STRESS

The relationship between Vitamin D andnovel coronavirus pneumonia (COVID-19)

Application of radiology in the prevention and control system of emergency respiratory infectious diseases

Study for the impact on fetus and neonates of vertical transmission of 2019-nCoV

Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)
Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline;

Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)

A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)

Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)

Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)
Pittsburgh sleep quality index;Self-rating anxiety scale;Self-rating depression scale;CD-RISC scale;

A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)

A prognosis study of novel coronavirus pneumonia (COVID-19)
demographic information;exposure history;clinical symptoms;Laboratory examination;radiological findings;treatment;disease progression;

Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period
postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;

A Study for SARS-COV-2 RNA Level in Blood and Excrement of Novel Coronavirus Pneumonia (COVID-19) Convalescent Patients
Serum SARS-COV-2 RNA;Swallow swab SARS-COV-2 RNA;feces SARS-COV-2 RNA;Sputum SARS-COV-2 RNA;Urine SARS-COV-2 RNA;

Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial.

A medical records based study for the value of Upper Respiratory Tract Virus Detection in the assessment of rehabilitation of novel coronavirus pneumonia (COVID-19) patient

A medical records based study for the diagnosis and prognosis prediction AI model of novel coronavirus pneumonia (COVID-19)

Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial

A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
improvement or recovery of respiratory symptoms;viral nucleic acid shedding;

Correlation of T lymphocytes level and clinical severity in novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study

Psychological Responses of Medical Staff during the Metaphase of novel coronavirus pneumonia (COVID-19) Outbreak in Hubei, China
Pittsburgh sleep quality index;hospital anxiety and depression scale;

A Medical Records Based Retrospective Study for Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19) in WuHan

Myocardial injury and arrythmias in the novel coronavirus pneumonia (COVID-19) patients

Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study

Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design

A medical records based study for clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia (COVID-19)

Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19)

Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19)
Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;

Venous Thrombosis Risk of novel coronavirus pneumonia (COVID-19) Patients: A Prospective Study

Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR and CRP

A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggan, Hubei in Huanggang.

Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19)
nuclear acid test of faeces;nuclear acid test of the upper respiratory tract;IgM;IgG;CT test of lung;glutamic oxalacetic transaminase;glutamic-pyruvic transaminase;total bilirubin;direct bilirubin;urea nitrogen;lactic dehydrogenase;creatinine;lymphocyte;C-reactive protein;procalcitonin;erythrocyte sedimentation rate;

A Platform for Rapid Immuno-detection and Emergency Vaccine Development of Novel Coronavirus (2019-COV)

Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial

Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)

A Medical Records Based Study for Clinical Characteristic and Outcomes of Hospitalized Patients With Novel Coronavirus Pneumonia (COVID-19)
Time to negative conversion of severe acute respiratory syndrome coronavirus 2;

A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)
Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);

Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with novel coronavirus pneumonia (COVID-19)
COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality;

Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.
Albumin;Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4));

An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)
auto B line method;Semi-automatic manual measurement of line B;CT image score;NEWS score;hospital time;ICU time;Critical time;Hospital costs;mechanical ventilation time;prognosis of the patient;

A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)
adverse reactions 7 days post injection;

Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies

Cancelled by the investigator Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''

Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus

Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia (COVID-19)

the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study

Cancelled by the investigator Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)
SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;

Cancelled by the investigator A real world study for Compound Houttuyniae Mixture for prevention of novel coronavirus pneumonia (COVID-19)
Compared with the control group, the positive rate of NCP nucleic acid test on subjects used Compound Houttuynia Mixture.;

A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia

Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging
First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;

Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial

A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak

Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)

A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection
The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups The difference of;

A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)
novel coronavirus nucleic acid clearance rate;

Hydroxychloroquine as a treatment for coronavirus disease COVID-19
Main Objective: To shorten the period of virus carrying and thus contagion;Secondary Objective: To evaluate the clinical effectiveness of treatment on time to apyrexia, normalization of respiratory rate, and average length of hospital stay and mortality.;Primary end point(s): Results of SARS-COV2 virus detection ;Timepoint(s) of evaluation of this end point: Day 1, Day 4, Day 7 and Day 14
Interventional clinical trial of medicinal product

ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease
1. Date of ECMO discontinuation
2. Date of invasive mechanical ventilation discontinuation
3. Date of ICU Discharge
4. Date of Hospital Discharge
5. Mortality at 28 days
6. Main cause of death

Washed Microbiota Transplantation for Patients With 2019-nCoV Infection
Number of participants with improvement from severe type to common type

A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
Rate of disease remission;Time for lung recovery

A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
Rate of disease remission;Time for lung recovery

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
Rate of disease remission;Rate and time of entering the critical stage

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Occupancy rate in the intensive care unit (ICU);Mechanical Ventilation;Death

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine
Clinical improvement based on the 7-point scale;Lower Murray lung injury score

Study for Novel Coronavirus Pneumonia (NCP)

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Time course of body temperature (fever);Viral load over time

The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19

Prognostic Factors of Patients With COVID-19

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus
Size of lesion area by chest imaging;Blood oxygen saturation

A Pilot Study of Sildenafil in COVID-19
Rate of disease remission;Rate of entering the critical stage;Time of entering the critical stage

Social Media Use During COVID-19
Assessment of COVID-19 situation;Depression, Anxiety and Stress Scale

Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14

Tetrandrine Tablets Used in the Treatment of COVID-19

Sequential Oxygen Therapy Strategy for Patients With COVID-19

Myocardial Damage in COVID-19
The myocardial injury incidence;The risk factors analysis for the death

Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia

Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.

Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19
Number of patients with constant negative results;Number of patients with positive test with a positive PCR for COVID-19;Overall Number of patients positive for COVID-19;Overall Number of patients negative for COVID-19;Number of patients with contrasting results

Mechanisms for Organ Dysfunction in Covid-19

ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19

Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis

To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients
proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;

Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)
fever;Chest CT;cough;;Anesthesia during cesarean section;Adverse reactions;Apgar score for neonates; Intraoperative blood loss;diagnosis of COVID-19 during perioperative;the medical observations of anesthesiologists participating in anesthesia management;

Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19)

The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic
eye axial length;corneal diopter;Tear film rupture time;Visual acuity;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;

AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)

Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation
Axle length;Visual acuity;corneal diopter;Tear film rupture time;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;

Influence of novel coronavirus pneumonia (COVID-19) on disease activity, medical and mental condition of patients with rheumatic diseases
medication possession ratio;selfrating anxiety scale;selfrating depression scale;Disease activity score-28;Systemic lupus erythematosus disease activity index;Ankylosing spondylits disease activity score;Visual analogue scale;

The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients
Self-assessment of sleep quality;Efficient of sleep improvement;

The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of novel coronavirus pneumonia (COVID-19)

Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients

A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury

A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death
clinical features of COVID-19 patients and risk factors of death;

Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk

The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak

Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)
Hospital stay or death ratio of experimental group / death ratio of control group;

Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection
Demographic data;Epidemiological characteristics;Routine laboratory testing;Viral nucleic acid test;Patient reports symptoms daily;

Study on the mental state of medical staff during the epidemic period of novel coronavirus pneumonia (COVID-19)

Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)
IgG antibody;IgM antibody;Throat swab virus nucleic acid test;

Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients: a medical records based retrospective study
Rate of COVID-19, distribution, time of onset and outcome;

Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a medical records based study
RT-PCR test for Covid-19;CT image;Covid-19 antibody test;

Clinical features and prognosis of invasive echanicalventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study

Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis
Modified dyspnea index scale;St.George's Respiratory Questionnaire;Self-Rating Depression Scale;

A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)

Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)

A medical records based study for clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)

Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients

A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)

Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic

A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)

Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study
fatality rate;the ratio of patients transforming from severe/critical to light;Non-invasive/invasive mechanical ventilation time;

Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)
Quantitative table of main symptom grading;Quantitative table of lung physical signs grading;

Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia (COVID-19)

A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen
The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;

A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19)
Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;

The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)
Incidence of COVID-19 pneumonia;COVID-19 pneumonia rate of improvement;

Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound
Two-dimensional ultrasound;M mode echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;

Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)

Cancelled by the investigator Clinical research of 6-minute walk training on motor function of novel coronavirus pneumonia (COVID-19)

Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial
The time to 2019-nCoV RNA negativity in patients;

Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China

Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)

Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)
Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lymphocyte count;CD4+ T lymphocyte count;CD8+ T lymphocyte count;B lymphocyte count;NK cell count;Proportion of navie CD4+ T lymphocytes to CD4+ T lymphocytes;Proportion of memory CD4+ T lymphocyte to CD4+ T lymphocytes;Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes;Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes;Activation ratio of CD8+ T lymphocytes;Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes;

Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism
Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Metabolomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;

Sarilumab COVID-19
Main Objective: Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19
Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19
;Secondary Objective: Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity, changes in the National Early Warning Score 2, duration of predefined symptoms and signs, duration of supplemental oxygen dependency, incidence of new mechanical ventilation use, the duration of new mechanical ventilation use, need for admission into ICU, duration of hospitalization, 28-day mortality rate.
Secondary safety objectives are to evaluate the safety of sarilumab compared to the control arm as assessed by incidence of: SAEs, Grade 4 neutropenia (ANC<500/mm3) with concurrent severe or life-threatening bacterial, invasive fungal, or opportunistic infection, Grade =2 infusion related reactions, Grade =2 hypersensitivity reactions, Increase in ALT =3X ULN (for patients with normal baseline) or >3X ULN and at least 2-fold increase from baseline value (for patients with abnormal baseline), Invasive bacterial or fungal infections of clinical significance with confirmed diagnosis ;Primary end point(s): Phase 2: time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner
Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale;Timepoint(s) of evaluation of this end point: Baseline to Day 29
Interventional clinical trial of medicinal product

Reducing health care workers absenteeism in Coronavirus 2019 pandemic nu enhancement of the immune system through vaccination with Bacillus Calmette-Guérin
Main Objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Secondary Objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Primary end point(s): Number of days of unplanned absenteeism for any reason ;Timepoint(s) of evaluation of this end point: Between day 0 up to day 180 after inclusion
Interventional clinical trial of medicinal product

a trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in patients with COVID-19
Main Objective: To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.;Secondary Objective: To understand more about the biology of how SNG001 affects patients and the virus infection, this will be done by assessing changes in biomarkers in blood and sputum if they are available.;Primary end point(s): Primary Endpoint:
Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period.
The Ordinal Scale for Clinical Improvement is a World Health Organisation recommended scale for use in COVID-19 trials.
;Timepoint(s) of evaluation of this end point: The dosing period is 14 days. Changes in the ordinal scale during the dosing period will be assessed.

Eculizumab (Soliris) in Covid-19 Infected Patients

Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.

Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT
The time from randomization to clinical improvement

Acute Kidney Injury in Patients Hospitalized With COVID-19

Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress
International Physical Activity Questionnaire (IPAQ);Health-Related Quality of Life SF-12 Scale;Beck Depression Scale

Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia
Time of Improvement or recovery of respiratory symptoms;Number of days virus nucleic acid shedding;Frequency of Improvement or recovery of respiratory symptoms

Escin in Patients With Covid-19 Infection
Mortality rate;Clinical status evaluated in agreement with guidelines

The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?

Traditional Chinese Medicine for Severe COVID-19

Use of Ascorbic Acid in Patients With COVID 19

Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
Clinical response;Side effects in the treatment group

Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY
The incidence of cardiovascular complications in patients with COVID-19

Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong

Audio Data Collection for Identification and Classification of Coughing

Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing?
Time from COVID-19 test being requested to the result being available to clinical teams in minutes and hours, recorded during hospitalisation

Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)
Sleep diary;The insomnia severity index;Sleep visual analogue scale;

Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)

Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune

Investigation for the sleep quality in non-health care workers during the pandemic of novel coronavirus pneumonia (COVID-19)

A paired clinical study for novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital

Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)
6minu tewalkingtest,6MWT;mMRC;Rating of Perceived Exertion Scale;SAS;

Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic

Survey of psychological status and related factors of emergency medical staff in the country during the novel coronavirus pneumonia (COVID-19) pandemic

A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province

Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)
Exposure time in the medical cabin;Hospitalization period;Detection rate of arrhythmia;

The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study

Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)

Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study

Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)

Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial

Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)
2019-ncov nucleic acid yin rate;Blood 2019-ncov nucleic acid positive;Positive 2019-ncov nucleic acid in feces;Nasopharyngeal swab positive for 2019-ncov nucleic acid;

Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial

A medical records based study for novel coronavirus pneumonia (COVID-19) patients undergoing endotracheal intubation
Success rate of intubation;Exposure classification of glottis;

Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic
Phone time before and during the outbreak;Physical exercise time before and during the outbreak;Symptoms worsened in patients with previous cervical spondylosis since the outbreak;Symptoms in people with no previous symptoms of cervical spondylosis since the outbreak;

A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adults

Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis
Electrocardiogram;St George's Respiratory Questionnaire Score;High resolution CT for chest;Blood gas analysis;Percutaneous blood oxygen saturation;6 min walking distance;Pulmonary function VCmax;Blood routine;Liver and kidney function;Cytokine analysis;Immunoglobulin;Lymphocyte subsets;Coagulation;Myocardial enzymes;Serum ferritin;Procalcitonin;IL-6;Lactic acid;D-Dimer;CRP;

The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study

Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)
SARS-CoV-2 antibody;SEN, SPE, ACC, AUC of ROC;

Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial

A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy

A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)

Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit..
Main Objective: to describe the pharmacokinetics of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.;Secondary Objective: - Describe the relationship between HCQ concentration and cardiac toxicity.
- To describe the pharmacokinetic (concentration) and pharmacodynamic (viral load) relationship of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.
- To define the best modalities of administration of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2 based on the PK/PD relationship.;Primary end point(s): determination of the blood concentration of hydroxychloroquine by liquid chromatography coupled with mass spectrometry.;Timepoint(s) of evaluation of this end point: daily for 10 days

Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy
Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19.
• The primary endpoint is subject clinical status (on a 7-point ordinal scale) at day 15
;Secondary Objective: Evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by:
-Clinical Severity (Ordinal scale, National Early Warning Score (NEWS), Oxygenation, Mechanical Ventilation)
-Hospitalization : duration of hospitalization (days).
-Mortality
-Evaluate the safety of different investigational therapeutics through 28 days of follow-up as compared to the control arm
-Evaluate the virologic efficacy of different investigational therapeutics as compared to the control arm as assessed ;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):
1. Not hospitalized, no limitations on activities
2. Not hospitalized, limitation on activities;
3. Hospitalized, not requiring supplemental oxygen;
4. Hospitalized, requiring supplemental oxygen;
5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;
6. Hospitalized, on invasive mechanical ventilation or ECMO;
7. Death.
;Timepoint(s) of evaluation of this end point: Day 15

Countering Lung Damage in COVID-19 infection: the CounterCovid Study
Main Objective: To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.;Secondary Objective: The secondary objective is to evaluate the pharmacokinetics of a 10-day course of oral imatinib in patients with severe Covid19 pneumonitis.;Primary end point(s): Composite outcome of death / need for invasive ventilation / need for ECMO ;Timepoint(s) of evaluation of this end point: 28 days

NORWEGIAN CORONAVIRUS DISEASE 2019 [NO-COVID-19] STUDY: A TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION
Main Objective: To assess whether early treatment with chloroquine in patients with established COVID-19 will significantly reduce replication rate of SARS-CoV-2.;Secondary Objective: • Assess the impact of early treatment with chloroquine in patients with established COVID-19 on rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR from baseline to 96 hours
• Assess the impact of early treatment with chloroquine in patients with established COVID-19 on changes in NEWS score
• Assess the impact of early treatment with chloroquine in patients with established COVID-19 on admission rate to ICU
• Assess the impact of early treatment with chloroquine in patients with established COVID-19 on in hospital mortality
;Primary end point(s): Rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR in samples collected at baseline, 48 and 96 hours after randomization;Timepoint(s) of evaluation of this end point: 96 hours.

Efficacy of Tocilizumab - COVID-19
Main Objective: ;Secondary Objective: ;Primary end point(s):

ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)
Mortality
[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]

Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia
Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
Percent of subjects who have returned to room air;Percent change of subjects return to baseline oxygen requirement

Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff

Behavior, Environment And Treatments for Covid-19

Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients

Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
interleukin-6 (IL-6) level after 72 hours

Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients;Number of patients included in this platform

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

Early CPAP in COVID Patients With Respiratory Failure.

Treating COVID-19 With a Bidirectional Oxygenation Valve

PREdiction of DIagnosed Covid-19 infecTion in IUC Patients
Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU

Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
Mortality changes in day 10;Mortality changes in day 30;Changes of C-reactive protein;Changes of C-reactive protein;Changes of C-reactive protein;Changes of Interleukin 6;Changes of Interleukin 6;Changes of Interleukin 6;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio

The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19

Effectiveness of Hydroxychloroquine in Covid-19 Patients
National Early Warning Score equal to zero

Clinical Characteristics and Prognostic Factors of Patients With COVID-19
Time to negative conversion of severe acute respiratory syndrome coronavirus 2

Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)
To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.

COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
All-cause mortality of COVID-19 patients with liver cirrhosis

Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)

Clinical Characteristics and Outcomes of Pediatric COVID-19
Clinical characteristics of children with SARS-CoV-2;Factors associated with severe COVID-19 outcomes

A Trial of Ciclesonide in Adults With Mild COVID-19
Rate of SARS-CoV-2 eradication at day 14 from study enrollment

Renin-Angiotensin System Inhibitors and COVID-19
Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents;Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS
Adverse reaction (AE) and severe adverse reaction (SAE);Changes of lung imaging examinations

COVID-19 Biological Samples Collection

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

Study Testing Convalescent Plasma vs Best Supportive Care
reduction in oxygen and ventilation support

Piclidenoson for Treatment of COVID-19
Duration of viral shedding in days;Time to clinical recovery (TTCR) in days;Treatment-emergent adverse events (AEs)

Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study

Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy
Fraction of healthcare workers infected with SARS-CoV-2

Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +
Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity

Defibrotide in COVID-19 Pneumonia
to able to reduce the progression of acute respiratory failure

Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care
Integration to community as measured on the Reintegration to Normal Living Index (RNLI) - A 11-item questionnaire-based instrument that measures the degree to which individuals achieve reintegration into normal social activities (such as recreation, movement in the community, and interaction in family or other relationships). [Baseline,
Three (3) months following baseline assessment. ]

COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial)
Describe the clinical features of COVID-19.
(This is verbatim from submitted protocol)[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints. ];Describe the response to treatment, including supportive care and novel therapeutics, based on data linkage to medical records. (composite primary outcome)
(This is verbatim from submitted protocol)
[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints.]

Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease
Distress measured on Kessler Psychological Distress Scale (K10)[Baseline, post-intervention (within one week since the completion of the intervention, primary endpoint), 3 months post-intervention]

Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19
Dose adjustment required to attain a steady-state target trough hydroxychloroquine concentration of 0.24mg/L using TDM (proportion of patients / magnitude of adjustments)
Dose adjustment data will be collected and maintained by the senior ICU clinical pharmacist.[Up to the point of ICU discharge, in the first 10 days after commencement of initial HCQ dose, ]

Utilizing lung ultrasound in COVID-19 patients in ICU – comparison of management strategies on survival and time on ventilation.
Mortality[During Intensive care unit stay < 14 days];Mortality[28 day post discharge from ICU];Length of stay intensive care unit from patient medical record[Discharge from intensive care]

Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy
Maternal mortality from COVID-19[During pregnancy until 6 weeks postpartum];Perinatal mortality (stillbirth, neonatal death)[During pregnancy and until day 28 in the neonate]

Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection?
In non-ventilated patients- Mean change in the worst (highest) level of oxygenation (oxygen flow in litres/min). This will be assessed by the nursing documentation in the participant's electronic record of the flow rate of oxygen delivered and the delivery method (ie nasal prongs, Hudson mask, or non-breather mask).
In ventilated patients- Mean change in the worst (lowest) PaO2 /FiO2 ratio (in mmHg). This will be assessed by nursing documented PaO2 and FiO2 levels in the patient chart.[Worst recorded level of oxygenation during the 7 days of intervention.];Feasibility will be assesses by the following measures:
• The primary assessment of our ability to blind treatment of the HDIVZn in a 250-ml saline preparation
• Drug availability from supplier, storage and timely delivery to a patient
• Good clinical practice documentation of drug prescription on Cerner (an electronic medical record), delivery to ICU by project research officer, double signing by nursing staff
• Appropriate preparation of drug- onsite refrigeration storage, preparation with SOPs, maintenance of sterile conditions, protocol compliance, breaches, and variation, documentation processes including patient retention and follow-up rates
• Determine the per-patient cost to estimate subsequent pivotal trial costs
• Assess the process for efficient and effective data entry and analysis
These will be assessed by our research investigators on a regular basis and data collected in the case report forms.[During 7 days of intervention]

Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients

A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome

A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)

A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19)
clinical characteristics and risk factors of death;inflammatory factors;

Investigation for Prevention Awareness against COVID-19
attitudes toward COVID-19;Consciousness awareness toward COVID-19;

A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19)
Incidence of SARS-CoV-2 infection (including confirmed SARS-CoV-2 detection, but might asymptomatic);Incidence of COVID-19 pneumonia;

A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)
Adverse reactions 0-14 days post vaccination;Anti-S antibody IgG titer on day 28 post vaccination;Anti-SARS-CoV-2 neutralizing antibody titer on day 28 post vaccination;

Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system

Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)
Psycho Educational Profile,PEP;Self-Rated Anxiety Scale,SAS;Self-Rated Depression Scale,SDS;Parenting Stress Index-Short Form,PSI-SF;

Experiences in nursing care for patients with suspected novel coronavirus pneumonia (COVID-19) in Shanghai

A medical records based observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)

Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function
Colour Sonography;electrocardiogram;Pulmonary function(TLC, FVC, FEV1, DLCO);

Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19)
Monitoring of adverse events within 24 hours after infusion (including infusion related events and severe adverse reactions associated with non-primary disease);

Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial
Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;

Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)

Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent
new coronavirus nucleocapsid (N) antigen;SEN, SPE, ACC, AUC of ROC;

Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients
proteomics;metabonomics;S antibody IgG;S antibody IgM;S-RBD antibody IgG;S-RBD antibody IgM;N antibody IgG;N antibody IgM;SEN, SPE, ACC, AUC of ROC;

A medical records based retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)
Perioperative fever;Perioperative cough;Outcome of lung CT;Operative time;Volume of Postpartum hemorrhage;postoperative hospitalization;Stay in isolation ward;Apgar score of newborn;Neonatal admission to NICU;Medical observation of personnel involved in the operation;

Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)

A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia
Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;

Early risk stratification of the novel coronavirus infected diseases (COVID-19): a multicenter retrospective study (ERS-COVID-19 study)

Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui

Cancelled by the investigator Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)
Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;

Efficacy of Addition of Naproxen for COVID-19 Infection / Enacovid Study
Main Objective: To demonstrate the superiority of naproxen treatment addition to standard of care compared to standard of care in term of 30-day mortality;Secondary Objective: To demonstrate the effect of naproxen treatment to in-hospital mortality, morbidity, virus concentration;Primary end point(s): 30-day mortality all causes;Timepoint(s) of evaluation of this end point: 30 days

An open label phase II/III study of IFX-1 in patients with severe COVID-19 Pneumonia
Main Objective: The primary objective of Phase II is:
• To explore the effect of IFX-1 on COVID-19 related severe pneumonia (hypothesis generating)
The primary objective of Phase III is
• To demonstrate the efficacy of IFX-1 to improve of symptoms and outcome of severe COVID-19 pneumonia (confirmative)
;Secondary Objective: The secondary objectives of Phase II and Phase III are:
• To assess and define other parameters of efficacy
• To assess the safety of IFX-1
;Primary end point(s): Phase II:
The primary endpoint in Phase II is the relative change (%) from baseline (day 1 prior to study drug administration at ± 1h of randomization) in Oxygenation Index (PaO2 / FiO2) in supine position at day 3, 5, 9, and 15.
Phase III:
The primary, secondary, and other endpoints for Phase III are the same as those for Phase II if not adjusted according to recommendations of the expert committee.
;Timepoint(s) of evaluation of this end point: Day 3, 5, 9 and 15

Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial
Secondary Objective: 1. To evaluate the occurrence of adverse events in each arm,
2. To evaluate the discontinuation rates of the investigational drug in each arm,
3. To evaluate the adherence of participants to study drug,
4. To evaluate the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,
5. To evaluate the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm, at to 2,5 months after randomization,
6. To evaluate the incidence of severe cases of SARS-CoV-2 infection in each arm. ;Primary end point(s): The primary endpoint is the occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)
An infection by SARS-CoV-2 is defined by either:
• a positive specific RT-PCR on periodic systematic nasopharyngeal swab during follow-up
OR
• a positive specific RT-PCR on a respiratory sample in case of onset of symptoms consistent with COVID-19 during follow-up
• a seroconversion to SARS-CoV-2 after randomization.;Timepoint(s) of evaluation of this end point: Day: 7, 14, 21, 28, 35, 42, 49, 57, 71 after the start of the drug;Main Objective: To explore whether a 2-month treatment with either LPV/r or hydroxychloroquine may reduce the incidence of symptomatic or asymptomatic infection by SARS-CoV-2, as compared to their placebo in healthcare workers exposed to SARS-CoV-2.

Study comparing the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection
Main Objective: The main objective is to compare versus standard of care short-term mortality rates in advanced or metastatic cancer patients who are positive for COVID-19 treated with a chloroquine analog (GNS561), an anti-PD1 (nivolumab) or an anti-IL-6R antibody (tocilizumab).;Secondary Objective: The secondary objectives will be to describe in each arm of the study:
• Time to clinical improvement
• Clinical status at days 7, 14 and 28
• Mean change in clinical status from baseline to days 7, 14 and 28
• Overall survival
• Length of stay in Intensive Care Unit and in Resuscitation Unit
• Duration of mechanical ventilation or high flow oxygen devices
• Duration of hospitalization
• Rate of throat swab negativation at days 7, 14 and 28
• Quantitative SARS-CoV-2 virus in throat swab at days 7, 14 and 28
• Quantitative SARS-CoV-2 virus in blood at days 7, 14 and 28
• Rate of secondary infection by other documented pathogens (bacteria, fungi)
• Biological parameters (hematological parameters and markers of inflammation)
• Safety of experimental treatments.
And to perform Cost-Effectiveness Analyses (CEA) with Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.
;Primary end point(s): The primary endpoint will be the 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization.
;Timepoint(s) of evaluation of this end point: 28-day

COVID-19 - ACORES-2 study: ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection
Main Objective: To compare the effect of discontinuation versus continuation of RAS blockers on the clinical course of patients with confirmed COVID-19 infection leading to hospitalization;Secondary Objective: 1. Evaluate the cardiovascular safety of RAS blockers discontinuation in patients hospitalized for COVID-19 by a composite endpoint of MACE.
2. Evaluate the efficacy of RAS blockers discontinuation in patients hospitalized for COVID-19 by the secondary efficacy endpoints.
;Primary end point(s): Primary endpoint:
Time to clinical improvement from day 0 to day 28.
Clinical improvement is defined as an improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first, as recommended by the WHO R&D Blueprint expert group (3).
The seven-category ordinal scale consisted of the following categories:
1. not hospitalized with resumption of normal activities
2. not hospitalized, but unable to resume normal activities
3. hospitalized, not requiring supplemental oxygen
4. hospitalized, requiring supplemental oxygen
5. hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both
6. hospitalized, requiring ECMO, invasive mechanical ventilation, or both
7. death. ;Timepoint(s) of evaluation of this end point: 28 days

COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients
Main Objective: To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).
To evaluate the Covid-19 disease mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).
;Secondary Objective: To evaluate the safety, Covid-19 disease severity, response to cancer treatment, Progression-free survival (PFS), cancer mortality, and Overall Survival (OS) of cancer patients infected by SARS-Cov2.
To follow the evolution of SARS-CoV-2 infection and viral load in different compartments (nasal epithelia, blood and urine) during the course of therapy.
To evaluate the impact of mutation shifts in SARS-CoV-2 genotype (in sever cases only).
To follow the humoral and cellular immune responses to the virus, to cancer and control antigens during infection with SARS-CoV-2.
To deconvolute SARS-CoV-2-specific MHC class I and II binding epitopes to follow T cell responses with tetramers and Elispot assays, as well as cancer antigens (NY-ESO-1, MAGEn, preprocalcitonin, actinin...)-specific responses.
;Primary end point(s): The primary endpoints of the study are for the:
o Part A: prevalence at first visit and 12 weeks cumulative incidence (in a competing risk model with mortality) of SARS-CoV-2 positive subjects (RT-PCR)
o Part B: Covid-19 disease specific mortality;Timepoint(s) of evaluation of this end point: 12 weeks and 12 month (mortality)

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
Main Objective: The aim of this core protocol is to compare the effects on major outcomes in hospital of the local standard of care alone versus the local standard of care plus one of four alternative anti-viral agents.
The primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death.

Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia
Main Objective: The main objective is to assess the impact of dexamethasone on overall mortality at day-60 after randomization in patients admitted in ICU for severe COVID-19 infection.
In non mechanical ventilation (MV) patients, the additional objective is to assess whether oxygen support based on either HFNO or CPAP modality in COVID-19 related AHRF reduces the need for mechanical ventilation at day-28.
;Secondary Objective: For the study of the effect of corticosteroids, secondary objectives include:
1.To compare the evolution of the viral load in the respiratory tract
2.To compare the occurrence of healthcare-associated infections
3.To compare the exposition to mechanical ventilation
4.To compare the evolution of SOFA score
5.To compare the exposition to renal replacement therapy
6.To compare the lengths of ICU and hospital-stay
For the study of the effect of oxygen support modalities, secondary objectives are, to compare each of oxygen support group to the control group in terms of:
1.overall survival
2.occurrence of healthcare-associated infections
3.length of ICU and hospital-stay
;Primary end point(s): , the primary endpoint is the time-to-death from all causes within the first 60 days after randomization.and the time to need for mechanical ventilation (MV);Timepoint(s) of evaluation of this end point: october 2020

CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)
Main Objective: Main objective:
- To study the time (days) to reach clinical stability after randomization in hospitalized patients with severe pneumonia secondary to COVID-19, and elevated inflammatory parameters.;Secondary Objective: Clinical
-time to reach an afebrile state during 48 hours.
-time to reach PaO2/FiO2 >400 and/or SatO2/FiO2 >400
-time until you reach a FR = 24 rpm for 48 hours
-time to D-dimer normalization (<250 ug/L)
-time until PCR is normalized (<5mg/L).
-time to normalisation of ferritin (<400ug/L).
-impact of immunosuppressive treatment on viral dynamics using quantitative PCR.
-duration of treatment with tacrolimus.
-duration of the inpatient stay.
-Percentage of patients requiring artificial respiratory support
-duration of artificial respiratory support needs to be maintained.
-mortality Incidence COVID at 28 and 56 days
-mortality incidence all-cause at 28 and 56 days
-relapses of COVID-19 pneumonia at 28 and 56 days
-Analysis of expanded cytokine profile (day 0 and every 7 days)
Safety
-side effects according to the severity attributed to tacrolimus during its administration.
-side effects according to the severity attributed to other treatments administered;Primary end point(s): Primary endpoint (for the main objective of effectiveness):
- Time (days) to clinical stability after initiation of trial treatment in hospitalised patients with severe pneumonia secondary to COVID-19 and elevated inflammatory parameters;Timepoint(s) of evaluation of this end point: Throughout the study until clinical stability

Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19
Main Objective: To evaluate in-hospital mortality or mechanical ventilation in the Intensive Care Unit (ICU), or need for a rescue dose of tocilizumab in patients with confirmed infection by COVID-19 in treatment with hydroxychloroquine and azithromycin combined or non-tocilizumab.;Secondary Objective: To assess the clinical efficacy of tocilizumab in COVID-19 infection compared to the control arm by:
Clinical severity:
Patient score according to the WHO 7-point ordinal scale
National Early Warning Score (NEWS)
Oxygen therapy
Mechanic ventilation
Hospitalization
Mortality at 15, 30 and 90 days
To assess the safety of the intervention 30 days after treatment compared to the control arm.
To assess the safety of the intervention at 90 days of treatment compared to the control arm.
- Cumulative incidence of serious adverse effects (SAEs).
- Cumulative incidence of grade 3 and 4 adverse effects (AEs).
- Discontinuation or suspension of treatment for any reason.
- Changes in the white blood cell count, hemoglobin, platelets, creatinine, glucose, total bilirubin, AST, ALT, GGT, LDH, C-reactive protein, D-dimer, troponin, ferritin, fibrinogen, KL-6 during follow-up.;Primary end point(s): In-hospital mortality or need for mechanical ventilation in the Intensive Care Unit.;Timepoint(s) of evaluation of this end point: During hospitalization

EPICOS - Experimental clinical trial for PreventIon or COronavirus in health Care professionalS
Main Objective: To assess the efficacy of a daily single dose of TDF (300 mg)/FTC (200 mg), a daily single dose of HC (200 mg), daily single dose of TDF (300 mg)/FTC (200 mg) plus HC (200 mg) or placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing the clinical severity of the coronavirus infection (COVID-19) among hospital healthcare workers aged 18 to 65 years who are exposed to coronavirus infection (COVID-19) in Spain.;Secondary Objective: not applicable;Primary end point(s): number of symptomatic confirmed infections by SARS-CoV-2 (COVID-19);Timepoint(s) of evaluation of this end point: 12 weeks treatment + 4 weeks F/U

DEFIBROTIDE AS PREVENTION AND TREATMENT OF RESPIRATORY DISTRESS AND CYTOKINE RELEASE SYNDROME OF COVID-19
Main Objective: To determine the efficacy of the intravenous infusion of Defibrotide (Defitelio) to reduce mortality in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.;Secondary Objective: To assess the safety of intravenous Defibrotide (Defitelio) infusion in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.
? To analyze the effects of the intravenous infusion of Defibrotide (Defitelio) on the clinical state of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.
? Assess the capacity of intravenous infusion of Defibrotide (Defitelio) to improve the radiological response of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.
? Study the action of Defibrotide (Defitelio) on risk biomarkers in patients with SARS-CoV-2 infection with grade 4, 5 or 6 clinical status according to the WHO classification.;Primary end point(s): Mortality rate 30 days after starting treatment.;Timepoint(s) of evaluation of this end point: 15, 30 ,60 days

Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial
Main Objective: Assess, in patients with ARDS caused by COVID-19, the efficacy of dexamethasone (DXM) associated with hydroxychloroquine (HCQ) compared to HCQ alone on mortality at 28 days;Secondary Objective: Assess, in patients with ARDS causedd by COVID-19, the efficacy of DXM associated with HCQ compared to HCQ alone on :
- the ventilator-free days
- mortality in intensive care unit
- mortality on D60
- the occurrence of infectious complications ;Primary end point(s): Mortality on D28
;Timepoint(s) of evaluation of this end point: the 28th day after the start of treatment

Interest in the administration of Dornase alpha aerosol in Acute Respiratory Distress Syndrome secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19
Main Objective: To evaluate the efficacy of intratracheal administration of dornase alfa (Pulmozyme) on the evolution of ventilatory parameters at D7;Secondary Objective: 1) all-cause mortality at D28
2) the clinical evolution at D28 ;
3) the duration of mechanical ventilation;
4) the number of days without mechanical ventilation at D28;
5) the length of stay in intensive care ;
6) the concentrations of blood markers of inflammation over time;
7) NET concentrations in bronchial secretions over time
8) the occurrence of adverse events;Primary end point(s): Comparison between the two treatment arms of the evolution of the PaO2/FiO2 ratio between D0 (inclusion) and D7;Timepoint(s) of evaluation of this end point: D7

Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19)
Main Objective: To determine the protective efficacy of mefloquine prophylaxis against placebo in close contacts of people with COVID-19.;Secondary Objective: -Establish if the preventive administration of mefloquine attenuates the clinical manifestations of COVID-19 in people who become infected.
-Evaluate the safety of prophylactic mefloquine in this setting.;Primary end point(s): COVID-19 infection.;Timepoint(s) of evaluation of this end point: The patient will be evaluated weekly for 30 days from enrollment in the study to rule out / confirm COVID-19 infection.

Prevention of novel Coronavirus infection with hydroxychloroquine
Main Objective: To compare the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of COVID-19 disease during an epidemic period.;Secondary Objective: 1) To assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period.
2) To evaluate the safety of PrEP with hydroxychloroquine in adults.
3) To describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection.
4) To identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection.
5) To set up a repository (biobank) of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.;Primary end point(s): Confirmed cases of a COVID-19 (defined by symptoms compatible with COVID-19 and/or a positive PCR for SARS-CoV-2) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 at day 0.;Timepoint(s) of evaluation of this end point: 6 months

Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.
Main Objective: To assess the efficacy of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals by negative PCR.;Secondary Objective: To assess the safety of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.
To assess the efficacy of personal protective equipment against SARS-CoV-2 (COVID-19) infection in healthcare professionals;Primary end point(s): Diagnosis of SARS-CoV-2 COVID-19 infection;Timepoint(s) of evaluation of this end point: - At the end of prophylaxis treatment
- Fourteen days after the last dose of treatment

Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection
Main Objective: Demonstrate the therapeutic effectiveness of Hydroxychloroquine associated with Azithromycin treatment for symptom control and negative viral load, in patients with comorbidities without pneumonia and COVID-19 infection.;Secondary Objective: - Evaluate the safety of the treatment
- Assess tolerance of treatment;Primary end point(s): Proportion of patients with negative viral load by CODV-19 [SARS-CoV-2 (PCR)] at 6 days after the start of treatment;Timepoint(s) of evaluation of this end point: 30 DAYS

Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection.
Main Objective: To evaluate the efficacy of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary tp SARS-CoV-2 .;Secondary Objective: To evaluate the safety of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary to SARS-CoV-2.;Primary end point(s): The primary end point of efficacy will be death for any cause in the first 28 days after randomization.;Timepoint(s) of evaluation of this end point: The first 28 days after randomization.

MANAGEMENT OF NOVEL SARS CORONAVIRUS
Main Objective: Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs. ;Secondary Objective: Not applicable;Primary end point(s): The study primary endpoint is composite and contains the achievement of at least one of the following goals or both goals after 7 days (study visit of day 8):
• At least 25% decrease of baseline total SOFA score or increase of the pO2/FiO2 ratio by at least 50%
• Clinical improvement of lung involvement
Patients discharged from hospital alive before study visit of day 8 are considered achieving the primary endpoint. Patients dying before study visit of day 8 are considered non-achieving the primary endpoint.;Timepoint(s) of evaluation of this end point: Visit study day 8

Lessening Organ Dysfunction With VITamin C
Number of deceased participants or with persistent organ dysfunction

Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV
Detection sensitivity is greater than 95%;Detection specificity is greater than 95%

Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;The mortality rate of subjects at weeks 2

Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool

COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus

Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

Expanded Access Remdesivir (RDV; GS-5734™)

Blood Donor Recruitment During Epidemic of COVID-19
Differences of attitude about blood donation towards different questionnaires

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
arrest in deterioration of pulmonary function;improving in pulmonary function

Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak
Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice

Outcomes and Prognostic Factors in COVID-19

Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals

Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure
Time to independence from supplementary oxygen therapy

Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

Convalescent Plasma to Limit Coronavirus Associated Complications
RNA in SARS-CoV-2;ICU Admissions;Hospital Mortality;Hospital Length of Stay (LOS)

Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2
National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)

Understanding COVID-19
Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days;Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis

Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection
Incidence rate of new COVID-19 cases in both arms;Prevalence of COVID-19 cases in both arms;Mortality rate secondary to COVID-19 cases in both groups;Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups

Survey of the Anxiety Associated With the COVID-19 Pandemic
Characteristics of COVID-19-related anxiety;COVID-19-related anxiety symptoms

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

COVID-19 Symptom Tracker
Physical health symptoms;Lack of physical health symptoms

Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more);Number of adverse events

Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic

Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19
In-hospital mortality;Need for mechanical ventilation in the Intensive Care Unit

Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia
Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.
All-cause mortality at 30 days after admission

Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19
Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).

COVID-19 in Patients With HIV

Vitamin D on Prevention and Treatment of COVID-19
Composite of cumulative death (i.e. mortality) for all causes and for specific causes.

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19
Hospitalization within 14 days of enrollment

COVID-19 Registry Rhineland-Palatinate (Germany)
Chest x-ray;Chest CT;Supportive care - ICU;Supportive care - oxygen therapy;Supportive care - ventilation;Medication;Therapeutic strategies;Lab parameters;Intra-hospital complications;Vital status at discharge

Cardiovascular Manifestations of COVID-19
Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.

Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients

Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19

Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?
Measure frequency of people suffered from unusual flu-like symptoms before December 2019

Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine
International Physical Activity Questionnaire;Pittsburgh Sleep Quality Index;Perceived Stress Scale;Numerical Pain Rating Scale

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
Time from randomization to clinical recovery

Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment

Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)

Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)

Clinical and Radiomic Model of COVID-19

Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System

Beat COVID-19 - Observational Trial

Hemodynamic Characteristics of Patients With SARS-CoV-2
Body temperature;Blood pressure;Pulse (heart rate);Respiratory rate;Data provided by transpulmonary thermodilution-CI;Data provided by transpulmonary thermodilution-GEDV;Data provided by transpulmonary thermodilution-EVLW;Data provided by transpulmonary thermodilution-PVPI;Incidence of abnormal laboratory test results

Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT

Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19

Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19

Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt
Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group;Clinical manifestations of Coronavirus Disease 2019 (COVID-19);Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort;Radiological features of Coronavirus Disease 2019 (COVID-19) cohort

COVID-19 Risk Stratification

Max COVID19- Study

Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia
The immune function (TNF-a ?IL-1ß?IL-6?TGF-ß?IL-8?PCT?CRP);Blood oxygen saturation

Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
Breath volatile organic compound profiles;Utility of breath profiles for disease diagnosis or prognosis

Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury

AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience
Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19

Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients
Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients;Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin

The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19

Non-contact ECG Sensor System for COVID19

Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers

Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient

NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure

Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak
The Rapid Office Strain Assessment (ROSA)

Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study

Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours

Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey
overview of surgical management on preventive measures of hospital infection spread during covid 19

Effect of a Brief Problem Management Intervention on Covid 19-Related Anxiety and Depression
Anxiety and depression represent a composite primary outcome, as measured by the Hospital Anxiety and Depression scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 15). ]

The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable.
Recorded tidal volumes whilst continuously using the pandemic cuirass ventilator for 60 minutes. Tidal volumes will be recorded using a face mask connected to an existing GE Anaesthetic Machine.[Tidal volumes will be assessed every 15 minutes. Total sedation time will be 60 minutes.]

Adapting the Decathlon Group Easybreathe® snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection.
Patient comfort and tolerability as assessed by a 6 point question item originally developed for CPAP use. We will use a modified version of the 6 point scale developed by Balachandran et al JCSM 2013. It is a 6 point Likert scale.[At 24 hours after initiation of therapy and every subsequent 24 hours of use of the mask until disposition from hospital.]

Mental health and wellbeing on general population during the COVID-19 outbreak
the prevalence of depression which will be assessed by the 9-item Patient Health Questionnaire[Assessed at baseline];the prevalence of anxiety, which will be assessed by the 7-item Generalized Anxiety Disorder scale[Assessed at baseline];the prevalence of insomnia, which will be assessed by the 7-item Insomnia Severity Index. [Assessed at baseline]

Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus. Virus concentration is measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]

Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85
Proportion of health care workers (HCW) contracting an lower respiratory illness necessitating workforce removal, assessed from workforce information including rosters and medical records.[Assessed at the end of month 3, prior to the wait-list control (WLC) commencing treatment.]

Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study
Ventilation free survival days as assessed by reviewing medical records[At 90 days after initiation of mechanical ventilation]

Cord Blood Therapy to prevent progression of COVID-19 related pneumonia
Safety and tolerability of UCB cell administration (absence of immediate and short-term side effects, including allergic reactions, line related effects, infection)
This will be assessed based on partipant rports, and hospital charts and monitoring[24 hrs (collection of hourly vital monitoring data, examination at 24 hrs)];Clinical improvement, as documented by change of patient status on a seven-category ordinal scale (to be completed by hospital staff or researcher)
Seven-category ordinal scale:
1, not hospitalised with resumption of normal activities; 2, not hospitalised, but unable to resume normal activities; 3, hospitalised, not requiring supplemental oxygen; 4, hospitalised, requiring supplemental oxygen; 5, hospitalised, requiring humidified nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 6,hospitalised, requiring ECMO, invasive mechanical ventilation, ECMO or both; and 7, death.[ Assessed every day until resolution of symptoms or death]

Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers (SUPPORT COVID-19 Healthcare Workers)
Scores on the Perceived Stress Scale. The PSS is a widely used measure of the appraisal of how stressful events over the previous month are. Scores range from 0 to 40 with higher scores representing higher levels of stress. [Perceived Stress Scale scores will be measured at baseline and following a 12 week intervention period, with the primary time point of interest being scores post the 12 week intervention period.]

Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19)
Blood routine;Blood biochemistry;C-reactive protein;chest CT;2019-ncov-RNA;TCM symptom;

Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19)
Changes in anxiety and depression scale scores;difference between two interventions;

A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)

The prevention and treatment strategy of the protective respirator related facial pressure injuries among healthcare professionals fighting novel coronavirus pneumonia (COVID-19)
temperature;area of facial indents;gray level of facial indents;pain;

Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)

Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multi-center Clinical Research

Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease

Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people
Relief time and rate of symptoms of laryngeal discomfort, sore throat, dry and hot pharynx, and pharyngeal mucosal congestion;New fever, cough, muscle soreness, headache, the time it takes for symptoms to disappear or to subside;Symptom scores;Occurrence of adverse events/reactions;

Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine

Medical Records Based Study for Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19)
pregnancy maternal complications;labor complications;mode of delivery;birth weight;Neonatal disease;Apgar score;neonatal infection;NICU admitting rate;neonates with COVID-19;

Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial

Analysis of clinical characteristics and therapeutic effect of 9 cases of novel coronavirus pneumonia (COVID-19)
Blood routine tests;Liver function;Renal function;CK-MB;B-BNP;myoglobin;Hypersensitive troponin;Interleukin - 6;Tumor necrotizing factor-alpha;Interleukin - 10;

Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community
Delineate the true prevalence of SARS-CoV-2 infection in Hong Kong;Estimate the size of outbreak at different periods;Understand the epidemiology and characteristics of asymptomatic and mild infections;

A medical records based study for ''Guangdong Pneumonia NO.1'' in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
syndrome;nucleic acid of nCoV-19;blood count;liver and kidney function;cardiac enzymes;lung CT;

Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment

Cancelled by the investigator Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients
Time to disease recovery;Exacerbation (transfer to RICU) time;

The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19)

A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)
Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;

A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)
Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;

Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia
Main Objective: To assess the efficacy of a management strategy combining a broad panel respiratory mPCR and an algorithm of early antibiotic de-escalation and discontinuation based on both the mPCR results and the procalcitonin, on antibiotics exposure, as compared with a conventional strategy, in severe confirmed COVID-19 pneumonia.;Secondary Objective: Mortality rates at 28 (D28) and 90 days (D90);
- Overall antibiotics use, including broad- and narrow-spectrum antibiotics;
- Total exposure to antibiotics at D28;
- Number of organ-failure free days at D28;
- Incidence rates of bacterial super-infections and colonization/infection with resistant pathogens at D28;
- ICU and hospital lengths of stay;
- Quality of life at D90.;Primary end point(s): The primary assessment criterion is the number of antibiotic free days at D28, which corresponds to the number of days alive without any antibiotic at Day 28. The D28 time point is usual in studies assessing antibiotic use in ICU patients.;Timepoint(s) of evaluation of this end point: D28

A clinicial trial to investigate te effect of valsartan compared to placebo on acute respiratory failure in hospitalized SARS-CoV-2-infected patients
Main Objective: To investigate the effect of the ARB valsartan in comparison to placebo on the occurrence of one of the following items, within 14 days of randomization:1) ICU admission; 2) Mechanical ventilation; 3) Mortality.;Secondary Objective: • Death within 14 days, 30 days, 90 days and at 1 year, defined as all-cause mortality.
• Mechanical ventilation and ICU admission within 14 days.
• Time to ICU admission, mechanical ventilation and death.
• Occurrence of acute kidney injury within 14 days defined as a 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of >30 ml/min/1.73m2 and to a value below 60 ml/min/1.73m2.
;Primary end point(s): The primary study endpoint is the occurrence within 14 days of randomization of either: 1) ICU admission; 2) Mechanical ventilation; 3) Death. ;Timepoint(s) of evaluation of this end point: The occurrence of the main study endpoint will be assessed on a daily basis.

Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study
Main Objective: The main objective of this study is to evaluate the survival interest of Hydroxychloroquine 400 mg, Telmisartan 80 mg, Azithromycin 500 mg and Curcumin 800 mg daily on the survival of elderly patients with VIDOC-19 at 2 weeks from the start of treatment.;Secondary Objective: To evaluate adverse events, and particulary serious adverse avent.
ToEvaluate the effectiveness of different treatments on :
- SARS-Cov-2
- Survival to 4 weeks
- Inflammation
- The confusion
- Walking
- Functional capabilities
- Breathing rate
-Oxygen therapy
- Pulse rate
- Systolic and diastolic blood pressure
- Temperature
- Pneumonia
- Discharge
- Transfer to a convalescent hospital (SSR or equivalent)
- Necessity of add-on coritcosteroids or other immunomodulator or immunosuppressor
- Oxygen therapy
- The impulse rate
- The temperature
- The return home
- Disclaimer
- Transfer to a convalescent hospital (RHS or equivalent)
- The need for treatment with complementary, immonumodulating or immunosuppressive corticosteroids.;Primary end point(s): The primary endpoint will be two-weeks survival rate.;Timepoint(s) of evaluation of this end point: 14 days

Efficacy of different treatments in patients infected with COVID-19
Primary end point(s): Discharge from the patient or death;Timepoint(s) of evaluation of this end point: The main result is all-cause mortality, subdivided by disease severity at the time of randomization.;Main Objective: Provide reliable estimates of the effects of these antiviral treatments on hospital mortality.;Secondary Objective: The secondary objectives are to evaluate the effects of these antiviral treatments on the length of the hospital stay and on the reception of ventilation or intensive care.

Tocilizumab plus Pembrolizumab in COVID-19
Main Objective: To assess the efficacy –as determined by the proportion of patients with normalization of SpO2 =96%– of continued standard care together with tocilizumab plus pembrolizumab (MK-3475) in patients with COVID-19 pneumonia who are nonresponsive to frontline therapy within 48 hours from treatment initiation.;Secondary Objective: To assess the efficacy –as determined by:
the proportion of patients with normalization of fever– of study drugs in this population.
• the proportion of discharged patients– of study drugs in this population.
• the duration of hospitalization– of study drugs in this population.
• the Sequential Organ Failure Assessment (SOFA)– of study drugs in this population.
• the mortality rate– of study drugs in this population.
• the remission of respiratory symptoms– of study drugs in this population in terms of:
-Time to invasive mechanical ventilation;
-Time to independence from oxygen therapy.
• the radiological response– of study drugs in this population.
• the severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 negativization– of study drugs in this population.
•the change in laboratory parameters– of study drugs in this population.
•To evaluate the safety and tolerability of study drugs in this population.;Primary end point(s): Percentage of patients with normalization of SpO2 =96% through day 14 after study treatment initiation;Timepoint(s) of evaluation of this end point: through day 14 after study treatment initiation.

Clinical trial to assess the efficacy and safety of cyclosporin A treatment associated with standard treatment versus standard treatment only in hospitalized patients with confirmed coronavirus infection
Main Objective: To assess the efficacy of the association of CsA with standard treatment in reducing the severity of COVID19-confirmed infection in hospitalized patients.;Secondary Objective: -To assess the efficacy of CsA in combination with standard treatment in reducing mortality, days in hospital, days in ICU beds, and FiO2.
- Compare the evolution of BP, plasma creatinine, lymphocyte count, lymphocyte activation markers and CD4 between both groups.
- To evaluate the safety of the association of CsA with the standard treatment of hospitalized patients with confirmed infection by COVID19.
- To study the possible differences in the modification in the viral load and the seroconversion parameters (IgM and IgG to the virus) throughout the process in both groups.
-To assess the incidence of the use of CsA in combination with standard treatment in the reduction of ferritin, LDH and PCR levels from admission, in the CPK and D-dimer peak, in the KL6 peak and in IL6 levels at the same time. throughout evolution.
- Evaluate the relationship between CsA doses (mean in mg / kg / day and accumulated) and improvement parameters.;Primary end point(s): Proportion of patients in a non-serious category at 12 days of treatment;Timepoint(s) of evaluation of this end point: At 12 days of treatment

Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care
Main Objective: To assess the efficacy and safety of early treatment of sarilumab, added to standard treatment, in patients hospitalized for mild-moderate COVID-19 pneumonia, with criteria of a CURB 65 less than or equal to 1, oxygen saturation equal to or greater than 90%, MEWS less than 3 and with IL6 greater than 20 pg / mL.;Secondary Objective: To evaluate:
-Clinical status of patients on days 7 and 14 later than the treatment initiation.
-Proportion of patients discharged on day 14
-28-day mortality rate
-Proportion of patients who required mechanical ventilation and days of duration
-Days of hospital stay of patients who have survived to 28 days
-Time since start of treatment to death of the patient
-Possible serious adverse events related to sarilumab and possible causes of discontinuation of sarilumab treatment
to analyze:
-type of medications received during admission and days since onset of symptoms to starting glucocorticoids
-the evolution of prognostic factors: IL6, D-dimer, ferritin, calprotectin;Primary end point(s): Time to clinical improvement, defined as the time from randomization to a two-point improvement (from randomization status) on an ordinal scale of seven categories or hospital discharge, whichever occurs first.
The seven-category ordinal scale consisted of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and 7, death.;Timepoint(s) of evaluation of this end point: 28 days

efficacy and safety of a bitherapy by hydroxychloroquine + azythromycin vs monotherapy by hydroxychoroquine in adult patients with documentated infection by covid19
Main Objective: Evaluation of efficacy of a bitherapy by hydroxychloroquine + azythromycin vs monotherapy by hydroxychoroquine administered for 10 days, on patient infected with SarS COV 2 with either a moderate clinical form (level 3), or a severe non-resuscitative clinical form (level 4);Secondary Objective: - Evaluation of the safety of a bitherapy by hydroxychloroquine + azythromycin vs monotherapy by hydroxychoroquine
- Need of oxygenotherapy
- virological, and pharmacokinetic assessment of each treatment
-PAtient transfer in ICU.
- hospitalization duration
Vital status
Adverses event;Primary end point(s): At least 1 level improvement in clinical status assessed by a level ordinal scale (at least 1 level) between D1 and D11 :
1. Not hospitalized, no limitation of activities
2. Not hospitalized, limitation of activities;
3. Hospitalized, not requiring oxygen supplementation
4. Hospitalized, requiring oxygen supplementation
5. Hospitalized, non-invasive ventilation or high flow oxygen device
6. Hospitalized, under invasive mechanical ventilation or ECMO (extracorporeal membrane oxygenation)
7. Death;Timepoint(s) of evaluation of this end point: D11

Corticoïdes au cours de la pneumonie virale Covid-19 liée à l’infection par le SARS-Cov-2
Main Objective: Réduire le nombre de patients présentant une indication théorique de transfert en réanimation d’indication respiratoire, évaluée par une SpO2 < 90% stabilisée au repos et sous un débit d’oxygène ne dépassant pas 5 L/min d’oxygène au masque à moyenne concentration à J7 de la randomisation (soit J14 des symptômes ±5 jours). Ce critère permet de déterminer objectivement la gravité de l’état respiratoire du patient.;Secondary Objective: Evalués à la visite 3, J7 de la randomisation (soit J14 des symptômes ±2jours) :
- Réduire la gravité sur une échelle ordinale à 7 niveaux
- Réduire les besoins en oxygénothérapie
- Réduire les signes radiologiques visibles sur l’imagerie thoracique
Evalués à la visite 4, J21 de la randomisation (soit J28 des symptômes ±2jours) :
- Réduire le nombre de patients transférés en réanimation ou soins intensifs
- Réduire le nombre de patients nécessitant un recours à la ventilation invasive
- Réduire la durée de l’oxygénothérapie
- Réduire la durée d’hospitalisation à partir de la randomisation
- Evaluer la tolérance de la corticothérapie et la fréquence des complications induites par la corticothérapie
- Evaluer la fréquence des infections autres que SARS-CoV-2
- Evaluer la mortalité globale à J21 (J28 des symptômes)
;Primary end point(s): Nombre de patients à J7 de la randomisation (soit J14 des symptômes ±5 jours), présentant une indication théorique de transfert en réanimation d’indication respiratoire évaluée par une SpO2 < 90% stabilisée au repos et sous 5 L/min d’oxygène au masque à moyenne concentration mesurée deux fois à 5-15 min d’intervalle. La valeur moyenne des deux mesures sera retenue.;Timepoint(s) of evaluation of this end point: J14 des symptômes ±5 jours

COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients
Main Objective: Evaluer l’efficacité d’une forte dose de cholecalciferol 400 000 UI per os en une fois versus une dose standard de 50 000 UI per os en une fois sur le taux de décès à 14 jours (J14) chez les patients âgés ayant ;Secondary Objective: 1) Evaluer l’efficacité de la forte dose de cholecalciferol versus la dose standard sur :
2) Evaluer la tolérance de la forte dose de cholecalciferol versus la dose standard sur la survenue d’évènements indésirables graves
3) Evaluer l’efficacité de la forte dose de cholecalciferol versus la dose standard dans le sous-groupe des participants ayant une hypovitaminose D sévère à l’inclusion, c’est-à-dire ayant une concentration sérique de 25-OHD <25 nmol/L à J1
4) Evaluer l’impact de la concentration sérique de 25-hydroxyvitamine D à J7 (< 75 nmol/L versus = 75 nmol/L) sur le taux de décès à J14 et J28 et l’évolution clinique (échelle OSCI) à J14 et J28
5) Dans le sous-groupe des participants présentant une hypovitaminose D sévère initiale (25-OHD <25 nmol/L à J1), comparer le taux de décès et l’évolution clinique (échelle OSCI) à J14 et J28 en fonction de la concentration sérique de 25-OHD atteinte à J7 (< 75 nmol/L versus = 75 nmol/L).
;Primary end point(s): Le critère d’évaluation principal est la survenue d’un décès quelle qu’en soit la cause dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J1).;Timepoint(s) of evaluation of this end point: Le critère d’évaluation principal est la survenue d’un décès quelle qu’en soit la cause dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J1).

Clinical trial phase II to evaluate the efficacy of 3 types of treatment in patients with pneumonia by COVID-19
Main Objective: To compare and evaluate the efficacy of 3 treatment regimens (Hydroxychloroquine in combination with baricitinib, imatinib or lopinavir / ritonavir) in SARS-CoV-2 patients with severe pneumonia requiring admission, considering primary efficacy as time to clinical improvement.;Secondary Objective: To assess the safety (serious adverse effects, premature discontinuation of treatment), tolerability and secondary efficacy parameters of the 3 treatment guidelines, understood as: absence of progression to respiratory failure, absence of increased O2 requirements; need for mechanical ventilation; reduction of analytical parameters associated with poor prognosis; radiological progression of the disease on day + 7 of starting treatment; average hospital stay, intensification treatments, such as steroid boluses and tocilizumab, ICU admission,% mortality at the end of follow-up.
In addition, in those patients who consent and participate in an additional sub-study, possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 will be evaluated using high-performance techniques with serum DNA from the participants.;Primary end point(s): 8.1 Demographics
Age
Sex
Tobacco
Alcohol
Significant comorbidity
- HTA
- Cardiovascular disease
- DM
- COPD
- Cancer
- Chronic liver disease
- I kidney
- Known immunosuppression
8.2 Laboratory parameters
COVID BIOMARKERS
- PCR
- Procalcitonin
- LDH
- Dimero D
- Ferritin
- IL6
BIOCHEMICAL PARAMETERS
- Enzymatic creatinine
- ALT
- AST
- Bilirubin
- GGT
- F Alkaline
- Albumine
- Venous lactate
- Ultrasensitive Troponin I
- Creatin Kinasa (CK)
HEMATOLOGICAL PARAMETERS
- White Series
- Leukocytes (in absolute value)
- Neutrophils (in absolute value)
- Lymphocytes (in absolute value)
- Neutrophil / lymphocyte ratio
- Platelet / lymphocyte ratio
- Red Series
- erythrocytes
- Hb
- Platelets
- Coagulation
- Fibrinogen
- Coagulation Study
MICROBIOLOGICAL PARAMETERS
- SARS-Cov2 PCR in nasopharyngeal exudate
8.3 Radiodiagnosis
- Unilateral, unilobar, bilobar pneumonia ...
- Bilateral pneumonia
- Resolution infiltrators
- Infiltration resolution days
- Stabilization
- Radiological progression
8.4 Clinical variables
- Symptom onset days
- Days resolution symptoms
- Fever days
- Respiratory improvement (days)
- Temperature (<38.4 / 38.4-39.4 /> 39.4) * From The The Hscore11
- Organomegaly (No, liver or spleen, both) * From The Hscore11
- Fever
- Dry cough
- productive cough
- Hemoptysis
- dyspnea
- Asthenia
- Myalgia
- headache
- nausea
Vomiting
- Diarrhea
- Abdominal discomfort
- ARDS
- I cardiac
- FRA
- SHOCK
- death
- Secondary infection
- O2 saturation levels.
- Need O2, nasal goggles, liters VM non-invasive reservoir Intubation
8.5 Clinical management variables
- Hospital stay
- ICU admission
- No. of registrations;Timepoint(s) of evaluation of this end point: Baseline, 7 days during treatment, day 14, day 35+/-5 and day 70+/-5

Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia
Main Objective: To assess the efficacy of siltuximab vs corticosteroids in hospitalized patients with COVID19 pneumonia by evaluating the number of admissions in the unit intensive care (ICU);Secondary Objective: -Stay in the ICU
-Time to resolution of fever for at least 48 hours, without administration of antipyretics
-Incidence of worsening in the oxygen therapy requirement
-Duration of supplemental oxygen dependence
-Incidence of the use of mechanical ventilation
-Duration of the use of mechanical ventilation
-Time to start of mechanical ventilation, non-invasive ventilation
or use of high flow nasal cannula
-Days of hospitalization
-Mortality rate at 29 days
-Incidence of SAEs
-Incidence of invasive bacterial or fungal infections or opportunistic with grade 4 neutropenia
-Incidence of invasive bacterial or fungal infections or opportunistic
-Incidence of hypersensitivity reactions or reactions grade 2 related to the infusion
-Incidence of GI perforations
-Incidence of new serious secondary infections or worsening of existing infections
-Changes in leukocytes, Hb, platelets, creatinine, bilirubin, ALT
-Changes in inflammatory biomarkers
-Changes in chest X-ray;Primary end point(s): Proportion of patients requiring ICU admission at any time within the study period.;Timepoint(s) of evaluation of this end point: 29 days

Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs
Main Objective: To assess the mortality impact at 28 days of an immunomodulatory strategy with 2 treatment regimens stratified according to IL-6 plasma levels, administered in addition to standard treatment, in adult patients with severe COVID-19 pneumonia.;Secondary Objective: To assess the impact of this strategy on the following variables: premature mortality (48 hours, 7 days and at hospital), mortality at intensive care unit, days of mechanical ventilation, virus clearance (viral clearance / viral shedding), time to normalization of oxygen saturation , time to defervescence, improvement of inflammatory reaction, days of hospitalization, days of intubation, safety and tolerability of the intervention;Primary end point(s): Mortality at day 28 after treatment initiation (proportion of patient died that day);Timepoint(s) of evaluation of this end point: Day 28 after treatment initiation

Clinical trial to avoid infection by SARS-CoV-2 in high-risk population. COVID-19
Main Objective: The main objective is to evaluate the efficacy of melatonin in the prevention of SARS-CoV-2 infection in healthcare personnel with high-risk contacts.;Secondary Objective: o Evaluate the efficacy of melatonin in the prevention of asymptomatic SARS-CoV-2 infections (COVID-19).
o To evaluate the efficacy of melatonin in preventing the development of severe COVID-19 in participants who acquire the infection during the development of the study.
o Assess the duration of symptoms of COVID-19 infection in participants receiving melatonin.
o Assess IgM / IgG seroconversion from symptom detection;Primary end point(s): Number of symptomatic infections confirmed by SARS-CoV-2 (COVID-19);Timepoint(s) of evaluation of this end point: 16 weeks

Preventing SARS-CoV-2 virus infection and severity of COVID-19 diseases during pregnancy with hydroxychloroquine
Main Objective: 1. To assess the effect of HCQ in reducing maternal viral load
2. To asses the efficacy of HCQ to prevent incident SARS-CoV-2 infection;Secondary Objective: 1. To determine the impact of HCQ on the clinical course and duration of the COVID-19 disease
2. To evaluate the effect of HCQ in avoiding the development of the COVID-19 disease in asymptomatic-infected women
3. To determine the safety and tolerability of HCQ in pregnant women
4. To describe the clinical presentation of SARS-CoV-2 and the effects on pregnancy outcomes
5. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2;Primary end point(s): - The mean reduction in viral load at day 14 after recruitment among those women infected by SARS-CoV-2, in the ITT and ATP cohorts, adjusted by age, gravidity, region(municipality) and other variables associated with the prevalence and viral load of SARS-CoV-2 infection.
- The comparison of the proportion of pregnant women who were close contacts of confirmed cases of SARS-CoV-2 infection, with a positive PCR for the infection at day 14, in the ITT and ATP cohorts, adjusted by adjusted by age, gravidity, region(municipality) and other variables associated with the prevalence of SARS-CoV-2 infection.;Timepoint(s) of evaluation of this end point: Day 14 after treatment initiation

Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.
Main Objective: -To evaluate the efficacy of the early administration of sarilumab subcutaneously in patients with moderate-severe COVID-19 infection in early stages compared to the current treatment standard.
-To compare the baseline clinical and biological parameters, including serum IL-6, of the intervention population against historical controls, to search for possible markers that identify candidates for treatment with subcutaneous IL-6 inhibitors and attempt an approximation to the time frame of “window of opportunity”.;Secondary Objective: Not applicable;Primary end point(s): - Time to become afebrile for a minimum period of 48 hours, without antipyretics
- Average change in the ordinal scale of 7 points from the inclusion in the study until day 7 (after randomization):
1. Death
2. Hospitalized, with mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
3. Hospitalized, with non-invasive mechanical ventilation, a mask with a reservoir or oxygen with high flow nasal goggles.
4. Hospitalized with oxygen supplement
5. Hospitalized, without oxygen supplement, but in need of continued medical care (related or not with COVID)
6. Hospitalized, without oxygen supplement and without the need for continued medical care
7. Not hospitalized
- Duration of hospitalization (days)
- Death
;Timepoint(s) of evaluation of this end point: The expected duration of subject participation in the trial is until resolution of the COVID-19 infection pattern, approximately 1 month. The overall duration of the study is estimated to be about 2 months, from the recruitment of the first patient to the end of the follow-up of the last patient included. The duration can be shortened if the current rate of income is maintained for at least one month.

COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)
Main Objective: The main objective of this study is to determine if short-term treatment with colchicine reduces the mortality rate and lung complications related to COVID-19.;Secondary Objective: The secondary objective is to determine the safety of colchicine treatment in this patient population.;Primary end point(s): The primary endpoint will be a composite endpoint of death or need for hospitalization from COVID-19 infection within 30 days of randomization.;Timepoint(s) of evaluation of this end point: 30 days

Pragmatic clinical trial of hydroxychloroquine in the treatment of oncohematological patients and health professionals with COVID-19 infection without radiological alteration.
Main Objective: To determine the efficacy of hydroxychloroquine in the treatment of SARS-COV2 infection in oncohaematological patients without radiological alteration and SARS-COV2 positive professionals without radiological alteration.;Secondary Objective: Evaluate the toxicity profile of the treatment.;Primary end point(s): Percentage of patients (cohort A) and professionals (cohort B) who achieve control of the disease without symptoms in 14 days, assessed by chest radiography without pneumonia.;Timepoint(s) of evaluation of this end point: 14 days after treatment initiation

Preventative Drug Treatment for COVID-19 Infectious Disease
Main Objective: The principle research objective is to determine whether giving the drug Hydroxychloroquine increases time to COVID-19 disease in healthy frontline healthcare workers compared to giving a placebo.;Secondary Objective: • To determine whether giving hydroxychloroquine daily versus weekly decreases time to COVID-19 disease in healthy frontline healthcare workers
• To compare the number of confirmed COVID-19 cases between each group on the basis of different testing methods
• To compare disease severity in each group
• To compare recovery time in each group;Primary end point(s): Time to positive COVID-19 disease
;Timepoint(s) of evaluation of this end point: Weekly over approximately 90 days

Prevention of severe respiratory failure in Covid-19
Main Objective: Recent data coming from the Hellenic Sepsis Study Group reveal that suPAR levels =6 ng/ml are early found among patients who will eventually develop severe respiratory failure (SRF) by Covid-19 with positive predictive value more than 80%. This signifies that an early pro-inflammatory reaction has been started in the lung. It is postulated that early anakinra treatment in these patients may halt this reaction and prevent development of SRF. In the SAVE study patients with sars-cov-2 infection with SARS-CoV-2 virus at high risk for progression to MSDs will be detected using the suPAR biomarker. They will begin early treatment with anakinra in the effort to prevent progression in SAA. ;Secondary Objective: Not applicable;Primary end point(s): This is defined on day 14 as the percentage of patients who will not experience SAIs (as defined in Annex V). Patients who die before the day 14 visit are considered to have failed at the primary endpoint.;Timepoint(s) of evaluation of this end point: Day 14

Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection
Main Objective: To evaluate the effect of 48-hour treatment with inhaled sevoflurane on arterial oxygenation, assessed by PaO2/FiO2 on day two, in patients with ARDS-CoVid19;Secondary Objective: - to quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19
- evaluate the 30-day mortality.;Primary end point(s): Efficacy will be assessed according to the defined objectives of oxygenation, reduction of inflammatory markers;Timepoint(s) of evaluation of this end point: 2 days - PaO2/FiO2 and TNF, IL-1b, IL-6 e IL-8 día 2.

Treatment of COVID-19 with allogeneic mesenchymal cells (MSV®).
Main Objective: Assessing the safety and efficacy of MSV-allo® in obtaining recovery from respiratory failure in patients with pneumonia due to severe / critical COVID-19 infection.;Secondary Objective: 1. Time to recover from the symptoms and clinical signs after the MSV-allo® administration
2. Time to reach the normalization of imaging tests, chest radiography and/or lung CT
3. Modification in the inflammatory response in terms of blood levels of cytokines and chemokines.
4. Modification in the number of leukocytes and lymphocyte populations.
5. Safety, tolerability and immunogenicity profiles of MSV-allo® in patients with severe COVID-19;Primary end point(s): 1. Proportion of patients in whom removal of invasive mechanical ventilation has been achieved in less than 7 days after IMP administration.
2. Proportion of patients surviving on day 28 from diagnosis;Timepoint(s) of evaluation of this end point: 7 days from treatment and 28 days from diagnosis

Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19
Main Objective: To study whether the administration of colchicine, compared to a control group, improves the clinical evolution of patients and prevents the inflammatory response.
1. Changes in the clinical status of patients on the 7-point ordinal scale (WHO R&D Blueprint expert group) (34) at 7, 14 and 28 days:
2. Change in IL-6 concentrations up to 28 days.;Secondary Objective: 1. Improvement of clinical status defined as time to reduction of at least 2 points on the WHO 7-point ordinal scale.
2. Changes in the Sequential Organ Failure Scale (SOFA,) during hospitalization and time to 50% reduction with respect to randomization.
3. Changes in NEWS severity scale score (33) during hospitalization and time to NEWS score =2 or 50% reduction from randomization.
4. Number of days in invasive mechanical ventilation or ECMO
5. Number of days with oxygen at high flow.
6. Changes of other inflammatory markers: C-reactive protein, TNF-alpha, GDF-15, IL-1ß up to 28 days with respect to randomization.
7. Changes in severity markers: D-dimer, leukocytes, lymphocytes, platelets, LDH and ferritin up to 28 days with respect to randomization.
8. Changes in markers of myocardial damage: hsTnT and NT-proBNP up to 28 days with respect to randomization.
9. Time to viral negative by RT-PCR
10. Duration in days of hospital stay
11. ICU income
12. Mortality from causes;Primary end point(s): 1. Ordinal 7-point clinical evaluation scale (WHO R&D Blueprint expert group (31).
2. IL-6 concentrations, which together with the rest of the laboratory result variables will be measured together at the end of the study.;Timepoint(s) of evaluation of this end point: END OF STUDY

Clinical trial of administration of MSC to patients with respiratory distress type COVID-19
Main Objective: The main objective of this project is to evaluate the efficacy of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19.;Secondary Objective: -To evaluate the safety of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19.
-To evaluate preclincial variables;Primary end point(s): ?% survival at 28 days after treatment
? Days from the patient enters the study until the temperature normalizes: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
o Normalization of the temperature defined as: reaching a body temperature between 35ºC and 37ºC
? Days until patient was extuted: defined as
(Total days with mechanical ventilation) - (Total days without mechanical ventilation) Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
? Number of patients who abandoned mechanical ventilation, defined as: (Total of patients with mechanical ventilation at the time of inclusion) - (Total of patients who abandoned mechanical ventilation)
Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
? Number of patients that go from Mechanical Ventilation to oxygen therapy: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
? Duration of oxygen therapy (days), defined as: (Total days in the study) - (Total days of need for oxygen therapy). Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
? Days of stay in the Intensive Care Unit: defined as (Total days in the study) - (Total days in the Intensive Care Unit).
? Duration of hospitalization (days): defined as (Total days in the study) - (Total days hospitalized)
? Oxygen saturation: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month
Pa PaO2 / FiO2 ratio: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month, and 6th month.
Radi Radiological pattern on Chest Radiography: decrease in interstitial alveolar infiltrates: yes / no. Measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
FA SOFA score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month.
? Murray score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month
? Analytical parameters: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month
o Hties, Hb, Hto, VCM, Leukocytes with leukocyte formula, platelets. procalcitonin
o Glucose, Glycosylated Hb, urea, uric acid, creatinine, total bilirubin, direct bilirubin, sodium, potassium, calcium, chlorine, total protein, C-reactive protein, AST, ALT, GGT, Cl Cr and FG.
o Coagulation: prothrombin time (TP), activated partial thromboplastin time (APTT), thrombin time (TT), Fibrinogen, INR.
o IL-6, IL-2, DD, lactate dehydrogenase, CK (Creatin Kinase), Alkaline Phosphatase
o Lymphocyte population: CD4 +, CD8 + T lymphocytes, B lymphocytes, NK cells
or C3, C4, IgG, IgA, IgM.
;Timepoint(s) of evaluation of this end point: Day 1, Day 3, Day 7, day 10, Third Month, Sixth Month

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Main Objective: Primary Objective
To provide reliable estimates of the effect of study treatments on postoperative pulmonary complications during the COVID-19 pandemic. ;Secondary Objective: To assess the effects of study treatments on:
-Post-operative proven COVID-19 pulmonary complications
-Overall SARS-CoV-2 infected rate
-Duration of intensive care and total hospital stay
-Pulmonary function in keeping with WHO Solidarity Trial outcome scale
-Safety and tolerability of study treatments
;Primary end point(s): Trial outcomes will only be based on routinely available data. Patients will not undergo any additional investigations for trial purposes.
Primary outcome measure
The primary outcome is any one of the following COVID-19 specific, inpatient, postoperative pulmonary complications (definitions are given in an Appendix in the protocol and through brief online training):
• Pneumonia
• Acute respiratory distress syndrome (ARDS)
• Death
Definitions for each outcome are provided in the protocol. The components of the composite outcome have all been internationally validated. The feasibility of collecting these endpoints within routine care pathways has been demonstrated by our RECON cohort (11,500 patients, 4 countries).
;Timepoint(s) of evaluation of this end point: Up to 30 days following surgery

Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19
Main Objective: The primary objective is to investigate whether the administration of inhaled sargramostim (Leukine®) at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure .;Secondary Objective: - to study if early intervention with sargramostim is safe (number of AEs/SAEs)
- to study if early intervention with inhaled sargramostim affects clinical outcome defined by
duration of hospital stay, 6-point ordinal scale, clinical sign score, SOFA score, NEWS2 score
- to study if early intervention with sargramostim affects the rate of nosocomial infection
- to study if early intervention with inhaled sargramostim affects progression to mechanical ventilation and/or ARDS
- to study if treatment with sargramostim affects all-cause mortality rate at 4 and 20 weeks post inclusion
-to study if treatment with sargramostim affects features of secondary haemophagocytic lymphohistiocytosis, defined by HS score
- to study if treatment with sargramostim has a favourable effect on long term 10-20 week follow up
;Primary end point(s): To measure the effectiveness of sargramostim on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation after 5 DAYS of inhaled (and intravenous) treatment through assessment of pretreatment (day 0) and post-treatment (day 5) ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID -19 ward or ICU COVID-19 unit. Preferentially, this measurement should be done in the upright position, while breathing room air for a minimum of 3 minutes.. If this is impossible due to need for supplemental oxygen, FiO2 and oxygen supplementation method should be recorded in patient record, so that A-a gradient can be normalized for age expected normal A-a gradient while on supplemental oxygen use.
During the 5 day treatment period, we will perform daily measurements of oxygen saturation (pulse oximetry) in relation to FiO2, and the slope of alterations in this parameters could also be an indicator that our hypothesis is correct.
If the patient leaves hospital prior to the day 6 analysis point, oxygenation at day of discharge will be used as value for measuring primary endpoint.
;Timepoint(s) of evaluation of this end point: day 5

Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients
Primary outcome: complete remission of clinical signs of disease. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Negative result for COVID-19 RT-PCR test. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Results of qRT-PCR test.;Normal CT Scan. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Result of CT scan.

Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with corona virus disease-2019 (COVID-19) referring to Sina Hospital in 2020
Death. Timepoint: 3 months. Method of measurement: Number of deceased patients.

Combination therapy in COVID 19
Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data.

Interferon in treatment of COVID-19
Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.

Interferon ß in treatment of COVID-19
Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.

Effect of herbal syrup and solution in treatment of COVID-19
Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough (zero or mild) that persist for at least 24 hours. Cough will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.;Complications of the treatment. Timepoint: Daily, until the tenth day. Method of measurement: Interview and patient's record.

Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)
Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.

Effect of vitamin A in patients with COVID19
Hospitalization duration. Timepoint: until discharge from hospital. Method of measurement: Questionnaire.

?Effect of sofosbuvir/ ledipasvir on COVID-19
Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Cutaneous complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Neurological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Renal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Hematological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.

Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia
Lung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan.;Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation.;Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation.

The effect of Noscapine on clinical and pulmonary manifestations of COVID-19 patients
Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.

Effect of hydroxychloroquine on prevention of covid-19 virus
Covid-19 infection. Timepoint: One, two and three months after starting the drug. Method of measurement: Covid-19 PCR test and clinical symptoms.

Effect of Benson Relaxation on Quality of Life and job stress in nurses
Job stress. Timepoint: Before the intervention, one month after intervention. Method of measurement: Job Stress Questionnaire Osipow.;Quality of working life. Timepoint: Before the intervention, one month after intervention. Method of measurement: Work-Related Quality of Life questionnaire.

The effect of stem cell transplantation in the treatment of COVID-19
Death. Timepoint: Up to 28 days after starting the study. Method of measurement: Patient observation and evaluation of vital signs.

Remedy of human coroviruse infection with genetic nanocomposit drug
The treatment of patients with corona infection. In healthy subjects the CT image of the lungs signs an improvement of the corona contamination. Timepoint: At the beginning of the test, positive people are determined based on who tests and then the severity of disease is classified through fever and CT-pulmonary image. Then, after 8-10, the initial cases including fever and CT lungs, as well as general individuals, were analyzed. Method of measurement: CT scan.;Fever. Timepoint: At the beginning of the test, then 8 - 10 days after taking the new drug and ensuring efficacy. Method of measurement: Thermometers.

?Effect of febuxostat against coronavirus
CT-scan findings. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: CT-scan.

Persian Medicine Products in Covid-19
Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: respiratory Count.

ReciGen for treatment of Covid-19
Hospital stay. Timepoint: discharge date. Method of measurement: checklist.;Need for ICU admission. Timepoint: discharge date. Method of measurement: check list based on treating clinicians judgment.;Need for intubation. Timepoint: discharge date. Method of measurement: check list based on treating clinicians judgment.

The effect of dental pulp mesenchymal stem cells in treatment of corona disease
Pulmonary Condition. Timepoint: Before intervention and 14, 28 days after intervention. Method of measurement: CT scan.;Expression of nucleic acid of virus. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: real time PCR.;Lymphocytes count. Timepoint: Before intervention and 14 and 28 days after intervention. Method of measurement: Flowcytometry.;Patients clinical signs. Timepoint: before intervention and 14 and 28 days after intervention. Method of measurement: Observation.

Effect of Licorice in COVID-19
Patient discharge. Timepoint: Daily. Method of measurement: Yes or no.;Increase or decrease of respiratory rates more than 25% of primary respiratory rate. Timepoint: Daily. Method of measurement: Respiratory rate in minute.;Myocardial Infarction or unstable angina. Timepoint: Daily. Method of measurement: Yes or no.;Rising of creatinine more than 25% primary creatinine. Timepoint: Daily. Method of measurement: milligram in deciliter.;Patient death. Timepoint: Daily. Method of measurement: Yes or no.

Evaluation the Efficacy and Safety of Tocilizumab in COVID-19
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.

Effect of metformin in COVID-19 symptom improvement and death
Decreased hospitalization period. Timepoint: at baseline and discharge time. Method of measurement: counting the day.;Mortality rate. Timepoint: at baseline and discharge time. Method of measurement: observation.;Decreased need for intubation. Timepoint: at baseline and discharge time. Method of measurement: observation.

Study of the metformin effect on the survival and recovery rate of patients with COVID-19
Decreased need to hospitalization. Timepoint: 2 weeks. Method of measurement: obsevation.;Decreased mortality. Timepoint: 2 weeks. Method of measurement: observation.

The effect of Trachyspermum copticum syrup on clinical manifestations of patients with COVID-19
Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.;The rate of lung inflammation. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: CT SCAN.

Comparison of efficacy of oral Levamisole and Formoterol+Budesonide inhaler with standard treatment of Corona infection.
Response to treatment in Lymphocytes count. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Response to treatment for COVID-19 specific PCR test. Timepoint: Days 0-3-7. Method of measurement: Using PCR apparatus.;Response to treatment in O2 level and CO2 level in ABG or VBG test. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Chest CT-Scan response to treatment including dispersion size of Ground Glass area, bronchitis and consolidation. Timepoint: Days 0-3-7. Method of measurement: CT scan apparatus.

Treatment of patients with Corona virus infection
Number of admission days. Timepoint: every day. Method of measurement: Number of days.;The mortality rate in COVID-19 patients. Timepoint: Everyday. Method of measurement: Number of death.;Assessment of potential side effects. Timepoint: Every day. Method of measurement: Inspection for potential side effects.

Evaluation of the effectiveness of Ipecac homeopathic remedy in control of Clinical manifestations of COVID-19
Fever. Timepoint: The first day, the second day, the third day. Method of measurement: Check body temperature with thermometer.;Cough. Timepoint: The first day, the second day, the third day. Method of measurement: Physician report.;Shortness of breath. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Chills. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;Myalgia. Timepoint: The first day, the second day, the third day. Method of measurement: Patient Report.;O2 arterial blood saturation. Timepoint: The first day, the second day, the third day. Method of measurement: Pulse Oximeter Report.;Number of lymphocytes. Timepoint: The first day, the second day, the third day. Method of measurement: Blood test.;Serum CRP. Timepoint: The first day, the second day, the third day. Method of measurement: Blood test.

Study of the effect of vitamin C in patients with Covid-19
Number of hospital days. Timepoint: Daily since hospitalization time. Method of measurement: Based on patient's file.

Convalescent Plasma therapy for COVID-19 Patients
Improving Respiratory function of patients. Timepoint: Every 24 hours. Method of measurement: Clinical and, Para-clinical.

Evaluation of the effect of traditional Iranian medicine product on improvement of clinical menifestation of COVID -19
Response to the treatment (Significant clinical improvement). Timepoint: At baseline and daily. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2 ° C), respiratory rate (=24 breaths per minute), oxygen saturation (> 94% at room temperature) and cough ; dyspnea ; headche and dirrhea that will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.

Effect of Fingolimod for treatment of COVID-19-induced cytokine storm
Improvement of the symptoms of lung, pulmonary infiltrates. Timepoint: At baseline (before intervention) and 2 day after drug administration. Method of measurement: Lung CT scan.;Decreased hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: counting the hospitalization days.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: observation.;Need for intubation. Timepoint: period of hospitalization. Method of measurement: observation or reading of hospitalized documents.

Mesenchymal Stem Cell therapy in COVID19
Respiratory function of patients. Timepoint: Every 24 hours after MSC infusion. Method of measurement: Clinical, lab test , CT scan.

Investigating the effectiveness of psychological interventions on mental health
Anxiety,. Timepoint: Before the intervention, immediately after the intervention. Method of measurement: Health Anxiety Assessment Questionnaire.;Depression. Timepoint: Before the intervention, immediately after the intervention. Method of measurement: Hospital Anxiety-Depression Index Questionnaire.

Effects of High-dose Vitamin C on COVID-19
Time to clinical improvement (TTIC). Timepoint: day 0, 5, at discharge. Method of measurement: assessing respiratory rate, blood oxygen saturation, fever.;Time to clinical improvement (TTIC) of NEWS2 (National Early Warning Score 2) of 0 maintained for 24 hours. Timepoint: day 0, 5, at discharge. Method of measurement: NEWS2 (National Early Warning Score 2) questionaire.

Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19
Improvement in SpO2 (increasing in level of SpO2 to levels higher than 90%). Timepoint: After finishing the intervetion. Method of measurement: By Pulse oximeter.

Evaluation of the effects of Losartan in patients with corona virus disease 2019
Mortality. Timepoint: 28 days. Method of measurement: Number of death.;Performance of patients. Timepoint: Primary and 14 days after. Method of measurement: Sequential Organ Failure Assessment (SOFA) Respiratory Score.;Length of hospitalization. Timepoint: 28 days. Method of measurement: Days between admission to discharge.;Laboratory Findings. Timepoint: Primary and 14 days after. Method of measurement: Laboratory methods.

Hemoperfusion in patients with COVID-19
Improving the general condition of the patient. Timepoint: Before intervention and one week after the third session of hemoperfusion. Method of measurement: No need to receive any intensive respiratory care in the patient.

supplementation in COVID-19
WBC, CRP, IL6,TNF-a, IFN-G ? ESR. Timepoint: Before and after intervention. Method of measurement: Laboratory blood test.;Intensity of pulmonary involvement. Timepoint: Before and after intervention. Method of measurement: CT scan.;Mortality. Timepoint: Before and after intervention. Method of measurement: Observation.

Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia
efficacy
Time to alleviation of body temperature, SpO2, and chest image findings, and time to SARS-CoV-2 RT-PCR negativity.

Favipiravir in patients infected with COVID-19
expected value and 95% CI of ratio of C-reactive protein before versus after the treatment

Risk factors of death from coronavirus disease 2019

Multicenter prospective cohort study evaluating outcome of COVID-19 in patients with hepatobiliary-pancreatic disease

Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized controlled trial
All cause death (odds ratio). Viral clearance on day 7

'' The Abdominal Crunch Position for COVID-19 Patients ''

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19
Size of lesion area by chest radiograph or CT;Side effects in the MSCs treatment group

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
Time to Clinical recoveryTime to Clinical Recovery (TTCR)

A Trial of Remdesivir in Adults With Severe COVID-19
Time to Clinical Improvement (TTCI) [Censored at Day 28]

Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

NK Cells Treatment for COVID-19
Improvement of clinical symptoms including duration of fever;Improvement of clinical symptoms including respiratory frequency;Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0

Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19
Determine the number of Covid-19 patients who were unable to complete SCE Therapy

COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic
Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff

Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)

Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.

Non-contact Endoscopy at Covid-19 Outbreak

COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir

The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients

Simple, Safe, Same: Lung Ultrasound for COVID-19
Lung ultrasound grading system for COVID-19 pneumonia

Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus
Rate of recovery from positive to negative swaps;Fever to normal temperature in days;Resolution of lung inflammation in CT or X ray

Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry
ICU and hospital mortality of COVID-19 patients

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Survival without needs of ventilator utilization at day 14.;WHO progression scale <=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14;WHO progression scale at day 4

DIgital Online SuPport for COVID-19 StrEss
Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score

"COVID-19 and Diabetes Outcomes"
Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19

Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients

Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19

Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
Time to improvement on a 7-point ordinal scale as compared to baseline

A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research

Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
Proportion of patients requiring ICU admission at any time within the study period.

Protective Role of Inhaled Steroids for Covid-19 Infection
Time (in days) to clinical improvement within 30 days after randomization

Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage
To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/;To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/

Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Chloroquine for Mild Symptomatic and Asymptomatic COVID-19
change in virus duration (viral shedding);change in the number of patients going from asymptomatic to moderately disease

Treatment of SARS Caused by COVID-19 With Ruxolitinib

Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)
Physical Activity Scale for the Elderly;Nottingham Health Profile;Loneliness Scale for the Elderly

COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology
Risk Factors for severe infection;Immunulogical mechanisms;Long term outcome

Rutgers COVID-19 Cohort Study

Impact of Covid-19 in Congenital Heart Disease
Prevalence of Covid-19 infection in the overall CHD population

Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study
Accuracy of the diagnosis of interstitial syndrome by lung ultrasound;Inter-observer variability

The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients
Rates of emergency visits needing surgical consult;The ratio of severe presentations to non-severe presentations

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.;To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.;To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.;To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.

French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study

Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults
Clinical course of COVID-19;Analysis of development of antibodies to SARS-CoV-2;Estimation of viral load;Detection of viral coinfections;Measurement of cytokine and chemokine response;Characterisation of virus-host-interaction;Identification of disease patterns in proteome;Analysis of change in lymphocyte subtypes;Analysis of histological changes in severe lung disease;Detection of bacterial coinfections

CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection
Survival without needs of ventilator utilization at day 14;WHO progression scale = 5;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14;Decrease of at least one point in WHO progression scale score

Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19
positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.

University of Utah COVID-19 Hydrochloroquine Trial

Acquiring Convalescent Specimens for COVID-19 Antibodies
Number of antibodies against coronaviruses isolated and identified from patient samples

Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection
Proportion of patients with onset of severe acute respiratory syndrome (SARS)

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection
Decrease incidence of intubation by 30% or greater

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment

Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia
Depression;Anxiety symptoms;Stress related problems;Behavior and emotional problem among children and adolescents

COPING With COVID-19( CWC-19)
Change in stress level as measured by survey

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
For patients hospitalized for COVID-19 but not intubated;Primary objective for patients with COVID-19 already intubated

Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19
Time to diagnosis of COVID-19 by RT-PCR in subjects

Pyridostigmine in Severe SARS-CoV-2 Infection

Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study
Proportion of "responder" patients to prone position

CovidDB: The Covid-19 Inpatient Database
Outcome comparison between different antiviral therapies;Outcome comparisons between ventilation types;Identification of risk factors;Number of days in hospital vs. clinical classification

Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus

Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19
Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

Convalescent Plasma vs. Standard Plasma for COVID-19

Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia

Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia
The time-to-death from all causes;The time to need for mechanical ventilation (MV)

Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
Survival without ventilation (VNI or mechanical ventilation);ventilator free survival

Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort
Proportion of surviving patients without need for intubation for respiratory support

Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health

Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality
Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic

Endoscopy-related Phone Consultation During the COVID-19 Outbreak

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
number of patients with virological cure

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression
The proportion of patients requiring mechanical ventilation;Mean days of ventilation

Testing for COVID-19 Infection in Asymptomatic Persons

Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients

Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital

Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak

The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.
Spontaneous recovery or death in both groups

Spironolactone in Covid-19 Induced ARDS

Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome
IL6 concentration;IL6 concentration change from baseline value;Complement parameters;Complement parameters change from baseline values;Inflammatory cytokines baseline concentrations;Inflammatory cytokines change from baseline values

To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database

Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19

A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease

COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff
Positive IgM/IgG tests;Positive IgM/IgG tests;Positive IgM/IgG tests;Comparison of the point of care test and Elisa;Comparison of the point of care test and Elisa;Comparison of the point of care test and Elisa;Re-infection rate;Re-infection rate;IgM/IgG positive participants on follow-up test;IgM/IgG positive participants on follow-up test

CoVid-19 - Infection and Antibody Formation in the Viennese Population

Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19

Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)
Changes of oxygenation index (PaO2/FiO2);Side effects in the BM-MSCs treatment group

Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit
Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit

Telerehabilitation for Patients Diagnosed With Coronavirus
Visual Analogue Scale;Modified Borg Scale;Leicester Cough Questionnaire;Timed Up and Go;30 Second Chair Stand Test;The Beck Depression Inventory;The Beck Anxiety Inventory

Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)
International Physical Activity Questionnaire - Short Form;Nottingham Health Profile;Beck Depression Inventory;Beck Anxiety Inventory;Pittsburgh Sleep Quality Index;Timed Get Up and Go Test;Flamingo Balance Test

Implementation of Physiotherapy on COVID-19 Patients in ICU
Time of physiotherapy;Time of physiotherapy;Time of physiotherapy

A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease

Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
Presence of sHLH as determined by expert chart review by two independent reviewers;Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection;Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin > 10000 µg/L) in Covid 19 viral infection;Characterization and incidence of the hyper-inflammatory state in COVID-19

A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)

Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
Pneumonia severity index;Need for ICU admission

Preventing COVID-19 in Healthcare Workers With HCQ: A RCT

Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE
The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.

Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19

How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?

Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.

Clinical and Biological Predictors of COVID-19 Disease in Older Patients

Evaluating the Immune Response for COVID-19
Proportion of symptomatic patients with immune response (IgM/IgG/IgA);Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)

Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

BAttLe Against COVID-19 Using MesenchYmal Stromal Cells
Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate);Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate

Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.
Percentage of patients who develop severe respiratory failure.

COVID-19 Antibody Self-testing Using Virtual Point-of-care
Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result;Clinical accuracy of the rapid tests based on Clinical diagnosis;Self-test interpretation of result vs expert clinical image interpretation of result

Plasma Rich Antibodies From Recovered Patients From COVID19

Saved From COVID-19
Number of symptomatic illness in at risk healthcare workers;Number of healthcare workers with symptomatic COVID infections;Number of severe illness in at risk healthcare workers

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
Improvement in FMTVDM Measurement with nuclear imaging.

Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia
A composite score based on all-cause mortality and the number of ventilator free-days (VFD)

ICU Trial in Critical Ill COVID-19 Patients
ICU CV risk and Biomarker (e.g. Troponin)

Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.

Emotional Burden of Healthcare Professionals and Covid Infection 19

Double Therapy With IFN-beta 1b and Hydroxychloroquine

Interferon Beta 1a in Hospitalized COVID-19 Patients

Umifenovir in Hospitalized COVID-19 Patients

Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19
incidence of confirmed COVID-19;Effectiveness of BCG vaccine

Efficacy of Faviprevir in COVID-19 Treatment

Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19
Survival rate in asymptomatic subjects at inclusion

Austrian COVID-19 Registry
Documentation of natural course and the therapeutic landscape of patients with COVID-19.

Ayurveda for Flu Like Illness During Covid-19 Outbreak
Time to achieve afebrile;Severity of symptom score

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19
Tolerability of high dose HCQ as measured by HCQ dose modification;Tolerability of high dose HCQ as measured by discontinuation of HCQ;Tolerability of High Dose HCQ as measured by Adverse Events

Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)
Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2;Antibody titres to SARS-CoV-2

Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
Success rate in production of SARS-CoV-2 specific T cells from convalescent donor

Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms

Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark

CORonavirus (COVID-19) Diagnostic Lung UltraSound Study
Diagnosis of COVID-19 on lung ultrasound;Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

Influence Physical Activity Psychological Responses COVID-19 Pandemic
Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21;IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21;Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21

COVID-19 and Vaccination Attitudes
How vaccination and other attitudes are affected by COVID

Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease
Safety - Incidence of unexpected adverse events;Efficacy - Frequency of progression to mechanical ventilation;Efficacy - Changes in length of mechanical ventilation;Efficacy - Changes in length of weaning of mechanical ventilation;Efficacy - Changes in length of hospital stay;Efficacy - Changes in mortality rate

COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses
Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days

The RAPID COVID TRIAGE Algorithm

COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial

Evaluation of Dental Emergency Treatments During COVID19 Crisis
Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable

French Single Centre Experience of Critically Ill Patients With Covid 19
Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU;Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU

Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19
White blood cell counts;White blood cell counts;Lymphocyte populations;Lymphocyte populations

AiM COVID for Covid 19 Tracking and Prediction

Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection
SARS-CoV-2 infection status;Olfactory and gustatory loss

Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
Clinical complete response criteria;Clinical Partial Response criteria

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale

Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection
Endotracheal intubation during present hospitalization, recorded through chart review

COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

The RIsk Stratification in COVID-19 Patients in the ICU Registry

COVID-19 Pandemic Burden in Severe Mental Disease Patients

Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection
Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality

Chloroquine Chemorophylaxis Countermeasure against COVID-19
Number of sick days (SDS) during the study period: The number of sick days will be obtained from participants medical records as defined as the number of days deemed 'not fit for duty/work' by their reviewing medical professional, and will be compared between participants randomised to chloroquine and vitamin C.[12 weeks post-commencement of the IMP. Study to commence Apr 2020.]

AUSTRALIAN CARDIOVASCULAR COVID-19 REGISTRY (AUS-COVID)
Incidence of in-hospital cardiac complications. This data will be collected from hospital medical records.[Discharge from hospital]

Hydroxychloroquine for the Community-Based Treatment of COVID-19
Efficacy of Hydroxychloroquine in the community-based management of COVID-19 assessed by the mean daily InFLUenza Patient-Reported Outcome (FLU-PRO) illness severity score[Day 5 of treatment administration]

A Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic
Feasibility. Measured by:
1. Participant retention (in program and completion of questionnaires).
2. Usage of the Facebook group (manual calculation of the sum of comments & likes)
3. Feasibility and acceptability questionnaire (modified version of Naslund et al's (2016) Feasibility and Acceptability questionnaire) [Post intervention (week 6)];SIDAS- Suicidal Ideation Attributes Scale[Post intervention (week 6)]

Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain
Anxiety assessed by the State-Trait Anxiety Inventory (STAI)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement).];Depression symptoms by the the Beck Depression Inventory (BDI-13)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement)..];Stress by the Perceived Stress Scale (PPS-10)[Baseline (after the first exercise session), after three weeks of exercise intervention and after the self-isolation period (approximately 6 weeks after intervention commencement)..]

Retrospective Study on surgical outcomes among surgical patients during the COVID-19 (SARS-CoV-2) Pandemic
Incidence of Sars-COV-2 infection during hospital stay :
- positive rt-PCR or high clinical suspicion with typical parenchymal lesion[From day of surgery until 2 weeks post operative. If hospital stay exceeds 2 weeks, it'll be assess at hospital discharge]

Study evaluating Front-line health care workers serial blood COVID-19 antibody results in relation to symptom presentation
To determine the rate of front-line healthcare workers at Albury Wodonga Health who demonstrate SARS-CoV-2 antibody seroconversion [Monthly for six months following enrollment or until presentation of Coronavirus symptoms]

A medical records based retrospective study for the effectiveness and safety of Xi-Yan-Ping injection combined with conventional protocol in the treatment of common type novel coronavirus pneumonia (COVID-19)

the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial

A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19)

Investigation on the mental health status and intervention of the medical staff of the national rescue medical team in hubei province during the pandemic of novel coronavirus pneumonia (COVID-19)
Acute stress disorder;Anxiety;Depression;Perception of stress;The need for spiritual care;Social support;Sleep disorders;

Efficacy of Liu-zi-jue in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19): a randomized controlled trial

Lingnan Fire-Needle Therapy Improves the Quality of Life in General Population Under the Pandemic of novel coronavirus pneumonia (COVID-19): A Prospective, Randomized Controlled Trial

A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension
Improvement rate and time required for improvement (hours);Clinical status decrease by two levels;Pulmonary-related mortality;All-cause mortality;

Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19)

A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)
Virus negative time;Medication 3, 5, 7, 9, 11, 13, 15 days mouthwash (pharyngeal swab) 2019-nCOVRNA negative rate (%);

A medical records based study for epidemiological characteristics of 88 patients with new coronavirus pneumonia (COVID-19) and its impact on severe disease

A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence
Clinical symptoms include fatigue, poor appetite, abdominal distension, loose stool and so on.;

Clinical study for the potential impact of novel coronavirus pneumonia (COVID-19) on endocrine system

Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients

A medical records based study for the impact of wearing medical masks on oxygen saturation in adult surgical patients after general anaesthesia during novel coronavirus pneumonia (COVID-19) pandemic

A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia

A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period

A medical records based study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients

A retrospective study for evolution and clinical outcomes study of novel coronavirus pneumonia (COVID-19) patients

Occupational health and safety among health care personnel in a COVID-19 pandemic
1. Respiratory rate, assessed by clinical observation at baseline and at the end of the 4-hour workday
2. Oxygen saturation, assessed using a Physio LifePAK® 15 monitor at baseline and at the end of the 4-hour workday
3. Heart rate, assessed using a Physio LifePAK® 15 monitor at baseline and at the end of the 4-hour workday
4. Blood pressure, assessed using a Physio LifePAK® 15 monitor at the start of the study and at the end of the 4-hour workday
5. Tympanic temperature evaluated using a Braun ThermoScan® PRO 6000 model at baseline and at the end of the 4-hour workday
6. Weight, with the TANITA BC 545-N scale at baseline
8. Size, with the SECA 206 tape measure at baseline
9. Analytical biomarkers: pH, pCO2, pO2, cHCO3-, BE (ecf), cSO2, Na +, K +, Ca ++, Cl-, TCO2, Agap, AGapK, Hct, Hb, BE (b), Glu , Lac, BUN, Urea and Crea, evaluated using COPD Siemens Healthcare at baseline and at the end of the 4-hour workday
10. Medical history of interest, through a structured questionnaire at baseline
11. Level of physical activity using the IPAQ questionnaire at baseline

Can the Ava fertility tracker device detect early signs of COVID-19?
Occurrence of COVID-19 infection, as assessed by clinical signs, serology and/or RT-PCR testing. Date of occurrence, clinical symptoms and laboratory results will be collected. The endpoints will be collected by periodic monthly reports obtained on questioning the study participants. Participants and the treating healthcare institutions will be contacted to obtain respective information.

Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus?
Microbiologically confirmed COVID-19 (i.e. SARS-CoV-2 infection). This is a composite endpoint which includes any validated SARS-CoV-2 diagnostic assay, including detection of viral RNA and seroconversion, performed on participant viral detection samples throughout the study period or venous samples for serologic testing collected at day 0, 30, 60, 90 and 120.

The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)
1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection
2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:
2.1. Type of procedure performed
2.2. Time taken from presentation to the surgical team to intervention
2.3. Mode of referral (primary vs. secondary care)
2.4. Site of surgery – hub or spoke hospital
2.5. Imaging modalities used and timings
2.6. Emergency classification i.e. urgent/emergency/elective
2.7. Operative technique(s) and device(s) used
2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)
2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)
2.10. Documentation of changes to usual practice for this specific procedure as per surgeon’s standard protocol (type of procedure, type of anaesthetic, post-procedural destination)
3. Management of all referred urgent vascular cases using the online survey, focusing on:
3.1. Chronic Limb Threatening Ischaemia (CLTI):
3.1.1. Decision to discharge/admit/refer to a "hot"/emergency clinic
3.1.2. Decision for endovascular or open surgery first
3.1.3. Decision for best medical therapy or palliation or primary amputation
3.2. Carotid disease:
3.2.1. Number of patients managed with best medical therapy (BMT)
3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)
3.2.3. Delays to treatment due to lack of theatre/bed availability
3.3. Abdominal Aortic Aneurysm (AAA)
3.3.1. Increasing use of Endovascular repair (if applicable)
3.3.2. Changes to criteria for intervention
3.3.3. Decisions for palliation, i.e. ‘turn down’
3.4. Acute Aortic syndrome (AAS)
3.4.1. Decision to manage in non-critical care beds
3.4.2. Changes to imaging protocol at unit level
3.4.3. Decision to defer surgery

RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19 – CPAP, high-flow nasal oxygen, and standard care
Composite outcome comprising tracheal intubation or mortality within 30 days. Mortality will be reported from hospital records up until discharge and tracked after discharge. Intubation will be obtained from hospital data.

Distress and resilience of healthcare professionals during the COVID-19 (coronavirus) pandemic
COVID-19 Anxiety (adapted SARS-Anxiety-Scale) at 3 time periods of 2 weeks over 6 months

A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.
Main Objective: The aim of the study is to conduct a clinical trial of IV AAT as a prospective anti-inflammatory therapy for severely ill COVID-19 patients with ARDS requiring ICU admission.
The primary objective is to demonstrate a biological effect of IV Prolastin administered weekly at 120mg per kilogram of ideal body weight in patients with severe COVID-19 illness requiring intubation and mechanical ventilation for ARDS by reducing circulating levels of IL-6 as measured by plasma ELISA. The study sample size is sufficient to demonstrate a significant difference in patients receiving Prolastin versus patients receiving placebo.;Secondary Objective: determine the safety and tolerability of [IV Prolastin administered once at 120mg/kg of ideal body weight] and [IV Prolastin administered weekly at 120mg/kg of ideal body weight for 4 weeks], as assessed by the number of AEs and SAEs and determine the effects of [IV Prolastin administered once at 120mg per kilogram of ideal body weight] and [IV Prolastin administered weekly at 120mg per kilogram of ideal body weight for 4 weeks] on:
Physiological indices of respiratory dysfunction reflecting severity of ARDS, as measured by oxygenation index (OI), respiratory compliance
Sequential organ failure assessment (SOFA) score
Mortality
Time on ventilator in days
Circulating alpha-1 antitrypsin (AAT) levels
Circulating levels of IL-1ß, IL-8, IL-10, soluble TNF receptor 1
Development of shock
Acute kidney injury
Need for renal replacement therapy
Clinical relapse
Length of ICU stay in days;Primary end point(s): The primary effectiveness outcome measure, a continuous variable, is IL-6 in plasma as measured by ELISA.;Timepoint(s) of evaluation of this end point: day 2 , day 7, day 14, day 21 and day 28

Therapy with Inhaled Nitric Oxide for Patients Infected with Coronavirus Suffering form Lung Failure
Main Objective: To assess the rate of change in oxygenation
;Secondary Objective: To assess an improvement in survival, organ damage and weaning from mechanical ventilation in SARS-CoV-2 patients. This would indicate an effect that cannot be addressed only the amelioration of V/Q mismatching in the course of a disease characterized by pneumonia and, in most severe cases, multiorgan failure.
To assess the time at which a patient is negative for SARS-CoV2, reflective of a possible antiviral effect.;Primary end point(s): Difference in oxygenation between the two groups;Timepoint(s) of evaluation of this end point: 48 hours

COVID-19: addition of azithromycin to chloroquine treatment
Main Objective: Does addition of azithromycin to standard chloroquine treatment result in a higher clinical cure rate at day 7 than treatment with chloroquine alone in patients with COVID-19.
Cure is considered when 4 criteria are present:
(1) O2 sat > 94% with room air
(2) 24 hours without fever (=38°C)
(3) Breathing frequency < 24/min
;Secondary Objective: Does addition of azithromycin to standard chloroquine treatment result in a higher viral clearance rate at day 7 confirmed by a negative COVID-19 PCR than treatment with chloroquine alone in patients with COVID-19.;Primary end point(s): The initial response to treatment will be evaluated during admission.
Cure is considered when 3 criteria are present:
The percentage of patients with clinical cure at day 7 will be calculated
;Timepoint(s) of evaluation of this end point: days of admission to day of discharge
primary endpoint will be determined at day 7

A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.
Main Objective: The study that chlorchine phosphate used outpatient and standard symptomatic treatment in combination with telemedical care in patients with SARS-CoV-2 infection with a higher risk of complications in the COVID-19 treatment, not requiring hospitalization - compared to standard symptomatic treatment used under isolation (during home quarantine or in isolation) in combination with telemedical care - prevents COVID-19 hospitalization and death of any cause in 15-day observation.;Secondary Objective: Not applicable;Primary end point(s): Hospitalisation due to COVID-19 or death for any cause in 15-day observation (up to and including the 15th study);Timepoint(s) of evaluation of this end point: Day 15 (the day after the 14-day treatment cycle)

Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.
Main Objective: Evaluate the impact of sarilumab on the progression of COVID 19-associated respiratory failure as measured by the change in a severity rating on a 7-point severity index.;Secondary Objective: 1. Assess the impact of sarilumab on markers of systemic inflammation and the coagulation cascade in the context of COVID-19.
2. Assess the impact of sarilumab on mortality caused by COVID-19.
3. Assess the impact of sarilumab on oxygenation.
4. Evaluate the safety of sarilumab in patients with severe pneumonia caused by COVID 19.;Primary end point(s): - Change in a severity rating on a 7-point ordinal scale
7-point Ordinal Scale:
1. Death
2. Hospitalized, on invasive mechanical ventilation or ECMO
3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
4. Hospitalized, requiring supplemental oxygen
5. Hospitalized, not requiring supplemental oxygen – requiring ongoing medical care (COVID-19 related or otherwise)
6. Hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care
7. Not hospitalized;Timepoint(s) of evaluation of this end point: Time Frame: day 15

Study of antithrombin as prophylaxis of acute respiratory disease in patients with COVID-19
Main Objective: Decrease the risk of developing ARDS and death in high-risk COVID-19 patients;Secondary Objective: - To evaluate the improvement in oxygenation at 12, 24, 48, 72 and 96 hours.
- To evaluate the improvement in analytical risk parameters for ARDS at 24, 48 and 72 hours.
- To evaluate the radiological improvement.
- To evaluate the rate of need for non-invasive and invasive mechanical ventilation.
- To evaluate the time of use of mechanical ventilation.
- To evaluate the mortality rate in hospital and one month after the pharmacological intervention.
- To reviews the safety profile of the established treatment.
- To Deepen in the anti-inflammatory mechanisms of AT.;Primary end point(s): Combined variable: mortality or worsening rate with need for non-invasive mechanical ventilation or with need for invasive mechanical ventilation.;Timepoint(s) of evaluation of this end point: Daily.

Clinical trial of Sarilumab in adults hospitalized with COVID-19
Main Objective: Decrease cases of ARDS in adults requiring HFNO or either non-invasive or invasive mechanical ventilation;Secondary Objective: To reduce crude mortality at 28 days
To reduce the time (in days) to clinical improvement
To reduce the time (in days) until improvement in oxygenation for at least 48 hours
To reduce the proportion of patients who require invasive mechanical ventilation
To study the effect of the drug on the negativization of the PCR to COVID-19
To study the effect of the drug on the profile of cytokines
To study the safety of the experimental drug;Primary end point(s): Proportion of patients requiring or time (in days) until required:
- High flow nasal oxygenation (HFNO)
- Non-invasive mechanical ventilation type BiPAP
- Non-invasive mechanical ventilation type CPAP
- Invasive mechanical ventilation;Timepoint(s) of evaluation of this end point: At day 28 or when the subject is discharged (whichever occurs first)

OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE
Main Objective: The aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission criteria.;Secondary Objective: Not applicable;Primary end point(s): referral from a Primary Care health professional, will be evaluated when they present symptoms of low respiratory tract, persistent cough, dyspnea, tightness in the chest, or for reappearance of fever, worsening or lack of improvement, after several days of previous clinic (general malaise, fever, upper tract symptoms, diarrhoea...).
In the Emergency Department, the established triage and action procedure will be performed, which includes confirmation of the infection by PCR or determination of Ag (as established by the health authorities). Patients with a confirmed diagnosis of infection in previous days, and who have not received other treatment that is not symptomatic, will also be included.
Variables to be determined include: auscultation, O2 saturation and/or blood gas and Chest x-ray, CBC, including inflammation markers and blood biometrics, ECG.
Depending on the results:
If the patient is an admission subsidiary, he is not included in the study.
If the patient can be managed on an outpatient basis, meets all the criteria for inclusion and none for exclusion, data will be taken from the data collection sheet by the person responsible, verbal informed consent will be requested in front of witnesses and recorded in the medical record, and treatment will be assigned according to 1:1 randomization (established by order of inclusion).
Group 1. Symptomatic treatment (paracetamol 1 g on demand) + Hydroxychloroquine + Azithromycin x 5 days
Group 2. Symptomatic treatment + Hydroxychloroquine + Azithromycin + Prednisone
The main result is admission after 30 days. Secondary outcomes are 30-day ICU admission and hospital stay. The safety variable will be the occurrence of outbreaks of steroid-related psychosis. All analyses will be by intention to treat.;Timepoint(s) of evaluation of this end point: Telephone follow-up for 2 weeks according to the protocol established in Primary Care. If favourable evolution, 14 days later auscultation and sat O2. Throughout the follow-up, decisions will be made to refer the patient to the Emergency Department or to modify the action, at the discretion of the physician in charge. If the evolution is favorable, a chest X-ray will be performed per month.

Study for the prevention of COVID-19 infection in healthcare personnel
Main Objective: To assess the efficacy of hydroxychloroquine preventive administration in healthcare personnel with risk of exposure to COVID-19 infected patients.;Secondary Objective: To assess the safety and tolerability of preventive use of hydroxychloroquine in healthcare personnel.;Primary end point(s): - Decrease of the contagion rate measured by RT-PCR of healthcare personnel who attends SARS-CoV-2 infected patients from 9% in control group to 3% in experimental group.
- Decrease of the incidence of coronavirus disease (COVID-19) in the healthcare personnel who attends SARS-CoV-2 infected patients from 9% in control group to 3% in experimental group.;Timepoint(s) of evaluation of this end point: At the end of treatment (day 60)

A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC
Main Objective: Cumulative number of SARS-COV-2 infections as verified by PCR from routine nasal swabs performed every 28 days (symptomatic or asymptomatic) at week 12 after
initiation of therapy;Secondary Objective: - To evaluate the capacity of azithromycin to prevent severe COVID-19 infections, defined as a combined endpoint of hospitalization and death in cancer patients undergoing active treatment with chemotherapy
- Severity of COVID-19 cases (see grading as defined by the WHO)
- All-cause mortality
- Safety and tolerability of IMP (clinical and laboratory, CTCAE criteria)
- Occurrence of viral or bacterial infections other than COVID-19
- Development of azithromycin-resistant bacterial strains as assessed by nasal swabs
;Primary end point(s): Number of SARS-COV-2 infections (symptomatic or asymptomatic): detected by routine SARS-COV-2 tests in all patients treated at the Division of Oncology, Medical University of Vienna. During the SARSCOV-2 pandemic, the routine approach to patients undergoing
chemotherapy at our institution is PCR from nasal swabs taken every 28 days. The cumulative number of infections detected (symptomatic or asymptomatic) at week 8 after initiation of therapy in both treatment arms serves as the primary endpoint.;Timepoint(s) of evaluation of this end point: after 12 weeks

Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.
Main Objective: Efficacy of therapy with ruxolitinib (Jakavi®) in patients with severe COVID-19 infection in respirator;Secondary Objective: 1. Safety of therapy with ruxolitinib in patients severely afflicted by the COVID-19 infection
2. Efficacy of therapy with ruxolitinib in patients with the COVID-19 infections in terms of a reduction in the number of patients who need respirator support by starting treatment before the patient is deemed to urgent need for respirator support
3. To demonstrate that ruxolitinib treatment is associated with a rapid decline in inflammatory cytokines, and improvement in aberrant numbers of circulating immune cells (dendritic cells, T-cells, NK-cells, B cells) and their functionality
4. To describe the genomic (as assessed by whole blood gene expression profiling and miRNA) and proteomic changes in COVID-19 infected patients during treatment with ruxolitinib.
5. To describe the microbiome before and during treatment with ruxolitinib. ;Primary end point(s): 30-days mortality;Timepoint(s) of evaluation of this end point: 30 days

An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19
Main Objective: To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative nasopharyngeal RT-PCR for SARS-CoV-2 by day 7 post diagnosis in the HC arm compared to the no-HC arm.;Secondary Objective: Secondary objective 1: To assess the safety of HC in COVID-19 patients treated in the ambulatory setting
Secondary objective 2: To assess the clinical efficacy of HC in COVID-19 patients
Secondary endpoint 3:To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative COVIDAM, Protocol version 3.0, dated 16/April/2020 9/49
nasopharyngeal RT-PCR for SARS-CoV-2 by day 7 post onset of symptoms (POS) in the HC arm compared to the no-HC arm.
Secondary Objective 4: To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative nasal AND salivary RT-PCR for SARS-CoV-2 by day 7 post diagnosis in the HC arm compared to the no-HC arm.;Primary end point(s): proportion of participants with a negative nasopharyngeal sample* by day 7 post diagnosis
* defined by a negative RT-PCR on a nasopharyngeal swab of two subsequent study visits. The date of the first negative sample will then be taken as the date of negativity
;Timepoint(s) of evaluation of this end point: Day 7 post diagnosis

Treatment of COVID-19 patients with anti-interleukin drugs
Secondary Objective: -to investigate whether treatment with either tocilizumab, siltuximab, anakinra or combinations thereof
-improves oxygenation
-causes defervescence, measured as time to first fever-free 48h period
-improves features of secondary haemophagocytic lymphohistiocytosis
-improves features of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6 and IL-1
-affects clinical outcome in relation to IL-6 and IL-1 levels
-affects the rate of nosocomial infection
-affects progression to mechanical ventilation, high oxygen delivery device, and/or ARDS in non-ventilated patients
-affects length of dependency of ventilation in ventilated patients
-affects all-cause mortality rate at 4 and 20 weeks post inclusion
-affects long term 10-20 week follow up clinical status and lung function
-is safe (number of AEs/SAEs)
-When there is a significant association between IL-6 blockade and time to clinical improvement, tocilizumab and siltuximab will be compared versus usual care ;Primary end point(s): Time to clinical improvement (defined as the time from randomization to either an improvement of two points on a six-category ordinal scale measured daily till day 28 or discharge from the hospital or death)
1. Death
2. Hospitalized, on invasive mechanical ventilation or ECMO;
3. Hospitalized, on non-invasive ventilation or high flow oxygen devices;
4. Hospitalized, requiring supplemental oxygen
5. Hospitalized, not requiring supplemental oxygen
6. Not hospitalized;Main Objective: Study if blockade of IL-6 +/- IL-1 to block the cytokine storm and acute lung injury in comparison with usual care reduces time to clinical improvement as defined by an increase of more than 2 on the 6 point ordinal scale or discharge from the hospital;Timepoint(s) of evaluation of this end point: 28 days

Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
Number of participants with symptomatic, lab-confirmed COVID-19.

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy

Mindfulness During COVID-19

Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19
Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay

Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)
The number of interventions;Duration of interventions

COVID-19 Pandemic Response Network
Number of participants who experience inpatient admission

COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)
Clinical presentation;Disease prognosis outcomes;Pregnancy outcomes;Obstetric outcomes;Neonatal outcomes;Modes of transmission of COVID-19

Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure

Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19
Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability

Longitudinal Population-based Observational Study of COVID-19 in the UK Population

Treatment of COVID-19 Patients With Anti-interleukin Drugs

CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Survival without needs of ventilator utilization at day 14. Group 1;WHO progression scale <=5 at day 4. Group 1.;Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.;WHO progression scale at day 4. Group 2.

Convalescent Plasma for Patients With COVID-19: A Pilot Study
Change in Viral Load;Change in Immunoglobulin M COVID-19 antibodies Titers;Change in Immunoglobulin G COVID-19 antibodies Titers

Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study
Change in Viral Load;Change in Immunoglobulin M COVID-19 Titers;Change in Immunoglobulin G COVID-19 Titers

Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive
Viral nucleic acid test negative conversion rate

Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019
Changes in high-resolution computer tomography of the lung;Change in 6-minute walking distance

International COVID19 Clinical Evaluation Registry,

EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
Evaluation of EPA-FFA efficacy compared to standard of care

Study of Open Label Losartan in COVID-19
Number of participants with treatment-related adverse events as assessed by protocol definition of AE

Renin Angiotensin System - CoronaVirus
overactivity of the renin / aldosterone system

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Change of baseline total sequential organ failure assessment (SOFA) score;Improvement of lung involvement measurements;Increase of pO2/FiO2 ratio

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)

Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF
Death rate;Transfer to intensive care unit;Ventilation analysis

Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)
Time to normalize the oxygen requirement (oxygeno-dependence)

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Incidence of unexpected adverse events;Improved oxygen saturations =93%

Anti COVID-19 Convalescent Plasma Therapy

Oropharyngeal Dysphagia in Patients With COVID-19

CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
Survival without needs of intubation at day 14;Change in organ failure at day 3

Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.

A Prospective "Universal" Observational Database for COVID-19
Need for hospitalization;Duration of hospitalization;Need for ICU/Ventilator Support;Duration of ICU/Ventilator Support;Overall Survival

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

Birth Experience During COVID-19 Confinement
"Labor Agentry Scale questionnaire" score in immediate post-partum (duration of hospital stay)

Beaumont Health Large-scale Automated Serologic Testing for COVID-19
Prevalence COVID antibodies in employees of Beaumont Health

Polyvalent Immunoglobulin in COVID-19 Related ARds

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
sustained improvement (>48h) of one point on the WHO Scale

Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room
Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.

Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
Safety indexes of adverse reactions;Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule (day 0,14);Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)

ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings

HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
Sub Study 1: Patients;Sub Study 2: Health Care Workers

Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
Number of subject acquiring COVID-19 infection

Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases
Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death

COVID-19 PrEP HCW HCQ Study

Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus
clinical state as reflected by NEWS scoring;positive PCR

Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns
Seroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman

Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)
Incidence of SARS-CoV-2 infection;Incidence of COVID-19

Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)
Efficacy of captopril nebulization addition to standard of care compared to standard of care.

Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit
Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.

Computed Tomography for COVID-19 Diagnosis

Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia

Ventil Device Usefulness in Mechanically Ventilated ICU Patients
Number of cases in which it was necessary to stop using Ventil and to step- back to ventilation without this flow divider

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors
New-onset cardiac arrhythmia;Elevation of NT-proBNP;Left ventricular dysfunction

Sevoflurane in COVID-19 ARDS (SevCov)
Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28

The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)
Patient Health Questionnaire 9;Generalized Anxiety Disorder 7;Measures of adherence

COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department
Incidence of healthcare workers with SARS-CoV-2;Incidence of ENT patients with SARS-CoV-2;Development of SARS-CoV-2 antibodies among healthcare workers

Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
Percentage of serological positive healthcare workers;Percentage of HCW with positive Saliva-sabs

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19
Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment

COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma

Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)

suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)
The ratio of patients who will not develop serious respiratory failure (SRF)

Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives
State Anxiety assessed by the State-Trait Anxiety Inventory (STAI);State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)

COVID-19 Epidemic Response Study
Identification of prognostic parameters for SARS-CoV-2 infected participants.

Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19
Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19

IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.
To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Incidence of adverse events;Incidence of serious adverse reactions;Incidence of adverse reactions

Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)
Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation;Duration of hospitalisation (days);Death

WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).

Clinical Trial of Sarilumab in Adults With COVID-19

Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey

PSYCHIATRIC Disorders and Covid-19
impact of the COVID-19 pandemic on psychiatric symptomatology

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

Rhu-pGSN for Severe Covid-19 Pneumonia
Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis;Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)

COVID-19 Mortality Prediction Model
Mortality outcome in COVID-19 ICU patients;Mortality outcome in mechanically ventilated ICU patients;Mortality outcome in pneumonia ICU patients

Classification of COVID-19 Infection in Posteroanterior Chest X-rays

Baricitinib Therapy in COVID-19
To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.

Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients

Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey

Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill
Number of patients with increased disease severity

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
Mortality;Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection

Different PEEP Settings of COVID-19 Induced ARDS

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

Azithromycin in Hospitalized COVID-19 Patients

Estrogen Patch for COVID-19 Symptoms
Rate of Hospitalization;Rate of Transfer to Intensive Care Unit;Rate of Intubation;Rate of Death

Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study
Nasal epithelial transcriptional response to SARS-CoV2

Favipiravir in Hospitalized COVID-19 Patients

A Study to Explore the Role of Gut Flora in COVID-19 Infection
Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing

Sequencing and Tracking of Phylogeny in COVID-19 Study
To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples

A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment

Neurocognitive Impairment in Patients With COVID-19
Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19;Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19;Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19;Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19

Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19

Study of Hemostasis in Case of Severe COVID-19
Platelet activation intensity with the occurrence of clinical thrombotic complications

Ivermectin and Nitazoxanide Combination Therapy for COVID-19
Number of Patients with COVID-19-negative PCR

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Long Term Outcomes of Patients With COVID-19

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

Precision Immunology to Determine the Immune Response in Patients With COVID-19

Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19
Event-free survival at 28 days post-randomization between experimental group and standard of care group

Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic

Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic

The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong

Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial

Evaluation of Antibody Tests for COVID-19

The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection
CRPxN/R ratio change;Clinical deterioration by the WHO definition;PCR Viral Load;CT severity involvement index

Physical Activity in University Students Around COVID-19 Confinement
: International Physical Activity Questionnaire - Short Form;: International Physical Activity Questionnaire - Short Form;: International Physical Activity Questionnaire - Short Form

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
Number of patients with COVID-19-negative PCR

Isotretinoin in Treatment of COVID-19

Lung Recruitment Device for COVID-19

Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR

Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter

Pilot Study on Cytokine Filtration in COVID-19 ARDS

COVID-19 in Liver Transplant Recipients
Incidence of COVID19 in LT recipients;Clinical characteristics of COVID19 in LT recipients;Survival and Mechanical ventilation / respiratory support;Observed treatments and immunosuppression management

Clinical Characterisation Protocol for COVID-19 in People Living With HIV
Describe the course of COVID-19 disease in patients infected with HIV,

Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19

Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)

Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study

Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19
No increase in oxygen requirement and no increase in respiratory support measures

Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection

Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic
Significant score reduction at the Perceived Stress Scale;Significant score reduction at the Perceived Stress Scale;Significant score reduction at the Perceived Stress Scale;Significant score reduction at the Perceived Stress Scale

Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults

Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.
clinical description of covid 19 ambulatory cases.

ACCESS A Master Digital Surveillance Protocol for COVID-19
Development of population-based models of disease risk;Relation between disease burden and geolocation;Effect of medications on symptoms of COVID19;Effect of medications on disease severity of COVID19

The CEDiD Study (COVID-19 Early Diagnosis in Doctors)

Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU
Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU;Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU

Local Thermotherapy for Patients With Moderate Symptoms of COVID-19

Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19)
Exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists

COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities
Intensity of the emotional response to hypoxic exposure (14.3 et 12.7% FIO2)

Needle Stick Injuries in Emergency Medical Service Practice

The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)
Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale

Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland
21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).

EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19
Pneumonia Severity indexes;Need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support;Hospital - and ICU/HCU length of stay;In-hospital mortality;Activities of daily life, quality of life, variations in home living status and employment status;Proportion of SARS-CoV2 positive patients

ARB, ACEi, DRi in COVID-19

Progesterone for the Treatment of COVID-19 in Hospitalized Men
Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale

Convalescent Plasma for COVID-19
Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors;Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma;Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1);Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs

A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.
Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis

Cardiovascular Effects of COVID-19
Proportion of subjects with decreased left ventricular ejection fraction =10% from baseline at time of hospitalization;Incidence of Adverse Events for patients receiving AT-001

Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection

Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology
UCLA Loneliness Scale-8 (ULS-8);Patient Health Questionnaire-9 (PHQ-9);Generalized Anxiety Disorder-7 (GAD-7)

The Prone Position in Covid-19 Affected Patients
Number of patients in whom the prone position caused an increase in oxygenation

Ramipril for the Treatment of COVID-19
Composite of mortality or need for ICU admission or ventilator use

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

SARS-CoV2 in children presenting to hospital: A repeating point prevalence study during the COVID-19 pandemic in South East Queensland
The primary outcome of this study is the proportion of children who test positive for SARS-CoV2 infection by PCR testing of upper airway swabs when presenting to an Emergency Department or admitted to hospital for any reason. [This is a repeating point prevalence study. The point prevalence will be calculated for each screening day and changes analysed over the duration of the 3 month study]

Testing a wellbeing app to support wellbeing during the Covid-19 pandemic
Emotional wellbeing: assessed via the World Health Organization Five Well-Being Index (WHO-5)(Bech, Olsen, Kjoller, & Rasmussen, 2003). [Baseline, 4 weeks after baseline and 3 months after baseline];Mental Well-being: assessed by the Short Warwick-Edinburgh Mental Well-being Scale (WEMWBS)(Fat, Scholes, Boniface, Mindell, & Stewart-Brown, 2017; Tennant et al., 2007). [Baseline, 4 weeks after baseline and 3 months after baseline]

COVID-19: Can Nebulised HepArin Reduce Time to Extubation in SARS-CoV-2 patients requiring mechanical ventilation (CHARTER Study)
Time to separation from invasive ventilation, censored at Day 28, with non-survivors treated as though never separated from the ventilator. This will be assessed from review of the medical records. [Day 28]

Neonatal CoVID-19 Study to evaluate the population health impacts of COVID-19 in mothers and their newborn infants cared for in tertiary and non-tertiary hospitals in Australia.
Need for resuscitation - collected from hospital records[At birth];Type of respiratory support required after birth - collected from hospital records[First week of life];Mortality - collected from hospital records[Discharge]

START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19)
Proportion of patients confirmed as negative for COVID-19 in 2 consecutive throat/nasal swabs (taken 24 hours apart) at 15 and 16 days

Expressive writing for the reduction of psychological difficulties during the COVID-19 pandemic
Severity of psychological difficulties assessed by DASS 21 - depression, anxiety and stress scale, short version at pre-test and post-test (2 weeks)

Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients
All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study

The influence of COVID-19 pandemic on cardiovascular patients

Diagnostic value of chest CT in outpatient for novel coronavirus pneumonia (COVID-19) compared to RT-PCR
chest CT;RT-PCR;SEN, SPE, ACC, AUC of ROC;

A randomized, double-blind, controlled trial for Bu-Fei-Huo-Xue Capsule in the treatment of novel coronavirus pneumonia (COVID-19) convalescence patient with ''Fei-Pi-Qi-Xu zhen''
St George's respiratory questionnaire score;Fatigue assessment scale;Six minute walking experiment;

Developing and validating of clinical prediction model for novel coronavirus pneumonia (COVID-19) patients progressing to critical type, acute respiratory distress syndrome and death: a medical records based study

Direct evidence of rectal cancer patient infected with novel coronavirus pneumonia (COVID-19)
the virus particles by electron microscopy;2019-nCoV antigens expressions in rectum;

Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities
Detection of nucleic acid and antibody of new coronavirus ;

Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19) convalescence
syndrome scale;Record of Disease;Record of Medication;

TCM Intervention study for novel coronavirus pneumonia (COVID-19) patient during home/designate-unit isolation based on community prevention and control
COVID symptom;Intervention record of TCM treatment;Intervention record of anti-virus treatment;

Analysis of clinical features of novel coronavirus pneumonia (COVID-19): a medical records based study

A medical records based retrospective study for effect of applying individualized Chinese herbal medicine in treatment of patients with novel coronavirus pneumonia (COVID-19)
conversion rate among mild, common, severe and critical symptoms;

Early warning model and new biomarker of severe novel coronavirus pneumonia (COVID-19)
CRP, Cys, SAA, IL-6, ESR, PCT;myoglobin, troponin, lactate dehydrogenase, urea nitrogen, total bilirubin, aspartate aminotransaminase, alanine aminotransaminase;APTT, PT, fibrinogen, D-D, albumin, glucose, uric acid;white blood cell count, neutrophil count, lymphocyte count, monocyte count, platelet count, mean platelet volume;

A phase I/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells)

A medical records based retrospective study: Leukopenia is more common in asymptomatic patients less than 18 years old with novel coronavirus pneumonia (COVID-19) in convalescence

Application of pulmonary rehabilitation exercise in the treatment of novel coronavirus pneumonia (COVID-19) patients during convalescence period.

A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19)
Improvement of anxiety, depression;CAP symptoms improvement;

A study for the mental health status of novel coronavirus pneumonia (COVID-19) convalescent patients and first-line medical staff and Isolate residents and Hospital staffand the intervention strategy of psychological crisis in Ningxia

Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)
mild cases: the critical illness rate of subjects at weeks 2;Severe or critical cases: the Changes of PaO2/FiO2 from baseline to day 1, 3, 5 and 24 hours later after the last administration;Safety data of COVID-19 patients treated with ulinastatin were collected;

Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs

Clinical characteristics and death risk factors in severe novel coronavirus pneumonia (COVID-19) patients: a single-center respective analysis based on medical records

Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)

A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study
Main Objective: The primary objective of the study is to evaluate the effect of treatment on the reduction of hospitalization rate among COVID19 patients with risk factors of poor prognosis. ;Secondary Objective: To evaluate the effect of treatment on
2. Death due to COVID
3. Need for ICU stay
4. Duration of ICU stay
5. Need of mechanical ventilation
6. Duration of mechanical ventilation
7. Time to hospitalization
8. Duration of Hospital stay
9. Duration of symptoms
To evaluate the safety of the different arms
To evaluate the respiratory impairment;Primary end point(s): Hospital admission rate between D0 and Day 20 ;Timepoint(s) of evaluation of this end point: DAY 20

Early Treatment to Patients with Coronavirus (COVID)
Main Objective: In patients who are admitted urgently to hospital with coronavirus infection (COVID-19) and symptoms, treatment with virus-modifying agent Hydroxyhloroquine as well as virus-immunomodulatory and antibacterial drug Azithromycin can lead to a shorter hospitalization.;Secondary Objective: The secondary objectives are to clarify whether the patients riscs of non-invasive ventilation, intensive care unit admittance and death can be reduced by hydroxychloroquine and azithromycine treatment. ;Primary end point(s): Days alive and discharged from hospital within 14 days ;Timepoint(s) of evaluation of this end point: 15 days

A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia
Main Objective: -Early evaluation criteria: Short-term improvement at Day7 of respiratory functions through Pa02 improvement in ambient air (cohort 1: COVID-19 severe pneumonia patients who don't require hospitalization in intensive care unit) or PaO2/FiO2 improvement at Day7 (cohort 2: COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in intensive care unit )
-Late evaluation criteria: number of days living without mechanical ventilation at D28 (Ventilator-free days or VFD28) (cohorts 1 and 2);Secondary Objective: -Reduce the number of patients transferred to intensive care unit
-Decrease the duration of hospital stay
-Decrease the duration of stay in intensive care units
-Decrease mortality at D28
-Improve the SOFA (organ failure) score of patients at D7
-Do not increase the occurrence of infectious complications (bacterial or fungal infections) under treatment with avdoralimab.;Primary end point(s): - Early evaluation endpoint: Short-term improvement in respiratory function assessed by a 30% improvement in Pa02 in ambient air at D7 (Cohort 1: Patients with severe COVID-19 pneumonia not requiring management in intensive care unit) and a 15% improvement in the PaO2/FiO2 ratio at D7 (Cohort 2: Patients with COVID-19 ARDS hospitalized in intensive care unit) in the experimental arm.
- Late evaluation endpoint: 3 days improvement in ventilator-free days à D28 (VFD28) in the experimental arm (cohorts 1 and 2)
;Timepoint(s) of evaluation of this end point: -Early evaluation criteria: Day7
-Late evaluation criteria: Day28

Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study
Main Objective: To describe the pharmacokinetics of enoxaparin in resuscitation patients infected with CoV-2-SARS.;Secondary Objective: - To describe the relationship between enoxaparin concentration and bleeding risk in resuscitation patients with CoV-2-SARS.
- To describe the relationship between enoxaparin concentration and thrombotic risk in resuscitation patients with CoV-2-SARS.
- To propose optimal enoxaparin administration regimens tailored to individual patient characteristics.;Primary end point(s): Measurement of the anti-Xa activity of enoxaparin by chromogenic method.;Timepoint(s) of evaluation of this end point: daily for 30 days or until the complete decrease of drug

Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.”
COVID-BCG
Main Objective: To evaluate among health care workers exposed to SARS CoV2 protection mediated by BCG against documented COVID-19.;Secondary Objective: - To evaluate protection mediated by BCG revaccination against :
a. Severe forms of COVID-19
b. Asymptomatic forms of SARS CoV2 infection
c. Respiratory infections
d. Absenteeism.
- To evaluate safety of BCG revaccination among health care workers.
- To evaluate the impact of COVID-19 on innate immunity in the context of BCG revaccination versus controls.
;Primary end point(s): Documented COVID-19, i.e.
- symptomatic COVID-19 confirmed by either positive nasopharyngeal tests for SARS CoV2 and/or by thoracic tomodensitometry compatible with the diagnosis.
- and/or SARS CoV2 seroconversion during the study period of 6 months.
;Timepoint(s) of evaluation of this end point: 6 months

Study with stem cells from allogenic adipose tissue, in patients with coronavirus severe pneumonia
Main Objective: To evaluate the safety and efficacy of the administration of two doses of Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in severe or critical pneumonia caused by COVID-19 infection;Secondary Objective: To assess the immunomodulatory effects of MSC against the control group through changes in immune markers, using flow cytometry, collecting samples on days 1, 3, 6, and 15 days after administration of the investigational therapy.
To study the expression of coronavirus receptors in mesenchymal cells through the analysis of gene expression of the angiotensin convertase-2 enzyme (ACE-2 or ACE2) and the TMPRSS2 protease used by SARS-CoV-2 as a gateway to the alveolar cell;Primary end point(s): Safety endpoints:
Incidence of Adverse Events and Serious Adverse Events, related to the investigational drug or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).
Efficacy endpoints:
Reduction of the SARS-CoV-2 viral load by PCR on days 6 and 15.
Mortality at day 15.
Mortality at day 28.
Proportion of patients in categories 5, 6 or 7 of the ordinal scale of 7 points on days 15 and 28 days
Proportion of patients needing rescue therapy (Tocilizumab, corticosteroids, or therapies under investigation in clinical trials)
Time to get an improvement in a category since admission to the ordinal scale.;Timepoint(s) of evaluation of this end point: For safety: 12 months post-infusión
For efficacy: At baseline and at 1, 3, 6, 9, 15, 21 and 28 days after infusion, acording to the visits and assessments schedule of the trial protocol.

Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation
Main Objective: To assess the impact of plasma exchange on mortality at 28 days in patients with covid-19 disease and invasive mechanical ventilation.;Secondary Objective: 1– Evaluate survival variables
2– Time in which mechanical ventilation, vasoactive support and renal support have been necessary.
3- Days of ICU stay, days of hospitalization.
4- Evaluation of the degree of organic failure (s) by daily calculation of SOFA and APACHE score during the intervention period (from day 1 to day 7), at discharge from the ICU and from the hospital.
5- Measure the basic systemic inflammatory response.
6- Measure the inflammatory response of advanced inflammatory serum mediators.
7. Evaluate which blood components and molecular pathways are altered and the impact of plasma turnover.
8- Safety variables and adverse events related or not to treatment during its administration period.;Primary end point(s): Impact of plasma exchange on the rate and probability of survival 28 days after inclusion.;Timepoint(s) of evaluation of this end point: Impact of plasma exchange on the rate and probability of survival 28 days after inclusion.

Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19)
Main Objective: All-cause mortality at day 28;Secondary Objective: 1- To assess the safety and feasibility of WJ-MSC administration compared to placebo in the treatment of patients with SARS-CoV-2 infection and ARDS
2- Need for treatment with rescue medication
3- Need and duration of mechanical ventilation
4- Ventilator free days
5- Evolution of PaO2 / FiO2 ratio at 3, 5, 7, 14, 21 and 28 days after starting treatment
6- Evolution of the SOFA index at 3, 5, 7, 14, 21 and 28 days after starting treatment
7- Evolution of the APACHE II score at 3, 5, 7, 14, 21 and 28 days after starting treatment
8- Duration of hospitalization
9- Evolution of disease biomarkers: RT-PCR, LDH, D-dimer and Ferritin at 3, 5, 7, 14, 21 y 28 after starting treatment
10- Evolution of markers of immune response (leucocyte count, neutrophils) at 3, 5, 7, 14, 21 y 28 days after starting treatment;Primary end point(s): Number of patients who died on day +28, by treatment group;Timepoint(s) of evaluation of this end point: Day 28

Prevention and treatment with Calcifediol of respiratory problems caused by COVID-19
Main Objective: To demonstrate that in patients =18 and <90 years, positive for coronavirus, newly hospitalized with or without oxygen respiratory support, conventional or non-invasive ventilation (BIPAP type), treatment with Calcifediol will decrease the need for ventilation invasive and admissions to the Intensive Care Unit and deaths;Secondary Objective: - To assess if the treatment in newly hospitalized patients with non-invasive ventilation will decrease the time at discharge
- To evaluate in patients who require invasive ventilation and ICU admission during the process, if the treatment will decrease the number of days until the withdrawal of invasive ventilation and if it will decrease the time (in days) upon discharge from the ICU
- To assess if the treatment improves the clinical evolution
- To evaluate if the treatment improves the evolution of hematimetry & biochemistry parameters
- To assess if the treatment decreases the markers of inflammation
- To confirm that low serum 25OHD levels have a role in the negative evolution of patients to SARS
- To evaluate improvement in the O2/FiO2 Saturation ratio, improvement in the degree of dyspnea according to the Borg analog scale, improvement of radiological findings by simple radiology, improvement in transcutaneous O2 saturation and potential side effects of treatment;Primary end point(s): 1) Admission to the Intensive Care Unit or
2) Death;Timepoint(s) of evaluation of this end point: Daily throughout the subject duration in the trial.

Pilot study of bevacizumab as a treatment for respiratory distress in patients with COVID-19
Main Objective: - To evaluate the crude mortality rate at 28 days.;Secondary Objective: - To evaluate the improvement in the PaO2 / FiO2 ratio at 24 hours, at 72 hours, at 7 days, 14 days and 28 days.
- To evaluate the improvement in the degree of dyspnea at 72 hours and at 7 days according to the Likert scale (-3 to +3).
- To evaluate the improvement of the radiological findings by (simple radiology) at 72 hours and at 7 days.
- To evaluate the improvement in transcutaneous O2 saturation at 24 hours, at 72 hours and at 7 days.
- To evaluate the improvement in PaO2.
- To measure the decrease in mortality (crude rate per month).
- To evaluate the toxicity of the established strategy.;Primary end point(s): 1. Crude mortality at 28 days.;Timepoint(s) of evaluation of this end point: 28 days after the inclusion of the patient.

Study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome in adult severely ill patients with COVID-19.
Main Objective: To investigate the efficacy of vafidemstat, in combination with standard of care treatment (e.g., hidroxihidroxichloroquine, lopinavir/ritonavir, azithromycin, or any other being applied by the Hospitals according to the current guides) to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with CoVID-19.;Secondary Objective: To evaluate the tolerability of vafidemstat, in combination with standard of care treatment (e.g., chloroquine, lopinavir/ritonavir, azithromycin, or any other being applied by the Hospitals according to the current guides), to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with CoVID-19.;Primary end point(s): • Reduction in the incidence of patients (%) requiring mechanical ventilation and referral to ICU within the period from Day 1 (i.e.: first study drug administration) to Day 14
• Decrease in global mortality and mortality associated to CoVID-19 pneumonias within the period from Day 1 (i.e.: first study drug administration) to Day 14;Timepoint(s) of evaluation of this end point: 14 days

Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
Main Objective: To assess clinical efficacy of APN01 using a composite outcome of all cause-death or need of invasive mechanical ventilation up to 28 days;Secondary Objective: To assess efficacy of APN01 using log transformed levels of Lactate dehydrogenase (LDH) as a surrogate marker for organ damage.
To evaluate the safety of APN01 in patients with severe COVID-19
To monitor other biomarker changes (e.g. IL-6, AngII) in patient with severe COVID-19 treated with APN01
;Primary end point(s): The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.;Timepoint(s) of evaluation of this end point: Continioulsy over the duration of the trial

Evaluation of efficacy and safety of an tocilizumab treatment in patients with severe COVID-19 pneumonia
Main Objective: Evaluation of the efficacy and safety of a treatment with Tocilizumab in patients with severe COVID-19 pneumonia;Secondary Objective: Not applicable;Primary end point(s): • Ventilator free days (d) (VFD) in the first 28 days after randomisation
o NIV, IMV and ECMO are defined as ventilator days
o VFD=0, if the patient dies in the first 28 days after randomisation
;Timepoint(s) of evaluation of this end point: 28 days after randomisation

CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS
Main Objective: Achieving one of two goals on day 8 visit from study initiation:
• 50% reduction in symptom score for patients with lower respiratory tract infection
• Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection
Patients leaving the hospital alive before day 8 visit are considered to have reached the primary endpoint. Patients who die before the day 8 visit are considered to have failed at the primary endpoint.;Secondary Objective: • Comparison of the primary endpoint with respective patients not receiving the treatment
• Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment
• Frequency of AEs and SAEs;Primary end point(s): • Recording of co-administered drugs, vital signs, absolute blood cell count (if any), biochemical markers (if any), microbiological tests and antibiotics (if any)
• Pneumonia symptoms ratings for patients with lower respiratory infection (Appendix V)
• Recording of adverse reactions (AEs) or serious adverse reactions (SAEs);Timepoint(s) of evaluation of this end point: Days 1, 2-7, 8

A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).
Main Objective: To investigate the effect of Remdesivir and Hydroxychloroquine on all-cause in-hospital mortality in moderate and in severe COVID 19.
;Secondary Objective: - To assess the effect of Remdesivir and Hydroxychloroquine treatment on hospital duration, receipt of ventilation or intensive care, and to identify any serious adverse reactions.
- To assess the effect of Remdesivir and Hydroxychloroquine treatment on 28 days mortality, viral clearance, kidney and myocardial failure, co-infections, organ dysfunction, health-related Quality of Life and biomarkers.
- To assess safety of Remdesivir and Hydroxychloroquine on severe, life-threatening and/or serious adverse events;Primary end point(s): All-cause in-hospital mortality. ;Timepoint(s) of evaluation of this end point: During hospitalisation.

Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia
Main Objective: The aim of this study is to evaluate the efficacy and safety of convalescent anti-SARS-CoV-2 plasma, hydroxychloroquine, sarilumab and baricitinib compared with placebo in combination with standard of care (SOC) for the treatment of moderate-to-severe COVID-19 pneumonia on the basis of the composite endpoint: All-cause mortality or need of invasive mechanical ventilation up to 28 days.;Secondary Objective: Not applicable;Primary end point(s): The primary outcome is a composite endpoint: All-cause mortality or need of invasive mechanical ventilation up to 28 days.;Timepoint(s) of evaluation of this end point: Day 28

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
Time to clinical recovery after treatment;Rate of aggravation

Hypertension in Patients Hospitalized With COVID-19

The Impact of Camostat Mesilate on COVID-19 Infection
Cohort 1: Days to clinical improvement from study enrolment;Cohort 2: Days to clinical improvement from study enrolment

Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
Median release from quarantine time;Rate of hospital discharge;Rate of infection

Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel
Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)

Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
Number of patients with ICU admission;Number of patients with intubation;Number of patients with death

Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation
overall response rate in reversal of hyperinflammation

Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic

Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Time to Improvement in the 7-point ordinal scale

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19
Incidence of hospitalization for COVID-19;Incidence of symptoms associated with COVID-19

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19
Incidence of hospitalization for COVID-19;Incidence of symptoms for COVID-19

PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients

Trial of Hydroxychloroquine In Covid-19 Kinetics
Percentage of virus free subjects;Disease severity

Epidemiological Characteristics of COVID-19 in Patients With MS or NMO

Nebulised Rt-PA for ARDS Due to COVID-19
treatment efficacy - Percentage change in PaO2/FiO2 ratio;Safety as measured by bleeds;Safety as measured by other (non-bleed related) adverse events;Safety as measured by fibrinogen levels

Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19)
Therapeutic failure within 14 days of randomization

A Comparison of 3D and 2D Telemedicine During Covid 19
University Hospitals of North Northway questionnaire;Mental effort rating scale

Nebulised Dornase Alfa for Treatment of COVID-19

Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Composition of the fecal bacterial and fungal microbiota

Plasma Therapy of COVID-19 in Critically Ill Patients

Atrium COVID-19 Syndromic and Serologic Surveillance
Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina;Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina

Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial

Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)
Proportion of patients who have achieved withdrawal of invasive mechanical ventilation;Rate of mortality

Passive Immunity Trial of Nashville II for COVID-19

Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital
the incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing

Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia
Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection

Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program

Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19
Prevalence and abundance of CD4+ T lymphocytes

Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
Incidence of symptomatic COVID-19 infection in healthcare workers

NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression

Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial
Percentage of patients with a negative RT-PCR test result to COVID-19

Protective Effect of Aspirin on COVID-19 Patients
clinical recovery time (TTCR);the time of SARS-CoV2 overcasting

Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City
Clinical consequences of a Covid-19 infection in the care population

Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment
Intubation success rate during at the first laryngoscopy

NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30
Evaluation of food intake at 1 month after discharge from hospital for COVID

A Novel Nomogram to Predict Severity of COVID-19
the consistency of predicted severe rate and observed severe rate of COVID-19 patients;Duration of severe illness

Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome

Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora
Delta in the number of patients requiring orotracheal intubation despite treatment

Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers
To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy;To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy;To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy;To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy

Patient Recovery From Heart Surgery During the Covid-19 Pandemic

Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers
Incidence of SARS CoV-2 infection in healthcare workers

Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est
Composite of death and mechanical ventilation

Intravascular Access of COVID-19 Patient Under Personal Protective Equipment
successful rate of first intravascular access attempt

Repurposing of Chlorpromazine in Covid-19 Treatment

Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy
Variation of thrombin time (in secondes) in Covid-19 patients with pneumonia admitted in ICU.;Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.;Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.;Variation of concentration of fibrin and fibrinogen degradation products (= 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU.

Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact
Proportion of patients with postpartum depression defined by an EPDS score >12;Proportion of patients with postpartum depression defined by an EPDS score >12

PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)
Proportion of patients who meet one or both following criteria: need for intubation (for mechanical ventilation), occurrence of death during hospital stay.

Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients
Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO
Age;Gender;Weight;Height;BMI;Pre-existing pulmonary disease y/n;Main co-morbidities y/n;Date of signs of COVID-19 infection;Date of positive swab;Pre-ECMO length of hospital stay;Pre-ECMO length of ICU stay;Pre-ECMO length of mechanical ventilation days;Use of antibiotics;Use of anti-viral treatment;Use of second line treatment;Indications for ECMO-implant;Type of ECMO-implant;Type of access;Date of ECMO implant;ECMO blood flow rate;ECMO gas flow rate;ECMO configuration change;Date of ECMO configuration change;New ECMO configuration;Indications for ECMO configuration change;Ventilator setting on ECMO;Anticoagulation during ECMO;Frequency of ECMO circuit change;ECMO complications;ECMO Weaning;ICU discharge;Main cause of death;Type of discharge;Alive/deceased

Intravascular Access in Suspected/Confirmed COVID-19 Patient
Success rate of first intravascular access attempt

To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)
we will compare the clinical outcome of the COVID 19 patients with their age and gender

Electrocardiogram Analysis in COVID-19 Patients
Phase 1: ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection;Phase 2: Correlation between ECG signs and needs for invasive mechanical ventilation and/or mortality in the acute phase;Phase 3: Correlation between ECG signs and cardiac involvement and mortality in the chronic phase

Rapid Detection of COVID-19 by Portable and Connected Biosensor
Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team

Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Rate of elevated creatine kinase in hyperacute phase

Social Media and COVID-19
Change in DASS scores across 9 days;Changes in fear with regards the COVID-19 situation across 1 week;Changes in amount of thinking about the COVID-19 situation across 1 week

COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)
Retrospective study on individuals with or without symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis.

The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19
Changes in depression-, anxiety- and psychosomatic stress symptoms

Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19

Cardiac Injury in COVID-19: a Pathology Study
Cardiac pathological findings from series of >= 50 patients dying from COVID-19 disease;viral load in cardiac tissues and the extent of damage;Co-localize the SARS-CoV-2 using RNAscope in situ hybridization, with its entry receptor ACE2 and serine protease TMPRSS2 in different cell types found in the heart

COVID-19 Infection in Patients With Hepatocellular Carcinoma
Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY
Management of Solid Organ Transplant during COVID-19 pandemic;Equity of resource distribution

Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial

Registry to Study Factors That May Impact COVID-19 Occurrence and Severity
COVID-19 symptom occurrence and severity;COVID-19 treatments;Hospitalization

COVID-19 Immune Repertoire Sequencing
provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions.

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression
Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia

Duke COVID-19 Shared Data and Specimen Repository
Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens

Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result

Telemedicine for Follow-up of Systemic Lupus Erythematosus
The percentage of patients in remission or LLDAS at one year.

Psychological Impairment Due to Covid-19
PCL5 Questionnaire;BSI - Brief symptom inventory;PHQD;WHO - QoL BREF;STAXI;AUDIT questionnaire

Lung Ultrasound to Diagnose COVID-19
Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease

Bacteriotherapy in the Treatment of COVID-19
delta of time of disappearance of acute diarrhea

Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

Neuroradiolological Analysis of COVID-19 Patients
Neuroradiological analysis of patients brain MRI

Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness
Rate of participant recruitment;Rate of retention;Completeness of data entry;Cost of interventions;Unexpected costs

Observational Study to Assess the Seroconversion Status of Health Care Workers and Suspected or Confirmed Cases of COVID-19 Patients

ARDS Caused by COVID-19

Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Vent

Anxiety And Depression During COVID-19 IN INDIA
Prevalence (magnitude) of anxiety of general adult population during COVID-19;prevalence (magnitude) of depression and anxiety of general adult population during COVID 19

A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic
Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections

Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic

The Psychological, Social, and Economic Impacts of COVID-19
Mental health - Stress;Mental health - Anxiety;Mental health - Depression

COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
Clinical evolution of COVID-19;SARS-CoV-2 elimination;Seroconversion rate and titration

Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)

Observational Study of COVID-19 Treatment Efficacy
Mortality during the COVID-19 treatment hospital encounter;ICU admission during the COVID-19 treatment hospital encounter;Ventilator use during the COVID-19 treatment hospital encounter

Covid-19 Epidemic on Acute Stroke Management
Study of the effect of pandemic covid-19 on the management of stroke patients

Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19
Construction of a composite clinical-echo score (VIRUScore) predictive of risk of worsening respiratory impairment in COVID-19 adult patients admitted to the Emergency Department

Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia
Negative Predictive Value of Lung Ultrasound in the diagnosis of COVID-19

Provider Burnout During COVID-19

Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up
Predictive modeling of in-hospital outcome;Clinical, pathophysiological and molecular mechanisms;Short -Term Sequelae

Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers

Prevalence of COVID-19 Infection Among HCW in a French University Hospital
the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection

Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.

SEVERITY SCORE FOR COVID-19 PNEUMONIA
To identify the best predictors of critical coronavirus pneumonia and to realize a simple severity score able to early classify high-risk individuals admitted to Internal Medicine Department for COVID-19 disease, needing an intensive approach

Convalescent Plasma for the Treatment of Patients With COVID-19

Study evaluating Coronavirus (COVID-19) nasal/oral swab results compared to blood antibody results in COVID-19 clinic patients.
To determine proportion of people with nucleic acid test (NAT) negative nasopharyngeal swab for SARS-CoV-2 (nasopharyngeal NAT) while exhibiting symptoms consistent with COVID-19 disease who then develop SARS-CoV-2 antibody seroconversion prior to, and during, the development of widespread community transmission.[Approximately 14 to 28 days after developing Coronavirus symptoms]

Evaluation of a remote monitoring smartphone application and care model of COVID-19 patients in the community (ReCOVER)
Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case, using a definition based on potentially avoidable general practitioner-type presentations as specified in the National Healthcare Agreement
[12 months];All-cause mortality rate at 30 days per diagnosed COVID-19 case[30 days]

Asymptomatic novel coronavirus pneumonia (COVID-19) patients Have Longer Treatment Cycle Than Mild and Moderate Patients: a medical records based study

A randomized,double blinded, parallel controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)
On day 7 and 14, Change (reduction) in viral load from baseline;

Correlation between novel coronavirus pneumonia (COVID-19) and mental health of breast cancer patients: a cross-sectional study in Hunan Province

A Medical Records Based Study for Clinical Efficacy and Safety of ''clear lung detoxification soup'' in the treatment of Novel Coronavirus Pneumonia (COVID-19)

The effectiveness of diaphragmatic breathing relaxation training for improving sleep quality among nursing staff during the novel coronavirus pneumonia (COVID-19) pandemic: a before and after study

Clinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosis

Efficacy and safety of high-dose vitamin C combined with traditional Chinese medicine in the treatment of moderate and severe novel coronavirus pneumonia (COVID-19)

High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients

Study for the application of novel coronavirus pneumonia (COVID-19) intestinal tract toxicity in diagnosis and its prognostic effect

Follow-up study of pregnancy outcomes of novel coronavirus pneumonia (COVID-19) complicated in the first and second trimester

Study for Screening of Chinese Patent Drugs in the Rehabilitation Treatment of novel coronavirus pneumonia (COVID-19)
Qualitative RT-PCR results of SARS-CoV-2 nucleic acid of oral / nasopharyngeal swabs, anal swabs, sputum and blood ;

A global registry of women affected by COVID-19 in pregnancy and their babies, to guide treatment and prevention
1. Confirmed SARS-CoV-2 infection in women in pregnancy or their neonates, measured using routine clinical data from 01/01/2020 to 31/03/2021
2. Suspected SARS-CoV-2 (defined as woman self-isolating for suspected COVID-19 with symptoms, symptoms will be recorded) measured using routine clinical data from 01/01/2020 to 31/03/2021

Efficacy of captopril in Covid-19 patients suffering of pneumonia
Main Objective: To demonstrate the efficacy of captopril nebulization addition to standard of care compared to standard of care in term of 14-day ventilation free survival;Secondary Objective: To demonstrate the efficacy and safety of captopril nebulization:
- Efficacy :
• Mortality at 28 day
• Need of invasive mechanical ventilation (IMV) at 28 days
• Length of hospitalization
• Length of stay in ICU
• Length of mechanical ventilation
- Safety :
• Respiratory tolerance
• Hemodynamic tolerance
• Metabolic tolerance
• Renal tolerance
• Skin tolerance;Primary end point(s): 14-day invasive mechanical ventilation free survival: defined as the proportion of patients requiring IMV or dying between randomization and Day 14;Timepoint(s) of evaluation of this end point: 14 days

Evaluation of a combination of Masitinib and Isoquercetin in the Treatment of Hospitalized COVID-19 Patients.
Main Objective: To compare the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients
;Secondary Objective: Secondary objectives are to assess the safety and efficacy of the combination of Masitinib and Isoquercetin in the patients under study by evaluating various parameters related to clinical status. ;Primary end point(s): • Clinical status of patients at day15 using the 7-point ordinal scale.
The 7-point ordinal scale for clinical status is: 1. Not hospitalized, no limitations on activities; 2.Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.
;Timepoint(s) of evaluation of this end point: Day 15

Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit
Main Objective: To show the interest of treatment with losartan and spironolactone in patients infected with COVID-19 and suffering from acute respiratory distress syndrome on the impact of organ failures judged on the SOFA score on the 7th day post-inclusion;Secondary Objective: Show the interest of ARA2 / Spironolactone treatment on organ failures judged on the SOFA score on the 3rd, 14th, 21st, 28th day post-inclusion.
Show the interest of ARA2 / Spironolactone treatment on oxygenation based on the PaO2 / FiO2 ratio.
Show the interest of ARA2 / Spironolactone treatment for the duration of mechanical ventilation.
To show the interest of ARA2 / Spironolactone treatment on mortality.
Evaluate the clinical and biological tolerance of these treatments.;Primary end point(s): Organ failures will be assessed on the SOFA score;Timepoint(s) of evaluation of this end point: 7th day post-inclusion

Study of efficacy and safety of canakinumab treatment for CRS in participants with COVID-19-induced pneumonia.
Main Objective: To demonstrate the benefit of canakinumab + SOC in increasing chance of survival without ever requiring invasive mechanical ventilation among patients with COVID-19-induced pneumonia and CRS.;Secondary Objective: - To demonstrate the benefit of canakinumab in reducing 4-week case fatality rate (CFR) among patients with COVID-19-induced pneumonia and CRS regardless of other subsequent clinical interventions
- To evaluate change in clinical serologic measurements related to CRS in COVID-19 patients with pneumonia
- To evaluate safety of canakinumab in patients with COVID-19-induced pneumonia and CRS.;Primary end point(s): Clinical response, defined as survival without ever requiring invasive mechanical ventilation from Day 3 (inclusive) up to Day 29 (inclusive). ;Timepoint(s) of evaluation of this end point: Day 29

Low-molecular-weight heparin to prevent venous thromboembolism in COVID-19 patients : a randomized controlled trial of different doses
Main Objective: To evaluate the effectiveness, during the hospitalization, of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism, causing death or not, in coronavirus 19 patients hospitalized in medical care units or intensive care units;Secondary Objective: To evaluate the effectiveness of a weight-ajusted increased prophylactic dose of low molecular weight heparin, compared with a lower prophylactic dose, on :
1a. Major bleeding,
1b. Major and clinical relevant non-major bleeding,
2. Net clinical benefit corresponding to the association of venous thromboembolism and major bleeding
3a. Venous thrombosis at other sites than the primary outcome,
3b. Symptomatic arterial thrombosis
4. All-cause mortality
5. Primary outcome in predefined sub-groups (eg. renal function)
6. To identify variables associated with the risk of venous thromboembolism
;Primary end point(s): The primary endpoint is the onset of a symptomatic venous thromboembolic event, during the hospitalization stay (and limited to D28 of hospitalization), as defined by a:
- Symptomatic deep venous thrombosis, whatever the site and confirmed by a compression ultrasonography or an abnormal computed tomography angiogram with venous opacification
or
- Symptomatic pulmonary embolism, confirmed by:
• a computed tomography angiogram,
• or a V/Q scan,
• or the presence, in a patient with a recent worsening dyspnea, of a deep venous thrombosis and/or a right ventricular dysfonction diagnosed by a transthoracic echocardiography in an unstable patients unable to benefit from a CT angiogram (2019 European Society of Cardiology Guidelines)
- Unexplained death when a pulmonary embolism cannot be excluded.
The primary endpoint is a composite measure of clinical events and/or survival, as recommended by the WHO guidelines on COVID-19 Therapeutic Trial Synopsis (february, 2020).
For each included patient, the onset of each event considered in the composite primary endpoint will be evaluated by a blinded independant endpoint adjudication committee. ;Timepoint(s) of evaluation of this end point: Between the trial inclusion and the hospitalization discharge (with a limitation of 28 days of hospitalization)

"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19
Main Objective: Evaluation of the efficacy of polyvalent IVIg in combination with the standard management of patients aged 75 and over with SARSCov2 infection with acute respiratory failure (saturation = 95%) requiring oxygen therapy> 5 L / min (i.e. patients considered as moderate to severe ARDS according to the Berlin definition, Pa02 / Fi02=200)
and disqualified from a care in the ICU.;Secondary Objective: Evaluate the consequences of treatment with immunoglobulins on
- The length of hospital stay
- The duration of oxygen therapy (oxygen dependence)
- The evolution of the parameters of inflammation
- Lung function and overall physical condition at 3 and 6 months
- The quality of life at 3 and 6 months
- The rate of death and re-hospitalization at 3 and 6 months;Primary end point(s): Mortality;Timepoint(s) of evaluation of this end point: On D14 of treatment D1

Curosurf® in Adult Acute Respiratory Distress Syndrome – 1
Main Objective: To show that the drug as used in this procedure improves blood oxygenation (PaO2/FiO2). ;Secondary Objective: To assess the impact of this procedure on improving the respiratory state and its duration: oxygenation, weaning time from mechanical ventilation, survival.;Primary end point(s): Primary outcome: PaO2 / FiO2 ratio increase between before and one hour after procedure.

EFFICACY OF INTRAVENOUS ALMITRINE IN REDUCING THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE DUE TO COVID-19-RELATED PNEUMONIA: A RANDOMIZED CONTROLLED DOUBLE-BLIND STUDYFROM THE SKIP-ICU CONSORTIUM
Main Objective: To assess the efficacy of 5-day almitrine therapy (2 µg.kg-1.min-1) in reducing the need for mechanical invasive ventilation in patients with hypoxemic respiratory failure due to COVID-19-related pneumonia at seven days;Secondary Objective: To assess the efficacy of intravenous almitrine in reducing:
-in-hospital mortality
-28-day all-cause mortality
-duration of mechanical ventilation
-hospitalization rate in the ICU
-length of stay in the ICU
-hospital length of stay
To assess safety and side effects of intravenous almitrine
;Primary end point(s): Endotracheal intubation within 7 days after randomization. Death will be considered as a failure (endotracheal intubation).;Timepoint(s) of evaluation of this end point: Day 7

A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe
Main Objective: To determine whether early intervention with either a combination of hydroxychloroquine, azithromycin and zinc or favipirivir improves time to significant improvement in clinical status.;Secondary Objective: To assess whether early intervention with Favipiravir or the combination of Hydroxychloroquine, Zinc and Azithromycin improves mortality in patients with COVID-19 infection
To determine whether early intervention with Favipiravir or the combination of Hydroxychloroquine, Zinc and Azithromycin reduces resource utilisation in patients with COVID-19 infection
To explore whether early intervention with Favipiravir or the combination of Hydroxychloroquine, Zinc and Azithromycin attenuates the excessive inflammatory cytokine response in patients with COVID-19 infection
;Primary end point(s): Time to clinical improvement (post randomisation) by two points on a seven-category ordinal scale or live discharge from the hospital, whichever comes first
The seven-category ordinal scale:
1: Not hospitalised with resumption of normal activities
2: Not hospitalised, but unable to resume normal
3: Hospitalised, not requiring supplemental oxygen
4: Hospitalised, requiring supplemental oxygen
5: Hospitalised, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation or both
6: Hospitalised, requiring ECMO (Extra-corporal membrane oxygenation), invasive mechanical ventilation or both
7: Death
;Timepoint(s) of evaluation of this end point: Data for assessment of primary endpoint will be collected until discharge from inpatient care, 28 day from enrolment or death.

Study of investigational medicinal product of CYT107 in patients with COVID-19 infection who have low number of lymphocytes in their blood (ILIAD 7 trial)
Main Objective: The primary objective of the Study is to improve the absolute lymphocyte count (ALC) of lymphopenic (ALC=700/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever comes first.;Secondary Objective: a) To obtain “clinical improvement” as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD
b) To determine if CYT107 will lead to a significant decline of SARS-CoV-2 viral load through day 30 or HD
c) To compare the incidence of grade 3-4 adverse events for CYT107 versus placebo through day 45
d) To compare the effect of CYT107 versus placebo on the frequency of secondary infections through day 45
e) To compare the effect of CYT107 versus placebo on the length of hospitalization
f) To compare the effect of CYT107 versus placebo on the length of stay in ICU
g) To compare the effect of CYT107 versus placebo on readmissions to ICU
h) To compare the effect of CYT107 versus placebo on organ support free days
i) To compare the effect of CYT107 versus placebo on the frequency of re-hospitalization through day 45
j) To assess the impact of CYT107 on all-cause mortality through day 45
AND objectives k, l, m and n
;Primary end point(s): An improvement in the absolute lymphocyte count (ALC) is defined as a statistically significant increase from randomization to day 30 or HD, and will also be assessed at defined timepoints (as indicated in the Schedule of Activities, to include all Study drug administration days).;Timepoint(s) of evaluation of this end point: Day -1, 0, 1, 3, 6/7*, 9/10/11*, 12-18*, 21, 30/Hospital discharge *Day for drug administration per PI discretion with 5 doses to be administered over approx. 2 weeks

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease
Main Objective: To assess the time from randomization until an improvement defined as two points on a seven point ordinal scale or live discharge from the hospital in high-risk patients with SARS-CoV-2 infection requiring hospital admission by infusion of plasma from subjects after convalescence of SARS-CoV-2 infection or standard of care.;Secondary Objective: 1. To assess overall survival, and the overall survival rate at 28, 56 and 84 days.
2. To assess SARS-CoV-2 viral clearance and load, cytokine changes over time as well as antiviral antibody titers.
3. To assess percentage of patients that required mechanical ventilation.
4. To assess time from randomization until discharge.;Primary end point(s): Time to clinical improvement by two points on
a seven point ordinal scale or live discharge from the hospital.;Timepoint(s) of evaluation of this end point: Treatment response is assessed continuously until day 28, thereafter weekly until day 56,
70 and finally at day 84.

Sinus-Wash Pilot Study
Main Objective: Does Povidine-Iodine reduce the amount of virus in the nose and throat when applied via a sinus rinse/mouth wash?;Secondary Objective: Does Povidine-Iodine as a nose rinse/mouthwash reduce transmission of the virus to co-residents?
Does Povidine-Iodine reduce the symptom severity in postive individuals as reported by self reported questionnaire via smart phone app?
;Primary end point(s): The primary outcome measure will be the change in Viral load in the two arms as measured by real time PCR.;Timepoint(s) of evaluation of this end point: Day 0,2,4,7 and 14 of trial period via oral and nasopharyngeal swabs

BCG vaccination against COVID-19 infection in Hungary
Main Objective: To reduce absenteeism among healthcare workers with direct COVID-19 positive patient contacts during the epidemic phase of COVID-19. ;Secondary Objective: Secondary objectives: To reduce COVID-19 infection, hospital admission, ICU admission, or death in healthcare workers with direct COVID-19 positive patient contacts during the epidemic phase of COVID-19;Primary end point(s): Primary End Point (repeat as necessary) Number of days of unplanned absenteeism because of documented COVID-19 infection ;Timepoint(s) of evaluation of this end point: End of study

CLARITHROMYCIN IN COVID-19
Main Objective: Recent information appearing from different countries suggest that treatment of Covid-19 with hydroxychloroquine or with a combination of hydroxychloroquine and azithromycin has either an indifferent effect on viral replication or substantial cardiotoxicity. This is a clinical trial aiming to prove that addition of oral clarithromycin to treatment regimen of Covid-19 is associated with early clinical improvement and attenuation of the high inflammatory burden of the host. The study will not comprise a placebo-comparator group since this is considered inappropriate in an era of a pandemic with substantial global mortality.;Secondary Objective: Not applicable;Primary end point(s): This is defined on day 8 (EOT visit). This is a composite score since it is defined differently for patients with upper respiratory tract infection or lower respiratory tract infection by SARS-CoV-2.
• For patients with an upper respiratory tract infection this is defined as no need for hospital admission in case of earlier discharge or as lack of progression into lower respiratory tract infection.
• For patients with a lower respiratory tract infection this is defined as at least 50% decrease of the score of respiratory symptoms from the baseline. This score is the sum of scoring for the symptoms of cough, dyspnea, purulent sputum expectoration and pleuritic chest pain.
Patients who develop by day 8 severe respiratory failure do not meet the study primary endpoint;Timepoint(s) of evaluation of this end point: Day 8

Discontinuation of ACE inhibitors in patients with COVID-19 infection
Main Objective: Patients with coronary artery disease, arterial hypertension or diabetes are often treated with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). Treatment with ACEI and ARB may be of great relevance for the course of COVID-19: Similar to SARS-CoV (epidemic 2002-2003), the novel SARS-CoV2 is also absorbed into human cells via angiotensin converting enzyme 2 (ACE2). Treatment with ACEI and ARB leads to a significant upregulation of the SARS-CoV2 receptor ACE2. An increased expression of ACE2 in turn correlates with a higher intake of SARS-CoV2 and possibly promotes a faster spread of the virus in the organism of infected patients.
The primary aim of the study is to test whether discontinuing chronic ACEI or ARB therapy in patients with proven SARS-CoV2 infection leads to a more favorable course of the disease of COVID-19 than the continuation of the ACEI or ARB therapy.;Secondary Objective: Secondarily, the effect of discontinuation on clinical and laboratory parameters of SARS-CoV2 therapy is examined.;Primary end point(s): Two primary endpoints are tested hierarchically:
Primary endpoint 1 is the combination of the maximum SOFA scores measured during the course of the disease (=30 days) and death. The minimum SOFA score is 0 and the maximum is 24. In the event of death, the patient receives the maximum value of 24 points. Patients in the ambulant setting receive a value of 0. Patients in the stationaire setting who are not ventilated receive 0 points for the parameter "Respiration" (variable PaO2 / FiO2). Clinical trials have demonstrated that the maximum SOFA score correlates with mortality.
Primary endpoint 2 is the combination of a combination of intensive care admission, intubation and death.;Timepoint(s) of evaluation of this end point: During the course of the disease (=30 days ±2 days)

Control of inflammatory parameters with fish oil in parenteral nutrition
Main Objective: In critically adult patients with parenteral nutrition with liver impairment related to parenteral nutrition, the main objective is to determinate wether the change to lipidic emulsion (with a 30% omega-3 fatty acids) is effective in reducing th liver impairment, measured as gamma-glutamyl-transferase (GGT);Secondary Objective: To analyze wether the use of PN with a 30% of omega-3 fatty acids is effective in reducing the infection rate, hyperglycemia rate, hypertrygliceridemia rate, ICU and hospital length of stay. As well as to study the differences in farnesoid-X receptor expression depending on the type of lipid received.;Primary end point(s): Primary end point is the change of liver function parameters: GGT ; from the value the day of inclusion to the end of PN.;Timepoint(s) of evaluation of this end point: Inclusion day and end of PN.

A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with a lung disease caused by coronavirus infection
ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)
Main Objective: To investigate the efficacy of various experimental therapeutics for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); for efficacy assessment an ordinal scale for clinical severity assessment as proposed by the World Health Organization will be used:
• Time to sustained improvement of one category from admission;Secondary Objective: • Time to discharge or to a NEWS of =2 and maintained for 24 hours, whichever occurs first
• Change from baseline
• Oxygenation free days until day 29
• Incidence and duration of new oxygen use during trial
• Ventilator free days until day 29
• Incidence and duration of new mechanical ventilation use
• Viral load/viral clearance change at baseline and three times a week
• Duration of hospitalization
• 15-day, 29-day mortality
• Renin-Angiotensin System (RAS)-fingerprint at baseline and at least once weekly (on days 7±1, 14±1, 21±1, 28±1, through recovery
• Within all patients, the impact of obesity and associated disesaes on mortality will be investigated
• Cumulative incidence of serious adverse events
• iscontinuation or temporary suspension of therapy
• Changes in WBC,hemoglobin,platelets,creatinine,glucose,total bilirubin,ALT,AST
• Within all patients, the impact of obesity and associated diseases on
mortality will be investigated;Primary end point(s): Time to sustained improvement of one category from admission in the 7-point clinical performance scale;Timepoint(s) of evaluation of this end point: measured daily until day 29

Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19)
Main Objective: To assess the impact of treatment with LMWH, using prophylactic versus intermediate doses, in terms of escalation in oxygen therapy or the need for invasive mechanical ventilation or mortality in patients admitted with SARS-CoV2 infection;Secondary Objective: Know the safety of LMWH guideline used in terms of bleeding events, days in hospital and to establish the most favorable patient profile for LMWH treatment.;Primary end point(s): Need for oxygen therapy escalation due to oxygen saturation (Sat O2) =92% with inspired fraction of oxygen (FiO2) =0.5 and respiratory rate (FR) =30 (IROX index = SatO2 / FiO2] / FR <5.5) or invasive mechanical ventilation or mortality during admission.;Timepoint(s) of evaluation of this end point: 30 días

Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failure
Main Objective: To investigate the effect of different types of IL-6 inhibition versus no adjuvant treatment compared to standard of care in patients with severe SARS-CoV-2 pneumonia. ;Secondary Objective: Not applicable;Primary end point(s): Time to independence from supplementary oxygen therapy in days ;Timepoint(s) of evaluation of this end point: Up to 28 days

CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19
Main Objective: To assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.;Secondary Objective: To assess the effect of anakinra in addition to standard treatment on mortality in patients with severe COVID-19 and CSS pneumonia.;Primary end point(s): Treatment success, defined as number of patients not requiring mechanical ventilation by Day 15.
Number of patients not requiring mechanical ventilation (day 28).? Time to mechanical ventilation (days)
? Time to oxygen saturation normalization
? Stay in ICU and hospitalization (days);Timepoint(s) of evaluation of this end point: 15 days

Clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19
Main Objective: To assess the impact of administering two different tocilizumab regimens versus the standard of care on IL-12 levels in patients with non-severe COVID-19 pneumonia.;Secondary Objective: 1. To evaluate and compare the clinical course and mortality of the patients assigned to the three treatment groups.
2. To evaluate and compare other inflammatory parameters and their changes over time in patients assigned to the three treatment groups.
3. To assess the safety of tocilizumab treatment for mild-to-moderate COVID-19 pneumonia.
4. To evaluate and compare pharmacokynetics of tocilizumab based on regimens administered;Primary end point(s): Mean increase in IL-12 levels in the 3 study groups from the start of treatment (D0) to days D+1 and D+3.
A mean difference >0.2 units between any of the three study groups will be considered a significant response in terms of IL-12 levels.;Timepoint(s) of evaluation of this end point: Day 0, day +1 and Day +3

EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS.
RANDOMIZED CONTROLLED CLINICAL TRIAL
Main Objective: To assess the efficacy of glucocorticoid boluses in the inflammatory phase of SARS-CoV-2 pneumonia.;Secondary Objective: • Compare mortality at 28 days.
• Compare the proportion of ICU admissions at 28 days.
• Compare the ratio need for rescue treatment with tocilizumab at 14 days.
• Compare the days of hospital admission.
• Compare the evolution of the analytical parameters of inflammation: C-reactive protein (PCR), interleukin 6 (IL-6), ferritin, D-dimer (DD).
• Compare the proportion of serious adverse events.
• Compare the proportion of bacterial, fungal, or opportunistic infections.
• Compare the clearance of the virus detected by nasopharyngeal PCR.;Primary end point(s): Proportion of patients with treatment failure up to 14 days after randomization.
Definition of treatment failure:
to. Death of the patient, or
b. ICU admission, or
c. Start of mechanical ventilation, or
d. Clinical deterioration / worsening, defined as decrease in SpO2 below 90% or PaO2 below 60 mmHg in ambient air + radiological progression.;Timepoint(s) of evaluation of this end point: 14 DAYS OF HOSPITALISATION

PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA)
Main Objective: To assess the efficacy and safety of 155 mg of hydroxychloroquine base as prophylaxis in health professionals subjected to repeated exposures to the COVID-19 virus, to reduce the contagion measured as development of Ig M antibodies. Professionals must be negative for the disease at the beginning of the randomized study.;Secondary Objective: ? Assess whether there are differences between the two groups in the severity of the disease if IgM antibodies appear. Gravity will be measured as:
o Duration of symptoms
o Development of viral pneumonia
o Specify hydroxychloroquine dose increase
o Increased antiviral medication (kaletra ... etc) during the study.
o Need for hospital admission
o ICU admission
? Assess the clinical safety of hydroxychloroquine in subjects without comorbidities and its QTc lengthening effect.
? Assess in both groups whether the appearance of Ig G antibodies protects against the new appearance of disease understood as the appearance of new IgM antibodies in the period studied.
? Estimation of the percentage of these toilets that have been able to pass the oligosymptomatic disease (Ig M or Ig G positive) in the initial sampling of healthy candidates.;Primary end point(s): ? Appearance of Ig M in rapid test YES / NO
? Appearance of Ig G in rapid test YES / NO
? Appearance of symptoms compatible with COVID-19: fever, cough, odynophagia, vomiting or diarrhea, headache, anosmia or hyposmia, ageusia or dysgeusia without any other alternative diagnosis
? Positive PCR with compatible symptoms carried out in occupational risks (YES / NO);Timepoint(s) of evaluation of this end point: 6 WEEKS

Ensayo clínico aleatorizado para investigar la eficacia de la administración anticipada de la colchicina en pacientes mayores de 70 años y de alto riesgo en tener complicaciones pulmonares como neumonía asociada al coronavirus.
Timepoint(s) of evaluation of this end point: 1 months;Secondary Objective: Not applicable;Primary end point(s): Number of participants who die or require hospitalization due to 19-COVID infection within 30 days of randomization;Main Objective: To determine if early treatment with colchicine reduces the rate of death and serious lung complications related to COVID-19 in patients over 70 years of age with at-risk comorbidities.

Study of the efficacy of ivermectin in the treatment and prevention of COVID-19
Main Objective: Demonstrate the effectiveness of Ivermectin in the prophylaxis and treatment of COVID-19;Secondary Objective: not applicable;Primary end point(s): Sub-study 1
Virological clearence at 3, 6, 9 and 12 days after starting treatment with Ivermectin
Sub-study 2
Incidence of secondary cases diagnosed by molecular biology and serology on the 7th, 14th, 21st day after starting prophylaxis with Ivermectin and with placebo;Timepoint(s) of evaluation of this end point: Sub-study 1
Day 3rd, 6th, 9th and 12th after starting treatment
Day 7th, 14, 21th after starting treatment

USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION
Main Objective: To evaluate the efficacy of early anti-inflammatory treatment with corticosteroids in patients who are in a phase of the disease in which viral replication has already been limited, but there is a marked systemic inflammatory response.;Secondary Objective: To evaluate the safety of early anti-inflammatory treatment with corticosteroids;Primary end point(s): Combination of death, ICU stay or non-invasive ventilation (NIV).;Timepoint(s) of evaluation of this end point: At the time of discharge or death

CLINICAL STUDY IN WHICH PATIENTS ARE RANDOMIZED TO RECEIVE HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE TO COMPARE THEIR EFFICACY IN THE TREATMENT OF COVID-19 PNEUMONIA.
Main Objective: To evaluate the efficacy of cyclosporine A and hydroxychloroquine (treatment group) versus hydroxychloroquine (control group) in patients with acute COVID-19 pneumonia .;Secondary Objective: Objective 1: To estimate the lack of response 3 months after the diagnosis of COVID-19 pneumonia, differentiating whether it is due to death or development of diffuse interstitial lung disease.
Objective 2: To assess the need for pharmacological rescue and invasive mechanical ventilation with orotracheal intubation 3 months after the diagnosis of COVID-19 pneumonia.
Objectives 3: To evaluate the safety of the therapeutic strategies of interest 3 months after the diagnosis of COVID-19 pneumonia.;Primary end point(s): Rate of patients achieving complete response 3 months after being diagnosed of COVID-19 pneumonia.;Timepoint(s) of evaluation of this end point: 3 months

Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission
Main Objective: To determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day seven post-treatment.;Secondary Objective: 1. To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab at day seven post treatment
2. To assess the efficacy of ivermectin to improve symptom progression in treated patients
3. To assess the proportion of seroconversions at day 21 in treated patients
4. To assess the safety of ivermectin at the proposed dose
5. To determine the magnitude of immune response against SARS-CoV-2
6. To assess the early kinetics of immunity against SARS-CoV-2;Primary end point(s): Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab;Timepoint(s) of evaluation of this end point: Day 7 post-treatment

Efficacy and safety study of IVIG in hospitalized subjects with COVID-19
Main Objective: To determine if high dose IVIG plus SMT can reduce the proportion of subjects dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus SMT alone in hospitalized subjects with COVID-19.;Secondary Objective: To compare high dose IVIG plus SMT versus SMT alone with regard to clinical efficacy as assessed by clinical severity, duration of hospital stay, dependency on oxygen or new need for ventilatory support, clinical response criteria including National Early Warning Score (NEWS), and clinical status scale through Day 29 in hospitalized subjects with COVID-19.;Primary end point(s): The primary efficacy variable is the proportion of subjects dying or requiring ICU admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29.;Timepoint(s) of evaluation of this end point: through Day 29

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Patients with Coronavirus Disease (COVID-19)
Main Objective: To determine if Prolastin plus SMT can reduce the proportion of subjects dying or requiring intensive care unit (ICU) admission on or before Day 15 or who are dependent on invasive mechanical ventilation on Day 15 versus SMT alone in hospitalized subjects with COVID-19.;Secondary Objective: To compare Prolastin plus SMT versus SMT alone with regard to clinical efficacy as assessed by clinical severity, duration of hospital stay, dependency on oxygen or new need for ventilatory support, or ICU admission, clinical response criteria including National Early Warning Score (NEWS), mortality and clinical status scale through Day 29 in hospitalized subjects with COVID-19.;Primary end point(s): The primary efficacy variable is the proportion of subjects dying or requiring ICU admission on or before Day 15 or who are dependent on invasive mechanical ventilation on Day 15.;Timepoint(s) of evaluation of this end point: Through Day 29

DAS181 for Severe COVID-19: Compassionate Use
Improved clinical status;Return to room air;Improved clinical status;Return to room air

Application of Desferal to Treat COVID-19

Distress in Crisis Situations During COVID-19
quantify and qualify distress over a large population in times of pandemic crisis.;quantify and qualify distress over a large population in times of pandemic crisis.

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

A Study on the Prospective Cohort Library of COVID-19 in Southeran
36-Item Short Form Survey Instrument (SF-36);the value of FEV1 by lung function test;the ratio of FEV1 to FVC by lung function test;36-Item Short Form Survey Instrument (SF-36);the value of FEV1 by lung function test;the ratio of FEV1 to FVC by lung function test

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Time to clinical improvement;Time to clinical improvement

A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia
Improvement on a 7-point Ordinal Scale;Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability);Improvement on a 7-point Ordinal Scale;Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability)

Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Trial to Study the Benefit of Colchicine in Patients With COVID-19
Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group;Changes in IL-6 concentrations;Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group;Changes in IL-6 concentrations

Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients
Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients;Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients

COVID-19 and Cancer Consortium Registry

COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2
Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.;Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.

Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)
PaO2/FiO2;SpO2;NEWS Score;Inflammation level -CRP;Inflammation level - ESR;white blood cells number;Cytokines - IL1;Cytokines - IL2;Cytokines - IL6;Cytokines - IL10;Cytokines - TNFalpha;Inflammation level - procalcitonin;Inflammation level - ferritin;PaO2/FiO2;SpO2;NEWS Score;Inflammation level -CRP;Inflammation level - ESR;white blood cells number;Cytokines - IL1;Cytokines - IL2;Cytokines - IL6;Cytokines - IL10;Cytokines - TNFalpha;Inflammation level - procalcitonin;Inflammation level - ferritin

Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism;the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism

COVID-19 Recovered Volunteer Research Participant Pool Registry
Serological testing of COVID patients;Immune response;Serological testing of COVID patients;Immune response

Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
Decrease the incidence of COVID-19 infection or its severity;Decrease the incidence of COVID-19 infection or its severity

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial
Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection;Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection

COVID-19 Survival - The COVIVA Study

Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation;Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation

C5a Receptor Expression - COVID-19 (C5-COV)
Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).;Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).

Obstetric and Perinatal Outcomes of Women With COVID-19
Compare the complications rates;Compare the complications rates

Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic
Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.;Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients
Proportion of patients remaining free of need for mechanical ventilation in both groups;Proportion of patients remaining free of need for mechanical ventilation in both groups

Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit During Covid-19 Pandemic
Prevalence of burnout among ICU nurses during Covid-19;Prevalence of depression among ICU nurses during Covid-19;Prevalence of self-perceived medical errors among ICU nurses during Covid-19;Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19;Prevalence of burnout among ICU nurses during Covid-19;Prevalence of depression among ICU nurses during Covid-19;Prevalence of self-perceived medical errors among ICU nurses during Covid-19;Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19

Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )
Number of patients alive and no longer hospitalized at D14;Number of ventilator-free days at Day 28 (VFD28);Number of patients alive and no longer hospitalized at D14;Number of ventilator-free days at Day 28 (VFD28)

Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients
Rate of patients with occurrence of an unfavorable outcome between randomization and day 14;Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14;Rate of patients with occurrence of an unfavorable outcome between randomization and day 14;Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14

Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients
Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation;Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation

Predicting Death and ICU Admission in COVID-19 Patients in ED

Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
Changes of oxygenation index (PaO2/FiO2) ,blood gas test;Changes of oxygenation index (PaO2/FiO2) ,blood gas test

Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients
Death (all-cause mortality) or discharge from ICU (limit of 4 months);Death (all-cause mortality) or discharge from ICU (limit of 4 months)

COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings
Clinical features of symptomatic COVID-19 in people living with HIV (PLWH);Clinical outcomes of symptomatic COVID-19 in PLWH;Clinical outcomes of symptomatic COVID-19 in PLWH;Clinical features of symptomatic COVID-19 in people living with HIV (PLWH);Clinical outcomes of symptomatic COVID-19 in PLWH;Clinical outcomes of symptomatic COVID-19 in PLWH

Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuébec Sub-study
Change in diet quality;Change in food insecurity;Change in diet quality;Change in food insecurity

Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19
Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7;Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Time to clinical change;Time to clinical change

Health Care Use During the Covid19 Crisis
Health care use;Postponed heath care use;Foregone health care use;Health care use;Postponed heath care use;Foregone health care use

Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
death;clinical worsening (composite criteria);Assisted-ventilation and/or hospitalization (composite criteria);death;clinical worsening (composite criteria);Assisted-ventilation and/or hospitalization (composite criteria)

SQuISH-COVID: A Pilot Study
To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.;To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.

Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients

Duvelisib to Combat COVID-19

WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound
Delay from the start of Mechanical Ventilation weaning process to extubation;Delay from the start of Mechanical Ventilation weaning process to extubation

Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement
Students' Learning Perception Questionnaire (SLPQ),;students' scholar achievement.;Students' Learning Perception Questionnaire (SLPQ),;students' scholar achievement.

Screening of Cancer Patients to Assess Impact of COVID-19
Rate of asymptomatic COVID-19 infection among cancer patients receiving cancer therapy;Rate of asymptomatic COVID-19 infection among cancer patients receiving cancer therapy

Stroke Rehabilitation Outcome During COVID-19 Lockdown
Rehabilitation data;Motor Activity Log - 14 Item Version;International Physical Activity Questionnaire;Patient-Reported Outcomes Measurement Information System - 29 Version;Rehabilitation data;Motor Activity Log - 14 Item Version;International Physical Activity Questionnaire;Patient-Reported Outcomes Measurement Information System - 29 Version

Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index

Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
Number of days of unplanned absenteeism for any reason;Number of days of unplanned absenteeism for any reason

Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic
Change in instances of burnout for hospital staff due to the Peer Resilience Champion intervention;Change in instances of burnout for hospital staff due to the Enriched Feedback Survey intervention;Change in instances of burnout for hospital staff due to the Peer Resilience Champion intervention;Change in instances of burnout for hospital staff due to the Enriched Feedback Survey intervention

Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels
Rate of positivity for Acute Pulmonary Embolism;Rate of positivity for Acute Pulmonary Embolism

Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study
effect of Ivermectin on eradication of virus.;effect of Ivermectin on eradication of virus.

Less Frequency Hemodialysis and COVID-19

Early Short Course Corticosteroids in COVID-19
Transfer to Intensive care unit (ICU);Need for Mechanical Ventilation;Mortality;Transfer to Intensive care unit (ICU);Need for Mechanical Ventilation;Mortality

COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit
Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.;Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.;Technical success rate of endoscopic procedures during the 30-days study period.;IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.;Adverse events rate of endoscopic procedures during the 30-days;Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.;Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.;Technical success rate of endoscopic procedures during the 30-days study period.;IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.;Adverse events rate of endoscopic procedures during the 30-days

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

COVID-19 Pandemic and Female Sexual Behavior
FSFI (Female Sexual Function Index)SCORE difference;FSFI (Female Sexual Function Index)SCORE difference

A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days;The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days

Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial
Impact of plasma exchange;Impact of plasma exchange

Asymptomatic COVID-19 Trial
The primary outcome is the rate of decline in viral load over the 10 days after randomization;The primary outcome is the rate of decline in viral load over the 10 days after randomization

Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19
Prior treatment by ACEi;Prior treatment by ARB;Prior treatment by ACEi;Prior treatment by ARB

Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients
Time to Clinical improvement (TTCI);Time to Clinical improvement (TTCI)

Monocytes and NK Cells Activity in Covid-19 Patients

Colchicine in COVID-19: a Pilot Study
Rate of entering the critical stage;Rate of entering the critical stage

Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection
The incidents of acute respiratory distress syndrome (ARDS) development

Adaptive COVID-19 Treatment Trial (ACTT)

Biomarkers for Identification of COVID-19 Infection

The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention
Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee;Maximal concentration of cardiac troponin

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

Safety in Convalescent Plasma Transfusion to COVID-19

CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION
Symptomatic COVID-19;Peak severity of COVID-19 over the study period

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
Changes in patients viral load;Second evaluation of changes in patients viral load

CAPTION AI to Minimize Risk of COVID Exposure
Percent of patient echos that are not interpretable;Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction);Time to acquire images as measured by time stamps

Safety and Efficacy of Baricitinib for COVID-19
Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs);Phase 2: Cumulative incidence of serious adverse events (SAEs);Phase 2: Changes in white blood cell count (CBC) through Day 15;Phase 2: Changes in hemoglobin through Day 15;Phase 2: Changes in platelets through Day 15;Phase 2: Changes in creatinine through Day 15;Phase 2: Changes in glucose through Day 15;Phase 2: Changes in prothrombin time (PT) through Day 15;Phase 2: Changes in total bilirubin through Day 15;Phase 2: Changes in ALT through Day 15;Phase 2: Changes in AST through Day 15;Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS);Phase 2: Changes in hemoglobin through End of Study (EOS);Phase 2: Changes in platelets through End of Study (EOS);Phase 2: Changes in creatinine through End of Study (EOS);Phase 2: Changes in glucose through End of Study (EOS);Phase 2: Changes in prothrombin time (PT) though End of Study (EOS);Phase 2: Changes in total bilirubin through End of Study (EOS);Phase 2: Changes in ALT through End of Study (EOS);Phase 2: Changes in AST through End of Study (EOS);Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15

Will Hydroxychloroquine Impede or Prevent COVID-19
To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
Need for ventilation (including invasive and non invasive ventilation), intensive care or death

Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19
Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis;Distribution of COVID-19 risk factors by participant characteristics;Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization);Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study;Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Cumulative incidence of serious adverse events associated with clazakizumab or placebo

COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
Number of death of any cause, during the 14 days following the inclusion and intervention.

Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak

Safety and Efficacy of Ruxolitinib for COVID-19
Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs);Phase 2: Cumulative incidence of serious adverse events (SAEs);Phase 2: Changes in white blood cell count (CBC) through Day 15;Phase 2: Changes in hemoglobin through Day 15;Phase 2: Changes in platelets through Day 15;Phase 2: Changes in creatinine through Day 15;Phase 2: Changes in glucose through Day 15;Phase 2: Changes in prothrombin time (PT) through Day 15;Phase 2: Changes in total bilirubin through Day 15;Phase 2: Changes in ALT through Day 15;Phase 2: Changes in AST through Day 15;Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS);Phase 2: Changes in hemoglobin through End of Study (EOS);Phase 2: Changes in platelets through End of Study (EOS);Phase 2: Changes in creatinine through End of Study (EOS);Phase 2: Changes in glucose through End of Study (EOS);Phase 2: Changes in prothrombin time (PT) though End of Study (EOS);Phase 2: Changes in total bilirubin through End of Study (EOS);Phase 2: Changes in ALT through End of Study (EOS);Phase 2: Changes in AST through End of Study (EOS);Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale

Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
Delta change in arterial partial pressure of carbon dioxide during ECCO2R treatment

International Lung UltraSound Analysis (ILUSA) Study
Diagnostic performance of LUS to predict poor outcome

Renal Outcome in Patients With COVID-19

Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection
Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection;Troponin greater than 99th percentile during hospitalization for Covid-19 infection

Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
Proportion of patients in both arms fulfilling the criteria for treatment failure

COVID-19 and Psychotic Symptoms in France
Total score of the Cardiff Anomalous Perceptions Scale (CAPS)

Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study
Rates of patients presenting with acute myocardial infarction

Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19
Number of days until complete resolution of symptoms per group;Number of hospital admissions per group

COVID-19 and the Developement of Phobic Fears of Disease

Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador
Clinical characteristics of patients with COVID-19

COVID 19 Biomarkers

Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula

Serology COVID-19 From the Cornwall Hospital Union

Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic
Change from baseline of the total score of a novel COVID-19 anxiety inventory

Study of the Pathogenesis of Olfactory Disorders in COVID-19
Molecular and cellular defects in olfactory epithelium

African Covid-19 Critical Care Outcomes Study

Acute Cardiovascular Events Triggered by COVID-19-Related Stress
Acute cardiovascular event triggered by COVID-19 stress;Ventricular tachycardia;acute stroke;Implantable cardioverter defibrillator (ICD) shock

Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.
Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period;Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment

Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures

Sirolimus in COVID-19 Phase 1
Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment

Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)
Compare the efficacy of detection of viral infection using serology and viral-RNA detection kits

Home Pulse Oximeter Use in Patients With COVID-19
Hospitalization in COVID-19 patients with low home SpO2

COVID-19 Among Healthcare Workers in Belgian Hospitals
Change of prevalence of COVID-19 infection among Belgian active hospital healthcare workers (HCW);Change of prevalence of COVID-19 infection among Belgian active hospital healthcare workers (HCW);Change of seroprevalence of SARS-CoV-2 among Belgian active hospital HCW;Change of seroprevalence of SARS-CoV-2 among Belgian active hospital HCW;Change in new cases (incidence) of COVID-19 among Belgian hospital HCW;Change in new cases (incidence) of COVID-19 among Belgian hospital HCW;Change in SARS-CoV-2 seroconversion among Belgian hospital HCW;Change in SARS-CoV-2 seroconversion among Belgian hospital HCW

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
Time to onset of change in the patient's clinical condition;Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE

Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study
Percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)

Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak

Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19

Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy
Number of participants who have clinical improvement at day 7 after randomization

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19

Effect of COVID-19 Pandemic on Pediatric Cancer Care
pediatric cancer care pattern during COVID 19 pandemic

Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?

Correlation Between Oxidative Stress Status and COVID-19 Severity

Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Stress state score, during the confinement period

Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases
Evolution of the proportion of positive SARS-COV-2 cases.

Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE)

Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals
Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic

Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19)

PET/CT Imaging in COVID-19 Patients
Administration of 18F-avß6-BP;Administration of 18F-avß6-BP;Administration of 18F-avß6-BP

Surgical Telemedicine in the COVID-19 Pandemic Era
Evaluate surgeon perceptions to telemedicine and perceived barriers to implementation;Evaluate patient perceptions to telemedicine and perceived barriers to implementation

Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19

CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch

Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19)

Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation
Proportion of caregivers and agents with a positive serodiagnosis

Slovenian National COVID-19 Prevalence Study
Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples;Prevalence of anti-SARS-CoV-2 antibodies in blood samples

The Role of Ultrasound in COVID-19
In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis;Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis;Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis

Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety
Measure of parental stress;Patient Health Questionnaire 9;Generalized Anxiety Disorder 7

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic

COVID-19 Prevalence and Cognitive Deficits in Neurological Patients
Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

COVID-19 - Quality of Life After Infection

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)
Lenght of hospital stay (days);Number of Intensive Care Unit admissions

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
Patient clinical status 15 days after randomization

COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior
Knowledge and Confidence in Knowledge of COVID-19;Beliefs about the effectiveness of public health recommendations;Intent to comply with public health recommendations;Perception of Risk of COVID-19 and other health threats;Perceptions of trust in common health information sources;Single most trusted news source

A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers

The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

Developement and Evaluation of Serological Assays for COVID-19

Safe Return to Regular Clinical Operation After COVID-19 Pandemic
Health care provider safe return to work

Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste
Percentage of people reporting changes in smell/taste;mortality rate

Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19
Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.;Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19

Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic
Change in Depressive symptoms measured by Patient Health Questionnaire-9;Change in Anxiety symptoms measured by Generalized Anxiety Disorder-7

Assessment of the Psycho-social Impact of COVID-19 Outbreak
Psychological impact of the outbreak, total score;Psychological impact of the outbreak: depression questions score;Psychological impact of the outbreak: anxiety questions score;Psychological impact of the outbreak: stress questions score;Psychological impact of the outbreak: PSTD questions score;Descriptive statistics for the non-psychological questions

Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin

Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19

Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
Survival without need of mechanical ventilation;WHO progression scale = 5 at day 4 since admission.;Cumulative incidence of successful tracheal extubation at day 14 since symptom onset.;WHO progression scale = 7 at day 4 since admission.

Neurologic Manifestations of COVID 19 in Children
Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19

Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19)
Profiles of volatile organic compounds (VOCs) in exhaled air between 2 health conditions

Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center

COVID-19 Infection in Patients Infected With HIV and/or on PrEP

COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)
Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg;Collection of samples for research

BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
Incidence of HCWs hospitalized due to COVID-19 per arm

Geriatric Population COVID-19 Observational Study (GEROCOVIDobs)
Health status (WHO classification);Incidence of Serious Adverse Events

Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19
A list of COVID-19 specific TCR sequences

Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)
Change in the score of the "Contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by COVID-19"

SUNLIGHT Study: Online Support Groups for MS to Address COVID-19

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
Proportion of patients, responded to the study therapy, in each of the treatment groups

Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19
Patient reported main complaint;Patient reported main complaint;Patient reported main complaint;Patient reported main complaint

A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
Change in absolute lymphocyte count (ALC)

Investigating the microorganisms found in the mouths of SARS-Cov-2 positive patients
Characterization of the microbial communities colonizing the oral cavity in patients infected by SARS-Cov-2 at visit 1 (baseline), 2 (0 - 14 days from diagnosis), 3 (at least 7 days after end of treatment). Methods include two types of molecular analyses for RNA and DNA: 1) Whole Genome Sequencing (WGS); 2) quantitative real-time PCR microarray.

Survive and Thrive: exploring the wellbeing of doctors in a post-COVID-19 era
A minimum set of measures of wellbeing for doctors, a Core Outcome Set, is being developed through a systematic review, Delphi study and doctor surveys. The Core Outcome Set of wellbeing measures will form the primary outcomes. Which questionnaires these will be determined in the first part of this study. They will be measured during the pandemic, separated by a month for those who consent to take part in more than one survey, and after the pandemic.

COVID-19 social study: the effects of quarantine on mental health
Measured weekly:
1. Depression (using the patient health questionnaire PHQ-9)
2. Anxiety (using the generalised anxiety disorder assessment GAD-7)

The COVID-19 Emergency Response Assessment Study: a survey of the psychological health of frontline doctors in the UK and Ireland during the coronavirus pandemic
1. The General Health Questionnaire-12 score from surveys administered at the acceleration, peak and declaration of the COVID-19 pandemic
2. The Impact of Events Scale-Revised from surveys administered at the acceleration, peak and deceleration of the COVID-19 pandemic (phase 2 and 3 surveys)

Novel coronavirus pneumonia (COVID-19) s-vax loaded autologous dendritic cell trial

A multicenter, randomized, double-blind, placebo-controlled trial for Lu-Dang-Shen oral liquid in the treatment of reduced digestion function of convalescent new coronavirus pneumonia (COVID-19) patient
Changes in the degree of clinical symptoms such as fatigue, poor appetite, abdominal distension, and loose stools caused by decreased digestive function of the two groups of subjects;

A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor
Tolerance;Viral load of nCoV;Blood routine;Immunological examination;Blood liver and kidney function test;Myocardial enzyme biochemical examination;ECG examination;Urine routine;body temperature;pulse;Breathe;blood pressure;CT examination of the lungs;

Epidemiological, clinical and prognosticated features of novel coronavirus pneumonia (COVID-19) in Zhuhai
chest CT;lung function;blood routine examination;liver function;renal function;heart function;clinical data;routine urine test;fecal routine test;blood clotting function;blood gas assay;Zung's self-rating anxiety scandal;Zung's self-rating depression scandal;DASS-21;diversity of microbe;

The duration and influencing factors of medical staff wearing disposable protective equipment in the isolation area during novel coronavirus pneumonia (COVID-19): an epidemiological study
The duration of medical staff wearing disposable protective equipment;

Rapid Detection 2019-nCOV via Surface Plasamon Resonance

Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-? plus anti-inflammatory factor TFF2)

A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia
????;time to clinical improvement;overall rates of clinical improvement assessed at days 7, 14, and 28;time to chest CT improvement; time to virus nucleic acid negative-conversion;overall rates of radiological improvement on days 7, 14, and 28;overall rates of virus nucleic acid negative-conversion on qRT-PCR in nasopharyngeal swabs samples on days 7, 14, and 28;serious adverse events;

A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)

Randomised controlled trial of an app-based intervention, Anchored, to support the mental health of Australians recently unemployed due to COVID-19.
Depressive symptom change as measured by the Patient Health Questionnaire-9 (PHQ-9).[Data will be collected at baseline, and 30 days, 3 months and 6 months after baseline.];Depression caseness (change or onset) as measured by the Patient Health Questionnaire-9 (PHQ-9) diagnostic algorithm.[Data will be aggregated across follow-up timepoints (30 days, 3 months and 6 months).]

ADAPT - COVID-19 Study - A prospective, observational cohort study at St Vincent’s Hospital Sydney
Primary outcome is the evolution of an immunological response to COVID-19 measured by COVID-19 antibody formation. [ 1, 4 and 12 months post COVID-19 diagnosis]

International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial
Composite: Change in severity and duration of symptoms,
assessed by data linkage to patient medical records
[once daily for 15 days since enrolment / baseline = admission to hospital];length of hospital stay = days discharge since hospital admission
[days in hospital since admission at hospital discharge];composite of need for invasive mechanical ventilation* or mortality within 15 days from enrolment assessed by data linkage to patient medical records
*Participants intubated or requiring imminent intubation at the time of enrolment will only be followed for the primary outcome of death.
[any time within 15 days from enrolment]

Randomised clinical trial of interventions for the treatment of COVID-19 in the community setting for high risk older people.
Compostite primary endpoints of rate of hospital admission or death. Assessment of hospital medical records following notification of admission by participant or local General Practitioner. Participant diaries will record on a daily basis the course of COVID-19 infection. Community based death events will be confirmed with participants local General Practitioner in local medical records.[28 days]

Pirfenidine in SARS-COV2
The scales of pulmonary involvement changes according to the scoring system defined, based on high resolution pulmonary computed tomography before and after the interventions. Timepoint: At visit 1 and then after 14 days. Method of measurement: Defined scoring system based on pulmonary involvement in high resolution pulmonary CT scan; score one: involvement in less than 5% of a lobe of a lung. Score two: Conflict about 25 percent of a lobe of a lung. Score three: Conflict about 26 to 49 percent of a lobe of a lung. Score four: Conflict about 50 to 75 percent of a lobe of a lung. Score Five: Conflict in more than 75% of a lobe of a lung.

Tocilizumab in severe COVID-19
All-cause mortality rate during the study (date and cause of death, if applicable). Timepoint: day 1 through 14. Method of measurement: Physical Examination.

Efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19
Improvement of pulmonary manifestations and the duration. Timepoint: One week, two weeks and 6 months after. Method of measurement: physical examination, labratory data and CT scan.;Improvement the radiologic parameters. Timepoint: after 7-10 days. Method of measurement: computed tomography.;Necessity and Duration to ICU admission and hospitalization. Timepoint: One to two weeks later. Method of measurement: Questionnaire.;Mortality. Timepoint: One month later. Method of measurement: Number.;The three months outcomes: complete improvement; improvement with transient complication; improvement with persistent complication. Timepoint: After three months. Method of measurement: Physical examination and history.

Atorvastatin effect on COVID-19
CRP level in Blood. Timepoint: At the beginning of the study at after 5 consecutive days. Method of measurement: Blood sampling and CRP measuring.

Remdesivir in treatment of COVID-19
Time to Clinical Improvement (TTCI): TTCI is defined as the time (in days) from initiation of study treatment until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death).6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC therapy;3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC);2. Hospitalization, not requiring supplemental oxygen; 1. Hospital discharge. IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation;HFNC, High-flow nasal cannula. Timepoint: Daily for 14 days. Method of measurement: Based on clinical evaluation.;Time to Clinical recovery (TTCR): TTCR is defined as the time (in hours) from initiation of study treatment until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough sustained for at least 72 hours.Normalization and alleviation criteria:• Fever - =36.9°C or -axilla, =37.2 °C oral,• Respiratory rate - =24/minute on room air,• Oxygen saturation - >94% on room air,• Cough - mild or absent on a patient-reported scale of severe, moderate, mild, absent. Timepoint: Daily for 14 days. Method of measurement: Based on clinical evaluation.

Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19
Time to clinical improvement defined as start of taking medication time to alive hospital discharge. Timepoint: The beginning of the study , the time of discharge and 21 days after discharge. Method of measurement: Medical record.

Efficacy evaluation of an herbal compound in COVID-19
Changing the patient's clinical status in the COVID-19 clinical classification table. Timepoint: Before and after intervention. Method of measurement: Clinical and Paraclinical Indicators in COVID-19 Classification Table.

Umifenovir effectiveness in the treatment of COVID-19
Clinical improvement includes fever rupture. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, thermometer, questionnaire.;Clinical improvement includes SPO2 >93%. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, pulse oxymetery,questionnaire.;Improvement of respiratory symptoms. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, ct scan,questionnaire.;Adverse effects. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Questionnaire, physical examination.

The effect of PHR spray on patients with coronavirus-19
Measurement of cough severity. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Standard cough questionnaire.;Severity of shortness of breath. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.

Interferon beta 1b in COVID-19
Clinical response to therapeutic regimen by respiratory rate. Timepoint: Daily. Method of measurement: physical exam.;Clinical response to therapeutic regimen by blood oxygen saturation. Timepoint: daily. Method of measurement: pulse oximeter.;Clinical response to therapeutic regimen by fever. Timepoint: daily. Method of measurement: thermometer.;Therapeutic regimen safety. Timepoint: daily. Method of measurement: patient tolerability.;LDH level reduction. Timepoint: three times weekly. Method of measurement: laboratory test.;CRP level reduction. Timepoint: three times weekly. Method of measurement: laboratory test.;Lymphocyte count recovery. Timepoint: daily. Method of measurement: laboratory test.;Cough recovery. Timepoint: daily. Method of measurement: physical exam.

The effect of MCT Oil on COVID-19
Temperature. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Thermometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.;Muscular pain. Timepoint: 0-1-2-3-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Urine Ketone. Timepoint: Four hours after taking MCT oil. Method of measurement: It is checked with a urine test strip.

Effect of Methylprednisolone in treatment of COVID-19 patients
PAO2/fio2. Timepoint: 5 days after intervention. Method of measurement: ABG.

Effect of oral multi-herbal preparation on COVID-19
O2 saturation percentage. Timepoint: Clinical examination and pulse oximetry at baseline, days 3, 6, 9, 12 and 14. Method of measurement: Pulse Oximeter.;Lung inflammation. Timepoint: CT scan at baseline, days 7 and 14. Method of measurement: CT scan.

Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir standard of care therapeutic regimenVelpatasvir” to “standard of caretherapeutic regimen” in patients with COVID-19
Clinical status. Timepoint: Beginning of the study, 10 days later, or discharge time. Method of measurement: By a doctor.

The efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 who have not responded to standard three-drug protocol
Fever. Timepoint: before and after treatment. Method of measurement: Thermometer.;Respiration rate. Timepoint: before and after treatment. Method of measurement: counting the number of breaths patients take per minute.;Findings of chest CT scan. Timepoint: before and after treatment. Method of measurement: CT scan machine.;Pulse. Timepoint: before, during and after treatment. Method of measurement: patient monitoring device.;SpO2. Timepoint: before, during and after treatment. Method of measurement: patient monitoring device.;WBC. Timepoint: before and after treatment. Method of measurement: biochemical tests.;Number of lymphocytes. Timepoint: before and after treatment. Method of measurement: biochemical tests.;Lactate dehydrogenase. Timepoint: before and after treatment. Method of measurement: biochemical tests.;C-Reactive Protein (CRP). Timepoint: before and after treatment. Method of measurement: biochemical tests.

Evaluation the Effect of Ticoplanin in Patients With Coronavirus Disease
Measurement of inflammatory markers (CRP). Timepoint: at baseline and discharge time. Method of measurement: ELISA.;WBC count. Timepoint: at baseline and discharge time. Method of measurement: Blood count.;Evaluation of lung CT scan. Timepoint: at baseline and discharge time. Method of measurement: Radiologic finding.;Evaluation of inflammatory marker ESR. Timepoint: at baseline and discharge time. Method of measurement: Blood count.

Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19)
Clinical symptoms (Coronavirus infection). Timepoint: Before starting the study and daily until discharge. Method of measurement: Laboratory values and radiographic changes or CT scans.

Evaluation the effects of Hydroxychloroquine administration for COVID-19 prophylaxis
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Questionnaire.;Dyspnea. Timepoint: Daily. Method of measurement: Questionnaire.;Sore throat. Timepoint: Daily. Method of measurement: Questionnaire.;Myalgia. Timepoint: Daily. Method of measurement: Questionnaire.

The effect of Tanacetum parthenium (L) Sch syrup on clinical manifestations of patients with COVID-19
Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.

Comparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19
Not need hospitalization, feels well, and is able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Not need hospitalization, feels ill but is able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Not need hospitalization, feels ill and isn't able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Need hospitalization, feels ill and isn't able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.

Effect of berberine on COVID-19
Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.

Effect of herbal capsule, Viroherb, and herbal syrup, Fenugreek in treatment of COVID-19
Body temperature. Timepoint: At the beginning of the study and on day 6. Method of measurement: thermometer.;Adverse events. Timepoint: whole duration of study. Method of measurement: type and number of adverse event.;Cough. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Dyspnea. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Myalgia. Timepoint: At the beginning of the study and on day 6. Method of measurement: Visual Analogue Scale.

The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients
Need of invasive and non invasive mechanical ventilation ,need of oxygen supplement , the median time for recovery and well-being. Timepoint: daily in all duration of study. Method of measurement: By designed investigator checklist.

Assessment of effect of levamisole on pneumonia caused by COVID-19
Prevent the development of pneumonia caused by Convid19. Timepoint: one week. Method of measurement: CT scan.;Reduce the need for hospitalization. Timepoint: two week. Method of measurement: Measure the length of hospital stay.;Death. Timepoint: 2 to 3 week. Method of measurement: Measuring mortality.

Evaluation the effect of licorice for treatment of coronavirus
Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Time of recovery.;Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.;CRP level. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit.

Evaluating the effect of Marshmallow and Licorice on COVID 19 patients
Viral diagnostic test. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Polymerase chain reaction.

Effect of IMFLUNA herbal compound on covid-19 pneumonia symptoms
Blood oxygen saturation. Timepoint: At beginning and regularly during study. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: At beginning and regularly during study. Method of measurement: Respiratory Count.;Lung inflammation. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.

Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected Corona (COVID-19)
Clinical signs Includes oxygen saturation, temperature, blood pressure, respiration rate, heart rate. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Individual profile and follow-up questionnaire.;Oxygen levels. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Oximeter.

The effect of SOVODAK in the treatment of COVID-19 patients
Symptoms ending. Timepoint: During the study. Method of measurement: Clinical examination.;Lymphopenic Status. Timepoint: Before the intervention and the seventh day. Method of measurement: Counting lymphocytes.;C-reactive protein Status. Timepoint: Before the intervention and the seventh day. Method of measurement: C-reactive protein serological test.;Saturation of Peripheral Oxygen. Timepoint: Before the intervention and the seventh day. Method of measurement: Pulseimetry.

Comparison of therapies for COVID-19
Primary Outcome: All-cause mortality. Timepoint: Any time death or discharge of patients occurs. Method of measurement: Death certificate signed by hospital clinicians or discharge documents.

Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease
Checking the amount of ventilation. Timepoint: Before intervention, 30 minutes after each step of intervention and daily. Method of measurement: Artificial respirator or ventilator.;White blood cell count, CRP in patients with COVID-19. Timepoint: Every 24 hours (Before and after intervention). Method of measurement: Cell counter.;Percentage of T CD8 in peripheral blood. Timepoint: Before and after the intervention. Method of measurement: Evaluation of T CD8 percentage by Flow cytometry.;Percentage of T CD4 in peripheral blood. Timepoint: Before and after the intervention. Method of measurement: Evaluation of T CD4 percentage by Flow cytometry.;C-Reactive Protein (CRP) in patients with COVID-19. Timepoint: Every 24 hours (Before and after intervention). Method of measurement: Rapid test.

Post-exposure hydroxycloroquine prophylaxis for Covid 19
Incidence of clinical symptoms of COVID-19 disease (especially pulmonary involvement) among people who are asymptomatic when entering the study. Timepoint: At the beginning of the study and 7, 14 and 21 days after the start of the intervention. Method of measurement: The number of cases with clinical symptoms, especially cases of pulmonary involvement in a period of 21 days among the participants in the studied groups and as needed using CT scan results.

The Impact of Family-Based Empowerment Model on Stress, Anxiety and Satisfaction
Stress. Timepoint: Stress will be measured once before the first intervention and once after the last intervention session. Method of measurement: Doss Stress Questionnaire.

Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients
Fever. Timepoint: Every day for 7 days. Method of measurement: termometer.;Lymphocyte count. Timepoint: Before and 7 days after intervention. Method of measurement: Cell counter device.;Erythrocyte sedimentation rate. Timepoint: Before and 7 days after intervention. Method of measurement: ESR device.

Evaluation the effects of Favipiravir in COVID-19 patients
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.

Prevention of Novel Coronavirus Disease by Hydroxychloroquine in cancer patients.
COVID-19 incidence rate in cancer patients under treatment. Timepoint: Patients are examined and investigated if they become symptomatic during the 2 months of study. Method of measurement: First, a history and physical examination are performed for the symptoms of COVID-19, and if the test is positive, a computerized tomography scan of the lungs and a nucleic acid amplification test for the SARS-CoV-2 virus.

The effect of elderberry syrup against COVID-19 symptoms
Fever. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Thermometer.;Shortness of breath. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Autosaturation device, Counting the number of breaths in 1 minute.;Coughs. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.;Myalgia. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.

Efficacy of Kelofan syrup on COVID-19
Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: Respiratory Count.

evaluation of Safety and efficacy of anti inflammatory regimens in COVID-19
Admission to intensive care unit. Timepoint: Once (when admitted to intensive care unit). Method of measurement: Hospital records.

Effect of Bromhexine Hydrochloride on patients with COVID-19
Hospitalization days. Timepoint: At baseline and discharge time. Method of measurement: Counting the days.;Need for mechanical ventilation. Timepoint: From baseline to discharge time. Method of measurement: Observation and documents.;Condition of discharge (death or recovery). Timepoint: End of hospitalization. Method of measurement: Observation and documents.;Period of mechanical ventilation. Timepoint: End of hospitalization. Method of measurement: Documents of hospitalization.

Efficacy and safety of convalescent plasma in the treatment of COVID-19
Clinical improvement within 14 days of admission. Timepoint: everyday. Method of measurement: Clinical improvement is defined as the patient's admission status of 6 grade scale score reduced by 2 points or patient discharge. (Clinical improvement was defined as a 2-point reduction or discharge of a 6-point scale for patient admission status. The 6-point scale includes: 6 points: death; 5 points: hospitalization for ECMO and / or mechanical ventilation; 4 points: non-invasive admission Ventilation and / or high-flow oxygen therapy; 3 points: hospitalization for oxygen therapy (but no high-flow or non-invasive ventilation is required); 2: points for hospitalization) Point1: discharge.

Evaluation and comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients
Body temperature. Timepoint: before the start of the intervention and 10 days after the supplement Vitamin A. Method of measurement: Measureing body temperature with a thermometer through the mouth.;Blood oxygen saturation percentage. Timepoint: Before and ten days after starting treatment. Method of measurement: Pulse oximeter.;Cough rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Physical examination.;C-Reactive Protein (CRP) Test rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Complete blood count (CBC) Rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Creat. Rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Lymphocytes Rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Erythrocyte Sedimentation Rate (ESR) rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Number of breaths. Timepoint: Before and ten days after starting treatment. Method of measurement: Physical examination.;The pH of the blood. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Creatine phosphokinase (CPK) rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Lactate Dehydrogenase (LDH) rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.;Liver function tests rate. Timepoint: Before and ten days after starting treatment. Method of measurement: Laboratory.

Effect of minocycline on COVID-19
Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.

Effect of crocetin on COVID-19
Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.

Effect of Trifluoperazine in treatment of COVID-19
Determining the efficacy of trifluoprazine in improving the Clinical manifestations of patients with confirmed COVID-19 infection by recording the patient's clinical parameters including 7 clinical parameters of respiration number, Blood Oxigen Saturation, oxygen support, temperature, heart rate, systolic blood pressure and Awareness level, assessment of lung involvement with Chest CT-Scan, measurement of c-reactive protein on treatment days, measurement of CBC indicators and biochemical factors such as urea and creatinine. Timepoint: Check of the patient's clinical condition and blood sampling of patients on days 1-14 in the hospital and also on the 28th day after the onset of the disease. Method of measurement: Measuring CBC indicators and biochemical factors using an autoanalyzer and examining heart function using EKG,Measurement of other factors using a thermometer and blood pressure monitor and patient bedside examinations.

Dose-Finding Study of Ivermectin in the Treatment of COVID-19
Chest image(CT scan). Timepoint: at hospital clearance. Method of measurement: Patient's profile(CT scan image).;Hospitalization time. Timepoint: end of intervention. Method of measurement: Hospitalization time.;CBC and CRP. Timepoint: Before intervention, 7 days after intervention. Method of measurement: Sampling and lab test.

Early tracheostomy in COVID-19
The oxygen blood saturation. Timepoint: Every 12 hours from the first day of hospitalization to the last day. Method of measurement: The pulse oximetry.;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.;The mortality rate. Timepoint: 10, 20 days after starting intervention. Method of measurement: Counting deaths.

Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm
Improving the general condition of the patient. Timepoint: Before and after intervention. Method of measurement: Lung CT scan; No need to receive any intensive respiratory care in the patient.;Mortality rate. Timepoint: At baseline and discharge time or patient death. Method of measurement: Observation.;Need for intubation. Timepoint: Period of hospitalization. Method of measurement: Observation or reading of hospitalized documents.

Treatment of COVID-19-induced cytokine storm by hemoperfusion
The general condition of the patient. Timepoint: Before intervention and 1 day after final intervention. Method of measurement: Lung CT scan; No need to receive any intensive respiratory care in the patient.;Mortality rate. Timepoint: At baseline and discharge time or patient death. Method of measurement: Observation.;Need for intubation. Timepoint: Period of hospitalization. Method of measurement: Observation or reading of hospitalized documents.;Period of hospitalization. Timepoint: At baseline and discharge time. Method of measurement: Number of hospitalized days.

Evaluating the effect of Phyllanthus Emblica on COVID 19 patients
Viral diagnostic test. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Polymerase chain reaction.

Evaluation the efficacy of hot foot-bath on COVID-19
Temperature. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Fisman scale.;Respiratory rate. Timepoint: Daily. Method of measurement: Counting the number of breaths per minute.;Weakness. Timepoint: Daily. Method of measurement: Visual analog scale.;Muscular pain. Timepoint: Daily. Method of measurement: Visual analog scale.;C Reactive Protein (CRP). Timepoint: Daily. Method of measurement: Blood test.;Lymphocyte count. Timepoint: Daily. Method of measurement: Blood test.;O2 Saturation percentage (SpO2). Timepoint: Daily. Method of measurement: Pulse oximetery.;Anxiety. Timepoint: Daily. Method of measurement: Beck questionnare.;Chest X Ray. Timepoint: Daily. Method of measurement: Analysis of radiography.

Evaluation of the effect of Iranian medicine product, Algro, on patients with coronavirus 19
Measurement of cough severity. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Standard cough questionnaire.;Severity of shortness of breath. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.

The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in Tabriz
Percentage of effect of Tocilizumab on COVID-19 patients. Timepoint: Patients receive the drug in a single dose over an hour, and resorption monitoring will be performed to improve oxygenation status and subsequent complications in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Method of measurement: Clinical and laboratory testing.

Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19
Death. Timepoint: At the time of discharge from the hospital. Method of measurement: Patient medical records.

Effect of interactive psycho-educational interventions on patients infected with COVID-19
Self-efficacy. Timepoint: Before, one week and two weeks after the intervention. Method of measurement: People to Promote Health (SUPPH) questionnaire.;Anxiety. Timepoint: Before, one week and two weeks after the intervention. Method of measurement: State-Trait Anxiety Inventory.

The effect of Naproxen in recovery and reducing mortality in patients with COVID-19
Recovery in COVID-19 patients. Timepoint: At the beginning (day zero) and the end of the treatment period (day 10). Method of measurement: Examination of clinical signs.;Mortality rate in COVID-19 patients. Timepoint: At the end of treatment period. Method of measurement: The percentage of mortality rate in the study population.

Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS
Mortality rate in first month from the time of entry into the study. Timepoint: The first month of entering the study. Method of measurement: Continuous clinical evaluation.

Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad
Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on clinical, paraclinical and laboratory findings.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient interview and file.;Radiologic response. Timepoint: one month after the beginning of the treatment. Method of measurement: lung HRCT.

Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection
Adverse events assesment. Timepoint: At the same time of each intervention, 24 hours after each intervention, on days 6, 7, 14 and 28 after the first intervention. Method of measurement: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.;Blood oxygen saturation. Timepoint: At Baseline, simultaneously with each intervention and on days 5, 6, 7, 14 after the first intervention. Method of measurement: Evaluation of Pneumonia Improvement.

Effect of Intravenous vitamin c in Patients with COVID-19
Improvement of SPO2 (stands for peripheral capillary oxygen saturation). Timepoint: Daily, until 3-5 days or discharge. Method of measurement: pulse oximetry.

Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19
Respiratory symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Respiratory symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: pulse oxymetery device.;Respiratory symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome
Mortality rate. Timepoint: from including to study to 60 days. Method of measurement: observation.;Blood O2 saturation. Timepoint: before and during the study for 14 days. Method of measurement: pulse Oximeter.;Oxygen therapy need. Timepoint: before and during the study for 14 days. Method of measurement: Clinical.

The effect of hydroxychloroquine to prevent coronavirus disease
Reduction of incubation time. Timepoint: Daily for 14 days. Method of measurement: Participants' clinical status.;Reducing the incidence of Symptomatic respiratory disease. Timepoint: 14 days after taking hydroxychloroquine. Method of measurement: CT-scan test.

The effect of melatonin on the quality of sleep in COVID-19 patients
Stop the fever. Timepoint: It will be reviewed for 7 days from the study onset. Method of measurement: It is recorded by a thermometer.;Transfer to ICU. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Mortality. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Sleep quality. Timepoint: Days 1, 2, 3, and 7. Method of measurement: The Leeds Sleep Evaluation questionnaire will be used.

Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients
Effect of convalescent plasma. Timepoint: Blood and plasma will be taken from patients who have been symptom free for 14-17 days. If it is less than 14 days, the donor should have 2 negative tests in two different days. Method of measurement: ELISA.

Evaluation the effect of asafoetida in the treatment of coronavirus infection
Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.

Effect of lithium carbonate on COVID-19

Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings
Confirmed and possible Coronavirus 2019. Timepoint: at the time of admission. Method of measurement: CT scan - PCR test Corona virus.

Effect of Atorvastatin in treatment of COVID-19 infection
Time to clinical improvement (TTIC). Timepoint: Daily. Method of measurement: Based on clinical findings such as fever, respiratory rate, percentage of oxygen saturation, cough.;Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Adverse effects. Timepoint: Daily. Method of measurement: Interview and patient's record.;Clinical outcome (cure or death). Timepoint: End of the treatment. Method of measurement: Patient's record.

Effect of Ozone therapy in treatment of COVID-19
Quantitative CRP. Timepoint: Before and after the intervention. Method of measurement: Lab kit.;Oxygen Saturation. Timepoint: Before and after the intervention. Method of measurement: Pulse Oximetry.;Body's temperature. Timepoint: Before and after the intervention. Method of measurement: Thermometer.;Dyspnea. Timepoint: Before and after the intervention. Method of measurement: Subjective assessment of the patient and physical examination.;Cough. Timepoint: Before and after the intervention. Method of measurement: subjective assessment of the patient.;Diarrhea. Timepoint: before and after the intervention. Method of measurement: subjective assessment of the patient.;Headache. Timepoint: Before and after the intervention. Method of measurement: Subjective assessment of the patient.;Chills. Timepoint: Before and after the intervention. Method of measurement: Subjective assessment of the patient.

effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital
Oxygenation. Timepoint: daily. Method of measurement: pulse oximetery.

Placental Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 1-2 Clinical Trial
Adverse events assesment. Timepoint: At the same time of each intervention, 24 hours after each intervention, on days 6, 7, 14 and 28 after the first intervention. Method of measurement: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.;Blood oxygen saturation. Timepoint: At Baseline, simultaneously with each intervention and on days 5, 6, 7, 14 after the first intervention. Method of measurement: Evaluation of Pneumonia Improvement.

The effectiveness of educational-treatment package based on psychological flexibility in burnout, quality of working life, work-family conflict and mental health
Quality of work life score in Walton's questionnaire. Timepoint: Before and after the implementation of the educational-therapeutic package. Method of measurement: Walton's Work Quality of Life Questionnaire.;Mental Health Score in the General Health Questionnaire (GHQ). Timepoint: Before and after the implementation of the educational-therapeutic package. Method of measurement: General Health Questionnaire (GHQ).;Work-Family Conflict Score and Family-Work Conflict in the Work-Family Conflict Questionnaire. Timepoint: Before and after the implementation of the educational-therapeutic package. Method of measurement: the Work-Family Conflict Questionnaire.;The burnout score on the burnout questionnaire is gold. Timepoint: Before and after the implementation of the educational-therapeutic package. Method of measurement: Goldard's burnout questionnaire.

Use of Convalescent Plasma in the treatment of COVID-19
Fever. Timepoint: registration day and week 4. Method of measurement: thermometer will be used for physical examination to check fever.;Resolution of infection. Timepoint: 28 days. Method of measurement: Two non-reactive Nucleic Acid Tests (NAT) for SARS-CoV-2 performed at an interval of at least 24 hours on nasopharyngeal swabs.;Lung infiltrates. Timepoint: registration day and week 4. Method of measurement: X-ray will be used.;Arterial blood oxygen saturation. Timepoint: registration day and week 4. Method of measurement: Lab test (blood from artery will used).;Respiratory rate. Timepoint: registration day and week 4. Method of measurement: physical examination was conducted to measure the breath rate by counting chest or abdomen rises number over a minute.

Effect of ppd on recovery of covid disease 19
Having covid 19. Timepoint: 3-7-14. Method of measurement: Negative test.

Effect of Formoterol in treatment of covid19
Time to Clinical Improvement. Timepoint: 1, 2, 3 weeks. Method of measurement: call interview follow up.;Relapse and re visiting. Timepoint: 10 days. Method of measurement: observation.

Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of coronavirus disease
Symptoms of disease. Timepoint: During the hospital stay, on a daily basis. Method of measurement: The severity of patient's clinical symptoms is measured on the basis of visual analog scale.;Vital Signs. Timepoint: During the hospital stay, on a daily basis. Method of measurement: Vital signs monitoring device.;C-Reactive Protein. Timepoint: During the hospital stay, on a daily basis. Method of measurement: C-Reactive Protein test.

Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19
Lung involvement in X-ray and CT-scan, SPO2, LDH enzyme, viral load, acute phase protein, white blood cell count, ESR, length of hospital stay, duration of mechanical ventilation. Timepoint: from the start of the intervention for 12 days. Method of measurement: Blood and biochemical factors are measured using laboratory tests by an autoanalyzer. Pulmonary function indicators are measured by pulse oximetry and ABG.

The effect of Intravenous immunoglobulin on COVID-19 infection
Pulmonary manifestations. Timepoint: before and after treatment. Method of measurement: Computed Tomography scan.

The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases
Improvement of clinical symptoms. Timepoint: Start of study and 7 days after study. Method of measurement: Questionnaire - telephone follow-up and.

The effect of azithromycin in treatment of COVID19
Peripheral capillary oxygen saturation. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: pulse oximeter.;Admission duration. Timepoint: From the beginning of the hospital visit to the discharge. Method of measurement: Questionnaire.;Fever. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: Mercury thermometer.;Need to ICU admission. Timepoint: During admission. Method of measurement: Questionnaire.

Effect of pomegranate tea on symptom relief of COVID-19 patients
Time to clinical improvement. Timepoint: Every day after randomization. Method of measurement: Patients' medical records.;Time to clinical deterioration. Timepoint: Every day after randomization. Method of measurement: Patients' medical records.;Duration of Hospitalization. Timepoint: Every day after randomization. Method of measurement: Patients' medical records.

Effect of NK cell therapy in COVID-19
Fever. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Thermometer.;Number of breathes per minute. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records of the number of breaths in a minute by Nurse in 3 consecutive minutes.;Pulmonary volume. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Pulmonary capacity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Airway resistance. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Lung elasticity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Chest pressure. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Cough. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.;Skin disorders. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.

Plasma therapy in patient with COVID-19
Size of lesion area in lung. Timepoint: On day of 1, 4,7,14, and 38 after plasma therapy. Method of measurement: Chest CT scan.;Fever duration. Timepoint: On day of 1, 4,7,14, and 38 after plasma therapy. Method of measurement: termometer.;Respiratory rate. Timepoint: On day of 1, 4,7,14, and 38 after plasma therapy. Method of measurement: the number of breaths per minute.;PaO2/FiO2 ratio. Timepoint: On day of 1, 4,7,14, and 38 after plasma therapy. Method of measurement: ventilator equipment.

Evaluation of the therapeutic effect of a combination drug including Apocynin, Niacin, and Tannin on COVID-19
Fever. Timepoint: BID. Method of measurement: Thermometer.;Hemodynamic signs. Timepoint: BID. Method of measurement: P/E.;O2 sat. Timepoint: BID. Method of measurement: Puls-Oximetery.;Clinical symptomes. Timepoint: TDS. Method of measurement: P/E and medical hx.

Stem cell therapy in COVID-19
Biomarker expression. Timepoint: two weeks after last cell therapy. Method of measurement: Flowcytometery.;IL-6 and IL-1 Level. Timepoint: Before Cell injection and two weeks after cell injection. Method of measurement: Elisa Kit.;Respiratory and lung function. Timepoint: Before Cell injection and two weeks after cell injection. Method of measurement: Physical examination , O2 saturation and CT Scan.

Effect of natural from Tahini oil product on corona
Fever. Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 14 days after the start of intervention. Method of measurement: check list.;Chills. Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 14 days after the start of intervention. Method of measurement: check list.;Respiratory rate. Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 14 days after the start of intervention. Method of measurement: check list.;Inpatient period. Timepoint: At the beginning of the study (before the intervention) and 7 and 14 days after the intervention. Method of measurement: check list.;Death of patients. Timepoint: At the beginning of the study (before the intervention) and 7 and 14 days after the intervention. Method of measurement: check list.

Trifluoperazine Effectiveness in Treatment of Coronavirus
Time to clinical improvment: normalization of body temperature to 37.2 and lower. Timepoint: Daily. Method of measurement: Clinical examination.;Time to clinical improvment: normalization of respiratory rate to 24 and fewer. Timepoint: Daily. Method of measurement: Clinical examination.;Time to clinical improvment: Oxygen saturation of 94% and more. Timepoint: Daily. Method of measurement: Palse oximeter.

Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19
Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: pulse oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

The prophylactic effect of Hydroxychloroquine on Novel Corona virus
The number of confirmed cases. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.;Serum CRP levels and cellular immunity (cd8 / cd4 ratio) are assessed at the beginning and end of the study for all subjects. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.;The two groups will also be examined in terms of disease severity (need for intubation, ICU hospitalization) and absolute lymphocyte count. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.

?Evaluation the effects of Sitagliptin administration in patients with COVID-19
Fever. Timepoint: Daily, From admission to discharge time. Method of measurement: Thermometer.;Cough. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.;Dyspnea. Timepoint: Daily, From admission to discharge time. Method of measurement: Observation.

Efficacy of tenofovir in covid-19
Vital signs. Timepoint: daily. Method of measurement: direct physical examination.;Body temperature. Timepoint: daily. Method of measurement: thermometer.;White blood cell count. Timepoint: daily. Method of measurement: blood sample analysis.

Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19
Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

Clinical trial study on the therapeutic effect of Tenofovir besides Kaletra and Chloroquinein in patients with Coronavirus disease 2019 (COVID-19)
Reduce the mortality rate of patients with Covid-19. Timepoint: days 0-7. Method of measurement: Based on the percentage of discharged Covid-19 patients.

Evaluation of the colchicine tablet efficacy as an adjuvant therapy for patients with mild to moderate COVID-19
Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on patients examination and interview.;Radiologic response. Timepoint: two weeks after treatment. Method of measurement: lung CT scan.;Laboratory response. Timepoint: weekly. Method of measurement: assessment of serum level of CRP and CBC diff.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient file and interview.

Effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)
Improvement in disease symptoms (Fever and breathing). Timepoint: This primary outcome is measured for patients before and during 5 days after treatment initiation. Method of measurement: Fever is calculated using mercury thermometers and respiration is calculated using the number of breaths per minute.

The effect of NBS powder in treatment of patients with COVID-19
Pulmonary symptoms. Timepoint: 4 weeks after intervention. Method of measurement: CT Scan.

Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19
Dyspnea. Timepoint: Every day for 3 weeks. Method of measurement: With taking history and physical examination.;Fever. Timepoint: Every day for 3 weeks. Method of measurement: With physical examination.;Cough. Timepoint: Every day for 3 weeks. Method of measurement: With taking history.

Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test
Complete recovery of clinical symptoms of 2019 disease. Timepoint: About a week after starting treatment. Method of measurement: Clinical and laboratory questionnaire.;Normalization of chest symptoms in CT scan. Timepoint: About 7 to 14 days after starting treatment. Method of measurement: CT scan result.

The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)
Clinical response. Timepoint: During hospitalization. Method of measurement: Cessation of fever, improvement of shortness of breath, reduction of cough, blood oxygenation (SaO2) and hemodynamic parameters.;Mortality. Timepoint: During hospitalization. Method of measurement: Count the number of dead patients.;Hospital stay. Timepoint: During hospitalization. Method of measurement: Count the number of hospital days to improve clinical symptoms.

Evaluation effect of Indomethacin for Covid19 infection
Time to clinical recovery. Timepoint: Control clinical signs daily until discharge from the hospital. Method of measurement: Fever control with thermometer, oxygen saturation control with pulsoximetry.;14 days readmission after discharge. Timepoint: Up to 14 days after discharge. Method of measurement: All patients will be given a contact number to notify them if they are hospitalized again. All patients will be monitored by phone weekly for up to 4 weeks after the first day they are admitted.;Time to intubation. Timepoint: Control of oxygen saturation, respiratory status every 6 hours during hospitalization. Method of measurement: If the patient needs intubation due to reduced oxygen saturation or increased respiration rate, the date of incubation will be recorded on a daily basis from the time of hospitalization.

Effect of curcumin-piperine in patients with coronavirus(COVID-19)
CT of the chest. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Find out - Photos - CT.;Body temperature. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using clinical thermometer.;Duration of hospitalization. Timepoint: At the time of discharge from the hospital. Method of measurement: By Using the patient's medical record.;Hs-CRP. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic method.;ESR. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic method.;ALT. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;AST. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;LDH. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Enzymatic photometric method.;BUN. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: urine sample.;Creatinine. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: by laboratory kit.;CBC. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: blood sample.;Blood oxidative stress indices ( SOD, MDA, TAC). Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using available commercial kits.;Albumin. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: blood sample.;Severity of the disease. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: By using clinical and laboratory evaluations.;Severity and number of coughs. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: Visual analogue scales (VAS) for cough.

Effect of of Inhalation of Thyme Oil in COVID-19
Percentage of oxygen saturation. Timepoint: Before the start of the intervention, 5 consecutive days during the intervention and one day after the intervention. Method of measurement: Pulse oximeter.;Respiratory rate. Timepoint: Before the start of the intervention, 5 consecutive days during the intervention and one day after the intervention. Method of measurement: Count the respiratory rate per minute.

Investigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19
Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19
Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer.

Study the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19
Disease recovery. Timepoint: The beginning of the study and the end of the study. Method of measurement: Based on laboratory and imaging criteria.

The Effect of Convalescent Plasma Therapy on Patients with 19-COVID
Reduction in all causes mortality. Timepoint: At the time of discharge of patients. Method of measurement: Patient documents.

effects of convalescent plasma in COVID-19
Hospitalization time. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.;ICU admission time. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.;Mechanical ventilation time. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.;Survival rate. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.

The effect of herbal syrup on patients with corona
Blood oxygen saturation level. Timepoint: 0,1,2,3,5,7 days after intervention. Method of measurement: Pulse oximetry.

Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19
Need to receive ICU service (occurrence of shock, resistant hypoxemia despite receiving oxygen via reservoir oxygen mask, GCS score drops below 12). Timepoint: The patient is monitored every 6 hours, but the results are recorded daily in the checklist. Method of measurement: Physical assessment.

The effect of addition of selenium to treatment regimen of hospitalized patients with corona on the outcome of disease compared with control group
Need mechanical ventilation. Timepoint: during hospitalization. Method of measurement: daily visit.;Need to be hospitalized in the intensive care unit. Timepoint: during hospitalization. Method of measurement: daily visit.;Duration of hospitalization. Timepoint: during hospitalization. Method of measurement: daily visit.

Evaluation of the effect of jujube product on Covid-19 patients
Clinical symptoms (Coronavirus infection). Timepoint: Before starting the study and daily until discharge. Method of measurement: Laboratory values and radiographic changes or CT scans and questionnaire.

effect of propolis in COVID-19
Cough. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Oxygen saturation. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Respiratory rate. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Body temperature. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;LI-6. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;TNF alpha. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;Crp-hs. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;CBC. Timepoint: First and 30 days after the intervention. Method of measurement: Cell counter.

Evaluation of the effectiveness of rabbit antibody against coronavirus in patients
Clinical improvement within 14 days after patient admission. Timepoint: every day. Method of measurement: 2-point decrease in the patient's level compared to the admission time level. 6-point scale includes: score 6: death score 5: hospitalization for ECMO and (or) mechanical ventilation score 4: non-invasive ventilation or high-current oxygen therapy score 3: hospitalization for oxygen therapy (not high current and mechanical ventilation) Not required) Score 2: Hospitalization Score 1: Clearance.;Patient mortality rate in 14 days. Timepoint: every day. Method of measurement: Clinical observation.

Radiotherapy in COVID-19
Increase in arterial oxygen pressure. Timepoint: day 1,2,3,4,5,6,7,14,21,28 post treatment. Method of measurement: Blood sample.

Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19
Need to mechanical ventilation. Timepoint: Within 28 days after the intervention. Method of measurement: By physical examination.;The patient's clinical status. Timepoint: Within 28 days after the intervention. Method of measurement: Based on the World Health Organization's 7-score system.;Mortality rate. Timepoint: Within 28 days after the intervention. Method of measurement: Based on medical document.

Psychiatric Consultation for COVID-19 Patients
PHQ-9 (Patient Health Questionnaire-9);GAD-7 (Patient Health Questionnaire-9);PC-PTSD-5 (Primary Care PTSD Screen for DSM-5);AIS (Athens Insomnia Scale);P4 (P4 Suicidality Screener);SF-36 (Short Form Health Survey Questionnaire)

Clinical efficacy of Nafamostat for COVID-19 pneumonia
Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
The overall objective of the study is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19.
-The primary objective will be determined by a pilot study of the first 100 subjects.
-Subject clinical status (8-point ordinal scale) at Day 15 is the default primary endpoint.

COVID-19 Registry

Multicenter observational study to examine the efficacy of protection during endoscopy examination for Covid-19 infection

Evaluating the social function of people with dementia under the COVID-19 epidemic
by the Japanese version of the social functioning in dementia scale

A Multicenter, Retrospective Study to Evaluate the Efficacy of Systemic Gluco-corticoid Against COVID-19
The odds ratio for improvement on a 7-point ordinal scale* on Day 15.
[*The scale is as follows: 1) Death, 2) Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO), 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4) Hospitalized, requiring low flow supplemental oxygen, 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise), 6) Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care, 7) Not hospitalized.]

Examination of test accuracy of COVID-19 rapid antibody kit

Changes of D-dimer in preventive period for COVID-19 for patients with chronic heart failure

Had COVID-19 Spread in Nagasaki Prefecture before the first confirmed case?
Detection rate of SARS-CoV-2 in the residual nasopharyngeal swabs obtained between November 2019 and March 13 2020.

Study on risk perception and behavioral change related to COVID-19

Simulation study of tracheal intubation through an aerosol-box assuming COVID-19

Prospective observational study on diagnosis and treatment of COVID-19
Aggravation rate
Recovery rate
Number of days until COVID-19 becomes negative
Presence of complications
Treatment content
Correlation between the results obtained by SARS-CoV-2 antibody test and real time PCR, next-generation sequencing, immunochromatography and blood sampling test items

Impacts of COVID-19 prevention life in community-dwelling older adults and support measures

A feasibility study of remote rehabilitation using a wearable biological monitoring device in the patients with COVID-19
remote rehabilitation under remote monitoring can be performed safely

Efficacy and Safety of Corticosteroids in COVID-19
the incidence of treatment failure in 14 days

Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19

Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
changes in the ratio of PaO2 to FiO2 from baseline

Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
Number of days alive and discharged from hospital within 14 days

Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic
Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs = 29).;Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21—Depression); in terms of proportions (0-4 vs = 5).;Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21—Anxiety); in terms of proportions (0-3 vs = 4).;Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21—Stress); in terms of proportions (0-7 vs = 8).

Hydroxychloroquine for the Treatment of Mild COVID-19 Disease
Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment

COVID-19 Plasma Collection
Number of patients who screen eligible for donation;Number of patients who consent to plasma donation;Number of plasma donations received

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
Subject alive and free of respiratory failure

COVID 19-Caregivers IGg Seroconversion

DAS181 for STOP COVID-19
COVID-19 Clinical Classification (CCC);Return to room air (RTRA)

Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain

Etoposide in Patients With COVID-19 Infection

Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19
Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment

COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers
Sample Size of enrolled CHAMPS Study participants by demographic characteristics during the first two years of the study;Exposure to SARS-CoV-2 based on models computed from participant baseline data and community variables, if available.;Infectious disease and chronic disease incidence rates by demographic characteristics;Completeness of data by demographic characteristics.

The COVID-ICU Healthcare Professional Study
Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic

Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19
Improvement in knowledge surrounding SRA policy;Improvement in anxiety surrounding SRA policy;Improvement in trust surrounding SRA policy

Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2
Time course of body temperature (fever);Viral load over time

Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);
Health-related quality of life; EuroQoL (EQ-5D-5L);6-minute walk test

Host-pathogen Interactions During SARS-CoV-2 Infection
Initial biological profile of children and adults with COVID-19 infection;Initial immunological profile of children and adults with COVID-19 infection

Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy
Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients;Variation of factor V concentration (U/dL) in Hospitalized Covid-19 patients.;Variation of factor II concentration (U/dL) in Hospitalized Covid-19 patients;Variation of concentration of fibrin and fibrinogen degradation products (= 10 µgm/mL) in Hospitalized Covid-19 patients.

Haemoglobin Concentration on COVID-19
Relationship between severity of disease and values of erythrocyte indices

Serological Testing for COVID-19 (SARS-CoV-2) in ESKD

Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
Successful cardiovascular intervention;Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention;absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI);Number of participants requiring mechanical ventilation for respiratory failure

Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19
Patient requires invasive mechanical ventilation and suffers from acute respiratory failure.;Patient is discharged;Patient is hospitalized, but does not require mechanical ventilation through the duration of hospital stay.

Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia
The changes of COVID Ordinal Outcomes Scale;Percentage of the patients with Clinical Recovery;The changes of the Borg's scale

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
Occurrence of Adverse Events and Serious Adverse Events;Subject alive and free of respiratory failure

Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19
percentage changes in the consumption of psychoactive substances

Almitrine and COVID-19 Related Hypoxemia
Changes from baseline PaO2 (mmHg);Changes from baseline ScvO2 (%)

Covid-19 Pandemic and Pancreatic Surgery in Italy
Changes in pancreatic cancer management during the COVID-19 pandemic

Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital

ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation
Patient Health Questionnaire (Löwe et al., 2002)

Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome

Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Cumulative incidence of serious adverse events associated with clazakizumab or placebo

Oral Health and Psychosocial Factors During the Covid-19 Pandemic
How do people assess their oral health-related quality of life in times of the Covid-19 pandemic?;Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment?

Transpulmonary Driving Pressure in ARDS COVID19 Patients

Direct and Indirect Impact of COVID-19 In Older Populations
mortality;Risk factors for death;mortality;Risk factors for death

Rehabilitation for People With COVID-19 in ICU

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
Duration of received supplemental oxygen therapy

Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19
Clinical status of the patient (according to 7-point ordinal scale)

Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
Death;Recovery from COVID-19;Progression to ICU care or ventilation

Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia
Mean hospitalization time;Mean Oxigenation index evolution;Rate of severe ARDS;Rate and time to dead;Mean time with invasive mechanical ventilation

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients
Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks );Mortality rate

Co-infection Management in COVID-19 Critically Ill

Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19
Time to resolution of symptoms as defined by the single question 'how unwell do you feel today'.

Impact of COVID-19 on Mental Health of Health Care Workers
Depressive symptoms at baseline;Change in depressive symptoms;Anxiety levels at baseline;Change in anxiety levels;Stress levels at baseline;Change in stress levels;Quality of life at baseline;Change in Quality of life;Covid-19 related psychological distress;Change in Covid-19 related psychological distress;Post traumatic stress symptoms;Change in post traumatic stress symptoms

Non-invasive Ventilatory Support of Patients Affected by COVID-19
The number of patients treated with non-invasive ventilation devices.

Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT
Radiological pattern of initial presentation, disease progress, healing and recovery;Survey of co-morbid lung diseases

A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction
Symptoms and signs;Respiratory function;The body function;ADL

Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic
Dispositional questionnaire 1;Dispositional questionnaire 1;Dispositional questionnaire 2;Dispositional questionnaire 3;Dispositional questionnaire 3;Dispositional questionnaire 4;Dispositional questionnaire 4

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
Change from Baseline Oxygenation on Day 1 to Day 5;Change from Baseline Oxygenation at Day 5

Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia
Short Physical Performance Battery (SPPB) Score

Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure
Mean change in oxygenation;Median change in oxygenation

Immunosupressive Treatment in COVID-19 Patients

Novel Regimens in COVID-19 Treatment
Number of patients with virological cure

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients
Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:

High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)
COVID-19 PCR status at completion of treatment (day 3) from tracheal aspirate

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)
Safety index-incidence of adverse reactions;Immunogenicity index-seroconversion rates of neutralizing antibody

Fear Among Dentists During COVID-19 Pandemic
fear among dentist during COVID 19 epidemic

Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales

Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic
Change of emergency department staff's level of stress during the covid19 pandemic, measured using the Chamoux et Simard visual analogic scale

The Geneva Covid-19 CVD Study
mobidity discharge;mobidity at 30 days;mobidity 1 year after hospitalization;mortality discharge;mortality 30 days after hospitalization;mortality 1 year after hospitalization

Genetic Basis of COVID-19 Infection
Mutations leading to increase susceptibility to SARS-COV-2 infection

Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19

Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)

Covid-19 Pandemic: Patients' Experience in T1D

Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers
Incidence of documented COVID-19 among health care workers exposed to SARS CoV2 and vaccinated with BCG compared to placebo.

COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)
in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma;safety of the use of convalescent plasma drom COVID 19 donors

Outcomes in Hospitalized Older Patients With COVID-19
To evaluate the relative contributions of comorbidities on intra-hospitalized death

Taiwan "Aerosol Box" Versus UMMC "Intubation Box"

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling;Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling;Elimination rate constant (ke) as measured by PK sampling;Half-life (t1/2) as measured by PK sampling;Absorption rate constant (ka) as measured by PK sampling;AUC (area under the curve) as measured by PK sampling;Maximum concentration (Cmax) as measured by PK sampling;Time to achieve maximum concentration (Tmax) as measured by PK sampling

Acute Respiratory Failure and COVID-19 in Real Life
Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System
Sensitivity, spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform

Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)

Prognostic Factors Keeping Track for COVID-19 Pneumonia

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection;Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection

An Observational Study of Patients With Coronavirus Disease 2019
Natural history of COVID-19: Characteristics of COVID-19;Natural history of COVID-19: Participant demographics;Natural history of COVID-19: Treatment use;Time point of clinical response

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
Number of participants with clinical infection with COVID-19 infection

Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation

Cardiovascular Complications and COVID-19 (CovCardioVasc)
Determine the incidence of cardiomyopathies and venous thromboembolism

Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)

COVID-19 Convalescent Plasma
Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients;Type of respiratory support

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.;Polymerase chain reaction assay (PCR) negative at day 30.;Polymerase chain reaction assay (PCR) negative at day 60.

Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome
Comparison of the percentage of clinically improved inpatients between D0 and D14

Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation

LunG canceR pAtients coVId19 Disease (GRAVID)
Clinical data of lung cancer patients with COVID-19 diagnoses;Diagnosis data;Treatments received;Prognostic factors

Assessment of Chilbains Occuring During Covid-19 Infection

Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
Change in SARS-CoV-2 mucosal immune response in the nasopharynx;Change in microbial load in the nasopharynx;Change in Viral Load in the nasopharynx over the course of COVID-19 infection

COVID-19 Remote Monitoring

Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being
Identification of prognostic factors for progression to a severe form of COVID-19 infection

Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020

PROLIFIC ChemoprophylaxisTrial (COVID-19)

Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure
Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint);Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint);Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint);Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)

A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection

Kidney Involvement in COVID-19 Disease (COVKID)

COVID-19 Among Egyptian Health Care Providers
The percentage of knowledge regarding COVID-19 information

Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia

Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)

Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients
Anosmia;Ageusia;Duration of the loss of anosmia ageusia

Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)
Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19

Obstructive Sleep Apnea & Covid-19 Outcomes

Anakinra for COVID-19 Respiratory Symptoms

Observational Cohort of COVID-19 Patients at Raymond-Poincare

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
Percent of healthcare workers testing positive for COVID-19.;Percent of patients testing positive for COVID-9.

Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)
Mortality;Immune response - Plasma cytokine profile;Immune response - Phenotype of circulating cells

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
Death;Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO;Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2);Cumulative incidence of grade 3 and 4 adverse events;Number of participants with serious adverse events;Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin

Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic

The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
Time for clinical improvement;Clinical parameter of acute lung disease;Biochemical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameters of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Biochemical parameter of acute lung disease;Biochemical parameter of acute lung disease;Biochemical parameter of acute lung disease;Biochemical parameter of acute lung disease;Biochemical parameter of acute lung disease

Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Ventilator-Free Days;Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0.

Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU

Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)
The proportion of patients with improved disease severity at day 2;The proportion of patients with improved disease severity at day 3;The proportion of patients with improved disease severity at the day before hospital discharge

Immunophenotyping Assessment in a COVID-19 Cohort
Mortality Rate Among COVID-19 Patients;Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28;Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28;Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28;Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12;Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28;Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28

A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715)
proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC=1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve

Analysis of Mortality of Critically Ill Patients With COVID-19

COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)
Change in serial monthly log-transformed antibody titre levels as measured

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
change in initiation of mechanical ventilation in patients with CoViD-19 compared to the control group.

Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic
Mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks during COVID-19 pandemic;Mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks 6 months after WHO declares pandemic over COVID-19 pandemic;Mental health symptoms change, well-being change from last 2 weeks before the pandemic to last 2 weeks 12 months after WHO declares pandemic over COVID-19 pandemic

Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
Presence or absence of olfactory and taste disturbances in study participants;Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection

Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study
Differences related to epidemiological demographic characteristics

Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19
Evolution of the PaO2 / FiO2 ratio between the measurements taken before (t0) and one hour after the end of the invasive procedure (H1).

"Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"
Evaluation of depression and anxiety score changes of covid-19 positive pregnants

Accelerated Prone Position Ventilation of Patients With COVID-19
Days alive without respiratory life support (invasive mechanical ventilation) at day 28.

Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis

Role of Inflammasomes in COVID-19 Disease
Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19

Hyperimmune Plasma in Patients With COVID-19 Severe Infection

COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study
To collect retrospective demographic information on 500 people admitted to selected hospital sites across the UK with a COVID-19 diagnosis confirmed through positive laboratory PCR swab.;To record the results of each patient's measured medical observations, clinical investigations and outcomes during the course of their admission.;To conduct retrospective analysis of data collected to map each patient's clinical journey during their admission

Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

Predictive Immune Biomarkers for COVID-19 Pathogenesis
Immune signature;Dosage of cytokines and chemokines in plasma samples

Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection
Existence of a post-intensive care syndrome-family ((combined score of the HAD ( Hospital Anxiety and Dépression scale) and IES-R ( Impact of Event Scale-Revised) questionnaires))

Convalescent Plasma for Patients With COVID-19
Improvement in respiratory disease;Improvement in respiratory disease;Improvement in respiratory disease;Improvement in respiratory disease;Improvement in respiratory disease;Improvement in respiratory disease;Improvement in respiratory disease

#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
Proportion of poor outcomes (in index cases)

Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
IL-6 reduction by 75% or more after 72 hours as compared to the baseline measurement;time to successful ECMO-explantation

Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia
Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure

Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital

Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients
COVID-19 infection;Oxygen therapy for COVID-19;Discharge following COVID-19 hospitalisation;Death due to COVID-19

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death

Neurologic Manifestations of COVID-19
Mortality (binary outcome);Respiratory failure (binary outcome)

Neonatal Complications of Coronavirus Disease (COVID-19)
Incidence of neonatal COVID-19;Incidence of vertically transmitted COVID-19

Study on the Use of Sarilumab in Patients With COVID-19 Infection
Proportion of patients who show an improvement of the respiratory function

Immune Changes in Severe COVID-19 Pulmonary Infections
Changes in monocytes HLA-DR expression;Changes in lymphocytes subpopulations numbers;Changes in monocytes number

Covid-19 and Prevention of Malnutrition After Confinement by Dentists

Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)

Detection of COVID-19 in Saliva Collection
Detection of SARS-CoV-2 RNA in the saliva sample;Concordance between the Saliva sample and the nasonasopharyngeal sample SARS-CoV-2 RT-PCR results

Kidney Injury Severity and COVID-19
The effect of COVID-19 severity on the severity of renal failure

COVID-19 Infection in Healthcare Workers

The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease
Patient's perception of COVID-19 and medical use patterns

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
Description of the ophthalmological problems observed

Protecting Health Care Workers During the COVID-19 Outbreak

Dornase Alfa Administered to Patients With COVID-19 (DACOVID)
Number of participants discharged from the intensive care unit (ICU);Number of participants who survived COVID-19

Detection of Anti-COVID-19 Antibody Levels in an Hospital Population

Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)
Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.

Epidemiological Study of the Covid-19 Presto Test
o study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures Department, 45 and CDG Orleans Metropolitan

Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19
Severity and death;Adverse events that require study treatment interruption

Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19

Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic
Prevalence of SARS-CoV-2 infection throughout pregnancy in women;Incidence of SARS-CoV-2 infection throughout pregnancy in women

Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention
the number confirmed COVID-19 cases;The person with COVID-19 like symptoms

COVID-19, bLOod Coagulation and Thrombosis
percentage of patients with one or more DVTs.

Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19
Overall number and characteristics of patients with COVID-19 in ICU

HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
Correlation between serology testing and clinical suspicion of COVID-19

Antimalarial and Covid 19 in Rheumatoid Arthritis

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion

The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19
Oxygenation index (OI) area under the curve (AUC)0-12

Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19

Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study
Presence or absence of olfactory and taste disturbances in COVID-19 patients;Prevalence of olfactory disturbances in COVID-19 patients;Prevalence of taste disturbances in COVID-19 patients

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

Early CPAP in COVID-19 Confirmed or Suspected Patients

Post-Pandemic Perception of Public Space in Singapore
EEG power in alpha band;EEG power in beta band;fNIRS haemodynamics

To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care
Proportion of participants alive and not having required intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen flow) at 15 days after enrolment.
This outcome is assessed by the number of patients who are not admitted into the intensive care unit (ICU)
[15 days after enrolment]

Tocilizumab for tReatment Of COVID-19 in intensive cARe patients (“TROCAR”)
The number of days alive and free of ventilatory support as a composite outcome determined by data from patient records.[up to day Day 29]

The safety and efficacy of STC3141 in patient with COVID-19 Acute Respiratory Distress Syndrome
Changes in PaO2/FiO2 assessed by arterial blood gases and ventilator measures[end of infusion in stage 2];Incidence, nature and severity of AEs and SAEs[D10 in stage 1];Incidence of treatment discontinuation due to AEs [D10 in stage 1]

Evaluation of Shift, a smartphone application for Junior Medical Officers in New South Wales during the COVID-19 epidemic.
Depression symptom change:
Depression will be measured using the Patient Health Questionnaire (PHQ-9), a reliable and valid nine-item screening tool to assess depression severity over the past fortnight. The PHQ-9 also includes a single item assessing level of difficulty in daily functioning due to depressive symptoms.[Depression symptoms will be assessed at baseline and post intervention (occurring between 4 and 6 weeks post baseline) ];Anxiety Symptom change:
The Generalised Anxiety Disorder scale (GAD-7) is a reliable and valid seven-item screener for generalised anxiety symptoms. The GAD-7 also includes a single item assessing level of difficulty in daily functioning due to anxiety-related symptoms.[Anxiety symptoms will be assessed at baseline and post intervention (occurring between 4 and 6 weeks post baseline) ]

Prevalence of the loss of smell in patients with COVID-19: The SMELLY Study
Prevalence of UPSIT score <26 (anosmia or severe hyposmia) in cases[The UPSIT test for each participant is assessed at a single visit. The study outcomes will be measured 6 months post-first patient recruited., when the study is expected to be completed.]

In a simulation environment, is there a difference in time taken for consultant anaesthetists to perform spinal anaesthesia as compared to general anaesthesia on women, with suspected or confirmed COVID-19, who require emergency caesarean delivery?
We want to check the amount of time taken to perform each of the two procedures. This will be recorded with a stopwatch. All the data will be collected in a separate sheet and inserted in a computer. We will consider the simulation “PART 3” this moment. It will be counted in minutes and seconds.[Recorded from simulation “PART 3” in minutes and seconds]

Psychological impact of COVID-19 pandemic on perioperative staff at the Royal Melbourne Hospital – a longitudinal study
To evaluate the psychological impact of COVID-19 on perioperative staff by using a set of repeat survey questionnaires during the pandemic period. We use a combination of measurement tools as listed below in our secondary outcome section. They include GAD-7, PHQ-9, PC-PTSD-5, IES-R-22, AMBI-9 and a few qualitative questions.[Every 4 weeks during the COVID-19 pandemic up to a maximum of 8 months ]

Using blood plasma to develop passive immunity to coronavirus in Ecuador
Case fatality rate assessed through data collected from the follow-up instrument and medical record at 21 and 28 days

School opening in Norway during the COVID-19 pandemic
Positive COVID-19 among tested adults (aged 25–65) who live in the same household as children born 2004–2009 measured at 6 weeks, i.e. from 2 weeks after commencement of the trial, and 4 weeks after the intervention period

The real-world study for the change of early breast cancer diagnosis and treatment mode under the pandemic of Coronavirus Disease 2019 (COVID-19)

Status of management of surgery in Beijing during COVID-19

Investigation of Mental Status for in-patients with gastrointestinal malignancy during the COVID-19 Pandemic
EQ5D;Patient Health Questionnaire-9, Scale,DS;Insomnia Severity Index, ISI;COVID-19 Global Questionnaire;

The research Of novel coronavirus pneumonia (COVID-19) patients' immune status and severity of disease

A follow-up study about clinically diagnosed cases of novel coronavirus pneumonia (COVID-19)
pulmonary function test;the antibodies level of IgG and IgM;St.George's Respiratory Questionnaire;Hamilton Anxiety Scale;Hamilton Depression Scale;

A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)

Associations between suboptimal health status and TraditChinese Medicine constitution of medical staff fighting the disease, recovered COVID-19 patients and the general public under the outbreak of novel coronavirus pneumonia: an epidemiological study
the score of Sub-Health Measurement Scale V1.0 (SHMS V1.0);the scores of the Constitution in Chinese Medicine Questionnaire (CCMQ);

Clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) patients with pre-existing HBV infection

Clinical study for rapid detection of novel coronavirus pneumonia (COVID-19) nucleic acid
COVID-19 nucleic acid;SEN, SPE, ACC, AUC of ROC;

A randomized controlled trial for determination of the clinical effect of Internet-assisted pulmonary rehabilitation on patients with novel coronavirus pneumonia (COVID-19)
30-second sit-to-stand test score;treadmill test score;the 9-item Patient Health Questionnaire score;the 7-item Generalized Anxiety Disorder Scale score;the Revised Version of the Impact of Event Scale score;the Hospital Anxiety and Depression Scale score;Number of acute exacerbation;the Depression, Anxiety, and Stress Scales score;

Convalescent Plasma in the treatment of 6 COVID-19 Patients

Novel coronavirus pneumonia (COVID-19) and Symptomatic Venous Thromboembolism: a Multicenter Retrospective Study

The investigation of psychosocial stress status in juveniles during the pandemic of the novel coronavirus pneumonia (COVID-19)
Post traumatic stress disorder self rating scale;Self rating Anxiety Scale (SAS);PHQ-9 depression screening scale;Sleep self rating scale;

Efficacy of Early Prone Positioning in Non-Mechanical Ventilation novel coronavirus pneumonia (COVID-19) Patients with Severe Hypoxia- a single-center prospective cohort study

Acute Care Surgery during novel coronavirus pneumonia (COVID-19) pandemic in Spain

Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study
C-reactive protein;temperature;Erythrocyte sedimentation rate;Lymphocyte;CD4+ T cell;PaO2/FiO2;D-dimer;Platelets;SOFA score;Serum lactate dehydrogenase;Total bilirubin;Creatinine;Prealbumin;

A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients
Viral load of nCoV;Blood test;Immunological examination;Blood liver and kidney function test;Myocardial enzyme biochemical examination;ECG examination;Routine urine test;body temperature;pulse;Breathe;blood pressure;CT examination of the lungs;

A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19
Main Objective: The overall objective of the study is to evaluate the clinical efficacy of Brensocatib compared to placebo on top of standard care in adult patients hospitalized with COVID-19;Secondary Objective: Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm
Quality of life;Primary end point(s): Clinical status on 7-point ordinal scale:
1. Not hospitalised, no limitations on activities
2. Not hospitalised, limitation on activities;
3. Hospitalised, not requiring supplemental oxygen;
4. Hospitalised, requiring supplemental oxygen;
5. Hospitalised, on non-invasive ventilation or high flow oxygen devices;
6. Hospitalised, on invasive mechanical ventilation or ECMO (Extracorporeal membrane oxygenation)
7. Death.
;Timepoint(s) of evaluation of this end point: Up to day 29

IMU-838 and Oseltamivir in treatment of Novel Coronavirus (COVID-19)
Main Objective: To evaluate the efficacy of IONIC Intervention (IMU-838 plus Oseltamivir and standard care) vs. Oseltamivir and standard care in adult subjects with COVID-19 in relation to time-to-clinical improvement.;Secondary Objective: Secondary objectives
1.To evaluate safety and tolerability of IONIC intervention vs. Oseltamivir in adult subjects with COVID-19.
2.To determine the effects of IONIC Intervention on improvement of at least two points in clinical status scale
3.To assess the effects of IONIC Intervention vs. Oseltamivir on the need for invasive ventilation, renal replacement therapy or ECMO
4.To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay
5.To assess the effects of (IONIC Intervention) vs. Oseltamivir the time from treatment initiation to death
;Primary end point(s): Time-to-clinical improvement;defined as the time from randomisation to a 2-point improvement on 7-point ordinal scale, or discharge from hospital ordeath (whichever occurs first).
A clinically significant difference, defined as a difference of at least a two-point improvement on the WHO ordinal scale.
;Timepoint(s) of evaluation of this end point: Clinical status will be confirmed daily from randomisation to day 14, hospital discharge, or death (which ever occurs sooner), with the worst score for that day recorded.

A Clinical Trial of Nebulized Bovactant (Alveofact ®) for the Treatment of Moderate to Severe COVID-19
Main Objective: To assess whether administration of surfactant therapy via the modified Aerogen nebuliser results in improved PaO2/FiO2 ratio and ventilation index in patients with COVID-19 after last dose of surfactant and the optimal dosing schedule to be used.;Secondary Objective: To assess the safety of surfactant therapy via the modified Aerogen nebuliser and mean clinical improvement of patients with COVID-19 following administration.;Primary end point(s):
Change in PaO2/FiO2 ratio at 48 hours after study initiation.
Change in the Ventilation Index at 48 hours after study initiation.;Timepoint(s) of evaluation of this end point: 48 hours after study initiation

Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of Azithromycine relative to the standard of care in patients hospitalized with COVID-19.;Secondary Objective: To evaluate clinical efficacy of Azithromycine as compared to the control arm as assessed by Clinical Severity, Oxygenation, Mechanical Ventilation, Hospitalisation, Mortality and Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm as assessed by
o Cumulative incidence of serious adverse events (SAEs) and adverse events (AEs) graded as grade 4 or 5.
o Discontinuation or temporary suspension of drug administration (for any reason).
o Changes in white cell count, haemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, and AST over time. ;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):
1. Not hospitalized, no limitations on activities
2. Not hospitalized, limitation on activities;
3. Hospitalized, not requiring supplemental oxygen;
4. Hospitalized, requiring supplemental oxygen;
5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;
6. Hospitalized, on invasive mechanical ventilation or ECMO;
7. Death.
Primary outcome will be time from Day 0 to sustained clinical improvement or life discharge, whichever comes first, whereby a sustained clinical improvement is defined as an improvement of = 2 points vs the highest value of Day 0 and 1 and sustained for at least 3 days.;Timepoint(s) of evaluation of this end point: Day 15

Experimental use of tocilizumab in COVID-19 related pneumonia.
Main Objective: to evaluate the safety
and efficacy of the tocilizumab (Roactemra®) in hospitalized adults diagnosed with COVID-19.;Secondary Objective: Not applicable;Primary end point(s): Clinical status assessed using a 7-category ordinal scale at Day 28;Timepoint(s) of evaluation of this end point: end of study

BCG vaccine for healthcare workers against COVID-19
Main Objective: To reduce absenteeism among health care workers with direct patient contacts during the COVID-19 pandemic. ;Secondary Objective: To reduce the number of health care workers that are infected with SARS-CoV-2 during the COVID-19 pandemic and to reduce the number of hospital admissions amongst health care workers with direct patient contacts during the COVID-19 pandemic.;Primary end point(s): Number of days of unplanned absenteeism for any reason.;Timepoint(s) of evaluation of this end point: End of study as well as weekly interim analysis.

Clinical trial to evaluate the efficacy and safety of tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study
Main Objective: To evaluate the effectiveness of IV tocilizumab in treating patients with COVID-19 pneumonia. Improvement of respiratory function based on:
- Time to intubation (if not previously intubated) and duration of intubation.
- Time of non-invasive mechanical ventilation.
- Time of oxygen therapy.
Mortality rate;Secondary Objective: - To describe oxygen saturation (SpO2), PaO2/FiO2 (<300), or the equivalent SaO2/FiO2 (<315)
- To evaluate radiological evolution
- To describe the duration of hospitalization and/or ICU stay
- To evaluate the requirement of additional organ support, including kidney dialysis, molecular adsorbent recirculating system (MARS), extracorporeal membrane oxygenation (ECMO), or other
- To evaluate the effect of IV tocilizumab on the serum levels of inflammatory markers
- To describe safety of IV tocilizumab in patients with COVID-19 pneumonia
- To identify prognosis factors of IV tocilizumab effectiveness related to inflammatory markers and clinical/radiological features.
- To assess time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity, as appropriate.
- To compare the effectiveness and safety outcomes based on the different doses of IV tocilizumab used in the participating centres.
- To identify patient profile suitable to be benefited with tocilizumab;Primary end point(s): - Respiratory function, defined as:
Start date of intubation (in patients not previously initiated).
Date of extubation.
Start date of NIMV and date of independence from NIMV (duration of NIMV).
Start date of oxygen therapy and date of independence from oxygen therapy (duration of oxygen therapy).
- Mortality rate.;Timepoint(s) of evaluation of this end point: End points will be evaluated on a ongoing basis during the clinical trial

Evaluation of the likely beneficial effects of vitamin D on infection with coronavirus.
Main Objective: The objective of the study is to analyze if the administration of a single dose of native vitamin D (100,000 IU of Colecalciferol) (1 ampoule of 100,000) has an influence on the evolution of clinical and biochemical parameters of the disease.;Secondary Objective: Not applicable;Primary end point(s): • Percentage and time of patients who have a negative SARS-CoV-2 viral load
• Clinical symptoms and time during hospitalization
• Improvement of biochemical and molecular parameters of inflammation
• Overall mean hospital stay
• Percentage of patients requiring transfer to the ICU
• Average stay in ICU
• Mortality during follow-up;Timepoint(s) of evaluation of this end point: 14 and 21 days or until a negative SARS-CoV-2 test every 7 days.

Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19).
Main Objective: To evaluate the efficacy of prophylaxis with Hydroxychloroquine for 2 months versus placebo in the prevention and reduction of symptomatic and asymptomatic CoV-2 SARS infection in healthcare personnel.;Secondary Objective: 1) To evaluate the safety of HCQ during 2 months in the healthcare personnel.
2) To evaluate the number of working days lost as a result of symptomatic or asymptomatic infection by COVID19.
3) To analyse the percentage of severe respiratory illness due to COVID-19 in healthcare personnel.
4) To define the incidence, prevalence and severity of SARS CoV-2 infection in healthcare personnel in the hospital setting.;Primary end point(s): - Number of healthcare professionals with symptomatic or asymptomatic SARS-CoV2 infection.
- Severity of the infection.;Timepoint(s) of evaluation of this end point: 2 months

TD-0903 for acute lung injury associated with COVID-19
Main Objective: Part 1
The objectives are:
• Evaluate the safety and tolerability of inhaled TD-0903 in subjects with COVID-19
• Assess the plasma pharmacokinetics (PK) of TD-0903 in subjects with COVID-19
• Characterize the effect of TD-0903 on reducing the acute lung injury associated with COVID-19
• Explore the effect of TD-0903 on nasal swab viral load, and blood biomarkers
Part 2
The primary objectives are:
• To characterize the efficacy of TD-0903 in reducing the acute lung injury associated with COVID-19
• To characterize the efficacy of TD-0903 as measured by ventilator-free days (VFDs);Secondary Objective: The secondary objectives are to evaluate the effect of TD-0903 on:
• Safety and tolerability
• Number of days not requiring care in the Intensive Care Unit (ICU-free days)
• Subjects with improvement in oxygenation
• Dyspnea as measured by the modified Borg Dyspnea Score
• The proportion of subjects discharged from hospital during the study
• Time to hospital discharge
• The 28-day mortality rate
• Clinical outcomes as measured by a 6-point clinical status scale;Primary end point(s): Part 1:
Endpoints (through Day 7)
Safety
• Change from baseline in vital signs and clinical laboratory results
• Incidence and severity of treatment-emergent AEs (TEAEs)
Pharmacokinetics
• Plasma PK parameters on Day 1 and Day 7
Pharmacodynamics (PD)
• Change from baseline in SaO2/FiO2 ratio
Additional Endpoints (through Day 28)
• Change from baseline in vital signs, and clinical laboratory results
• Incidence and severity of TEAEs
The co-primary efficacy endpoints are:
• Change from baseline in SaO2/FiO2 ratio on Day 7
• Number of VFDs from randomization to Day 28;Timepoint(s) of evaluation of this end point: Part 1:
Endpoints
Safety (Vital signs, clinical laboratory results, TEAEs): Day 1 through 7
PD (SaO2/FiO2 ratio): Day 1, 2, 5, 7
Additional Endpoints
Safety (Vital signs, clinical laboratory results, TEAEs): Day 1 through 28
SaO2/FiO2 ratio: Day 7
VFDs: up to Day 28

Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia

Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Clinical status of subject at day 15 (on a 7 point ordinal scale).

Colchicine Counteracting Inflammation in COVID-19 Pneumonia

Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease
Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.

Evaluation of Novel Diagnostic Tests for COVID-19

Household Transmission Investigation Study for COVID-19 in French Guiana
Evaluation of the extent of the virus transmission within households

Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia
Prevalence of symptoms;Prevalence of positive Sars CoV-2 PCR;Prevalence of positive radiological findings

COVID-19 and Deep Venous Thrombosis
the prevalence of a DVT in patients at the ICU.

The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
Occurrence of adverse reactions;Anti SARS-CoV-2 S IgG antibody response(ELISA);Neutralizing antibody response to SARS-CoV-2

Effects of DPP4 Inhibition on COVID-19

Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first

Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?
Rate of UCI admission for surgery-related complication

Echocardiographic Manifestation in Patient With COVID-19 (EARLY-MYO COVID-19)

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia

Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19
COVID-19-free survival in experimental arms compared to placebo

Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia
Number of participants with Dose Limiting Toxicity Events

Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Change in C-reactive protein (CRP) level

Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
Incidence of venous thromboembolism detected by imaging

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
Time to Resolution of Symptoms relative to baseline (day 1 of trial);Time to Resolution of Symptoms relative to baseline (day 1 of trial);Time to Resolution of Symptoms relative to baseline (day 1 of trial);Number of participants hospitalized and/or requiring repeat ER visits;ICU Length of Stay;Ventilator

VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection
Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.;Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.

DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)
Percentage of Patients with Clinical Respiratory Aggravation;Percentage of patients hospitalized;Percentage of patients requiring ventilatory assistance

Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
Survival time without needs of a ventilator.

Community Pharmacists Behaviour During Covid-19

Treatment of Angiotensin Peptide (1-7) for COVID-19

Prediction of Clinical Course in COVID19 Patients

Effect of Quercetin on Prophylaxis and Treatment of COVID-19
Prevalence of COVID-19 calculated using a questionnaire;Standardized Mortality rate

Post Covid-19 Cardiopulmonary and Immunological Changes
measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis;measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure

Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
Sperm density;Sperm activity;Erection hardness and duration;IIEF-5/QEQ questionnaire score;Detection rate of SARS-CoV-2 in male genitourinary system

Inhaled Nitric Oxide for Preventing Progression in COVID-19
Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.

Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic

COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)
Adverse reaction (AE) and severe AE (SAE);Efficacy Assessment;The Rate of Recovery Without Mechanical Ventilator

Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic
Highest VIS (Vasoactive-Inotropic Score) in the first 12 hours postoperatively.

Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)
Prevalence of contagiousness in asymptomatic individuals by PCR;Ratio of asymptomatic immunized (IgA/IgM and IgG) population

Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors
Overall survival of patients with metastatic colorectal cancer or metastatic pancreatic cancer

Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
Serious adverse events in convalescent plasma treated patients;Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients;Transfer to ICU;in-hospital death;Virologic clearance in plasma of convalescent plasma treated patients

TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia
Prevention of severe Respiratory Failure requiring mechanical ventilation

Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure.

Immunogenetics Predictors With COVID-19

Low Dose Radiotherapy in COVID-19 Pneumonia
Change from baseline blood oxygenation;Number of Hospital stay days;Number of ICU stay days;Number of intubation events

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure

Study to Evaluate the Effect of a Probiotic in COVID-19

Convalescent Plasma for COVID-19 Close Contacts

The Global PCHF-COVICAV Registry

The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines
Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines

Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context
The resting energy expenditure (in Kcal / 24h) measured by indirect calorimetry during the stay in intensive care.

Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease
Patient Disposition Post treatment;oxygenation;IL-6 levels;Chest Xray radiographic results;Brescia-COVID Respiratory Severity Scale;SMART-COP Score;PSI Score;CRP levels

Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males

Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population

Registry of CytoSorb Therapy in COVID-19 ICU Patients

Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19
Prognostic factors for healing of COVID-19 infection

Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS
Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization

Colchicine Plus Phenolic Monoterpenes to Treat COVID-19

Proctologic Practice and Covid-19
Predictive power of respondents' and hospitals' demographics on the change of status of proctologic surgical and outpatient activities

Incidence of COVID-19 Test Conversion in Post-surgical Patients

Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis
Cumulative incidence of SARS-Cov2 infection in the general population.

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study
Kinetics over time of HLA-DR expression on the surface of monocytes

New Antiviral Drugs for Treatment of COVID-19

Upper Limb Robotic Rehabilitation During COVID-19 Outbreak
System Usability Scale (SUS);Technology Acceptance Model (TAM);Likert Scale

Efficacy of Ivermectin in COVID-19

Clinical Use of Stem Cells for the Treatment of Covid-19

At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study
Does Participant Accurately Read Result;Acceptability and Usability of Tests

Impact of an Intensified Thromboprofylaxis Protocol in COVID-19

Imaging Feature of SARS-CoV2 Infection
Describe qualitative and quantitative variables;Describe qualitative and quantitative variables;Ability of imaging to predict disease progression;Ability of imaging to predict disease evolution

Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.
Impact of intervention program on health-related quality of life (VAS)

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
Oxygen Therapy Status at Day 2;Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2

sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?
Association between concentration of circulating sFlt1 and use of vasopressor

Silymarin in COVID-19 Pneumonia

National Survey on the Lockdown of Children With Disabilities
Experience during lockdown;Health risk during lockdown;Impact on medical and rehabilitation follow up;Impact on daily living

Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.
Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.

Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Change of arterial oxygenation at 48 hours from enrollment

COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2

Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France
Prevalence of positivity of COVID-19 virus measured by rt-PCR

Evaluation of Covid 19 Anxiety in Endometriosis Patients
Covid 19 Anxiety levels in Endometriosis Patients

Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED

Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy
Measure of the impact of COVID Emergency on surgical specialist training programs

Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
Proportion of patients who are alive and free from advanced respiratory support measures at day 28.

COVID-19 Endoscopy Survey
Effect of GI societies recommendations on prevention of SARS-CoV-2 infection;To measure the percentage change in performed endoscopic procedure in response to COVID-19

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort
Survival without needs of ventilator utilization or use of immunomodulatory drugs;WHO progression scale =6

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
ICU length of stay;Safety of convalescent plasma & Serious adverse reactions.

Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19

Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions
To determine SARS-CoV-2 viral load and infectivity in saliva that may contribute to asymptomatic transmission

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
Safety and Tolerability of SAD of TD-0903: Adverse Events;Safety and Tolerability of MAD of TD-0903: Adverse Events

Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak
Frequency of RA patients with emotional impact (feeling of isolation)

Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak
percentage of patient with feeling of disabilities

Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak
Hospital Anxiety and Depression Scale questionnaire

Ruxolitinib to Combat COVID-19

Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)

Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19
Seroconversion against SARS-CoV2 in children of the Parisian area

CoVID-19 Plasma in Treatment of COVID-19 Patients

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Percentage of participants who achieve clinical response

PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients
Changes in lung compliance;Change in global impedance;Change in recruitability

Leflunomide in Mild COVID-19 Patients
Tolerability of high dose leflunomide as measured by leflunomide dose modifications;Tolerability of high dose leflunomide as measured by discontinuation of leflunomide;Tolerability of high dose leflunomide as measured by Adverse Events

Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families

The Psychological Impact of the COVID-19 on Students.

Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
Composite of death and mechanical ventilation

Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization
Change in imputed partial pressure of oxygen over fraction of inspired oxygen (PaO2/FiO2) from peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2)

Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study
Physical Performance;Cardiorespiratory fitness;Lower limb Strength;Health Related Quality of Life;Anxiety and Depression;Physical Activity

Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers
Incidence of contamination of any part of the base clothing or exposed skin of the upper body

Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
Proportion of conjunctival samples tested positive for SARS-CoV-2

A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic

Use of the Nasal Cannula During COVID-19
Number of physician using los flow nasal cannula during COVID 19 pandemia

Atorvastatin as Adjunctive Therapy in COVID-19
Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death

Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome

COVID-19 Outbreak Consequences for Outpatients Followed in PRM
Proportion of patients necessitating the scheduling of a medical consultation

Advanced Endoscopy During COVID-19
Age, gender, nationality;Indication for procedure, status of SARS-CoV-2 infection;Complete blood count and liver functions tests;procedure related complications

Compassionate Use of Hyperbaric Oxygen Therapy
Gather information on patients treated with hyperbaric oxygen therapy

Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia
correlation of anosmia and ageusia to covid19 positive patients

Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial
Proportion of patients with a positive SARS-CoV-2 PCR

COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality
Chronic medications as risk factor of intensive care for COVID-19;Comorbidities as risk factor of intensive care for COVID-19

Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)

Association Between BMI and COVID-19
Relationship between body mass index (BMI) and SARS-CoV-2

Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive

Baricitinib Compared to Standard Therapy in Patients With COVID-19

Longitudinal COVID-19 Cohort Study

Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)

Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)

Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms
Body temperature;Cough Frequency;Respiratory frequency;Heart Rate Instantaneous heart rate every 15 minutes.

Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19

SINUS WASH Pilot Study in Adults Testing Positive for COVID-19
Change in viral load in the oral and nasopharyngeal cavity

Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19

COVID-19 and Cancer Patients
Describe presenting characteristics and severity or SARS-CoV-2 infection in patients with cancer;Assessing what factors are involved in prognosis of cancer patients with COVID-19

A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period
Loneliness (UCLA-8 Loneliness Scale);Mindfulness (FFMQ);Quality of life (EQ-5D-5L Questionnaire)

Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?

Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress
The CoRonavIruS Health Impact Survey (CRISIS);The CoRonavIruS Health Impact Survey (CRISIS);The CoRonavIruS Health Impact Survey (CRISIS)

Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation
Analysis of risk factors for intubation tube obstruction

Hydroxychloroquine in COVID-19 Patients

COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
Rate of Therapeutic failure, defined as a combined outcome of rate of intubation or death

A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)
The proportion of patients who are alive, without evidence of ARDS (i.e. PaO2/FIO2 >300 mm Hg), who do not require any oxygen support (in room air).;The proportion of patients assigned to each category, of a six-category ordinal scale.

Arrhythmias in Patients With COVID-19
In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis;Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis

1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study

Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed

International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
Symptoms;Length of hospital stay;invasive mechanical ventilation or mortality

SARS-CoV-2 Disguise Study

Sexual Function During COVID 19 Pandemic
The percentage of study participants diagnosed with sexual dysfunction

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
Mortality at Day 60;Dialysis Dependency;Ventilation at Day 28

Ayurveda as Prophylaxis for Suspected COVID-19 Patients

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)
Proportions (active vs. placebo) of subjects who progress to respiratory failure;Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events

Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care
Mobility level;Time taken to first mobilise

Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire;Patients reproductive behaviour by using a questionnaire;Patients views on resuming fertility treatment by using a questionnaire

The Professional Peer Resilience Initiative

Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19

Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe

COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada
Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.

COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study

Efficacy and Safety of COVID-19 Convalescent Plasma
Duration of oxygenation and ventilation support;Hospital length of stay (LOS);ICU admission;Ventilator free days;Incidence of serious adverse events

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients
Percentage of ecological momentary assessments completed;Percentage of satisfied mHealth app users

RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19
the SARS-Cov-2 positivity rate in patients with Covid-19 with or without signs of conjunctivitis

Remote Monitoring of Cancer Patients With Suspected Covid-19
Device Tolerability (Attrition);Correlation of physiological data with clinical events

COVID-19: Study of INFLAmmasome and PLAtelets Functions
Activation of platelet NLRP3 inflammasome;Activation of platelet NLRP3 inflammasome

Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population
worsening of cardiovascular risk (treatments);worsening of cardiovascular risk (smoking consumption);worsening of cardiovascular risk (food balance);worsening of cardiovascular risk (weight gain);worsening of cardiovascular risk (physical activity)

Mental Health Outcomes in Healthcare Workers During COVID-19
Impact of Event Scale - Revised (IES-R);General Anxiety Disorder (GAD-7);Patient Health Questionnaire (PHQ-9)

Characteristics of COVID-19 Infection Among PREGnant Women

A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic
Patient Health Questionnaire - 4;Patient Health Questionnaire - 4;Patient Health Questionnaire - 4;Patient Health Questionnaire - 4;World Health Organization Well Being Questionnaire;World Health Organization Well Being Questionnaire;World Health Organization Well Being Questionnaire;World Health Organization Well Being Questionnaire;Affective Experience;Treatment Acceptability Questionnaire

iNOPulse for COVID-19
Incidence of treatment emergent adverse events;Incidence of adverse events;Incidence of methemoglobinemia

ACT-20 in Patients With Severe COVID-19 Pneumonia

Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19

Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0

Post-Intensive Care Nutrition Status in Patients with COVID-19
Nutrition service delivery assessed from patient medical records e.g. frequency of dietetic review in ICU and post-ICU ward[At any time during intensive care admission and acute ward admission, every 7 days for up to 28 days.];Nutrition provision at the patient level assessed from patient medical records. e.g. provision of parenteral nutrition, enteral nutrition, oral intake[At any time during intensive care admission and acute ward admission, every 7 days for up to 28 days.];Proportion of patients diagnosed with malnutrition using any of the the validated malnutrition screening and assessment tools, For example malnutrition screening tools:
-Malnutrition Screening Tool (MST),
-Malnutrition Universal Screening Tool (MUST)
-Modified NUTrition Risk In the Critically ill (mNUTRIC)
-Mini Nutritional Assessment (MNA)
-Mini Nutritional Assessment – Short Form (MNA-SF)
-Nutrition Risk Screening (NRS-2002).
For example malnutrition assessment tool:
-Patent Generated Subjective Global Assessment (PG-SGA)
-Subjective Global Assessment (SGA)
-Mini-Nutritional Assessment (MNA)[Validated malnutrition screening and assessment tools used at any time during intensive care admission and anytime on the post-ICU acute ward up to 28 days.]

Multi-site audit of COVID-19 airway interventions
Assessment of PPE use
- this will be assessed via the study audit form; completed by intubating clinicians following each intervention. Clinicians will indicate all of the PPE available to them and used in the procedure.[The intervention will be assessed immediately following each episode of airway management. ]; Adherence to COVID-19 airway intervention protocols
- this will be assessed via the study audit form; completed by intubating clinicians following each intervention. Clinicians will indicate the number of attempts and details of procedure.[The intervention will be assessed immediately following each episode of airway management. ]

Has the threat of SARS COVID-19 increased influenza vaccination rates in pregnant women?
Rate of influenza vaccination in women giving birth at greater than 20 weeks gestation
Data extracted from medical record system and validated with batch number of actual vaccination[Birth of baby]

Covid-19 Biobank of clinical samples and data for use in research to help understand the immune characteristics of people who are diagnosed with COVID19.
Create biological bank of clinical samples (viral nose/throat swabs, blood samples and remnant samples) from individuals with COVID-19 infection who are in high risk groups for poor outcomes or critically unwell [December 2021];Create a database of clinical information including; date of COVID 19 diagnosis, risk factors of infection, age, gender, co-morbidities, NEWS score, health status assessment, of infected individuals from hospital medical records [December 2021]

The MEND (MEseNchymal coviD-19) Trial: a pilot study to investigate early efficacy of mesenchymal stem cells in adults with COVID-19
To evaluate the early efficacy of CYP-001 in adults with COVID-19 being treated in intensive care units (ICU), based on improvements in P/F ratio compared to controls. This outcome is defined as a proportion of participants showing a 50% improvement in P/F ratio by day 7. P/F ratio is collected from ventilatory support data combined with arterial blood gas measures
[By day 7 after enrolment in the study (within days 1-7). P/F ratio will be collected as per routine standard collection of data to inform respiratory function (at least 4 hourly when relevant) plus every 15 minutes during cell adminstration and 1, 2, 3, 4 and 5 hours after];To assess the safety and tolerability of CYP-001 in adults with COVID-19 being treated in ICU measured by the incidence and severity of treatment-emergent adverse events (including events related with reactions to cryoprotectant; fever read from digital thermometer, allergy, olfactory/taste disturbances), safety laboratory evaluations (immunology screen with full blood examination) and vital signs (including significant fluctuations from clinically acceptable BP, and HR and SaO2 levels measured via pulse oximetry)[Up to day 28 after enrolment in the study. On days 0-7 this will be collected routinely in standard care (at least 4-hourly) plus every 15 minutes during cell administration and 1, 2, 3, 4 and 5 hours after, then daily after day 8]

Study for the Effect of Internet-based Cognitive Behavior Intervention on Perinatal Depression and Anxiety during the novel coronavirus pneumonia (COVID-19) pandemic

Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19): A non-Randomized Controlled Study

A correlation study between food intake and risk factors of PTSD after the COVID-19 of shift medical staff
The PTSD Checklist Civilian Version, PLC-C;morningnsee eveningness questionnaire, MEQ;Pittsburgh sleep quality index, PSQI;Self-Rating Anxiety Scale,SAS;Self-rating depression scale, SDS;

Epidemiological and Clinical Characteristics of 20 Re-positive novel coronavirus pneumonia (COVID-19) Patients

Erythrocyte Sedimentation Rate in novel coronavirus pneumonia (COVID-19) patients

Study for the effect of Traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-1) in the high risk area

The comprehensive evaluation of therapeutic drugs for pediatric novel coronavirus pneumonia (COVID-19)
Body temperature;Respiratory syndrome;Pulmonary imaging;Nucleic acid testing;

Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma; A case series

Study for Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)

A follow up research of exercise, cardiopulmonary and quality of Life for patients of novel coronavirus pneumonia (COVID-19)

Efficacy of Liu-zi-jue in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19): a randomized controlled trial
Modify Borg Dyspnea Score;Fatigue scale-14;Patient Health Questionnaire;Clinical Respiratory Symptom Scale;

Psychiatric admissions during the COVID-19 pandemic

A Randomized, Double-blind, Placebo-controlled trial for determination of the Efficacy and Safety of Baicalein in Hospitalized Adult Mild and Moderate Patients of novel coronavirus pneumonia (COVID-19)

Study for the improvement of the quality of life of severe patients of novel coronavirus pneumonia (COVID-19) by the integrated Chinese medicine and Western medicine therapy
Vital Capacity;Total Vital Capacity;Forced Vital Capacity;The Predicted Forced Vital Capacity;Diffusion Capacity for Carbon Monoxide;The Predicted Diffusion Capacity for Carbon Monoxide;The maximum Vital Capacity;Maximal Midle Expiratory Flow;Immune cell;Immune factor;AGE;weight;6 min distance on foot;SCL-90 TABLE;SF-36 TABLE;Borg Dyspnea Index;

Usefulness of abdominal massage and ST-36 (Zusanli) acupressure in improving appetite of novel coronavirus pneumonia (COVID-19) patients treated in makeshift hospital

A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)
Incidence of ARDS;Mortality within 28 days;

Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population
the occurrence of a patient-reported common cold;

Online parent training for reducing parenting stress during the coronavirus pandemic
In the parent, according to self-report, measured in four time-points: at baseline, post-treatment, 1- and 3-months follow-up:
1. Perceived stress (Perceived Stress Scale, four-item version, PSS4)
2. Psychological well-being (WHO Well-being Index, WBI)
3. Parenting stress (Parental Stress Scale, shortened)
4. Parental competence (Parental Sense of Competence Scale, PSOC)

A pilot study of the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19
Amounts of cultured SARS-CoV-2 and quantitative PCR results of viral RNA in saliva and nasal samples at baseline, and 5 further time points up to 2 h after administration. Results will be expressed as actual counts per ml saliva and the mean log reduction after application of PVP-I determined, taking into account any dilution effect by the mouthwash or spray which will be analysed in a control group given water instead of PVP-I

Investigating blood clotting changes in patients with COVID-19
1. Coagulation parameters (PT, aPTT, fibrinogen, D-dimer) measured using standard hospital laboratory methods in blood taken on days 1, 2, 3, 7, 14, 21 and 28 during hospital stay
2. Blood clotting capability measured by thromboelastography (TEG) using a TEG 5000 machine in whole blood taken on days 1, 2, 3, 7, 14, 21 and 28 during hospital stay
3. Full blood count (FBC) results (platelet count, haemoglobin, white cell count [WCC] and differential) measured using standard hospital laboratory methods in blood taken on days 1, 2, 3, 7, 14, 21 and 28 during hospital stay
4. Presence of venous thrombosis defined as radiological confirmed evidence of DVT by compression ultrasound or PE by CT pulmonary angiogram (CTPA) or ventilation/perfusion (VQ) scan from date of admission to 90 days following discharge
5. Presence of arterial thrombosis defined as ECG evidence of a myocardial infarction or CT/MRI evidence of an ischaemic stroke during hospital admission

STOP-COVID19: Superiority Trial Of Protease inhibition in COVID-19 (coronavirus infection)
Participant clinical status (on a 7-point ordinal scale); up to day 29

How effective are infection prevention and control measures that are informed by genetic analysis of coronavirus (rapid and standard) at preventing COVID-19 in NHS hospitals?
1. Incidence rate of IPC-defined HOCIs, measured as incidence rate of recorded cases per week per 100 inpatients based on case report forms during each phase of the study
2. Identification of nosocomial transmission using sequencing data in potential HOCIs in whom this was not identified by pre-sequencing IPC evaluation, measured using pre- and post-sequencing case report forms for each enrolled patient during study phases in which the sequence reporting tool is in use

The symptoms, virology and immunity of COVID in healthcare workers
COVID-19 symptoms measured using online daily symptom diary every day for 3 months

A therapeutic study in pre-ICU patients admitted with coronavirus using repurposed drugs
Time to incidence (up to Day 14) of the composite endpoint of:
2. Mechanical ventilation
3. Extracorporeal membrane oxygenation
4. Cardiovascular organ support (balloon pump or inotropes)
5. Renal failure (estimated creatinine clearance (by Cockcroft-Gault formula) <15 ml /min/1.73 m2), haemofiltration or dialysis
All measured using patient records

Preventative treatment for patients at risk of COVID-19 infection (PROTECT)
Time to confirmed COVID-19 diagnosis via online questionnaires at 6 weekly intervals

Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure
Extravascular lung water index EVLWI measured using TPTD (PiCCO; Pulsion Medical Systems; Feldkirechen Germany) daily from intubation until extubation

A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
Main Objective: The overall objective of the study is to evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19;Secondary Objective: To assess pharmacokinetics of acalabrutinib and its active metabolite in subjects with COVID-19 when administered with BSC
;Primary end point(s): The primary endpoint is treatment failure rate, where treatment failure is defined as use of assisted ventilation or death. For the purpose of this study assisted ventilation is defined as noninvasive ventilation (eg, continuous positive airway pressure [CPAP] ventilation), invasive mechanical ventilation, or ECMO machine;Timepoint(s) of evaluation of this end point: Approximately 30 days

Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection
Main Objective: The primary objective of the study is to improve the absolute lymphocyte count (ALC) of lymphopenic (ALC=700/mm3) COVID-19 infected participants out to 30 days or Hospital discharge (HD), whichever comes first.;Secondary Objective: -Obtain “clinical improvement” as defined by a 2 points improvement in a 7-point ordinal scale, through D30 or HD
-determine if CYT107 will lead to a significant decline of SARS-CoV-2 viral load through D30 or HD
-Compare: incidence of grade 3-4 AE for CYT107 vs placebo through D45
Effect of CYT107 vs placebo on the frequency of secondary infections through D45, on the length of hospitalization, on the length of stay in ICU, on readmissions to ICU, on organ support free days through day 30 or HD following initial drug administration, on the frequency of re-hospitalization through D45
-Assess the impact of CYT107 on all-cause mortality through D45
-Determine the effect of CYT107 on T cell counts (CD4+,CD8+) through day 30 or HD
-Track and evaluate other biomarkers: of immune function: monocyte HLA-DR expression and of inflammation: CRP, D-dimer, Ferritin
-Evaluation of physiological status through NEWS2 score;Primary end point(s): An improvement in the absolute lymphocyte count (ALC) is defined as a statistically significant increase from randomization to day 30 or HD, and will also be assessed at defined timepoints (as indicated in the Schedule of Activities, to include all Study drug administration days).;Timepoint(s) of evaluation of this end point: days 0, 1, 5 or 6, 14, 21 and 30 or hospital discharge

An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease
Main Objective: Evaluate the therapeutic efficacy of anakinra or tocilizumab alone or in combination with ruxolitinib in severe (2b and 3) forms of COVID-19.
The primary outcome criteria is ventilation free days at D28 (VFD28). ;Secondary Objective: Evaluate the therapeutic efficacy of anakinra or tocilizumab alone or in combination with ruxolitinib in severe (2b and 3) forms of COVID-19 on:
Number of patients admitted in ICU (for stage 2b)
Number of days in ICU (for stage 3)
Death at D28 for all patients
Number of days in hospital
Time to oxygenation weaning
Visceral insufficiency improvement (SOFA score)
Number of days without fever at D7 (without antipyretics for 48h)
No increase in the number of bacteriamia or fungemia
Time to improvement of biological inflammatory markers (C reactive protein, fibrinogen, ferritinemia)
Time to improvement of biological markers (blood cells counts, creatininemia, transaminases, LDH, gGT, coagulation tests)
Improvement of blood cytokine concentrations and NLRP3 constituents
Blood concentrations of tocilizumab and search for acquired circulating anti-tocilizumab inhibitory antibodies
Lung tomodensitometry and lung ventilation capacity evaluation at D90 after hospitalization exit
;Primary end point(s): ventilation free days at D28 (VFD28) (an increase of 5 days VFD28 is expected);Timepoint(s) of evaluation of this end point: 28 days

Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib
Main Objective: To compare clinical and biological efficacy of a therapeutic strategy using ANAKINRA with or without RUXOLITINIB for serious cases of SARS-CoV-2 infection, oxygen dependent, needing or not an invasive ventilation on systemic inflammation;Secondary Objective: To compare the efficacy of this strategy on :
• The number of days of oxygen dependency
• The number of admission in the intensive care for patient of regular unit (Expected result : 20% decrease, admission fall in number from 50% to 30%)
• Patients’ mortality at D28 (Expected result : 20% decrease)
• Length of stay in the intensive care unit (Expected result : 3 days decrease)
• Length of stay in the hospital (Expected result : 3 days decrease)
• The evolution of organ failure score SOFA (Expected result : 3 points decrease)
• The number of days without fever at D7 (Expected result : 2 days decrease)
• The absence of increase on number of bacterial or fungal sepsis of more than 10%
;Primary end point(s): Biological criteria: validation if at least 3 parameters are met including CRP and/or Ferritin
1) CRP : decrease > 50%
2) Ferritinemia : decrease > 1/3
3) Serum creatinine : decrease > 1/3
4) AST/ALT : decrease > 50%
5) Eosinophils > 50 /mm3
6) Lymphocytes > 1000 /mm3
;Timepoint(s) of evaluation of this end point: D7, D10, D14, D28

Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare
personnel with high risk of infection.
Main Objective: 1. Incidence of symptomatic healthcare professionals with positive PCR
between day 15 and day 30 of inclusion in the study. Health
professionals with high risk of transmission taking prophylaxis (Group
A) and the control group of high risk health professionals who decide not
to take it (Group C1) will be compared.
2. Incidence of symptomatic healthcare professionals with positive PCR
between day 15 and day 30 of inclusion in the study. Professionals with
high risk of transmission taking prophylaxis (Group A) and the control
group of professionals with low risk of transmission (Group C2) will be
compared.;Secondary Objective: 1. Incidence of cases of COVID-19 requiring hospitalization in a
conventional plant between day 15 and day 30 of inclusion in the study,
comparing the three study groups.
3. Duration of symptoms of COVID-19 in those infected with positive PCR
between day 15 and day 30 of inclusion in the study, comparing the
three study groups.
4. Incidence and severity (hospital admissions, ICU admissions) of
COVID cases in the first 15 days after enrollment in the study, comparing
the three study groups.;Primary end point(s): 1. Incidence of symptomatic healthcare professionals with positive PCR
compared.;Timepoint(s) of evaluation of this end point: Inclusion in the study: A serology of SARS-CoV-2 will be performed
before inclusion,.
Day 15 from inclusion: the incubation period of a possible infection ends
prior to the inclusion of the study. Events from now on will count for
Objectives 1-5.
Day 30 from enrollment: end of treatment period and active follow-up. A
second SARS-CoV-2 serology will be performed on all professionals.
Day 45 from inclusion: end of the study. It will be evaluated if the health
personnel have had symptoms of illness within 15 days after the end of
the treatment. The appearance of possible adverse effects will be
evaluated.

Phase 2/3 study of ABX464, once daily oral capsule, in high risk patients infected by SARS-CoV-2 prior to COVID-19 associated respiratory distress.
Main Objective: The primary objective of the study is to determine the efficacy of ABX464 50mg to prevent respiratory failure or death in study patients.;Secondary Objective: To evaluate the proportion of patients requiring hospitalization
To assess the proportion of patients reporting each severity rating on a 7-point ordinal scale during the course of the study
To assess the time to an improvement of one category of the a 7-point on an ordinal scale
To evaluate and compare the effect of ABX464 on immunophenotyping and cytokines
To evaluate the proportion of patient requiring oxygen supplementation (>3L/min)
To assess the time to hospitalization
To evaluate the time to application of invasive and non-invasive mechanical ventilation (IMV and NIV, respectively) or high flow oxygen therapy
To assess the IMV and/or NIV duration
To assess the oxygen supplementation (>3L/min) duration
To assess the hospital stay duration
To evaluate the effect of ABX464 on miR-124 expression
To assess the change over time in CRP, Troponin I & T and D-dimer levels
To evaluate the prevention of Covid-19 related deaths
To evaluate the safety ;Primary end point(s): Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive at the end of the 28 days period.;Timepoint(s) of evaluation of this end point: Day 28

ravulizumab for the treatment of patients with Coronavirus Disease 2019
Main Objective: To evaluate the effect of ravulizumab + Best Supportive Care (BSC) compared with BSC alone on the survival of patients with COVID-19;Secondary Objective: To evaluate the efficacy of ravulizumab + BSC compared with BSC alone on outcomes in patients with COVID-19
To characterize the overall safety of ravulizumab + BSC compared with BSC alone in patients with COVID-19
To characterize the PK/PD and immunogenicity of ravulizumab in patients with COVID-19
To assess the effect of C5 inhibition on systemic activation of complement and inflammation in patients with COVID-19;Primary end point(s): Survival;Timepoint(s) of evaluation of this end point: Day 29

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19.
Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the standard of care in patients hospitalized with COVID-19.;Secondary Objective: To evaluate the clinical efficacy of different investigational therapeutics as compared to one another or the control arm as assessed by Clinical Severity, Oxygenation, Mechanical Ventilation, Hospitalisation, Host thrombo-inflammatory status, Mortality and
Evaluate the safety of the interventions through 28 days of follow-up as compared to the control arm as assessed by
o Cumulative incidence of serious adverse events (SAEs) and adverse events (AEs) graded as severe.
o Discontinuation or temporary suspension of drug administration (for any reason).
o Changes in white cell count, haemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, and AST over time.;Primary end point(s): Pilot phase of DAWN-ANTICO:
D-dimer on day 6
Clinical status of subject at day 15 (on a 7-point ordinal scale):
1. Not hospitalized, no limitations on activities
2. Not hospitalized, limitation on activities;
3. Hospitalized, not requiring supplemental oxygen;
4. Hospitalized, requiring supplemental oxygen;
Primary outcome will be time from Day 0 to sustained clinical improvement or life discharge, whichever comes first, whereby a sustained clinical improvement is defined as an improvement of > 2 points vs the highest value of Day 0 and 1 and sustained for at least 3 days.;Timepoint(s) of evaluation of this end point: Day 6 and 15

Study to assess efficacy and safety of DFV890 in patients with COVID-19 pneumonia and impaired respiratory function
Main Objective: Evaluate the effect of DFV890 in addition to SoC, compared with SoC alone on the Acute Physiology and Chronic Health Evaluation II (APACHE II) score;Secondary Objective: • To evaluate the effect of DFV890 in addition to SoC, compared with SoC alone, on inflammatory status
• To evaluate the effect of DFV890 in addition to SoC, compared with SoC alone, on clinical status
• To evaluate the safety of DFV890 in addition to SoC, compared with SoC alone
;Primary end point(s): Evaluate the effect of DFV890 in addition to SoC, compared with SoC alone on the Acute Physiology and Chronic Health Evaluation II (APACHE II) score;Timepoint(s) of evaluation of this end point: Day 15 or on day of discharge (whichever is earlier)

Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study)
Main Objective: The primary objective of the study is to determine whether the administration of intravenous triiodothyronine in ICU patients diagnosed with pulmonary infection due to COVID-19 facilitates weaning from cardiorespiratory support compared to placebo.;Secondary Objective: 1.Assessment of hemodynamic status
2.Assessment of pulmonary function
3.Assessment of hepatic and renal function
4.Assessment of cardiac function
5.Assessment of the course of COVID-19 infection
6.Assessment of clinical outcome and safety;Primary end point(s): The primary end-point assessed in the present study will be the percentage of patients successfully weaned after 30 days of follow-up. Successful weaning is expected in 15% of patients in placebo group. We assume that T3 treatment can increase successful weaning to 50% of patients which is a significant clinical improvement in prognosis.;Timepoint(s) of evaluation of this end point: Treatment period will last till successful weaning or end of follow-up. Follow up will be performed for 1 month.

A study to investigate whether the experimental medication IMU-838 is safe and effective when it is given to Covid-19 patients in addition to their normal treatment
Main Objective: To evaluate the efficacy of IMU-838 plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC in the treatment of coronavirus disease 2019 (COVID-19) based on the need for invasive ventilation (INV) up to 28 days;Secondary Objective: - To evaluate the efficacy of IMU-838 (+SoC) vs placebo (+SoC) in the treatment of COVID-19 based on the duration of hospitalization in intensive care unit (ICU) and all-cause mortality up to 28 days
- To evaluate the efficacy of IMU-838 (+SoC) vs placebo (+SoC) in the treatment of COVID-19 based on a variety of further variables and time points (e.g., clinical status, renal impairment, oxygenation, hospitalization, concomitant vasoactive treatments, clinical recovery)
- To evaluate trough plasma levels of IMU-838
- To evaluate safety and tolerability of IMU-838
- To explore blood levels of disease markers
- To explore viral titers, measures of viral virulence and inflammatory markers;Primary end point(s): Proportion of patients without any need for INV until end-of-study (EoS);Timepoint(s) of evaluation of this end point: Day 0 to day 28

COVID 19 prevention in nursing homes
Main Objective: To evaluate the effectiveness of prophylactic administration of hydroxychloroquine in the staff who provide direct care and in institutionalized people, on the incidence of secondary cases of SARS-CoV-2 infection in residents and professionals in the 4 weeks after the start of the trial. The effects on reduction in mortality and hospital admissions, incidence of symptoms, and drug safety will also be evaluated. Likewise, it will be evaluated whether the weekly review of some aspects of infection prevention (staff knowledge of protective measures, cross infection circuits, etc) interacts with hydroxychloroquine chemoprophylaxis.;Secondary Objective: a) Determine the possible impact on the mortality of residents at 14 and 28 days.
b) Know the compliance of the treatment in the professionals included in the treatment.
c) Examine the incidence of typical symptoms of SARS-CoV-2 infection: fever, cough, headache, arthromyalgia, pharyngeal pain, dyspnea, diarrhea, vomiting, abdominal pain, anosmia.
d) Compare the incidence of hospital admissions of staff and residents who contract SARS-CoV-2 infection during the study.
e) Evaluate the safety of the administered chemoprophylactic regimen.
f) Study the proportion of subjects who drop out of the study for any reason.
g) Analyze the proportion of subjects who do not adhere to chemoprophylaxis.;Primary end point(s): To evaluate the effectiveness of prophylactic administration of hydroxychloroquine in the staff who provide direct care and in institutionalized people, on the incidence of secondary cases of SARS-CoV-2 infection in residents and professionals in the 4 weeks after the start of the trial. The effects on reduction in mortality and hospital admissions, incidence of symptoms, and drug safety will also be evaluated. Likewise, it will be evaluated whether the weekly review of some aspects of infection prevention (staff knowledge of protective measures, cross infection circuits, etc) interacts with hydroxychloroquine chemoprophylaxis.;Timepoint(s) of evaluation of this end point: Days: 6, 14 and 28

Efficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms: a multicenter open-label controlled randomized trial
Main Objective: The main objective of the ANACONDA-COVID-19 trial is to assess the efficacy of Anakinra + optimized Standard of Care (oSOC) as compared to oSOC alone on the condition of patients with COVID-19 infection and worsening respiratory symptoms. Success defined as patient alive and free of invasive mechanical ventilation (IMV) and free of Extracorporeal Membrane Oxygenation (ECMO) at Day 14. ;Secondary Objective: 1. To assess the efficacy of Anakinra + oSOC as compared to oSOC alone on:
- Treatment success (same definition than primary outcome) up to Day 28
- Patient’s condition as defined by the OMS 7 point scale up to Day 28
- Patient’s mortality up to Day 28
- Patient’s admission in ICU
- Pulmonary function (need for ventilator support, SP02, PaO2/FiO2) up to Day 28
- Inflammation parameters up to Day 28
2. To evaluate the safety profile of Anakinra
3. To identify Biomarkers of efficacy of Anakinra.
;Primary end point(s): The primary endpoint is treatment success at Day 14, defined as a patient alive and not requiring any of the following: Invasive mechanical ventilation (IMV) or Extracorporeal membrane oxygenation (ECMO). ;Timepoint(s) of evaluation of this end point: 14 days

Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients
Main Objective: To evaluate the efficacy of an early intervention with sarilumab in the prevention of progression to severe respiratory failure/ICU admission or death in SARS-CoV-2 infected patients with pneumonia and regular oxygen supplement requirements -(Brescia-COVID Score= 1).;Secondary Objective: 1. To assess differences between both strategies in the following:
• Time to respiratory failure
• Time to reduction of supplemental oxygen requirements
• Time to non-invasive or invasive ventilation.
• The duration of hospitalization
• Mortality rate and survival.
• Rate of ICU admission
2. To evaluate the efficacy of sarilumab in in COVID-19 infected patients with pneumonia Brescia-COVID- >2 (open-label follow up phase).
3. To evaluate safety of sarilumab treatment in treating patients with COVID-19 pneumonia.
4. To evaluate differences in the effect of sarilumab on the serum levels of inflammatory cytokines.
5. To evaluate differences in the proportion of patients showing more than >1 organ failure, e.g. cardiovascular, liver and kidney failure
6. To identify prognosis factors of sarilumab efficacy related to laboratory parameters or disease features.;Primary end point(s): The primary endpoint is the proportion of patients progressing to severe respiratory failure (Brescia-COVID Scale =2), ICU admission, or death.;Timepoint(s) of evaluation of this end point: From baseline up to Day-15

Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19)
Main Objective: Assess whether the group of patients receiving vitamin D supplements presents a less serious evolution of his pneumonia translated into lower mortality than patients who do not receive this supplement;Secondary Objective: - Determine the number of ICU admissions in both groups
- To determine the hospital stay (days of admission) in both study groups
- Estimate the prevalence of vitamin D deficiency in all the patients studied and the efficacy of the supplementation strategy in correcting hypervitaminosis D with a record of episodes of hypercalcemia or hypelcalciuria
- Request at baseline (study), 24 and 48 hours after placebo supplementation or vitamin D and at the end of the protocol, the permit for storage in the Basque Research Biobank of plasma, serum and urine samples (at -80ºC) that allows the hypotheses of interest to be evaluated a posteriori
- Establish the final degree of complexity of both groups according to the international classification
- Carrying out a cost-effectiveness study on the value of vitamin D treatment in these patients;Primary end point(s): Thus evaluating patients receiving vitamin D substitutes present a less serious evolution of respiratory syndrome compared to patients who do not receive a supplement, in terms of mortality and ICU admission;Timepoint(s) of evaluation of this end point: Until the end of the study

Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19
Main Objective: To determine whether the use of colchicine in patients hospitalized for COVID-19 pneumonia and with hyperinflammation data reduces the start of non-invasive ventilation (CPAP / BiPAP), admission to the ICU, start of invasive ventilation or death.;Secondary Objective: - To determine if the use of colchicine in a hospitalized patient due to COVID-19 pneumonia and hyperinflammation data is capable of limiting the overproduction of inflammatory cytokines while maintaining a good safety profile for the patient.
- To determine if the use of colchicine in a patient hospitalized for COVID-19 pneumonia and hyperinflammation data reduces the days of hospitalization.
- To determine if the use of colchicine in a hospitalized patient due to COVID19 pneumonia and hyperinflammation data reduces myocardial damage.
;Primary end point(s): 1. Support compound with CPAP / BiPAP, ICU admission, invasive ventilation or death.
2. Cytokine levels (IL-6) and inflammatory parameters (PCR, ESR, ferritin, fibrinogen, blood count) at recruitment, at 48 hours and on the fifth day of treatment.
3. Ultrasensitive troponin on the fifth day of treatment.;Timepoint(s) of evaluation of this end point: - Hospitalization
- At recruitment, at 48 hours and on the fifth day of treatment.
- On the fifth day of treatment.

A clinical trial of nebulised recombinant tissue plasminogen activator (rtPA) in patients with COVID-19 Acute Respiratory Distress Syndrome to decrease the duration of ventilatory support and mortality: A pilot study (the PACA trial)
Main Objective: 1. Efficacy: Investigate the potential for efficacy of nebulised rt-PA in patients presenting with severe COVID-19 requiring IMV or NIV including continuous positive airway pressure (CPAP) OR high flow oxygen with either venture or reservoir mask
2. Safety: Evaluate the safety of nebulised rt-PA treatment.
;Secondary Objective: 1. Investigate the impact on patient’s clinical status over time using the WHO ordinal scale of clinical improvement.
2. Investigate the effect of nebulised rt-PA on other respiratory markers
3. Investigate the impact on in hospital mortality and resource utilisation
;Primary end point(s): Efficacy
1. Percentage change in PaO2/FiO2 ratio from baseline, daily during treatment, end of treatment and 5 days post treatment in the groups receiving rtPA.
Safety
1. Incidence and severity of major bleeding events directly attributable to the study drug
2. Decrease in fibrinogen levels over 72 hrs post initiation of treatment to < 1.5 gm/L during treatment period and 48 hrs after the last dose of treatment
3. More than 1 treatment-emergent serious adverse event (SAE) during and up to 4824 hours after last dose of the treatment
;Timepoint(s) of evaluation of this end point: Efficacy - daily during treatment, end of treatment and 5 days post treatment
Safety - every day of trial (and as indicated in each primary outcome measure)

Senicapoc treatment of COVID-19 positive patients in intensive care
Main Objective: To treat respiratory insufficiency due to COVID19;Secondary Objective: Not applicable;Primary end point(s): The primary outcome will be the PaO2/FiO2 ratio 72 hours after
randomization. The PaO2/FiO2 ratio will be calculated based on the
arterial gas closest to the time-point of 72 hours after randomization. If
no clinically-indicated arterial gas is performed or planned within ± 2
hours of the time-point, an arterial gas will be performed. The ratio will
be calculated based on the PaO2 from the arterial gas and the FiO2 at
the same time point. If the patient is receiving mechanical ventilation
(invasive or non-invasive) or is receiving oxygen through a high-flow
nasal cannula, the FiO2 will be obtained directly from the ventilator. If
the patient is receiving oxygen through a regular nasal cannula, the FiO2
will be calculated based on the following: FiO2 = 21% + 4%/(l/min) x
O2 flow in l/min. For face masks, with or without reservoir, the FiO2 will
be estimated based on the approach used in EPIC2.40,41 Patients who
dies prior to the 72-hour time point will be handled as described in
Section 6.2.3.
The PaO2/FiO2 ratio is a commonly used measure of illness severity in
patients with acute lung injury and ARDS and is used to define these two
conditions.17 Furthermore, the PaO2/FiO2 ratio is associated with
mortality17,20 making it a potential useful surrogate outcome for phase
II trials. Although data is sparse, a lower PaO2/FiO2 ratio has also been
associated with worse outcomes in patients with COVID-19.10,42
Furthermore, animal studies in mice have shown that Senicapoc
improves the PaO2/FiO2 ratio in experimentally induced ARDS (Section
1.3.2). Based on these considerations, and the fact that hypoxemic
respiratory failure is the hallmark of severe COVID-19 infection, the
PaO2/FiO2 ratio is a reasonable primary outcome for a phase II trial.
The primary measure of the PaO2/FiO2 ratio will be done 72-hours after
randomization. This time-point was chosen to allow adequate time for
the intervention to work while avoiding missing data due to deaths.;Timepoint(s) of evaluation of this end point: The primary measure of the PaO2/FIO2 ratio will be done 72-hours after
randomization. This time point was chosen to allow adequate time for
the interventions to work while avoiding missing data due to deaths.

A clinical trial to gather information on the safety and effectiveness of drugs in patients with the COVID-19 infection, that could be used in larger trials.
Main Objective: The primary objective of the CATALYST Trial are to measure the change over time in the amount of oxygen being carried in the blood compared to the amount of oxygen being breathed in, in patients with COVID-19.
;Secondary Objective: We also want to look at:
1) How good is the treatment (and usual care) over time and whether this leads to an improvement in the patient's overall condition/ wellbeing
2) Clinical measures such as breathing rate, body temperature, how long you are in hospital for
3) Levels and changes in certain blood test results
4) Looking at how safe these treatments are by looking at their side effects treatments;Primary end point(s): The ratio of the oxygen saturation to fractional inspired oxygen concentration (SpO2/FiO2), measured from randomisation to day 14, hospital discharge, death. SpO2 and FiO2 (or inspired oxygen) are measured as part of routine clinical care at least 4 hourly in intensive care, and 4-6 hourly on the wards for patients receiving active management. The ratio will be derived from these data from the electronic patient record. ;Timepoint(s) of evaluation of this end point: measured from baseline to day 14

A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection
Main Objective: Day 14 Ordinal Scale Improvement (OSI);Secondary Objective: Key secondary objectives:
-To evaluate improvement in clinical measures across the 2 treatment arms
Additional secondary objectives:
-To evaluate improvement in additional clinical measures across the 2 treatment arms
-To determine the anti-inflammatory and immune effect of selinexor
-To assess safety and tolerability of selinexor [time frame: up to 28 days];Primary end point(s): Proportion of patients with at least a 2 point improvement (increase) in the Ordinal Scale from baseline to Day 14.
The Ordinal Scale is an assessment of the clinical status at the first assessment on each day of hospitalization.
1.Death;
2.Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
3.Hospitalized, on non-invasive ventilation or high flow oxygen devices;
4.Hospitalized, requiring supplemental oxygen;
5.Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);
6.Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;
7.Not hospitalized, limitation on activities and/or requiring home oxygen;
8.Not hospitalized, no limitations on activities.
;Timepoint(s) of evaluation of this end point: Throughout the study

Ruxolitinib for treatment of Covid-19 Patienten with acute respiratory
distress syndrome
Main Objective: Overall survival after 28 days after registration into this trial;Secondary Objective: - Overall survival after 90 days after registration into this trial
- Assessment of the duration of ventilation support
- Assessment of the extent of cytokine storm reduction (IL-6, CRP, ferritin)
- To assess time on ICU
- To assess toxicity and safety of ruxolitinib treatment
- To assess seroconversion under ruxolitinib (SARS-Co-19- IgG)
- To assess pulmonary function (time point discharge from hospital)
;Primary end point(s): Overall survival ;Timepoint(s) of evaluation of this end point: 28 days after registration

Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial
Main Objective: The primary objective is to investigate whether continuous infusion of iloprost at a dose of 1 ng/kg/min for 72-hours reduces the severity of respiratory failure in the ICU as compared to placebo.;Secondary Objective: Not applicable;Primary end point(s): Days alive without mechanical ventilation in the ICU at day 28;Timepoint(s) of evaluation of this end point: Day 28

Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir/ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection
Main Objective: To compare the proportion of patients with COVID-19 infection who achieve a score of less than 2 on the Brescia-COVID respiratory severity scale after treatment with hidroxycloroquine + azithromycin versus actual practice;Secondary Objective: - Time to reach a score lower than 2 on the Brescia-COVID respiratory severity scale.
- Proportion of subjects who die and time to death.
- Subject ratio (negative PCR) at the end of the treatment and time until denial.
- Proportion of subjects admitted to the ICU, time until admission to the ICU and length os stay.
- Duration of the hospital discharge.
- Time until intubation or invasive mechanical ventilation.
- Duration of the invasive mechanical ventilation.
- Proportion of subjects with adverse effects associated with the received treatment.;Primary end point(s): Respiratory severity scale Brescia-COVID;Timepoint(s) of evaluation of this end point: During hospital admission

Clinical trial, randomized, open-label, to evaluate the efficacy of high-dose vitamin D in patients with COVID-19 pneumonia
Main Objective: The aim of this trial is to provide estimates of increased levels of 25-hydroxyvitamin D3 on days 7 and 14 after high-dose vitamin D treatment (10. 000 IU/d) Thorens@ 25000 IU single-dose vials oral solution 2.5 ml=1ml/day on admission (maximum 14 days) compared with conventional dosing (2,000 IU/d) Thorens@ 25000 IU single-dose vials oral solution 2.5 ml=0.2 ml/day on admission (maximum 14 days)
;Secondary Objective: 1.Assess the safety and tolerability of both treatment guidelines.
2. Comparison of secondary efficacy parameters between the two treatment guidelines on days 7 and 14 of treatment initiation: no progression to respiratory failure, no increased oxygen requirements; need for mechanical ventilation; reduction of analytical parameters associated with poor prognosis; radiological progression of the disease; average hospital stay; intensification treatments such as steroid boluses, Tocilizumab or Anakinra; ICU admission and % mortality at end of follow-up.
3. Evolution of the analytical parameters on the 7th and 14th days of treatment
3.1 Haematological.
3.2 Biochemicals
3.3. Phospho-calcium metabolism.
4. Immunological study:
Comparison of the immunological parameters on days 7 and 14 of the beginning of the treatment of IL1b, IL2r, IL6, IL8, IL10, TNF alpha, MIP-1 alpha, CD14, GM-CSF, IFN alpha, IFN beta and IFN gamma.
.
;Primary end point(s): Increased levels of 25-hydroxyvitamin D3 will be determined on days 7,
and 14 after initiation of treatment;Timepoint(s) of evaluation of this end point: IT will be determined on days 7 and 14

A clinical trial to investigate the efficacy and safety of a new compound for the treatment of COVID-19, called BDB-001. Patients in the trial will be randomly allocated to either the new treatment or the conventional treatment and will be aware of which treatment they are receiving
Main Objective: Efficacy and safety assessments of BDB-001 for infusion in treating patients with progressive severe COVID-19.;Secondary Objective: Not applicable;Primary end point(s): Percentage of patient number (%) achieve recovery [Oxygenation index =300mmHg from baseline (day 1 prior to investigational drug administration), in supine position OR discharge from hospital].;Timepoint(s) of evaluation of this end point: days 3, 7, 11, 14.

Investigating otilimab in patients with severe coronavirus related lung disease.
Main Objective: To compare the efficacy of otilimab IV versus placebo. ;Secondary Objective: To compare the efficacy of otilimab IV versus placebo.
To compare the safety and tolerability of otilimab IV versus placebo.
;Primary end point(s): Participants alive and free of respiratory failure;Timepoint(s) of evaluation of this end point: Day 28

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)
Dose Escalation and Cancer Treatment Expansions: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs);Dose Escalation and Cancer Treatment Expansions: Number of Participants With Dose Limiting Toxicities (DLTs);Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More Serious Adverse Events (SAEs);Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations;Dose Escalation and Cancer Treatment Expansions: Number of Participants With Greater Than or Equal to (>=) Grade 3 TEAEs;Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Laboratory Values;Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Vital Sign Measurements;Dose Escalation and Cancer Treatment Expansions: Number of Participants who Experience Cytokine Release Syndrome CRS);COVID-19 Expansion: Number of Participants With >=2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples

Sero-epidemiological Survey of England in 2019/2020
Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds;Feasibility of developing an England based sero epidemiological survey in 0-24 year olds;Feasibility of developing an England based sero epidemiological survey in 0-24 year olds;Feasibility of developing an England based sero epidemiological survey in 0-24 year olds

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation

Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
Predictive association between CT-V, PBM score and disease progression

Chloroquine as Antiviral Treatment in Coronavirus Infection 2020

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

Covid-19 Pediatric Observatory
Percentage of children with severe or critical form.

CAP-1002 in Severe COVID-19 Disease

Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19
Characteristics of pulmonary ultrasound for Covid-19 patients

Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19

An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19
The change of viral load in patients with SARS-COVID-19.;The frequency of development of Acute Respiratory Distress Syndrome (ADRS);Duration of hospitalization;The frequency of early mortality;The frequency of late mortality;Clinical status at the time of completion of participation in the study

BCG Vaccine for Health Care Workers as Defense Against COVID 19

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

The Covid-19 HEalth caRe wOrkErS (HEROES) Study

St. Jude Tracking of Viral and Host Factors Associated With COVID-19
Proportion of asymptomatic subjects;Positive CD4 and CD8 cell epitope positive response

One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting
Mean in quality of life score at one year on the Short Form Health Survey (SF-36)

Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series

Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19
One-year utility score of health-related quality of life

Incidence of Covid-19 in School Children
evaluation of the prevalence of positive real-time-polymerase chain reaction (rt-PCR) in school children during the pandemic period in Nice

Nudges to Improve Health Behaviors That Limit COVID-19 Spread

Tableted COVID-19 Therapeutic Vaccine
Effect on CBC as per CTCAE v4.0;Effect on biochemistry parameters as per CTCAE v4.0

Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction
predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

The Effects of Mindfulness-based Training in Undergraduate Students of Translation and Interpreting
Change on the Five Facets Mindfulness Questionnaire;Change on the Emotion Regulation Questionnaire;Change on the Depression Anxiety Stress Scale;Change on the Trait Emotional Intelligence Questionnaire;Change on the Cultural Intelligence Scale;Change on the Mind Wandering questionnaire;Change on the ANTIVEA task;Change on the Test on creativity;Change on the Motivated Strategies for Learning Questionnaire

Using PRP and Cord Blood in Treatment of Covid -19
the number of patients with positive covid 19 who will improve after receiving stem cells

Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial

Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury
A qualitative analysis of parenchymal lung damage induced by COVID-19;A quantitative analysis of parenchymal lung damage induced by COVID-19

Pediatric Acute and Critical Care COVID-19 Registry of Asia

Psychiatric Consultation for COVID-19 Patients
Change of PHQ-9 (Patient Health Questionnaire-9);Change of GAD-7 (Patient Health Questionnaire-9);Change of PC-PTSD-5 (Primary Care PTSD Screen for DSM-5);Change of AIS (Athens Insomnia Scale);Change of P4 (P4 Suicidality Screener);Change of SF-36 (Short Form Health Survey Questionnaire)

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)
Reduction in the dependency on oxygen supplementation

The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients
Number of cases of SARS-COV-2 infection and mortality rate directly related to the infection in patients being followed for digestive, thoracic, head and neck, gynecologic, cerebral, urologic or cutaneous cancer

Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early
Clinical outcome negative for two parameters(hospital admission/disease progression);At least 50% change of the score of respiratory symptoms from the baseline

Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER)
Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case;All cause mortality per diagnosed COVID-19 case All-cause mortality rate at 30 days per diagnosed COVID-19 case

Niclosamide for Mild to Moderate COVID-19
Change in respiratory viral clearance (by PCR)

Mechanisms of Multi-organ Failure in COVID-19
Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19;Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19;Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19

The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19
Presence of viral pneumonia caused by COVID 19

Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial
Response to treatment: absence of moderate to severe oxygenation impairment (Berlin criteria);Response to treatment: survival

Ozone Therapy in the Prevention of COVID-19 Infection
The survey that was taken by telephone calls

"Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention"
Recruitment rate (monthly);Participant retention;Participant intervention satisfaction/evaluation

Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation
Medical Research Council sum score (MRC- SS).;Medical Research Council sum score (MRC- SS).;The Functional Status Score for the ICU (FSS-ICU)

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Attitude and Perception Towards COVID-19 Pandemic
Knowledge about COVID-19 by questionnaire;Perception about COVID-19 by questionnaire;Attitude towards COVID-19 by questionnaire

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol for COVID-19

Using GM-CSF as a Host Directed Therapeutic Against COVID-19

Attitude of Egyptian Population Toward COVID 19 in Ramadan
Attitude of the Egyptian population during the COVID 19 pandemic in Ramadan

Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak

One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)
Evaluation of recovery of quality of life in first year after ICU discharged in patients hospitalised for severe pneumonia at SARS-CoV2

Status of Management of Surgery in Beijing During COVID-19
treatment of fevers at arrival;treatment of post-operative fevers;assorted surgical parameters

Lessening Organ Dysfunction With VITamin C - COVID-19

Nigella Sativa in COVID-19
Proportion of patients who are clinically recovered

Predictive Models for Intensive Care Admission and Death of COVID-19

How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department
routine biomarkers and blood cell count are discriminant to diagnose COVID-19

Recovery of Patients From COVID-19 After Critical Illness

Distance Learning for Dental Student During COVID-19 Pandemic
assessment of distance education learning environment experiences among dental students enrolled in pediatric dentistry online course during COVID-19 crisis

Anti-SARS Cov-2 T Cell Infusions for COVID 19
Safety of administering partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.

TXA COVID-19 Clinical Trial
Incidence of acute kidney injury;Incidence of respiratory failure

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

Characteristics of Neonatal Covid-19 in Turkey

COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection

Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
Number of participants negative by RT-PCR for the virus at 4-10 days after initiation of therapy.;Number of participants with lung condition change assessed with X-ray.

Psychological Impact of the Covid-19 Pandemic on Student Nurses
Prevalence of PTSD-related symptoms assessed by the IES-R

IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With Nasopharyngeal PCR Testing.

Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Adverse events related to SGB;All Adverse events;Death

The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients
Modified Medical Research Council Dyspnea Score;Timed up and go test;Visual analog scale to assess the pain severity;The Short Physical Performance Battery (SPPB);Visual analog scale to assess the fatigue severity

The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19

NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE

Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic

Convalescent Plasma Therapy in Severe COVID-19 Infection
Proportion of In-hospital mortality;Time to death

Ivermectin and Doxycycine in COVID-19 Treatment
The number of patients with resolved viral infection

Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic
Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic

Somerset and South Essex Coronavirus Antigen Testing
To compare the result of SARS-COV2 PCR test to PCL rapid antigen test

The Açaí Berry COVID-19 Anti-Inflammation Trial

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment

Hyperimmune Plasma for Critical Patients With COVID-19

BCG Vaccination to Protect Healthcare Workers Against COVID-19
COVID-19 disease incidence;Severe COVID-19 disease incidence

In-depth Immunological Investigation of COVID-19.
Clinical Features;Immune host response at systemic level;Immune host response at local level;Host genetic variation

Pre-exposure Prophylaxis for SARS-Coronavirus-2

The Vietnam Chloroquine Treatment on COVID-19

LIBERATE Trial in COVID-19

Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia

ASC Therapy for Patients With Severe Respiratory COVID-19
Changes in clinical critical treatment index

Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic

Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
All-cause mortality or need of invasive mechanical ventilation

Test and Treat COVID 65plus+
? Rate of hospitalization or death at day 7 after study inclusion

Treatment for COVID-19 in High-Risk Adult Outpatients
Lower respiratory tract infection (LRTI) rates;Incidence of hospitalization or mortality;Change in upper respiratory viral shedding

Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial

Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections
Cumulative incidence of ventilator-associated lower respiratory tract infection

A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19

Long-term Impact of Infection With Novel Coronavirus (COVID-19)
Participant age;Participant sex;Participant race/ethnicity;Proportion of participants previously hospitalized.

COVID-19 Search in Conjunctival Cells
Conjunctival swab results based on RT-PCR

Evaluating AVM0703 for Treatment of COVID-19
Dose-Limiting Toxicities;28 day all-cause mortality will be a primary end point for Phase 1 and 2

COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box

Health Behavior Change During COVID-19 Pandemic

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant
Subjects with solicited AEs - Phase 1;Safety Laboratory Values (serum chemistry, hematology) - Phase 1;Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) - Phase 1

Human Ab Response & immunoMONItoring of COVID-19 Patients
Number of increased immune population;Number of decreased immune population;Number of statically different phenotypes compared to control patients

Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.

Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)
the number of intubations in COVID-19 patients initially hospitalised in wards

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Progression of respiratory failure or death

Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU

Mindfulness Training for Seniors
Change in mindfulness skills as measured by Five-Facet Mindfulness Questionnaire (5FMQ);Change in mindfulness skills as measured by decentering - Experiences Questionnaire (EQ).;Change in psychological health as measured by Patient Health Questionnaire 4 items (PHQ4).;Change in positive affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).;Change in negative affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).;Change in loneliness measured by the loneliness questions from the social isolation battery.;Change in loneliness measured by a loneliness question.

COVID-19 and ICU-acquired MDR Bacteria
Cumulative incidence of ICU-acquired colonization related multidrug resistant bacteria

COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress

Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden
Demographic characteristics of patients with Covid-19 receiving intensive care

Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study
Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy

Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU
Analysis of Clinical, Biological and Histological Pulmonary and Renal Impairment Related to SARS-CoV-2

Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.

Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers
Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG) in health personnel;COVID-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus;Incidence of reactivation/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2

COVID-19 Convalescent Plasma for Mechanically Ventilated Population
Participants with serious adverse events.;Time to clinical improvement.

The Critical Care Response to the COVID-19 Pandemic in Madrid

COVID-19 Wellness Survey

Home Usability Study of the SARS-CoV-2 (COVID-19) Test

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Acceptance of Telemedicine During the COVID-19 Pandemic

COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder
Score of the Impact of Event Scale Revisited scale

COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells
Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.

Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)

Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy
Vrological profile of newborns.;Immunological profile of newborns.

Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Changes in cytokines associated with SARS CoV-2 infection;Evaluation of cellular response;TLRs activation;KIR phenotype determination

COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial
change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline

Tannin Specific Natural Extract for COVID-19 Infection

Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus
Performance evaluation of RealDetect™ COVID-19 RT-PCR kit

Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

Validation of COVID-19 Tests
Identification of asymptomatic carriers of SARS-CoV-2

Setting up a COVID-19 Care Facility at a Prison in Pakistan

Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic
Incidence of COVID-19 among children with cancer

CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome

COVID-19 Ozanimod Intervention Study
The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%;Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale

TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial

Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry
Number of patients with post-traumatic stress disorder (PTSD) defined by a total score on PCL-5 = 31 at the time of quarantine;Number of patients with post-traumatic stress disorder (PTSD) defined by a total score on PCL-5 = 31 at the time of quarantine;Number of patients with post-traumatic stress disorder (PTSD) defined by a total score on PCL-5 = 31 at the time of quarantine

Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19
Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection

Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19

Thromboembolic Events in Severe COVID-19 Patients
Analysis of incidence of thromboembolic events in patients with Sars-CoV-2

Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease

Viral Specific T-cells for Treatment of COVID-19
Successful production of viral specific T-cells

Endovascular Thrombectomy in COVID-19 Infected Patients

Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19

Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique
Correlation between impudence deterioration to clinical conditions and hospitalization period

Home-Based Covid-19 Rehabilitation Program
Change in pulmonary function (St George's Respiratory questionnaire: SGRQ);Change in physical function (Activity Measure for Post-Acute Care: AM-PAC)

Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

Prediction of Acute Kidney Injury in Patients With COVID-19

An Observational Study to Identify the Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic and the Resulting Lockdown

COVID-19 Research in Organ Transplant Recipients
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Seroprevalence of SARS-Cov-2 antibodies (positive antibody test);Change in levels of SARS-Cov-2 antibodies (antibody titers)

STATIN THERAPY AND COVID-19 INFECTION
SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy

Vitamin D Testing and Treatment for COVID 19
Vitamin D levels;severity of COVID 19 symptoms

COVID-19 Impact on Rheumatic Patients
Score of five-item Brief Symptom Rating Scale (BSRS-5)

Vienna Versus SARS-CoV-2 Virus Study
Prevalence of antibody status in healthcare workers and in patients admitted for non-COVID-19 related symptoms over time

Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19
analyze the relationship between the prone position and the need for orotracheal intubation.

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Participants with a disease control status defined as no disease progression to severe.

Dietary Intake and Eating Habits During the COVID-19 Pandemic

COPD in the Time of COVID-19

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
Prevalence of antibodies against SARS-CoV-2 through serological testing;Frequency of participants with a positive RT-PCR test result for SARS-CoV-2

Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions
Participation Barriers;Number of Eligible Participants;Number of Participants Approached;Number of Participants Consented;Rates of Refusal;Reasons for Refusal;Number of Sessions Completed in Total;Adherence Index;Amount of time (in weeks) to complete the intervention;Intervention Acceptability;Participant Satisfaction;Working Alliance Inventory after First Intervention Session;Working Alliance Inventory after Sixth Intervention Session;Working Alliance Inventory after Final Intervention Session

Use of Convalescent Plasma for COVID-19
Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate;Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection;Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate;Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate

Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure

High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:

Endothelial Function, Inflammation and Organ Dysfunction in COVID-19
Plasma bio-adrenomedullin, proenkephalin, dipeptidyl peptidase-3, renin and angiotensin II

Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
Brain regional homogeneity between COVID-19 patients with and without anosmia

A phase II, open label non-randomised clinical trial of the safety and efficacy of the CovidCare app to support self-monitoring for COVID-19 symptoms in self-isolation and to determine the impacts on mental health
Efficacy will be determined by an audit conducted by a data analyst of the daily vital sign entries to assess appropriateness of values and accuracy of triage outcomes. Statistical evaluations will be completed of threshold ranges to determine accuracy and safety of vital sign monitoring and triage.[Data is entered daily from days 1-4 and 2 times per day for days 5-14 post COVID-19 diagnosis. Additional data may be requested to be entered by the CovidCare app if data is beyond pre-determined thresholds and requires verification.];Safety will be determined by evaluating the raw vital sign data entered into the app to ensure that the data has triggered the correct notifications to participants based on the pre-determined thresholds established to identify deterioration warranting further medical advice.
[Data will be analysed daily for 14 days]

Open label, prospective study for the Biofourmis Everion armband telemonitoring solution for patients during COVID-19 home isolation within South Western Sydney
To assess the feasibility of the Everion armband device in the telemonitoring of COVID-19 high risk patients under home isolation period using data from the Everion armband device and a study-specific questionnaire[After receiving clinical clearance ];To assess the suitability of the Everion armband device in the telemonitoring of COVID-19 high risk patients under home isolation period using data from the Everion armband device and a study specific questionnaire[After receiving clinical clearance.]

Ventricular Arrhythmias in Implantable Cardioverter Defibrillator Patients During the COVID-19 Pandemic
Primary Outcome- the impact of the COVID-19 pandemic on the occurrence of ventricular arrhythmias
This outcome will be measured by comparison of the number of ventricular arrhythmia episodes, and patients affected by ventricular arrhythmia episodes, between the COVID period, and the two control periods.
The number of ventricular arrhythmias, and the number of patients who experience a ventricular arrhythmia will be derived from the PaceMate remote monitoring database.[The primary outcome measure will be assessed daily during in each participant, during the 100-day COVID period, and daily during the two distinct 100-day control periods.]

COACHING FOR COVID-19: A Pilot Study Investigating the Effectiveness of Coaching on Psychological Outcomes in Hospital-Based Senior Doctors
Psychological distress, as measured by the 21-item Depression Anxiety Stress Scale (DASS-21), in a cohort of Senior Doctors at Liverpool Hospital through the implementation of a one-on-one virtual coaching program during the COVID-19 pandemic.[Baseline, 1-week post program (primary timepoint), and 3-months post program]

Testing an Online Coping Skills Intervention for People Living with Chronic Illness During the Covid-19 Pandemic
Depression scores are assessed by the brief Depression, Anxiety, and Stress Scale (DASS; Lovibond & Lovibond, 1995).[Baseline and post-intervention (4 weeks after baseline)];Anxiety scores are assessed by the brief Depression, Anxiety, and Stress Scale (DASS; Lovibond & Lovibond, 1995).[Baseline and post-intervention (4 weeks after baseline)];Stress scores are assessed by the brief Depression, Anxiety, and Stress Scale (DASS; Lovibond & Lovibond, 1995).[Baseline and post-intervention (4 weeks after baseline)]

Angiotensin II Infusion in COVID-19-Associated Vasodilatory Shock: A multinational, multicentre registry
Time until being discharged alive from the intensive care unit (ICU) (defined as the time from ICU admission until ICU discharge alive, assessed by the date of admission and date of discharge retrieved from medical records)[Until ICU discharge]

In vivo use of ivermectin (IVR) for treatment for corona virus infected patients: a randomized controlled trial
Reduction of viral load and treating COVID-19 infection;

A medical records based study for nano short peptide nutrition intervention on the prognosis of patients with novel coronavirus pneumonia (COVID-19)

Analysis of Characteristics of recurrent positive RT-PCR findings of recovered patients from novel coronavirus pneumonia (COVID-19) in Wuhan, China: a medical records based study

Effectiveness of day care service on improving the physical and psychological well-being of people with dementia and easing the caregiving burden in COVID-19 pandemic

A Survey Among Collage Students for Changes and impact factors of Lifestyle, Psychology and Weight During Keep Stay at Home for four months in the Pandemic of Novel Coronavirus Pneumonia (COVID-19)

Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance

Investigating the impact of COVID-19 and its response, on people with severe mental illness in South Asia
Depression, anxiety and wellbeing are measured via a telephone survey using the validated GAD7, PHQ9, and WEMWBS scales at baseline and possible follow-ups (depending on the evolution of the pandemic)

Supporting weight management during COVID-19
Self-reported weight (kg) at baseline and 4 months

A collaborative pilot study to monitor and optimise access to urgent surgery during the period of reduced resources in Genoa, Italy caused by the COVID-19 pandemic, using a bespoke referral process and the SWALIS 2020 model to prioritise surgery by clinical urgency and waiting time
Measured weekly, i.e. every Tuesday following the just-finished week: feasibility (weeks 1 and 2), pilot (weeks 3, 4, 5, 6):
1. Clinical complications and adverse events reportedly caused by the pathway (safety), measured by recording and numbering single reports by surgeons responsible for patient care on identified proforma at weekly MDT meetings
2. According to the SWALIS model, the waiting list is measured weekly through purposely designed performance indexes, including cross-sectional (for patients currently on the list at an index day) and retrospective views (for patients who received treatment during a given period T):
2.1. Priority (as average and SD) on the list (new for SWALIS 2020) (for each and all urgency categories)
2.2. Waiting time in days (as median and range) (for each and all urgency categories)
2.3. Waiting list length (as average and SD) (for each and all urgency categories)

Survival of patients suffering an out-of-hospital cardiac arrest treated by emergency services in Spain during the COVID-19 pandemic and 1 year later
Survival at hospital discharge with good neurological status, expressed as percentage of patients with Cerebral Performance Category scale = 2, during the COVID-19 pandemic and 1 year later

Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic
Insomnia severity measured using the Insomnia Severity Index at one week post-intervention

Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center
Hospital admission for any reason among patients who tested positive for SARS-CoV-2 within 30 days following initial consultation for SARS-CoV-2 testing. Information will be collected from participants via follow-up phone calls at days 7, 14, and 60 after consultation, as well as via patient records from general practitioners and/or treating physicians in hospitals after 60 days.

A study to test the effectiveness and safety of bacteria called Bifidobacterium breve in patients with COVID-19 infections
Main Objective: To determine the effect of MRx-4DP0004 on the clinical outcome of participants with COVID-19 symptoms;Secondary Objective: To determine the safety of MRx-4DP0004 in participants with COVID-19 symptoms;Primary end point(s): Change in mean clinical status score as measured by the WHO Ordinal Scale for Clinical Improvement;Timepoint(s) of evaluation of this end point: Throughout the duration of the trial

A First-in-Human Study in Adult Subjects Hospitalized with Covid-19 to Investigate a new product called ARGX-117
Main Objective: To evaluate the safety and tolerability of ARGX-117 IV administered in adult subjects initially hospitalized with COVID-19 infection
In part B and part C of the trial the primary objectives will be to investigate efficacy and safety of ARGX-117 IV administered in subjects initially hospitalized with Covid-19;Secondary Objective: 1. To investigate the pharmacokinetics (PK) of ARGX-117 IV administered in differing dose regimens in subjects initially hospitalized with Covid-19
2. To investigate the pharmacodynamics (PD) and immunogenicity (ADA) effects of ARGX-117 IV administered in differing dose regimens in subjects initially hospitalized with Covid-19
3. To investigate the preliminary efficacy of ARGX-117 IV administered in differing dose regimens in subjects initially hospitalized with Covid-19
;Primary end point(s): The safety and tolerability of ARGX-117 will be assessed by the totality of safety and tolerability data, including incidence and frequency of AEs and SAEs; vital sign results; physical examination findings; ECG recordings; and clinical laboratory tests (routine hematology, clinical chemistry, and urinalysis), and specialty laboratory testing (CRP, ferritin, procalcitonin, D-dimer, cytokine panel).;Timepoint(s) of evaluation of this end point: Safety will be continuously monitored until end of study
other endpoints D1 until D4, D6, D8, D15, D22, D29, D36, D50, D64, D92 or end of study

Study evaluating the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among health care workers in Poland during the COVID-19 pandemic
Main Objective: 1) To confirm that, after additional BCG vaccination, there are fewer COVID-19 cases and deaths among subjects with negative RT23 test, and that these subjects present milder course of SARS CoV-2 infection than those who have not been vaccinated with BCG;
2) To confirm that among people with a positive RT23 test, previously vaccinated with tuberculosis vaccine, there is a lower morbidity and mortality resulting from COVID-19 infection, and that these subjects have a milder course of this disease than people with a negative RT23 test who have not received a vaccine against tuberculosis;Secondary Objective: 1) to examine whether the percentage of positive RT23 tests in the four examined provinces remains in correlation with the number of COVID-19 cases in those provinces?
2) to examine whether the presence of a scar or scars from previous BCG vaccination has an impact on the course of SARS-CoV-2 infection?
3) to ascertain whether the time since the last BCG vaccination has an influence on the occurrence and course of COVID-19?;Primary end point(s): - death or life-threatening / severe health impairment (cardiac arrest with effective resuscitation, shock, severe respiratory failure, severe kidney failure, stroke / transient ischemic attack);;Timepoint(s) of evaluation of this end point: Over the entire 18-month period following the inclusion in the study

A study comparing favipiravir versus standard of care management as an early treatment arm in COVID-19 Hospitalized patients
Main Objective: Assess the efficacy of favipiravir in addition to supportive care in hospitalised patients with COVID-19 in reducing the severity of disease compared to supportive care alone;Secondary Objective: (1) Assess the effect of favipiravir in addition to supportive care in the study population compared to supportive care alone.
(2) Evaluate the safety and tolerability of favipiravir in the study population;Primary end point(s): (1) Assess the efficacy of favipiravir in addition to supportive care in hospitalised patients with COVID-19 in reducing the severity of disease compared to supportive care alone;Timepoint(s) of evaluation of this end point: Clinical status as assessed by WHO COVID 10 point ordinal severity scale at day 14

Study of ivermectin against COVID-19
Main Objective: To evaluate the efficacy of Ivermectin plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC in the treatment of coronavirus disease 2019 (COVID-19) based on the qualitative virological clearance in upper respiratory tract swab samples on Day 7. ;Secondary Objective: 1. To evaluate the efficacy of Ivermectin plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC in the treatment of coronavirus disease 2019 (COVID-19) based on clinical improvement on Day7 and Day14
2. To evaluate the efficacy of Ivermectin plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC in the treatment of coronavirus disease 2019 (COVID-19) based on clinical recovery on Day 7 and Day 14.
Additional secondary objectives
1. To evaluate the efficacy of Ivermectin plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC in the treatment of coronavirus disease 2019 (COVID-19) based on different additional clinical endpoints
2. To evaluate the effect of treatment with Ivermectin plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC on hematology and inflammatory markers
;Primary end point(s): Rate of subjects converted to negative SARS-CoV-2 (qualitative) test on Days 7;Timepoint(s) of evaluation of this end point: Day 7

A study to investigate whether vaccination with VPM1002 can reduce elderly people's days with severe respiratory infectious diseases at hospital and/or at home
Timepoint(s) of evaluation of this end point: From day 0 to day 240;Main Objective: To assess the reduction of days with severe respiratory infectious diseases at hospital and/or at home in elderly subjects during the pandemic of SARS-CoV-2;Secondary Objective: To assess the reduction of disease severity, the duration of hospital admission, intensive care unit (ICU) admission, or death in elderly subjects during the pandemic of SARS-CoV-2;Primary end point(s): Number of days with severe respiratory disease at hospital and/or at home

Treatment of COVID-19 with the inhalation drug pulmozyme
Main Objective: To compare the treatment effect of aerosolized DNase I (Pulmozyme) to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy or discharge from hospital in hospitalized patients with COVID-19 and respiratory dysfunction.;Secondary Objective: To compare the treatment effect of aerosolized DNase I (Pulmozyme) to that of placebo (NaCl, 0,9%) on
28-day mortality, days alive and without ventilator treatment, days alive and without high flow nasal oxygen treatment (Optiflow), days alive and free of stay in the Intensive care unit (ICU), days alive and outside hospital, days alive and free of new of episode with saturation =93% after the primary endpoint has been met, days alive and without need for supplemental oxygen, adverse reactions.
Exploratory objectives: quantification of NETs in respiratory secretions and on the incidence of clinical thromboembolic events.;Primary end point(s): Time (days) until the study patient has an oxygen saturation of >93% without supplemental oxygen for 24 hours or until the patient is discharged from the hospital. ;Timepoint(s) of evaluation of this end point: day 1 through 28

Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms: Randomized clinical trial
Main Objective: A randomized study assessing amiodarone and verapamil compared with conventional therapy in the early, symptomatic stage of infection in symptomatic patients with confirmed COVID-19;Secondary Objective: Not applicable;Primary end point(s): The primary end point of the study is the clinical improvement defined according to WHO classification, that was used in recent COVID-19 trials. The end point is defined as time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7. Improvement is considered as the increase of one category of the scale or discharge. Lower scores indicate worse outcomes and higher scores outcome improved.
The ordinal scale has the following items, ranging from 1 to 7:
8.Death.
9.Hospitalized patients who require mechanical ventilation, ECMO, or both;
10.Hospitalized patients who require nasal oxygen therapy in high flow, non-invasive mechanical ventilation, or both;
11.Hospitalized patients who require oxygen therapy;
12.Hospitalized patients who do not require oxygen therapy;
13.Not hospitalized, but unable to resume normal activities;
14.Not hospitalized with resumption of normal activities.;Timepoint(s) of evaluation of this end point: The primary endpoint will be evaluated during the period from the inclusion of the patient until the end of the study.

Adaptive trial in severe pneumonia (REMAP-CAP)
Main Objective: The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by the occurrence of death during the index hospital admission censored 90 days (or 21 days in case of pandemic) from the date of enrolment.
;Secondary Objective: The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months (in case of a pandemic, 90 days outcome will be a secondary objective), health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS).;Primary end point(s): The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days (or at 21 days in case of a pandemic);Timepoint(s) of evaluation of this end point: 90 Days from the date of enrolment.

Study to investigate the safety and effects of vaccines in healthy adults.
Main Objective: To describe the safety and tolerability profiles of prophylactic BNT162 vaccines in healthy adults after single dose (SD; prime only) or prime/boost (P/B) immunization;Secondary Objective: To describe the immune response in healthy adults after SD or P/B immunization measured by a functional antibody titer, e.g., virus neutralization test or an equivalent assay available by the time of trial conduct.;Primary end point(s): Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 d after each immunization.
Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 d after each immunization.
The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):
For BNT162a1, BNT162b1, BNT162b2 (P/B): occurring up to 21±2 d after the prime immunization and 28±4 d after the boost immunization.
For BNT162c2 (SD): The proportion of subjects with at least 1 unsolicited TEAE occurring up to 28±4 d after the immunization.
;Timepoint(s) of evaluation of this end point: see Clinical Trial Protocol, Section 9.4.2 Primary endpoints

Zilucoplan® in patients with acute hypoxic respiratory failure due to COVID-19
Main Objective: The primary objective of this intervention is to study if Zilucoplan® affects the the median and/or mean change in oxygenation between enrolment (baseline) and at predose day 6 and day 15 (or discharge, whichever comes first) through assessment of the PaO2/FiO2 ratio and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID-19 ward or ICU COVID-19 unit. For patients on ECMO the PaO2/FiO2 ratio and Aa-gradient cannot be calculated as in this case the FiO2 will be missing. Therefore, the last available value of PaO2/FiO2 ratio and Aa gradient prior to ECMO can be used at that timepoint.;Secondary Objective: -to study if early intervention with Zilucoplan® is safe (number of AEs/SAEs)
-to study if early intervention with Zilucoplan® affects clinical outcome defined by duration of hospital stay, 6-point ordinal scale, time to defervescence, supplemental oxygen use and SOFA score
- to study if early intervention with Zilucoplan® affects progression to mechanical ventilation and/or ARDS and duration of ICU stay
-to study if early intervention with Zilucoplan® affects the rate of nosocomial infection
-to study if treatment with Zilucoplan® has a favourable effect on long term at follow up 12-22 weeks post-randomization
-to study if treatment with Zilucoplan® affects all-cause mortality rate at day 28 and at 12-22 weeks post-randomization;Primary end point(s): To measure the effectiveness of SC Zilucoplan® treatment on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation at predose day 6 and day 15 (or at discharge, whichever comes first) through assessment of the mean and/or median change from pretreatment (day 1) to post-treatment (day 6 and 15 or at discharge, whichever comes first) PaO2/FiO2 ratio, P(A-a)O2 gradient and a/A pO2 ratio, which can easily be performed in the setting of clinical observation of patients admitted to the COVID-19 ward or ICU COVID-19 unit. These measurements derived from an arterial blood gas sampling are taken when the patient is sitting upright and breathing room air. Since supplemental oxygen will be indispensable in some patients, the A-a gradient will be normalized against age and FiO2 expected A-a gradient, according to validated formulas. If patients leave hospital between day 6 and day 15, that day of discharge will be taken as measurement point for primary endpoint instead of day 15. For patients on ECMO the PaO2/FiO2 ratio and Aa-gradient cannot be calculated as in this case the FiO2 will be missing. Therefore, the last available value of PaO2/FiO2 ratio and Aa gradient prior to ECMO can be used at that timepoint.;Timepoint(s) of evaluation of this end point: day 6
day 15
at discharge

Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection
Secondary Objective: - Time to clinical improvement on WHO R&D Blueprint seven-category ordinal scale by 2
- Adverse events
- Case fatality rate on days 21, 35 and 60
- Length of hospital stay
- Length of ICU stay
- Duration of ventilation Support / ECMO
- Time until negative SARS-CoV-2 PCR
- Predictive value of comorbidities and inflammation markers
- Feasibility of collection of plasma units
- Kinetics of anti-SARS-CoV-2 antibodies in plasma of patients = plasma donors who recovered
from a SARS-CoV-2 infection
- Titer of anti-SARS-CoV-2 in transfused plasma units
- Impact of donor characteristics on anti-SARS-CoV-2 humoral response
- Course of anti-SARS-CoV-2 titer in patients
- Effect of timing of plasma transfusions on outcome
;Main Objective: To improve survival
AND
remove criteria of severe COVID-19 (CoV-2 infection) within 21 days after randomization;Primary end point(s): Composite endpoint of:
- Survival
- no longer fulfilling criteria of severe COVID-19 within 21 days after randomization
All criteria must be met in order to fulfill the primary endpoint.
;Timepoint(s) of evaluation of this end point: Treatment group: Day 21
Control group: Days 14 and 21

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
Frequency of solicited local reactogenicity adverse events (AEs);Frequency of any medically-attended adverse events (MAAEs);Frequency of any new-onset chronic medical conditions (NOCMCs);Frequency of any serious adverse events (SAEs);Frequency of any unsolicited adverse events (AEs);Frequency of solicited systemic reactogenicity adverse events (AEs);Grade of any unsolicited adverse events (AEs);Grade of solicited local reactogenicity adverse events (AEs);Grade of solicited systemic reactogenicity adverse events (AEs)

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)

An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19
Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial;Change from baseline Serum ferritin level at end of the trial;Change from baseline serum Interleukin-6 concentration at end of the trial;Change from baseline serum C-reactive protein concentration at end of the trial;Change from baseline serum Tumor necrosis factor-a concentration at end of the trial;Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial

Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

Outcomes of Patients With COVID-19 in the Intensive Care Unit

Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease
Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).

Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients
Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Proportion of participants with no evidence of SARS-CoV-2 infection;Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples

Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial
50% reduction in symptom score for patients with lower respiratory tract infection;Lack of progression for patients with upper respiratory tract infection

Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry
Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice;Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice;Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice

Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals
Risk categorization of healthcare workers;COVID-19 infection rate among health care workers;Risk factors for COVID-19 among health care workers;Adherence of health care workers to infection prevention;Validity of the available rapid serological test for detecting COVID-19 virus infection

Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
Assessment of weaning from cardiorespiratory support

Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE)
Efficacy of intratracheal administration: occurrence of at least one grade improvement

Evolution of Facial Trauma During COVID Containment Measures
evolution of number of maxillofacial trauma

The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19
Mixed venous O2 pressure (PVO2);Mixed venous O2 pressure (PVO2);Mixed venous CO2 pressure (PVCO2);Mixed venous CO2 pressure (PVCO2);PH;PH;HCO3;HCO3;Oxygen saturation (O2 Sat) from VBG;Oxygen saturation (O2 Sat) from VBG;Three minute walk test;Three minute walk test;O2 Sat after one minute walking;O2 Sat after one minute walking;O2 Sat after two minutes use of Partial Rebreather;O2 Sat after two minutes use of Partial Rebreather;O2 Sat after two minutes free air breathing;O2 Sat after two minutes free air breathing;O2 sat/ Fio2;O2 sat/ Fio2

Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients

Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)
the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.;the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.

Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)

XPro1595 for the Treatment of Pulmonary Complications From COVID-19
Proportion of participants with disease progression from randomization to 28 days post-randomization

Recruit Blood Donors Via SMS During Epidemic of COVID-19

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
Proportion of patients requiring invasive mechanical ventilation or dying

Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events

Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic
Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19
Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence;Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.;Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts

D-dimer Levels in Pregnant With COVID-19
Compare D-dimer values of COVID-19 patients and healthy pregnant women

Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation
Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
Participants with serious adverse events.;Comparison of clinical severity score between patients on the experimental versus control arms;

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
Incidence of AEs;Mortality;Death;Number of ventilator-free days

COVID-19: Herd Immunity Study in the Czech Republic
Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 Pneumonia
An improvement of two points on the seven-point ordinal scale

Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.
Susceptibility to SARS CoV-2 infection according to ACE2 receptor;Cellular immune response to SARS CoV-2 infection;Susceptibility to infections according to KIR phenoytpes

CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
Hospital mortality or discharge to hospice

Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency

Determination of Acute Encephalopathy Predictors in Patients With COVID-19
The percentage of patients who have developed encephalopathy

Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO

Exploring Brain Damages After COVID-19 Infection
Latency of electrophysiological response;Delay of Muscle contraction;Delay of silent period;Duration of silent period;Inhibition rate

Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic
Anxiety/depression by means of Hospital Anxiety and Depression Scale (HADS);Medical problems induced by deferred elective surgery or delayed postoperative ambulatory visit;Reduced access to medical and psychological help

Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.
To evaluate, through laser doppler, the presence of changes in systemic microvascular endothelial function in patients in the acute phase of COVID-19.

Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
Description of the characteristics of patients

Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease
Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

COVID-19 and Mental Health

The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Intubation and Mortality Rates in Hypoxic Patients With COVID-19.
Oxygen saturation;In-hospital Intubation/Mechanical Ventilation;In-hospital Mortality;Length of Hospitalization

Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly
Hypoxic respiratory failure;Hypoxic respiratory failure;Hypoxic respiratory failure;Hypoxic respiratory failure

Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)
Diagnostic values of anosmia and ageusia for COVID-19

COVID-SErology in Rheumatoid Arthritis (COVID-19)
Evaluate the false positive results rate

Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near
Evaluation of feasibility of telemedicine in outpatient visit in bariatric patients

Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study

A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS): Tennant et al., 2007

Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19)
If the participant has an active SARS-CoV-2 infection during admission;The participant has had a past SARS-CoV-2 infection

QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine
Short Form-36 Health Survey (SF36);Short Form (36) Health Survey (SF36);Short Form (36) Health Survey (SF36);Beck Anxiety Inventory (BAI);Beck Anxiety Inventory (BAI);Beck Anxiety Inventory (BAI);Beck Depression Inventory-II (BDI-II);Beck Depression Inventory-II (BDI-II);Beck Depression Inventory-II (BDI-II)

Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

Improving Activity Engagement Among Persons With SCI During COVID-19

Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients
estimation of inflammatory changes in Covid 19 pneumonia by using MVP/PLT ratio

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
Incidence confirmed case of COVID-19;Incidence of probable case of COVID-19

Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection
Characterization of specific T cell responses in peripheral blood isolated from patients that have been exposed to SARS-CoV-2.

Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network
Analyse the variation in weight loss kinetics before, during and after confinement in patients enrolled in a weight reduction programme (RNPC) in France

Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
The percentage of subjects who develop laboratory-confirmed COVID-19: - with protocol-defined progressive symptoms OR - are hospitalized OR - die

Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients

Effects of the COVID-19 Health Emergency on Biopsychosocial Health
World Health Organization Quality of Life-Brief Scale

Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic
Change in Insomnia Clinical Diagnosis;Change in Beck Depression Inventory-II (BDI) Scale Score;Change in Beck Anxiety Inventory (BAI) Scale Score;Change in Quality of Life (SF-36) Scale Score;Change in Sheehan Suicidality Tracking Scale (S-STS) Score;Change in Ford Insomnia Response to Stress Test (FIRST) Scale Score;Change in UCLA Loneliness Scale Score;Change in Social Network Index (SNI) Scale Score;Change in Perceived Stress Scale Score;Change in Screen Time- Self Report;Change in International Physical Activity Questionnaire (IPAQ) Scale Score

Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care
Recruitment rate;Completion rate;Peri-traumatic distress inventory (negative emotions);Impact of Events Scale (6 item);Impact of Events Scale (6 item);Impact of Events Scale (6 item)

COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department
Rate of SARS-CoV-2/COVID-19 in a selected cohort of urological patients undergoing surgery;Post-operative COVID-19 related complication rates

Pharmacy Education During Covid-19 Outbreak
Impact of Covid-19 on pharmacy Education study in Egypt

Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19
Forced expiratory volume in the first second/forced vital capacity;Total lung capacity;Lung diffusion capacity for carbon monoxide;6-minute walk test distance;Short-form 36 questionnaire (SF-36)

Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches
Change of pro-inflammatory response over the ICU stay as a causative for primary endothelial dysfunction;Time-to-event "pulmonary bacterial superinfection or death";Positive bacteria and/ or SARS-CoV-2 cultures on handheld devices used in clinical routine and correlation to the adherence to disinfection protocols

Aggrenox To Treat Acute Covid-19

Recruit Blood Donors Via SMS During Epidemic of COVID-19 (Repeat Trial)

Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients

P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
Evaluate the efficacy of P2Et in reducing the length of hospital stay of patients with clinical suspicion or confirmed case of COVID-19

Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency

Pulmonary Optical Coherence Tomography in COVID-19 Patients
optical coherence tomography pulmonary microthrombosis assessment in COVID-19 pneumonia patients

Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy
Number of PCR confirmed cases among pregnant women

Can the Prediction Market Improve Predictions of COVID-19?
Predictions of COVID-19 Cases and Deaths

Glycaemia and Cardiac Function in Patients With COVID-19
Plasma glucose levels and left ventricular ejection fraction

COVID-19 PCR Test Results in Asymptomatic Pregnants
Rate of positive COVID-19 cases in asymptomatic pregnant women

Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
Time to recovery (discharge);Decrease in viral load

COVID-19, Obesity and Lifestyle in Children
Change in weight child;Change in weight parents

Epigenetic Tools as Prognostic Predictors in Covid19
Determination of the relationship between the severity of disease and epigenetic factors in COVID 19

Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD
Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.

Study of Sargramostim in Patients With COVID-19
Change in oxygenation parameter of P(A-a)O2 gradient by Day 6;Percent of patients who have been intubated by Day 14

Effect of Using Barrier Devices for Intubation in COVID-19 Patients

To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic
Efficiency of the telephone consultation,;Patient satisfaction

The Seniors COvid-19 Pandemic and Exercise Study

Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury
Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.

Covid-19: Possible Role of Neutrophil Extracellular Traps
NETOSIS AND MORTALITY;NETOSIS AND DCOVID-19 SEVERITY

Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
Survival rate.;Rate of disease remission.;The number of patients with PCR negative results.

Echocardiography in Patients With Covid-19

COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits
Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19

Menstrual Cycle Characteristics of Healthcare Professionals
Rate of irregular menstrual cycle;Length of cycle;Rate of prolonged bleeding;Amount of flow;Rate of dysmenorrhea

Implementation of the Integrated Care of Older People App and ICOPE Monitor in Primary Care (ICOPE)

TCM Differentiation and Treatment Protocol of COVID-19
The relief of main symptoms/ disappearance rate of time;Chest CT absorption

Trial of Treatments for COVID-19 in Hospitalized Adults
Percentage of subjects reporting each severity rating on a 7-point ordinal scale

Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19

Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19

Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study
Evaluation of covid-19 knowledge level of turkish physicians

Hyperbaric Oxygen for COVID-19 Patients

Hydroxychloroquine in Outpatient Adults With COVID-19
Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available);Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events of Special Interest (AESIs);Change from Baseline in Antigen-Specific Binding Antibody Titers;Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-?) Cellular Immune Response

Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial
Proportion of alive patients free off mechanical ventilation

The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation
Correlation of FAST+ pulmonary findings with active COVID infection

Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER
The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.

Efficacy of Ivermectin as Add on Therapy in COVID19 Patients

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA
Rate of patients reaching a significant hypoxemia, in each arms.

IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group

Predict Adverse Events by Covid-19 Nephritis

Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease
Evaluate the safety of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

Telmisartan for Treatment of COVID-19 Patients

CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19
Clinical improvement;improvement in tomographic image;test positivity for COVID-19;early and late complications associated to convalescent plasma

Plasma Adsorption in Patients With Confirmed COVID-19

Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia
Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers
The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.;The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.

Sarilumab for Patients With Moderate COVID-19 Disease

The COVID-19 ICU PRAYER Study
Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.

COVID-19 Detection Test in Oncology
To evaluate the ability of SARS-CoV-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of COVID-19 within 3 months.

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
Time to reach normal body temperature;Development of COVID-19 symptoms during HCQ preventive therapy in staff

Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )

Moxibustion Plus Cupping in Convalescent Patients With COVID-19
The change of the average VAS score from baseline to week 4

Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic
Perceived Stress Scale;Perceived Stress Scale;Perceived Stress Scale

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours in comparison to routine treatment;Percentage of participants with definite or probable drug related adverse events

Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2

COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers
Proportion of participants in whom there was a clinical finding of COVID-19.;Symptomatic COVID-19 infections.

International SARS-CoV-2 (COVID-19) Infection Observational Study

Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth
Change in 6 Minute Walk Test;Change in Short Form 35 (SF-36) Questionnaire

Vitamin D and COVID-19 Management

Famotidine Outpatient COVID-19 Treatment Study

Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus

Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease
The number and proportion of patients with the normal body temperature (=37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure

Trial of Imatinib for Hospitalized Adults With COVID-19
The proportion of patients with a two-point change using the 8-category ordinal scale

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Maternal-foetal Transmission of SARS-Cov-2
COVID-19 by positive PCR in cord blood and / or positive serologies

The COVID-19 Pandemic and Exercise Study
Changes in depressive symptomology over the course of the exercise intervention

Cardiac Imaging in SARS-CoV-2 (COVID-19)
The primary cardiac outcome is the proportion of patients with a diagnosis of myocardial inflammation (myocarditis).;The primary cardio-pulmonary outcome is the proportion of patients with thrombosis

COVID-19: A POC Test Under Research & Evaluation
Performance of the LumiraDx Assay versus reference methods with regards to clinical sensitivity and specificity for the detection of the SARS-COV-2 IgG/IgM and viral antigen in patient samples.

GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel
Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0;Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group

Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome
Proportions of patients with mean arterial pressure = 65 mmHg or an increase of mean arterial pressure =10 mmHg at 3 hours

Chat-based Support for Preveting Smoking Relapse

COVID 19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals
the time of Covid 19 viral clearance in medical healthcare workers and its relation to clinical presentation, severity among and resolution of symptoms.

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
Primary endpoint: Venous or arterial thrombotic events

PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic
Flare of IBD needing change in therapy or surgery

Cholecalciferol to Improve the Outcomes of COVID-19 Patients
Respiratory SOFA.;Need of a high dose of oxygen or mechanical ventilation.

Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome
Duration of mechanical ventilation and 28 days ventilator free days

Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare

Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection

PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis
Primary outcome measure: The need for in-hospital colectomy or rescue therapy

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit

Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient
Need of mechanical ventilation, transfer to an intensive care unit or death within 21 days of admission.

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
Adverse reactions/events rate;Adverse reactions/events rate;Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule);Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule);Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule);Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)

Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19
Identification of requirement of mechanical ventilation

Covid-19 and Diabetes in West of Algeria
Prevalence of diabetes among all hospitalized COVID-19;Diabetes-related factors risk

A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS
Clinical status (on a 7-point ordinal scale) at day 28

Self-compassion for Chronic Pain Virtual Group Treatment Program
Change over time in Scores on the Self-Compassion Scale (SCS);Change over time in Scores on the Pain Disability Index

Novel COVID-19, A National Analysis

Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection

Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19
Change of inflammatory cytokines concentration (mmol / L) in Covid19 + patients from Baseline at 6 months

Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA
Rate of known, expected, or unanticipated adverse device effects

COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants
Assess the serological status/rate of past infections in the children of priority staff in the nursery during the containment period

Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients

Ruxolitinib in the Treatment of Covid-19
Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)

Tools for Wellbeing COVID-19 National Study of Undergraduate Students

Echocardiography in Critically-ill Patients With COVID-19 Pneumonia
Incidence of Left ventricular systolic dysfunction;Incidence of RV failure;Incidence of Vasoplegia;Incidence of Hypovolemia

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Determining the Reproductive Health of Men Post-COVID-19 Infection
Semen parameters;Sperm Parameters;Sperm Parameters;Hormones measurement;Hormones measurement;Hormones measurement

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19
Proportion of subjects alive and free of respiratory failure

Tofacitinib for Treatment of Moderate COVID-19

Extracellular Water in Covid 19 Pneumonia

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation

The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic

Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 1 month;Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 3 months;Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 6 months

Photodynamic Therapy for the Treatment of COVID-19
Participants Achieving Either a Major Clinical Response or Partial Clinical Response (PCR) Defined by WHO

Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19
Functional Respiratory changes: PaO2 / FiO2 ratio;Clinical cardiac changes: Heart rate per minute;Clinical Respiratory Changes: Respiratory rate per minute;Changes in body temperature

COVID-19 Pandemic and Worldwide Organ Procurement
Organ transplantation activity during COVID-19 pandemic

COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)
rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.

Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak
Interview of the parents : contextual data;Interview of the children/adolescents/ parents : Experience of the confinement in general;Interview of the children/adolescents/ parents : Experience of the confinement in general;Interview of the children/adolescents/ parents : Experience of the confinement in general;Interview of the referring caregiver : data relating to disease and management of care

COVID-19 and Pregnancy Outcomes

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias
Rate of serious coronavirus infection in different MNP patient subgroups;Proportion of MNP patients who had COVID-19 infection during the 2020 epidemic.;Rate of death of MNP patients who had COVID-19;Rate of passages in intensive care with need for mechanical ventilation

Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge
Comparison of values between two devices

Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination

Vocal Feature Analysis Algorithm

Project Resurgence Communication Trial
Percent with visit or procedure with provider

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
Decrease in Respiratory Rate;Hospital length of stay (LOS);Need for mechanical ventilation;Length of time intubated;Need for hospitalization;Recovery disposition

COVID-19 in care homes (VIVALDI)
1. Proportion of care home staff and residents who have been infected with SARS-CoV-2 measured using antibody testing at baseline

Sulodexide in the treatment of COVID-19
The Clinical-Therapeutic response will be defined as the need for hospitalization, presence of thromboembolic complications, length of stay in hospital (days), need for use of mechanical ventilation, need for hemodialysis, major haemorrhagic complications, death measured using patient records throughout the study

Investigation of COVID-19 symptoms and potential immunity in the general population
1. Symptoms compatible with COVID-19 measured using online questionnaire information monthly for 12 months
2. Population immunity measured using assay of biomarkers (e.g., IgG antibodies to SARS-CoV-2) on blood samples (obtained at home via finger prick) monthly for 12 months

A study to assess the usefulness of combination of Vitamin D, magnesium and Vitamin B12 in older COVID-19 patients
The risk of clinical deterioration, defined as the requirement for supplemental oxygen and/or intensive care support, measured using patient records from hospital information system at day 30

What’s the STORY: serum testing of representative youngsters including SARS-CoV-2 (COVID-19), diphtheria and meningitis C
1. Feasibility of a population-based seroepidemiological programme measured by response rate and participation in the study as proved by questionnaire completion, sample collection and database records at baseline
2. Added public health benefit measured by comparison with serological markers of immunity for vaccine-preventable diseases as measured in an age-matched cohort in the current residual sera programme which will occur at the end of the study

Serum protein marker in patients with novel coronavirus pneumonia (COVID-19)

Development and Application of a Low-Cost Ear-Contactless Stethoscope Powered by Raspberry Pi and Python

The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19): A medical records based retrospective cohort study

A medical records based retrospective study of novel coronavirus pneumonia (COVID-19) patients

A medical records based study for predictors of novel coronavirus pneumonia (COVID-19) elderly patients

A medical records based study for analysis of Tongue Features of novel coronavirus pneumonia (COVID-19) Patients

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets in Treating Pediatric novel coronavirus pneumonia (COVID-19)

Clinical study on the effect of Clarenicol oral liquid on the relief of pharyngeal symptoms of novel coronavirus pneumonia (COVID-19) in convalescence, suspected patients and other susceptible populations
Pharyngeal discomfort symptoms such as sore throat, dry pharyngeal burning, congestion of pharyngeal mucosa relief time and relief rate.;The time required for a new fever, cough, muscle soreness, headache, symptom resolution or relief;

A study for long-term prognosis in hospitalized novel coronavirus pneumonia (COVID-19) patients
Follow-up questionnaire: included improved BMA dyspnea index, measurement of quality of life questionnaire, and cardiovascular and cerebrovascular system (cardiovascular and cerebrovascular events);Cooperate with test item: 6 minute walk test.;Laboratory tests: renal function (including at least creatinine) + random blood glucose test and hemoglobin a1c;The lopinavir/Ritonavir cohort was tested for neutralizing antibodies.;Special items: respiratory system (chest HRCT, lung function (30min)), abdomen (liver, gallbladder, spleen, pancreas, kidney and portal vein) and lower limb venous ultrasound (30min);

Clinical observation of the relieving effect of Clarenicol oral liquid on the throat symptoms of novel coronavirus pneumonia (COVID-19) in convalescence, suspected patients and other susceptible people
Pharyngeal discomfort symptoms such as sore throat, dry pharyngeal burning, congestion of pharyngeal mucosa relief time and relief rate.;The time required for a new fever, cough, muscle soreness, headache, symptom resolution or relief;Drug use;

Hip Fracture in elderly people during COVID-19 State of Alarm in Spain: reports from a specialized Center

A medical records based study for the preliminary efficacy of Tocilizumab in the treatment of the patients with novel coronavirus pneumonia (COVID-19)

Hydroxychloroquine for prevention of COVID-19 in patients on chronic dialysis
Main Objective: The main objective of the following multicentre parallel-group open randomized clinical trial aims to investigate the benefit, tolerability, and safety of initiating prophylactic hydroxychloroquine versus no treatment in patients on chronic dialysis in Denmark. The anticipated results from this project will provide evidence as to the appropriateness of initiating prophylactic treatment for prevention of symptomatic SAR-COV-2 in dialysis populations with direct effects on clinical management and guidelines pertaining to these patients.;Secondary Objective: Not applicable;Primary end point(s): The primary efficacy outcome of hospitalization due to SAR-COV-2 infections will be compared between patients allocated hydroxychloroquine and no treatment.;Timepoint(s) of evaluation of this end point: End of study as defined by 3 months following last inclusion

Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19
Main Objective: To demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related ARDS.
;Secondary Objective: To assess the safety of low dose interleukin-2 (Ld-IL2) compared with placebo
-To demonstrate that Ld-IL2 improves the components of the composite endpoint of mortality and duration of mechanical ventilation.
-To demonstrate that Ld-IL2 shortens SARS-CoV2-related ARDS resolution
-To demonstrate that Ld-IL2 shortens mechanical ventilation weaning process in SARS-CoV2-related ARDS
-To demonstrate that Ld-IL2 reduces nursing workload, rate of prone positioning
-To demonstrate that Ld-IL2 reduces the number of days alive in hospital during 28 days
-To demonstrate that Ld-IL2 reduces the number of organ dysfunctions
- Exploratory objectives
;Primary end point(s): The PaO2/FiO2 ratio at D7;Timepoint(s) of evaluation of this end point: Day 7

Medication for prevention of Corona-virus for Danish nursing home residents
Main Objective: To investigate whether prophylactic treatment with daily hydroxychloroquine, vitamin D, and zinc supplementation reduces the risk of COVID-19, the severity of the disease, the hospitalization rate, and death in nursing home residents.;Secondary Objective: To assess the effect of prophylactic treatment with hydroxychloroquine, vitamin D, and zinc compared with no treatment in nursing home residents not previously infected with SARS-CoV-2 on:
- SARS-CoV-2 positive real-time PCR from nasopharyngeal samples
- Influenza positive real-time PCR from nasopharyngeal samples
- Hospitalization (related)
- Hospitalization (any)
- Need for intensive care respiratory support if hospitalized
- Length of disease course
- Contact to general practitioner (any)
- Side effects (stomach pain, nausea, reduced appetite, diarrhea, vomiting, headache, skin rash, decreased hepatic functioning, or prolonged cardiac QT interval)
- Death (30 days, 90 days)
;Primary end point(s): SARS-CoV-2 positive rtPCR from nasopharyngeal samples during 2 months prophylactic treatment with hydroxychloroquine, vitamin D, and zinc supplement or no prophylactic treatment;Timepoint(s) of evaluation of this end point: 0, 30, 60, and 90 days

Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients
Main Objective: Evaluate the effect of hydroxychloroquine (HCQ) + standard of care as compared to standard of care only on oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio in adult patients hospitalized with moderate to severe Coronavirus Disease 2019 (COVID-19) ;Secondary Objective: Evaluate the clinical efficacy of HCQ + standard of care as compared to standard of care only in adult patients hospitalized with moderate to severe COVID-19
Evaluate the effect of HCQ + standard of care as compared to standard of care only on the virologic load in nasopharynx as assessed by quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) counts in adult patients hospitalized with moderate to severe COVID-19
Evaluate the safety of HCQ + standard of care as compared to standard of care ;Primary end point(s): 1. Phase 2: Change in SpO2/FiO2 ratio from baseline to Day 15.
2. Phase 3 (may be reassessed after review of phase 2): Change in SpO2/FiO2 ratio from baseline to Day 15;Timepoint(s) of evaluation of this end point: 1, 2. Baseline to Day 15

Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)
Main Objective: To evaluate the efficacy (as measured by a composite endpoint of proportion of patients who die, develop respiratory failure [require mechanical ventilation], or require intensive care unit [ICU] care) of ruxolitinib + standard-of-care (SoC) therapy compared with placebo + SoC therapy, for the treatment of COVID-19 by Day 29;Secondary Objective: evaluate efficacy (as measured by clinical status using a 9-point ordinal scale) of ruxolitinib + SoC therapy compared with placebo + SoC therapy, for treatment of COVID-19.
evaluate efficacy of ruxolitinib + standard-of-care (SoC) therapy compared with placebo + SoC therapy, on in-hospital outcomes in patients with COVID-19.
evaluate efficacy of ruxolitinib + SoC therapy, compared with placebo + SoC therapy, in change in the National Early Warning Score (NEWS2) score in patients with COVID-19.
evaluate efficacy of ruxolitinib + SoC therapy, compared with placebo + SoC therapy, in change in SpO2/FiO2 ratio in patients with COVID-19.
evaluate efficacy of ruxolitinib + SoC therapy, compared with placebo + SoC therapy, in proportion of patients with no oxygen therapy (defined as oxygen saturation = 94% on room air) in patients with COVID-19.
evaluate safety of ruxolitinib + standard-of-care (SoC) therapy compared with placebo + SoC therapy, in treatment of patients with COVID-19.
;Primary end point(s): composite endpoint defined as proportion of patients who
- die OR
- develop respiratory failure (require mechanical ventilation) OR
- require intensive care unit (ICU) care;Timepoint(s) of evaluation of this end point: 29 days

A study to investigate whether vaccination with VPM1002 can reduce the sick days of healthcare professionals during the SARS-CoV-2 pandemic
Primary end point(s): Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection);Timepoint(s) of evaluation of this end point: From day 0 to day 240;Main Objective: To assess the reduction of absenteeism among HCPs with direct patient contacts during the epidemic phase of COVID-19.;Secondary Objective: To assess the incidence of SARS-CoV-2 infection or symptoms of infection, reduction of hospital admission, ICU admission or death in HCPs with direct patient contacts during the epidemic phase of COVID-19.

Low Dose Oral Selinexor in Patients with Severe COVID-19 Infection
Main Objective: Day 14 Ordinal Scale improvement
(OSI);Secondary Objective: Key Secondary Objectives:
- To evaluate improvement in clinical measures across the 2 treatment
arms
Additional Secondary Objectives:
- To evaluate improvement in additional
clinical measures across the 2 treatment
- To determine the anti-inflammatory and
immune effect of selinexor
- To assess safety and tolerability of
selinexor [time frame: up to 28 days];Primary end point(s): Proportion of patients with at least a 2 point improvement (increase) in the Ordinal Scale from baseline to Day 14.
The Ordinal Scale is an assessment of the clinical status at the first assessment on each day of hospitalization. The scale is as follows:
1. Death;
2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);
6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;
7. Not hospitalized, limitation on activities and/or requiring home oxygen;
8. Not hospitalized, no limitations on activities.;Timepoint(s) of evaluation of this end point: Throughout the study

Testing the Efficacy and Safety of BIO101, for the Prevention of Respiratory Deterioration, in Patients with COVID-19 Pneumonia (COVA study)
Primary end point(s): For end-of-part-1 interim analysis:
For futility analysis intended to facilitate the decision to begin part 2, time frame – up to 28 days:
Safety and tolerability to BIO101:
• SUSARs, SAEs, AESIs, AEs
• Vital signs
• Safety labs
• ECGs
For interim analysis intended to obtain indication of activity of BIO101 and a decision on study extension, time frame – up to 28 days:
Primary:
• Proportion of subjects with 'negative' events, of either of the following:
o Respiratory failure, defined as any of the following:
- Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage)
- Requiring ECMO
- Requiring high-flow oxygen
o All-cause mortality
Additional:
• SpO2/FiO2
• Inflammatory markers including:
o IL 6
o TNFa
o D-dimer
• RAS / MAS biomarkers:
o Angiotensin 2
o Angiotensin-converting enzyme (ACE) levels
For part-2 sample size interim analysis:
For sample size re-assessment for part 2, time frame – up to 28 days:
• Proportion of participants with 'negative' events, of either of the following:
For the final analysis:
Primary, time frame – up to 28 days:
;Timepoint(s) of evaluation of this end point: For end-of-part-1 interim analysis:
For futility analysis intended to facilitate the decision to begin part 2 , time frame – up to 28 days:
For sample size re-assessment for part 2 – time frame - up to 28 days:
;Secondary Objective: Not applicable;Main Objective: Part 1
• Obtain preliminary indication of activity of BIO101, in preventing respiratory deterioration in the target population
Part 2
• Re-assess the sample size that is needed for the confirmatory part of the study
• Provide confirmation on the benefit of BIO101 in the target population
• Identify and assess potential biomarkers for further understanding of the effect of BIO101 in the target population

STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects
Main Objective: To demonstrate the efficacy of DAS181 on clinical outcome as measured by frequency of return to room air (RTRA) responders compared to placebo;Secondary Objective: To evaluate the effect of DAS181 on the frequency and rate of return to room air (RTRA) compared to placebo
To evaluate the effect of DAS181 on mortality (all-cause and pulmonary infection-related) compared to placebo
To evaluate the effect of DAS181 on the frequency and rate of return to Clinical Stability (CS) compared to placebo
To evaluate the effect of DAS181 on the length of initial hospital stay and of total days of hospitalization compared to placebo
To evaluate the effect of DAS181 on pulmonary function compared to placebo;Primary end point(s): Percent of subjects who ‘Return to Room Air’ by Day 28;Timepoint(s) of evaluation of this end point: by Day 28

The COVASE study:
Investigation of an approved nebulised human Dnase enzyme (Pulmozyme) to reduce hyperinflammation in hospitalised people with COVID-19
Main Objective: to assess the effect of nebulised dornase alpha on C-reactive Protein (CRP) in hospitalised participants with COVID-19;Secondary Objective: to assess the effect of nebulised dornase alpha on clinical responses in hospitalised participants with COVID-19 ;Primary end point(s): The primary endpoint is the change from baseline in acute phase reactant (C-Reactive Protein (CRP)). This is a blood test that will be measured on day 0,1,3,5,7, and at study end. This endpoint is on a continuous scale. ;Timepoint(s) of evaluation of this end point: Day 0,1,3,5,7, and at study end.

COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.
Main Objective: Assessment of the efficacy of 7 days orally inhaled 100 mg solnatide in Covid-19 patients with moderate-to-severe ARDS.
Primary endpoint:
• Days free of mechanical ventilation (ventilator free days, VFD) within 28 days.
;Secondary Objective: • Assessment on the effect of solnatide on the extravascular lung-water-index (EVLWI), if available
• Hemodynamic parameters
• Ordinal Scale for Clinical Improvement, as proposed by the WHO
;Primary end point(s): • Days free of mechanical ventilation (ventilator free days, VFD) within 28 days
• Drug-related adverse events (through day 14)
• All adverse events through day 28
• All-cause deaths through day 28
• Vital signs daily through day 14 (heart rate, systolic and diastolic blood pressure, and body temperature)
• ECG parameters including heart rate PQ, QRS, QT and QTc intervals through day 7
• Clinical laboratory assessments (haematology, clinical chemistry, blood gases and urine analysis) daily through day 14
• 24-hour fluid balance through day 7
• Hemodynamic parameters: mean arterial pressure, pulmonary blood volume (PBV), cardiac index and cardiac output assessed at screening and daily until end of treatment
• Need for vasoactive drugs assessed at screening and daily until end of treatment;Timepoint(s) of evaluation of this end point: Baseline to day 7, respectively to day 14 or day 28.

Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial
Number of participants symptomatic for COVID-19. (Symptomatic illness will be defined as presence of fever with cough, shortness of breath, sore throat, anosmia or diarrhoea) [Time frame: from the time of recruitment until the completion of 14 days]
Number of participants testing positive for SARS-CoV-2 virus using rRT-PCR [ Time frame: day 14 from the time of recruitment]

Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19)
Clinical recovery (composite) within 14 days from initiation of study treatment until normalization of fever (=37.2 °C oral), respiratory rate (=24/minute on room air), and oxygen saturation (=94% on room air), sustained for at least 24 hours. Timepoint: daily up to 14 days after starting the trial. Method of measurement: Clinical examination.

treatment of COVID-19 whit vitamin A
Rate of O2 saturation. Timepoint: 1-3-5-7-10-14. Method of measurement: PCR, CT scan and clinical symptoms.;Clinical symptoms. Timepoint: 1-3-5-7-10-14. Method of measurement: PCR, CT scan and clinical symptoms.

The effect of naproxen on the healing process of patients with COVID-19
Time to clinical improvement defined as start of taking medication time to the next 28 days. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Medical record.

Efficacy of the myrtle syrup in the treatment of novel corona
Temperature. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Termometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Muscular pain. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.

Efficacy of the barley-based remedy in the treatment of novel corona
Temperature. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Termometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Muscular pain. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.

Comparison of vitamin D3 and N-acetylcysteine prescription in COVID-19 patients and their effect on recovery process
Time to clinical improvement defined as start of taking medication time to Discharge Time. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Medical record.

Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19
Admission to intensive care unit. Timepoint: Once (when admitted to intensive care unit). Method of measurement: Hospital records.

Effect of colchicine in treatment of COVID-19
-Clinical symptoms including fever, cough, shortness of breath. Timepoint: The first, third, seventh, fourteenth and 6-8 days after entering the study. Method of measurement: questionnaire.;Pulmonary infiltration findings on CT scan. Timepoint: Two weeks later and 6-8 weeks later. Method of measurement: CT-scan.;O2sat at the time of hospitalization and discharge. Timepoint: The first, third, seventh, fourteenth and 6-8 days after entering the study. Method of measurement: Pulse Oximeter.;Laboratory symptoms (ESR, CRP, NLR, LDH, ferritin, D-dimer, CBC diff). Timepoint: Hospitalization time and discharge time. Method of measurement: Blood test.

Evaluation of the efficacy of oral 25-hydroxyvitamin D3 on COVID-19
Infection duration. Timepoint: during study. Method of measurement: WHO criteria.

Effect of Arbidol in treatment of COVID-19
Measurement of patients fever. Timepoint: Measurement of patient's body temperature at the beginning of the study and 7 days after starting treatment. Method of measurement: Thermometer.;Measurement of complete blood count test. Timepoint: Performing a complete blood cell count test at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Determination of C-reactive protein test. Timepoint: Measurement of C-reactive protein level at the beginning of the study and 7 days after starting treatment. Method of measurement: Blood test.;Chest CT Scan view symptoms. Timepoint: Patient's chest CT scan check at the beginning of the study and 30 days after starting treatment. Method of measurement: Taking a chest CT scan.;Measurement of blood oxygen saturation and no adjuvant oxygen therapy. Timepoint: Measurement of oxygen saturation level at the beginning of the study and 7 days after starting treatment. Method of measurement: Pulse oximeter.

Effect of Methylprednisolone on treatment of COVID-19
Radiographic features Findings. Timepoint: Before and at discharge time only in patients agreed ?to give informed consent. Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after. Method of measurement: Observation.;O2 saturation. Timepoint: Before and after ( by 3 days of treatment and at discharge). Method of measurement: Pulse Oximeter.;Need an oxygen therapy ?. Timepoint: Before and after (at day 3 and discharge time). Method of measurement: clinical.

A study on melatonin and Vitamin C and zinc efficacy in patients with COVID19
Number of breaths per minute. Timepoint: Before the intervention, from the start of treatment to the patient's recovery. Method of measurement: Vital signs monitoring devices.;The rate of decline of lung infection. Timepoint: Before the intervention, from the start of treatment to the patient's recovery. Method of measurement: Clinical examination, if necessary, radiography or CT scan.;The course of the disease. Timepoint: Before the intervention, from the start of treatment to the patient's recovery. Method of measurement: Clinical examination, if necessary, radiography or CT scan.;Heart rate. Timepoint: Before the intervention, from the start of treatment to the patient's recovery. Method of measurement: Vital signs monitoring devices.

Effect of Prednisolone on treatment of COVID-19
Radiographic features findings. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after treatment with Prednisolone. Method of measurement: Observation.;O2 saturation. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Pulse Oximeter.;Need for an oxygen therapy. Timepoint: Before treatment with Prednisolone and at days 8 and 14 after treatment. Method of measurement: Clinical.

The effect of surfactant on clinical outcome of patients with COVID-19
Time for mechanical ventilation. Timepoint: throughout the study, the time that patient has stayed under mechanical ventilation. Method of measurement: clinical records.

Evaluation of the efficacy of oral 25-hydroxyvitamin D3 on COVID-19
Affected by COVID-19. Timepoint: Sign of COVID-19 during study. Method of measurement: patients over 18 years of age with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or definite diagnosis of Covid-19 with real-time polymerase chain reaction (PCR).

Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection
Adverse events assesment. Timepoint: At the same time of each intervention, 24 hours after each intervention, on days 6, 7, 14 and 28 after the first intervention. Method of measurement: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.

The effect of Stopcivir syrup in patients with COVID-19
Length of hospitalization. Timepoint: Hospitalization time and Hospital discharge time. Method of measurement: Check List.;Shortness of breath. Timepoint: Variable will be completed in the form of a checklist at the beginning of the Hospitalization and daily until the end of hospitalization. Method of measurement: Check list.;Oxygen saturation. Timepoint: Variable will be completed in the form of a checklist at the beginning of the Hospitalization and daily until the end of hospitalization. Method of measurement: Check list.

ANIF1 effect on COVID-19
RT-PCR test.IL-6,CRP. Timepoint: at the beginning and end of study. Method of measurement: nasopharyngeal swab.;Lung CT-Scan. Timepoint: at the beginning and end of study. Method of measurement: CT-Scan.

web- based communication between nurse and family member
Perceived Stress. Timepoint: At the beginning of the study (before the start of the intervention) and 4 days later. Method of measurement: Perceived Stress Scale (PSS-14). A 14-item questionnaire in the 5-point Likert range between 0 and 4. The lowest score is zero and the highest score is 56, and getting a higher average score indicates more perceived stress.

Clinical trial of trans sodium crocetinate against COVID-19
Patients' mortality rate. Timepoint: During 7 days hospitalization. Method of measurement: Meedical Reports.

Effect of intrapulmonary injection of processed serum derived from covid-19 patients in reduction of pulmonary complications
Oxygenation. Timepoint: During 10 days from intratracheal injection. Method of measurement: Arterial blood gas analysis.

effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections
Fever. Timepoint: Before and after treatment. Method of measurement: Thermometer.;Respiration rate. Timepoint: Before and after treatment. Method of measurement: Counting the number of breaths patients take per minute.;Findings of chest CT scan. Timepoint: Before and after treatment. Method of measurement: CT scan machine.;Pulse. Timepoint: Before, during and after treatment. Method of measurement: Patient monitoring device.;SpO2. Timepoint: Before and after treatment. Method of measurement: Patient monitoring device.;WBC. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;Number of lymphocytes. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;Lactate dehydrogenase. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;C reactive protein (CRP). Timepoint: Before and after treatment. Method of measurement: Biochemical test.

Effect of selenium on covid-19 disease
Ferritin changes. Timepoint: Daily. Method of measurement: Laboratory.;Platelet. Timepoint: Daily. Method of measurement: Laboratory.;CRP. Timepoint: Daily. Method of measurement: Laboratory.;WBC changes. Timepoint: Daily. Method of measurement: Laboratory.

Effect of BCG Vaccine on Preventing COVID-19
COVID-19 infection. Timepoint: Time Frame: At the beginning and weekly for up to 12 months. Method of measurement: A questionare for assessment of fever (>38), cough, shortness of breath, respiratory failure, runny / blocked nose and PCR or serology for detection of SARS-Cov-2.;Severe COVID-19 disease. Timepoint: Time Frame: At the beginning and weekly for up to 12 months. Method of measurement: A questionare to assess hospitalization or death due to covid-19 infection.

Pembrolizumab (CinnaGen Co, Iran) in COVID-19
Incidence of death during the study. Timepoint: at least 7 days. Method of measurement: Recording the incidence of death.

Investigating the efficacy and safety of Niwasha mouthwash in controlling the symptoms of patients with COVID-19

Effect of bee products on COVID-19
Dyspnea grade. Timepoint: Dyspnea grade before intervention and daily after starting the intervention. Method of measurement: dyspnea grading according to New York heart association classification.;White blood cells (WBC) count. Timepoint: lab test before intervention and 3, and 7 days after intervention. Method of measurement: lab data assessment by blood sample.;Neutrophil to Lymphocyte count. Timepoint: lab test before intervention and 3, and 7 days after intervention. Method of measurement: lab data assessment by blood sample.;Interleukin-6 (IL-6) Level. Timepoint: lab test before intervention and 3, and 7 days after intervention. Method of measurement: lab data assessment by blood sample.;Anti SARS-Cov-2 IgG Level. Timepoint: one month after intervention. Method of measurement: blood sample.;C-reactive protein (CRP) level. Timepoint: lab test before intervention and 3, and 7 days after intervention. Method of measurement: lab data assessment by blood sample.

Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19
No fever for 3 days. Timepoint: Daily. Method of measurement: Medical Records.;- SpO2>93%. Timepoint: daily. Method of measurement: Medical Records.;CXR observation. Timepoint: After the end of the treatment period. Method of measurement: Observation.

IVIG and COVID19
Increasing of patient's O2 saturation above 90%, improvement of lung involvement in lung CT scan. Timepoint: before discharge. Method of measurement: percentile.

Effects of nokhod-ab on fatigue
Score of Fatigue Severity "Visual Analogue Fatigue Scale". Timepoint: Before the intervention,after the intervention(2 weeks later). Method of measurement: Using Visual Analogue Fatigue Scale questionnaire.

The effect of hot cupping on corona symptoms
Blood oxygen saturation level. Timepoint: 0,1,2,3,5,7 days after intervention. Method of measurement: Pulse oximetry.

Prone position effectiveness in Non invasive ventilation of covid-19 patients undergoing respiratory failure
Oxygenation. Timepoint: Up to four days after pron position. Method of measurement: pulse Oximetry.

Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia
Blood lymphocytes. Timepoint: Befor entering the study and 3 days after drug injection. Method of measurement: Using hemocytometer.

Effect of Laris-Teucrium Polium L.and Laris-Hyssop combined herbal medicine on the prevention of covid-19 disease
Symptoms of corona-virus. Timepoint: Day 5, 10, 15 and 20 of the taking combined herbal medicine. Method of measurement: Corona-virus Symptoms Questionnaire.

Evaluation of colchicine in treatment of coronavirus
Hospitalization outcome. Timepoint: Last day of hospitalization in the section. Method of measurement: Calendar.;Fever cessation. Timepoint: Before hospitalization and 1, 3, 5, 7 days after hospitalization. Method of measurement: calendar.;Hospitalization time. Timepoint: First and last day of hospitalization. Method of measurement: Calendar.

Vitamin A and COVID-19
Weaning time of ventilator. Timepoint: Before and after of intervention. Method of measurement: time assessment.

Low dose whole lung irradiation for treatment of COVID-19 pneumonia
Blood pressure. Timepoint: Before intervention and every 6 hours after intervention. Method of measurement: Sphygmomanometer.;Length of hospital stay. Timepoint: discharge date. Method of measurement: discharge date minus admission dates.;CT score. Timepoint: 5 days after intervention. Method of measurement: Scores will range from 0-5 based on each lung lobe's percentile involvement as 0 for non-involvement, 1 for less than 5% involvement, 2 for 5-24% involvement, 3 for 25-49% involvement, 4 for 50-74% involvement and, 5 for 75-100% involvement, and the sum of each lobe score will be compared between the initial CT and the CT scan performed after discharge.;Death. Timepoint: Until discharge. Method of measurement: Death verification.;Pulse Rate. Timepoint: Before intervention and every 6 hours after intervention. Method of measurement: Pulse Oxymeter.;Respiratory rate. Timepoint: Before intervention and every 6 hours after intervention. Method of measurement: Counting in one minute by physician.;Body temperature. Timepoint: Before intervention and every 6 hours after intervention. Method of measurement: Thermometer.;Oxygen saturation. Timepoint: Before intervention and every 6 hours after intervention. Method of measurement: Pulse oxymeter.

Efficacy of extract of of Zingiber cinnamomum and zataria multiflora in covid-19 disease
Clinical symptoms ( presence and severity of dry cough). Timepoint: 0--3--7- 10-14 days after starting intervention. Method of measurement: Physical examination,questionnaire.;Temperature. Timepoint: 0--3--7- 10-14 days after starting intervention. Method of measurement: Thermometer.;Clinical symptoms (dyspnea). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Respiratory rate. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: Counting the number of breaths per minute.;Blood pressure and pulse. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: With sphygmomanometer and pulse control.;Oxygen saturation. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: pulseoximeter.;Inflammatory response. Timepoint: Days 0,7. Method of measurement: Check of IL6,IL4,CBC,CRP,ESR.;Imaging findings. Timepoint: on the first and 7th day of treatment. Method of measurement: by chest x ray and CTscan.

Stem cell treatment for COVID-19
Death. Timepoint: Up to 28 days after starting the study. Method of measurement: Patient observation and evaluation of vital signs.

The efficacy of barely-based traditional remedy on COVID-19
Tempreture. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Fisman scale.;Respiratory rate. Timepoint: Daily. Method of measurement: Counting the number of breaths per minute.;Weakness. Timepoint: Daily. Method of measurement: Visual analog scale.;Muscular pain. Timepoint: Daily. Method of measurement: Visual analog scale.;C Reactive Protein (CRP). Timepoint: Daily. Method of measurement: Blood test.;Lymphocyte count. Timepoint: Daily. Method of measurement: Blood test.;O2 Saturation percentage (SpO2). Timepoint: Daily. Method of measurement: Pulse oximetery.;Chest X ray. Timepoint: Daily. Method of measurement: Analysis of radiography.

The effect of cognitive-behavioral intervention on improving COVID-19 fear symptoms, improving quality of life and improving mental health in patients with corona
Improving the psychological states of patients with COVID 19. Timepoint: Before and after the intervention. Method of measurement: Quality of Life Questionnaire.

Polio Vaccine and COVID-19
The age-adjusted incidence of COVID-19 in vaccinated people compared with that in unvaccinated general population (aRR). Timepoint: 2 months after vaccination. Method of measurement: daily count of new patients.

Effects of Licorice in treatment of COVID-19
Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: Respiratory Count.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.

Evaluation effect of Dinvl for Covid19 infection
Time to clinical recovery. Timepoint: Control clinical signs daily until discharge from the hospital. Method of measurement: Fever control with thermometer, oxygen saturation control with pulsoximetry.

Evaluating the effects of Umifenovir (Arbidol) in COVID-19
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.

sex hormones in coronavirus
Severity of disease. Timepoint: before intervention and every week until one month. Method of measurement: observation.;IL-6. Timepoint: before intervention and every week until one month. Method of measurement: Elisa.

Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients
Investigation of mortality rate of CIVID-19 patients. Timepoint: After treatment. Method of measurement: Situation of the patient's life.

Evaluating the effect of intravenous N-acetyl cysteine versus placebo in the treatment of patients with mild and moderate acute respiratory distress syndrome caused by COVID-19
Need to mechanical ventilation. Timepoint: Within 28 days after the intervention. Method of measurement: By physical examination.;The patient's clinical status. Timepoint: Within 28 days after the intervention. Method of measurement: Based on the World Health Organization's 7-score system.;Mortality rate. Timepoint: Within 28 days after the intervention. Method of measurement: Based on medical document.

Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in Mild to Moderate cases of Covid-19 at Baqiyatallal Hospital
The primary outcome was defined as the Time to Clinical recovery (TTCR), up to 14 days. TTCR is further defined as the time (in hours) from initiation of study treatment (active or placebo) until normalization of fever, and oxygen saturation sustained for at least 72 hours. Timepoint: before drug administration, daily up to day 14. Method of measurement: Thermometer (for fever) and pulse oximeter for oxygen saturation.

Effect of the combination of BCc1 & Hep-S on hospitalized COVID-19 patients
Hospitalization period. Timepoint: Hospitalization period. Method of measurement: Counting hospitalization days.;Mortality. Timepoint: Before and after being released. Method of measurement: Observation.;CT scan images of the lungs. Timepoint: Before hospitalization & 2 weeks after. Method of measurement: CT scan images.;Clinical indices. Timepoint: Before intervention, 3 & 6 days after intervention and before being released. Method of measurement: Questionnaire.;CT scan of the lungs. Timepoint: Before the start of the intervention, before being released & 2 weeks after. Method of measurement: CT scan machine.

Assessment of boron-containing compounds and Oleoylethanolamid supplementation in the treatment of COVID-19
Recovery trend. Timepoint: At baseline and at the end of intervention. Method of measurement: Examination.;Hospital admission time. Timepoint: At baseline and at the end of intervention. Method of measurement: Observation.;CBC,ESR. Timepoint: At baseline and at the end of intervention. Method of measurement: Blood sampling and testing with H1 device.;CRP. Timepoint: At baseline and at the end of intervention. Method of measurement: Blood sampling and measurement with Auto analyzer device.

Investigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19

Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19

Hydroxychloroquine in comparison with hydroxychloroquine + azithromycin in patients with covid-19
Length of stay in the intensive care unit. Timepoint: Once (when discharged from intensive care unit). Method of measurement: Hospital records.;In-hopital mortality. Timepoint: once. Method of measurement: Medical records.

Investigating the efficacy of Provita Capsule in controlling the symptoms of patients with COVID-19
Clinical symptoms (dry cough). Timepoint: Daily monitoring at the hospitalization, but the result of baseline (before the initiation of intervention), and day 7 and day 21 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring at the hospitalization, but the result of baseline (before the initiation of intervention), and day 7 and day 21 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring at the hospitalization, but the result of baseline (before the initiation of intervention), and day 7 and day 21 from the initiation, is recorded. Method of measurement: Thermometer.

The effects of Ginger in treatment COVID-19
Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: Respiratory Count.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.

Evaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19

Efficacy of Kelofan syrup on COVID-19
Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting intervention and regularly during hospitalized. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting intervention and regularly during hospitalized. Method of measurement: Respiratory Count.

Intervention
Shortness of breath, medicine, dry cough, chills and etc. Timepoint: May and June. Method of measurement: Quantitative and qualitative.

Evolution of the efficacy and safety of Dexamethasone administration in COVID-19
Need for invasive mechanical ventilation. Timepoint: Daily. Method of measurement: Medical record.;Death. Timepoint: At the end of the study. Method of measurement: Medical record.

Investigation of the effect of intravenous vitamin C on definite patients with coronavirus pneumonia
The amount of lung involvement in a CT scan: According to the radiologist, the appearance of lung involvement and the percentage of lung involvement are measured. Timepoint: Five days after receiving vitamin C intravenously. Method of measurement: According to the radiologist, the appearance of lung involvement and the extent of lung involvement are scoring.

Plasmapheresis and plasma exchanges;usefulness in covid-19 critically ill patients
Oxygen percentage. Timepoint: One day before the procedure and one day and four days and seven days after the procedure. Method of measurement: Pulse Oximeter device.;Interleukin 6 level. Timepoint: Before the procedure and one day and six days and seven days after the three-phase plasmapheresis. Method of measurement: Lab kit.

stem cell therapy in Covid-19
Respiratory symptoms and pulmonary function in patients. Timepoint: In onset of study and days 2, 7 and 14 after the second injection. Method of measurement: Using CT scan image , physical examination , Oxygen saturation Percentage.;Evaluation of IFN-?,IL4,TGF-ß,IL1-ß , IL-6 and TNF-a cytokine levels in patients blood. Timepoint: In onset of study and days 2, 7 and 14 after the second injection. Method of measurement: Using Elisa kits.;Cell markers and populations. Timepoint: In onset of study and days 2, 7 and 14 after the second injection. Method of measurement: Using Flow cytometery technique.

The effect of omega-3 supplementation in COVID-19
White blood cells (WBCs). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Neutrophils. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lymphocytes. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lactate dehydrogenase (LDH). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Creatine phosphokinase (CPK). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Cell blood count (CBC). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;C reactive protein. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.

Effect of Auriculotherapy in treatment of Covid 19
Improving the clinical course. Timepoint: Daily control of clinical symptoms up to 7 days after uricycliotherapy. Method of measurement: Arterial oxygen with pulse oximeter, anxiety with questionnaire, sleep quality with questionnaire,.

Comparison of combination therapies of COVID_19
Oxygen saturation following combination therapy for COVID-19. Timepoint: Daily examination of the patient during hospitalization. Method of measurement: pulse oxymetry.

Cyclosporin for the Prevention and Treatment of COVID-19 Disease
Improve oxygenation. Timepoint: 0,1,2,3,7after treatment with cyclosporin. Method of measurement: pulse oximeter.;Improve ct scan. Timepoint: seven day after cyclosporine treatment. Method of measurement: CT scan unit.

Effect of Laris - Hyssop combined herbal distilled on the improving clinical and paraclinical symptoms in patients with COVID-19
Serum CRP level. Timepoint: Before-After intervention (14 days). Method of measurement: Biochemical method.;Number of inpatient days. Timepoint: After intervention. Method of measurement: Questionnaire.;Mortality. Timepoint: Daily. Method of measurement: Questionnaire.;Respiratory Rate. Timepoint: Daily. Method of measurement: Observation.;Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter.;Serum White Blood Cell count. Timepoint: Before- After intervention (14 days). Method of measurement: laboratory cell counter.

Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19
Gene expression of inflammatory cytokines in peripheral blood mono-nuclear cells of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: real time-PCR.;Serum levels of inflammatory cytokines of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: ELISA technique.;Clinical symptoms of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Examination by a specialist.;Laboratory findings of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Laboratory findings in the Patient file.

Pentaglobin effect in critically ill patients with COVID-19
Need for invasive mechanical ventilation. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record.;Death. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record.;Supportive treatment with non-invasive oxygen. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record.

Using interferon to treat COVID-19
Body temperature. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Thermometer, Celsius.;Respiratory rate. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Pulse oximeter, Breaths per minute.;The ratio of arterial oxygen partial pressure to fractional inspired oxygen. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Ventilator, Millimeter of mercury (mmHg).;Blood gas level. Timepoint: Before intervention, on day of 1 until discharge with 3 day interval. Method of measurement: Blood Gas Analyzer, percent.

Investigating the efficacy and safety of Plasmapheresis in patients with Moderate to severe COVID-19
Need to receive ICU service (occurrence of shock, resistant hypoxemia despite receiving oxygen via reservoir oxygen mask, GCS score drops below 12). Timepoint: The patient is monitored every 6 hours, but the results are recorded daily in the checklist. Method of measurement: Physical assessment.

Investigation of the effects of prone position on cardiac and respiratory status in patients with Coronavirus
Mean blood pressure. Timepoint: At 0, 30, 60, 90 and 120 minutes after the first intervention. Method of measurement: Digital sphygmomanometer.;Heart rate. Timepoint: At 0, 30, 60, 90 and 120 minutes after the first intervention. Method of measurement: Pulse oximeter device.;Oxygen saturation. Timepoint: At 0, 30, 60, 90 and 120 minutes after the first intervention. Method of measurement: Pulse oximeter device.;Respiratory rate. Timepoint: At 0, 30, 60, 90 and 120 minutes after the first intervention. Method of measurement: Count the number of breaths per minute.;Breath shortness. Timepoint: At 0, 30, 60, 90 and 120 minutes after the first intervention. Method of measurement: Visual analog scale for breath shortness.

Clinical trial study of the therapeutic effect of Ivermectin, besides Kaletra and Chloroquinein in patients with Coronavirus disease 2019 (COVID-19)
Reduce the mortality rate of patients with Covid-19. Timepoint: days 0-7. Method of measurement: Based on the percentage of discharged Covid-19 patients.

Treatment of Covid-19 patients with convalescent plasma
Reduce 3 points on clinical signs or score less than 3 each earlier. Timepoint: At the beginning of the study (before the start of the intervention) and day 4 of hospitalization, day 7 of hospitalization and discharge time. Method of measurement: WHO Progression Scale.;Length of hospital stay. Timepoint: Hospitalization time to discharge. Method of measurement: Counting days.

Effect of Umifenovir in treatment of covid-19
Percentage of people improved with arbidol. Timepoint: 5, 7 and 14 days after taking Arbidol. Method of measurement: follow up with phone.

Evaluation the effects of Oxycodone administration on pain control in patients with COVID-19
Pain in hospitalized patients based on the pain questionnaire. Timepoint: The first to seventh days after the onset of oxycodone. Method of measurement: Pain scale (VAS).

Effect of Dinvl on improving of clinical and paraclinical symptoms in patients with COVID-19
Respiratory Rate. Timepoint: Daily. Method of measurement: Observation.;Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter.;Serum White Blood Cell count. Timepoint: Before- 14 days after intervention. Method of measurement: Laboratory cell counter.;Serum CRP level. Timepoint: Before- 14 days after intervention. Method of measurement: Biochemical method.;ESR (Erythrocyte Sedimentation Rate). Timepoint: Before- 14 days after intervention. Method of measurement: Checking the sedimentation rate of erythrocytes in a special tube within one hour.;Number of hospitalization days. Timepoint: After intervention. Method of measurement: Questionnaire.;Mortality. Timepoint: Daily. Method of measurement: Questionnaire.

effect of anakinra in treatment of COVID-19
No need for hospitalization. Timepoint: During first 14 days or hospitalization period. Method of measurement: Based on clinical status.;Hospitalization without need for oxygenation therapy. Timepoint: During first 14 days or hospitalization period. Method of measurement: Based on clinical status.;Hospitalization with oxygen therapy. Timepoint: During first 14 days or hospitalization period. Method of measurement: Based on clinical status.;Hospitalization with receiving non-invasive ventilation or high flow oxygen cannula. Timepoint: During first 14 days or hospitalization period. Method of measurement: Based on clinical status.;Hospitalization with receiving mechanical ventilation or extra-corporeal membrane oxygenation. Timepoint: During first 14 days or hospitalization period. Method of measurement: Based on clinical status.;Death. Timepoint: During first 14 days or hospitalization period. Method of measurement: Based on clinical status.

Evaluation the effect of raltegravir, and raltegravir/interferon beta combination on covid 19 patients
In this study, Sequential Organ Failure Assessment (SOFA) will be used to assess the severity of the disease. In this criterion, respiratory systems (PaO2 / Fio2 measurement), coagulation (platelet count), liver (bilirubin level), cardiovascular (hypotension), central nervous system (CNS) and kidney (creatinine level or urinary tract) Will be reviewed. Each parameter is graded on a 5-point Likert scale (score between zero and 4). The total score is between zero and 28. Higher scores indicate a worse patient condition. Timepoint: Before and after the intervention. Method of measurement: The data will be collected using the information in the patient's file.

A Trial of Ciclesonide in Adults with Mild COVID-19
Rate of SARS-CoV-2 eradication at day 14 from study enrollment

The effect of confinement on the mental health of individuals during the COVID-19 pandemic: an online survey
Name: Mental disorders (Depression; anxiety; eating disorders; substance use disorders);Timepoints: one month;Measure: DASS-21; SCOFF; CAGE-AID

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
Name: All-cause mortality, subdivided by severity of disease at the time of randomisation;Timepoints: At discharge or death;Measure: Discharge date or Cause of death

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan
safety, efficacy
Safety : Incidence and severity of adverse events, change from baseline in clinical laboratory test results
Efficacy : 7 category ordinal scale

new SARS-CoV-2 detection system (COVID-19)
Evaluate the positive match rate, negative match rate, and overall match rate of the test drug "new corona gene detection reagent" against the real-time RT-PCR method based on the National Institute of Infectious Diseases "Pathogen Detection Manual 2019-nCoV" .

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
-The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm among hospitalized adults who have COVID-19.
-To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.
-To evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 15

Triple combination therapy in patients infected with COVID-19
expected value and 95% CI of ratio of C-reactive protein before versus after the treatment

A multicenter, open-label, randomized controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19
Pneumonia incidence on day 8 of ciclesonide inhalation

Combination therapy of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia
Time to alleviation of body temperature, SpO2, and chest image findings, and time to SARS-CoV-2 PCR turn negative

Clinical safety and usefulness of the simple ventilator
(1) Stable usage rate 24 hours after the start of use; proportion of patients who cannot continue stable artificial respiration due to equipment replacement, equipment removal, and other equipment problems
(2) Ventilation success rate: Proportion of patients who survived spontaneous breathing due to respiratory withdrawal

Favipiravir for SARS-CoV-infected patients
Proportion of subjects with clearance of SARS-CoV2 in nasopharyngeal swab by Day 6

Teprenone for preventing aggravation of COVID-19

Prevention of COVID-19 infection in a medical institution
and maintenance of medical system
The positive rates of COVID-19-related markers in
medical workers.

A prospective cohort study to follow the health status of medical staff engage in COVID-19
The change of COVID-19 markers in medical staff engage in COVID-19

Fact-finding survey on subclinical infection of SARS-CoV-2 in Kanagawa Prefecture
SARS-CoV-2 positivity rate in IgG antibody tests

Immunological efficacy of Qing Fei Pai Du Tang for COVID-19
Plasma cytokine levels after administration of Qing Fei Pai Du Tang for 3 days

Examination in COVID-19 pandemic; Whether endoscopies really generate aerosol particles?
To assess the change of aerosol particle number at each time phase before, during, and after endoscopy and compare the trend of change of aerosol number in the situation of endoscopy and control group.

International survey to investigate the implementation of ICU daily care for COVID-19
The implementation rate of ABCDEF bundle

Immunological efficacy of Jinhua Qinggan Granule for COVID-19
Plasma cytokine levels 1 hour after the administration of JHQG

COVID 19 - What Families Think and Do? A Survey for Families Visiting the Pediatric Emergency Department
to assess parental attitudes towards COVID-19

Corona virus disease 2019 (COVID-19) antibody seroprevalence of the medical staff in the hospital with cluster of COVID-19.
Total number of COVID-19, including those infections that might have been missed (include asymptomatic cases)

Immunological efficacy of lactic acid bacteria for COVID-19
Plasma cytokine levels after the administration of lactic acid bacteria for 7 days .

Usefulness of PCR testing for COVID-19 before gastrointestinal endoscopy and hospitalization
The positive rate of PCR test for COVID-19 before gastrointestinal endoscopy and before hospitalization.

Prospective observational study on cytokine removal effect of continuous hemodiafiltration in COVID-19
Changes in various blood cytokine levels 2, 18 and 24 hours after the start of CHDF and the outcome 30 days later

The analysis of COVID-19 in saliva, gastric fluid and intestinal fluid on gastrointestinal endoscopy
The positive rate of COVID-19 in saliva, gastric fluid and intestinal fluid on gastrointestinal endoscopy

Clinical Outcomes of COVID-19 Infection in Hospitalized Patients with Cardiovascular Diseases and/or Risk Factors: CLAVIS-COVID

Homeopathy for Covid-19 in primary care
time to recovery, defined as the number of days elapsed before all the most common Covid-19 flu-like symptoms are recorded as mild or absent.

A retrospective study on the therapeutic effect of tocilizumab on COVID-19

Retrospective study on clinical and pathological aspects of COVID-19
Pathological results (including immunostaining and virus search)

A retrospective study on serum markers in the diagnosis and differentiation of COVID-19
Correlation between blood test results and SRAS-CoV-2 PCR results

prospective cohort study of COVID-19 antibody for medical stuff in hospital
evaluation of changes of antibodies of SARS-nCoV2 in medical stuff.

Longitudinal study on work style change, health and well-being due to pandemic of novel coronavirus infection (COVID-19)
Stress responses, Mental health, Work engagement, Job performance, Subjective health

SUrveillance of SARS-CoV-2 Virus Antibody in Health CarE and CloSe-Contact WorkerS
We examine the distribution of antibody positivity against COVID-19 among health-care professions and workplace workers at high risk of infection, using either the POC test kit or the laboratory test.

Lagos COVID-19 Chloroquine Treatment Trial (LACCTT)

Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)

Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot randomized trial
The mean time to negative test to COVID-19.;Presence of immune determinants.

Folic acid: A new suggested prevention and treatment of COVID-19 infection.
a. The conversion of health care workers at risk of COVID-19 from negative to positive as measured by PCR in the control and intervention groups.
b. The conversion from positive to negative in asymptomatic carriers and non-critical symptomatic COVID-19 patients in the control and intervention groups.

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
• Pneumonia
• Acute respiratory distress syndrome (ARDS)
• Death

A study to determine if a new COVID-19 vaccine safely generates protective immune responses in adults in Kenya
1. Occurrence of serious adverse events (SAEs) throughout the study duration 2. ELISA to quantify IgG antibodies against SARS- CoV-2 spike protein

Hydroxychloroquine, Azithromycine and Zinc for the treatment of SARS-Cov2 infection in Senegal. COVID-19
Percentage of patients with undetectable viral load 7 days after treatment initiation.

Effect of Interferential Therapy on SARS-CoV-2. COVID-19

Efficacy of a new COVID-19 treatment
This project will provide a better understanding of the efficacy of Artesunate IV alone or combined with Vitamin C in the form of Na-ascorbate compared to ISS in Madagascar in order to develop new strategies for the management of covid -19 adapted to the local context.

Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes
Peak Expiratory Flow (PEF). The evaluator will ask the patient to indicate their level of PEF assessed by Piko-1 device, twice each time. After obtaining values, patients will send them to the evaluator, by WhatsApp or email. We will calculate means of each 2 measurements, assessed by patients every day. ;Visual Analog Scale Fatigue (VASF), for fatigue measurement. Patients participating in the study will indicate the intensity of their fatigue by means of the VAS through the Smartphone application called “Visual Scale” (Apple Store and Google Play). They will have to signal in a horizontal line where they would place their fatigue, being 0 "no fatigue" and the 10 would be "the worst imaginable fatigue”. VASF will be controlled telematically by the evaluators through the Smartphone application. The evaluator will ask the patient to indicate their level of VASF in the "Visual Scale" application, and to take a screenshot of the smartphone to obtain the established value for VASF, which is calculated as the average value of two attempts. The patient must send the VASF screenshot daily to the evaluator, via WhatsApp or email.;Forced Expiratory Volume in one second (FEV1). The Piko-1 spirometer device will be sent to the home of each patient by post and a telematic control of its use will be carried out. The evaluator will ask the patient to indicate their level of FEV1 assessed by Piko-1 device, twice each time. FEV1 obtained values by patients must send to the evaluator, via WhatsApp or email. We will calculate means of each 2 measurements, assessed by patients every day. ;Six Minute Walk Test (6MWT). The 6MWT will be performed by all patients in their home, under the telematically supervision of a physiotherapist. All patients will receive the same instructions before the walk, and will be encouraged by the physiotherapist who repeated set phrases every minute during the walk. The distance covered during the test will be recorded in meters telematically by patient smartphone. Patients will be allowed to stop and rest during the test but they will be instructed to resume walking as soon as they felt able to do so. Patients will send the results of 6MWT screenshot daily to the evaluator, via WhatsApp or email. ;hirty Seconds Sit-To-Stand Test (30STST). Evaluators will ask patients to place a straight-backed armless chair, with a hard seat , which will be stabilized by placing it against a wall, considering floor to seat height will be between 45 - 50 cm. Seated participants will asked to come forward on the seat until their feet will be flat on the floor, and to fold their upper limbs across the chest, without moving it during all test. Patients will be then instructed to stand up all the way and sit down once without using the upper limbs. Patients will start in the seated position on the chair and, upon command telematically, they will stand up, and then they will return to sitting as many times as they could, in a 30-second time period. The evaluators will control this test telematically by videoconference.;Multidimensional Dysphnoea-12 (MD12) Spanish version. The MD12 questionnaire will be self-administered and will be performed at the end of the 6MWT. Patients will send the results of MD12 screenshot daily to the evaluator, via WhatsApp or email. ;Borg Scale (BS). The Borg scale, of perceived effort, measures the entire range of effort that the individual perceives when exercising. This scale gives criteria to make adjustments to the intensity of exercise, that is, to the workload, and thus forecast and dictate the different intensities of exercise in sports and medical rehabilitation. The BS will be completed by patients at the beginning of each session, and after completing the exercise program, as well as at the end of the tests, every day (6MWT, 30STST). Patients will send the results of BS screenshot daily to the evaluator, via WhatsApp or email.

Psychological effects of social isolation in the coronavirus pandemic
It is expected that social isolation will have an effect on the psychological parameters of optimism and affection of the studied populations, in a way that depends on cultural aspects related to socioeconomic conditions.

Treatment of 2019-nCoV Pneumonia with N-acetylcysteine
Reduction in in-hospital mortality in 5%, verified by medical record analysis, in patients receiving N-acetylcysteine compared to the group receiving Placebo

Telemedicine in the Covid-19 pandemic in Brazil
in a medical clinic in the supplementary health sector in São Paulo, Brazil
Better results with reduced morbidity and mortality with treatment proposed by telemedicine, score of clinical improvement of patients who followed the drug protocol.

Effects of tests for covid-19 on the preservation of the healthcare workforce during pandemia in Brazil
We anticipate a reduction in the total duration of work absence in the experimental group, as assessed through the difference in means for the time of absence from work between groups, with a moderate effect size (Cohen's d > or = 0,5), ultimately preventing excessive or unecessary absences.

Evaluation of the use of Hydroxychlorochine in Chinese flu
Negative viral load; RT-PCR was taken from a negative oropharynx swab; the RT-PCR value must be literally zero (0) for the patient to be considered cured

The role of early dialysis in the evolution of patients with COVID19
Control groups and intervention groups will be compared in relation to the prognosis (time of mechanical ventilation, ICU admission and mortality in 60 days between groups). Variables with normal distribution will be described as mean ± standard deviation and variables with non-normal distribution as median and interquartile range. Comparisons of continuous variables between the two groups will be performed using Student's t test for data with normal distribution and Mann-Whitney test for non-normal data. For the comparative analysis of categorical variables, the Chi-Square tests will be used. For comparisons of variables between groups by sessions, the mixed model of analysis of repeated measures over time with adjustment for Tukey will be used. Univariate and multivariate linear regression will be used for association with mechanical ventilation time and 60-day survival.
In all tests performed, the significance level of 5% will be considered.

Effect of convalescent plasma in patients with severe COVI-19
Temporal improvement in inflammatory biomarkers and organ dysfunction scores during ICU admission, measured by the daily reduction in 10% of biomarkers in plasma and respiratory secretions, per day for 14 days

Acute impairment of renal function in COVID-19: study on incidence, risk factors and mortality
Assess the presence of acute kidney injury. The results will be presented using descriptive statistics of the studied population and the occurrence of AKI will be established as a dependent variable, using the Chi-Square Test for the statistical significance between this variable and the categorical variables and the t Test for this variable and the variables continuous. Afterwards, multivariate analysis will be performed, through the construction of a logistic regression model, with Odds Ratio (OR) calculations, including all independent variables that showed an association with the outcome, with p under 0.20. A similar procedure will be performed from the establishment, as a dependent variable, the occurrence of death. All results of the hypothesis tests will be discussed at the 5% significance level (p under 0.05)

Acute and chronic cardiovascular and respiratory changes in COVID-19 hospitalized patients and the effect of physical rehabilitation supervised by telecommunication
Cardiovascular health profile: in Phase 1 (Hospital), patients are expected to have poor cardiovascular health, as assessed by the Ideal Cardiovascular Health Index. Lower rates are also expected to correlate with worse clinical outcomes.;Endothelial function: in Phase 1 (Hospital), patients are expected to have an important endothelial dysfunction, assessed by ultrasound of the brachial artery and by the flow-mediated dilation method (FMD); Phase 2 (30 days after hospital discharge): patients are expected to have a natural improvement in endothelial function (increased FMD), but still below what is considered ideal; Phase 3 (telerehabilitation): it is expected that patients in the physical training group show improvement in endothelial function (increase in FMD) when compared to those in the control group.;Functional capacity: in Phase 1 (Hospital), patients are expected to have a significant decrease in functional capacity, assessed by the Duke Activity Status Index, Baecke questionnaire and handgrip strength (dynamometry); Phase 2 (30 days after hospital discharge): patients are expected to show a natural improvement in functional capacity, but still below what is considered ideal; Phase 3 (telerehabilitation): it is expected that patients in the physical training group show improvement in functional capacity when compared to those in the control group.;Pulmonary function: 30 days after hospital discharge (Phase 2), as a respiratory sequela, patients are expected to have a decreased pulmonary function (mainly decreased vital capacity), as assessed by spirometry. In Phase 3 (telerehabilitation), patients in the physical training group are expected to show improvement in lung function when compared to the control group.;Respiratory muscle strength: 30 days after hospital discharge (Phase 2), patients are expected to have respiratory muscle weakness, assessed by manovacuometry to obtain maximum inspiratory (PI) and expiratory (PE) pressures. In Phase 3 (telerehabilitation), patients in the physical training group are expected to show improvement in respiratory muscle strength (PI and PE) when compared to those in the control group.;Arterial stiffness: 30 days after hospital discharge (Phase 2), patients are expected to have some degree of arterial stiffness, reflecting the increased carotid-femoral pulse wave velocity (PWV). In Phase 3 (telerehabilitation), it is expected that patients in the physical training group have decreased arterial stiffness (reduced PWV) when compared to the control group.;Cardiac autonomic modulation: 30 days after hospital discharge (Phase 2), it is expected that patients worsen in cardiac autonomic modulation, with reduced heart rate variability (HRV), increased sympathetic indices (low frequency) and reduced indices parasympathetic (high frequency). In Phase 3 (telerehabilitation), patients in the physical training group are expected to show an improvement in HRV when compared to the control group.;Cardiorespiratory fitness: 30 days after hospital discharge (Phase 2), patients are expected to have a low cardiorespiratory fitness, assessed by oxygen consumption (VO2) obtained in a cardiopulmonary exercise test. In Phase 3 (telerehabilitation), patients in the physical training group are expected to show an improvement in cardiorespiratory fitness (increased VO2) when compared to the control group.;Clinical outcomes: in Phase 1 (Hospital), events such as use of mechanical ventilation (including ventilatory parameters and pulmonary mechanics data), length of stay in the intensive care unit and hospital, complications and mortality will be evaluated. After hospital discharge, regardless of participation in the other phases, patients will be monitored by telephone, for 12 months, to assess cardiovascular and pulmonary events, reported functional capacity, hospitalizations and mortality.

Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus
Evaluate patient's health condition after 15 days. The primary outcome is based on seven possible patient's health conditions whithin 15 days:
;Outpatient, without activity limitation;Patient in hospital, without supplemental oxygen;Patient in hospital, with supplemental oxygen;Patient in hospital with non-invasive ventilation or high flow cannula;Patient in mechanical ventilation;Death;Outpatient, with limited activities

Mechanical ventilator for use in patients with respiratory failure due to Covid-19 (VExCO)
Assess need for hospitalization due to a COVID-19 compatible cause within 30 days after hospitalization through telephone contact by a trained professional, as it is believed that 90% of hospital admissions due to SARS-Cov2 occur within the first 15 sick days. The outcome period of 30 days was chosen to capture the 10% of the remaining hospitalizations, which are outliers, which will happen between 15 and 30 days of illness.;Secondary Outcome
Clinically assess efficacy for the presence of uncontrolled asthma after 5 or more days of medication initiation through telephone contact by trained staff

Evaluation with ultrasound on the bedside in serious patients with COVID-19
It is expected to find new sites for the passage of central venous access for critically ill patients with COVID 19. It is intended to present the number and possible parameters for central venous access in pronated patients.

Full versus prophylactic anticoagulation for the treatment of severe forms of Covid-19:
Evaluation of gas exchange between D0 / D4 /D7 /D14 evaluated through the PO2 / FIO2 ratio; days without mechanical ventilation (within 28 days of follow-up, how many days were out of mechanical ventilation, if the patient dies before 28 days of follow-up, it is considered that he did not stay any day out of mechanical ventilation)

Treatment of severe cases of Covid-19 with Eculizumab
Overall survival of patients who started treatment, assessed using Kaplan-meier curves and comparison with the historical survival of other patients affected by the severe form of COVID-19 in other studies.

Study of vascular complications in critically ill patients with coronavirus
the number (proportion in%) of deaths;the proportion of patients (%) with venous thromboembolism (assessed by some objective methods such as ultrasound, tomography, angiography or scintigraphy)

CIGB 2020 in contacts and SARS-CoV-2 infection suspects
Activation of markers of the innate immune system (in oropharyngeal scraping: relative concentration of dendritic cells; phenotypic analysis of leukocyte cells; transcriptional analysis of elements of molecules related to the immune response with expression at the level of epithelium and infiltrating leukocytes; quantification by ELISA of cytokines related to systemic inflammation such as IL-6, TNF alpha, IFN alpha and gamma, among other mediators of systemic inflammation, etc.). Measurement time: at baseline and, on days 4 and 8 post-treatment.

ESPERANZA study
1) Virological evaluation: Time until the negativity of the SARS-Cov-2 RNA (absence of the virus according to the qPCR technique in real time) in positive patients after starting antiviral therapy (the percentage of patients negative for SARS will be calculated). VOC-2 by qPCR in tissue of nasopharyngeal exudate Measurement time: 48, 72 and 96 hours after starting treatment. 2) Clinical evaluation: Time to progression to severe COVID-19 (the percentage of patients who become severe will be calculated). Measurement time: 3rd week, after completion of the antiviral treatment under investigation.

Pharmacodynamics of the Nasalferon in healthy volunteers.
Levels of local and systemic expression of markers of activity of the cellular signaling system stimulated by IFN alpha (2-5 oligo adenylate synthetase for antiviral activity and ?2-microglobulin for activity of the immune system), evaluated by PCR on tissue obtained from nasal scraping and sublingual (for evaluations at the local level) and in peripheral blood (for evaluations at the systemic level). Measurement time: At baseline, 72 hours after the first administration of IFN alfa and, 24 hours after the last administration.

Therapy for COVID-19-Phase I-II
Disease progression (present or absent). Measurement time: Daily until 14th day. Patients treated at home. The progression will be present when hospitalization or death occurs. In hospitalized patients: The progression will be present when they are in the usual hospital floor and without a ventilator, progression is considered when there is death or admission to the Intensive Care Unit (ICU) or requiring mechanical ventilation. Patients enrolled in the trial after admission to the ICU or already on mechanical ventilation. The progression will be present when death occurred.

Biomodulina T - IM- covid-19 - older adultos - Phase IV clinical trial
Adverse Events-AE (The AE will be classified according to Type, Location, Time of appearance, Duration, Previous knowledge, Intensity, Consequence, Causality, Result and, attitude regarding the study treatment). Measurement time: In each administration of the product and, 30 days after the last dose of the product was administered.

Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab
Reduction of deterioration of lung function (Patient rate without the need to increase FiO2 to keep SO2 stable and without the need for intubation and(or); Rate of patients decreasing positive pressure values at the end of exhalation (PPFE)). Measurement time: 7 days.

PrevengHo-Vir Homeoprohylaxis COVID-2019
Safety (Safety of the product for each patient once the safety assessment stage has been completed. Yes: once this stage is completed, the patient will not have any type of adverse event (AE), or those who will report are mild, related or not to PrevengHo(R)-Vir. No: once this stage was completed, the patient reported any AE with moderate or severe intensity, severe or non-severe, related to PrevengHo(R)-Vir). Measurement time: Close of the sixth week.

CIGB-258 at COVID-19
Mortality on discharge from the ICU (Proportion of patients who die, according to their causes). Measurement time: during the stay in the Intensive Care Unit.

VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2
EIndicators: No. of cases (suspected, confirmed, serious, critical, deceased) Unit of Measure: Proportional variation. Measurement time: weekly (statistical weeks until the end of the epidemic)

Evaluation of the synergistic effect of sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study
Lymphocytes T CD3+CD4+ (% of cells by flow cytometry). Measurement time: at baseline and, 7 days after end of treatment. Lymphocytes T CD3+CD8+ (% of cells by flow cytometry). Measurement time: at baseline and, 7 days after end of treatment. Lymphocytes B CD19+ (% of cells by flow cytometry). Measurement time: at baseline and, 7 days after end of treatment. NK cells CD3-CD56+ (% of cells by flow cytometry). Measurement time: at baseline and, 7 days after end of treatment. Monocyte cells CD14+ (% of cells by flow cytometry). Measurement time: at baseline and, 7 days after end of treatment. Dendritic cells CD11c+ (% of cells by flow cytometry). Measurement time: at baseline and, 7 days after end of treatment.

Exploratory study of BMT IM to stimulate immune response in patients with CKD-5 on iterated hemodialysis
Hemogram (Hemoglobin, Hematocrit, Leukogram with differential and Platelets). Measurement time: at baseline and, 8 weeks after randomization Lymphocyte subpopulations (CD3+/CD4+, CD3+/CD8+, CD19+ and, CD3-/CD56 +). Measurement time: at baseline and, 8 weeks after randomization Igs Quantification (IgA, IgM and, IgG). Measurement time: at baseline and, 8 weeks after randomization Complement Quantification (C3 and C4). Measurement time: at baseline and, 8 weeks after randomization

ATENEA-Co-300 study
Reduction of the time to the negativization of the coronavirus detection test (time to the negative of the coronavirus detection test by PCR-RT in the nasopharynx). Measurement time: 48 hours and on the 7th day after starting the treatment.

Heberon Alfa R in COVID-19
Proportion of patients discharged from the hospital (Patients with clinical discharge of the confirmed case according to clinical, radiological and, laboratory criteria divided by the number of recruited patients). Measurement time: at the end of treatment (14 days). -Clinical criteria: The patient's condition is stable and afebrile for more than 3 days, regular breathing and normal respiratory rate, clear conscience, unaffected speech and normal diet. -Radiological criteria: Lung images show significant improvement without signs of organ dysfunction. -Laboratory criteria: Two consecutive negative respiratory pathogenic nucleic acid tests (at least one day between tests).

Biomodulina T - IM - covid-19 - older adult - Confirmatory study
Respiratory infections (Number (0 to infinity), Type (- High Respiratory, including a common cold, Sinusitis, Otitis, Laryngitis or Pharyngotonsillitis; - Low Respiratory such as Bronchitis, Bronchopneumonia), Etiology (Bacterial, Viral, Fungal or Parasitic), Need for antibiotic treatment (Yes or No), Route of administration of antibiotic treatment (Oral or Parenteral), Need for hospital admission (Yes or No) and Mortality due to infection (Yes or No). Measurement time: In the initial evaluation, in the monthly evaluation and final evaluation (6 weeks)

Rectal Ozone in the COVID-19 treatment
Real-time polymerase chain reaction test-TR-PCR (Positive/Negative). Measurement time: day 0, day 6, day 11 Clinical signs (fever, pain head, fatigue, sore throat, dry cough, dyspnea. Every signs evaluted like Yes/No). Measurement time: day 0 to day 11, day 15 Progression of clinical signs (equal, better, worse). Measurement time : day 0 to day 11, day 15

A Randomized Controlled Trial on Effectiveness of Mental Health & Psychosocial Support Module (MHPSS) in Reduction of Depression, Anxiety and Stress among Healthcare Workers during COVID-19 Pandemic in Jerantut, Pahang
Depression Score [Timeframe Baseline and Post-Intervention Questionnaire] ;Anxiety Score [Timeframe Baseline and Post-Intervention Questionnaire] ;Stress Score [Timeframe Baseline and Post-Intervention Questionnaire]

Endotoxin and circulating bacteriome in severe COVID-19 patients
Endotoxin level [Timeframe Day 1, 3, 7 Chemiluminescent-based endotoxin activity assay ]

An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia â?? An open-label randomized controlled study â??
Time to improvement in body temperature and SpO2 without chest imaging findings, and negative SARS-C [Timeframe Day 1 to Day 28 Vital Sign, SpO2, and chest imaging ]

Chula Covid-19 Rapid Test for Pandemic Control
Antibody to Covid-19 infection [Timeframe at each visit Rapid antibody test kit]

Mental Health Circumstances Among Healthcare Workers and General Public Under the Pandemic Situation of COVID-19
Mental health problems (Depression, Anxiety, Stress, Resilience coping, Burnout, Insomia) [Timeframe Wave I (Aprâ??May/2020), Wave II (Julâ??Aug/2020), Wave III (Octâ??Nov/2020), Wave IV (Apr-May/2021) A self-administered questionnaire]

Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19
28-day mortality [Timeframe day 28 after enrollment status of patient (alive/dead)]

Use of Covid-19 Rapid Test for Hospital Care: GI Procedure
Antibody to Covid-19 infection [Timeframe 30 minutes Observation]

Comparative effectiveness of Chloroquine and Vitamin C prophylaxis in household contacts of confirmed COVID-19 patients
Seroconversion of SARS-CoV2 [Timeframe Day 21 Rate of seroconversion ]

Social, ethical and behavioural aspects of the novel coronavirus pandemic
Correlation between COVID-19 nonpharmaceutical interventions including communications, quarantine, t [Timeframe no time point administering online questionnaire, in-dept interview and focus group discussion ]

Covid-19 preparedness among Emergency Departments: a cross-sectional study in France.
Prepredness measurement [Timeframe at response date electronic survey with electronic questionnaire]

ED Response against Covid-19 pandemic
ED time interval [Timeframe hospital exit Time between ED arrival and hospital admission]

SOLIDARITY: AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS
Outcome name:Ratio of the number of deaths among patients enrolled in the study
Measure:All-cause mortality
Timepoints:5 months

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal;Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline;Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline;Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 not on mechanical ventilation but on high-intensity oxygen therapy* at baseline

Norwegian Coronavirus Disease 2019 Study
Rate of decline in SARS-CoV-2 viral load

Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases

Checkpoint Blockade in COVID-19 Pandemic
Percentage of patients with normalization of SpO2 =96% on room air (measured without any respiratory support for at least 15 minutes

Video-Based Exercises and Well-Being During Social Isolation
World Health Organization Quality of Life Questionnaire Bref

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
Recruitment Feasibility;Recourse utilization;Safety as reflected on the number and severity of adverse events and serious adverse events;Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.

Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19

Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients

Honey & Nigella Sativa Trial Against COVID-19
Days required to get a positive COVID-19 PCR to negative;HRCT/ X-ray findings of disease progression;Severity of symptoms progression;Duration of Hospital Saty;30 day mortality

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

A COVID-19 Symptom, Exposure and Immune Response Registry

Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)
Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device;Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device;Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients

Impact of the COVID-19 Pandemic in Gynecological Oncology
percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)

Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19
Days alive and out of hospital within 14 days after recruitment

Covid-19 in Lupus Patients
prevalence and severity of Covid-19 infection in patients with SLE

COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being
Automated Self-Administered 24-Hour Dietary Recall (ASA24);International Physical Activity Questionnaire (IPAQ)

Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab
serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab;serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab;serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab;serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab;serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab

Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19
Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate;Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate

Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic
Number of positive patient using saliva method compared to number of positive patient using standard method;Number of negative patient using saliva method compared to number of negative patient using standard method

Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19
Clinical worsening (yes/no) of the patient during hospitalization;D-DIMERS plasma levels in blood;Fibrin monomers plasma levels in blood;Antithrombin plasma levels in blood;Prothrombin Fragment 1 plasma levels in blood;Prothrombin Fragment 2 plasma levels in blood;Thrombin generation test plasma levels in blood;Microvesicles of platelet plasma levels in blood;Cross-linked platelets plasma levels in blood;Willebrand Factor plasma levels in blood;Factor VIII plasma levels in blood

Ozone Auto-hemotherapy for COVID-19 Pneumonia
Rate of patients achieving improvement in clinical condition at day 14 after recruitment

Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection
Describe the characteristics of patients admitted to reCOP units according to their virological status vis-à-vis COVID-19

QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.;Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)
extend of lung involvement;oxygen saturation on admission

COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia

A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)
Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)

The Impact of COVID-19 Pandemic on Cancer Care
patients' and survivors' perspective of their cancer care during COVID-19 pandemic

Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff
Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.;Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.;Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.

Digital Cardiac Counseling Trial: DCC Trial

Helmet CPAP Versus HFNC in COVID-19

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
Cumulative incidence of treatment-emergent serious adverse events and treatment-emergent adverse events.

Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Proportion of participants who were hospitalized for progression of COVID-19 disease;Proportion of participants who died due to COVID-19 progression and/ or complications

Impact of COVID-19 on Personal Protection Among Dentist in Egypt

Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)

Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff
Induced SARS-CoV2 immunity;Long-term protection of induced SARS-CoV2 immunity at 6 months;Long-term protection of induced SARS-CoV2 immunity at 1 year;Anti-SARS-CoV2 antibodies kinetics in blood throughout the study;Anti-SARS-CoV2 antibodies kinetics in saliva throughout the study;Kinetics of serum neutralization in blood throughout the study

Frailty in Elderly Patients With COVID-19
Development of a tool to measure frailty

Timing of Tracheotomy in Covid-19 Patients

Yoga Pranayama Adjuvant to Treat Burden COVID -19

Treatment of Patients With COVID-19 With Convalescent Plasma
Time elapsed until clinical improvement or hospital discharge

Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.

STerOids in COVID-19 Study
Emergency department attendance of hospitalisation related to COVID-19

Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19

Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia
Proportion of patients with clinical improvement

Patient Preference Trial for COVID-19 (PPT-COVID)
Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.

Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19

CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis
Vital status;Patient requiring more than 3 liters of oxygen to maintain a saturation >95% (intensive care unit or resuscitation department);Percentage of lung affected on CT;Percentage of lung affected by ground glass opacity on scan;Percentage of lung affected by condensation on scan

Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP)
Identification of markers associated with asymptomatic COVID + status (results of the serological test) versus symptomatic COVID + status through a questionnaire (medical history, work environment, lifestyle) and a biological collection

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness

Convalescent Antibodies Infusion in COVID 19 Patients

COVID-19 and Obstetric Transmission

Neuro-COVID-19: Neurological Complications of COVID-19
Prevalence of neurological complications;Prevalence and outcome of severe neurological complications;Impact of neurological complications;Characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF);Brain for pathological changes and histopathological findings (if patient dies).

Peri-Operative NLR in Emergency General Surgery During COVID-19 Pandemic

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Part 1 - Recommended dose of TL-895;Part 2 - Change in the need for artificial ventilation or death

COVID-19 Virtual Care at Home

Primary Prevention of Infection by COVID-19 in Health Providers

Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
Change in SSE performance;Identification of concerning mole;Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma

Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
origin of the ICU beds created during the COVID-19 outbreak in France.

Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease
Change in IL-6 concentration from baseline to day 7

Low Dose Radiotherapy for COVID-19 Pneumonitis

Mental Health and Academic Performance in COVID-19
Academic Self-Concept Scale Score;PHQ-9 Score;GAD-7 Score;Preference of teaching method;Self perceived academic performance;Academic grades changes

Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children

Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases

Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection

Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

QuadraMune(TM) for Prevention of COVID-19

Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19

Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
Establishment of a clinical basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.;Establishment of a biological basis for to describe the number and severity of Covid-19 infections in Cancer centres staff and patients.

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Ordinal Scale of COVID19 Disease Severity at 14 days

COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study

Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi
Change from Baseline Burnout at 2-3 months and 6 months;Change from Baseline Cardiovascular Risk Cardiovascular Risk Through Heart Rate Variability Markers at 2-3 months and 6 months;Change from Baseline Through Actigraphy at 2-3 months and 6 months;Change from Baseline Through Sleep Quality at 2-3 months and 6 months;Change from Baseline Cardiovascular Risk Through Fuster-BEWAT score at 2-3 months and 6 months;Change from Baseline Immune Dysfunction at 2-3 months and 6 months

Effects on the Qt Interval of COVID-19 Coronavirus Infection
Assessing the QT and QTc interval in patients admitted to intensive care units for COVID-19 infection

Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection

Needs of Persons With Spinal Cord Injury (SCI)
NIH Toolbox Instrumental Support Survey - change in instrumental support

Tocilizumab in Coronavirus-19 Positive Patients

Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia

Knowledge About Covid-19 Infection
The number of pregnant women who have knowledge about covid-19

BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalization
Change from baseline in clinical assessment score COVID 19 (CAS COVID 19)

SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

ARrest RESpiraTory Failure From PNEUMONIA

Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
Number of participants who die or require hospitalization due to COVID-19 infection

Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS

Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease
first occurrence of intensive care unit admission, mechanical ventilation or death

Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study
Evaluation of apgar status of newborns from covid 19 positive mothers

Dynamic Evaluation of COVID-19 Diagnostic Tests
Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies

TXA and Corona Virus 2019 (COVID19) in Outpatients

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Proportion (%) of subjects experiencing deterioration in clinical status;Treatment Emergent Adverse Events

COVID-19 Community Research Partnership
Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina;Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)

Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population

Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.

Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19
Total Leak Volume of Non Invasive Ventilation Mask

Collection of Anti-SARS-CoV-2 Immune Plasma
Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma

Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)
Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).

A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;Sequential Organ Failure Assessment (SOFA) scores;7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death);7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)

Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
Incidence of invasive mechanical ventilation (IMV) and/or Mortality

A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
Identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for ICU treatment (binary, yes/no);duration of hospitalization (in days);duration of Intensive Care Unit (ICU) stay (in days);in-hospital mortality (binary, yes/no);Number of infected cases within the city of Basel;whole genome sequencing to study pathogen evolution (number, type, and complexity of viral genome);Identification which treatment modality is associated with adverse events (binary, yes/no);Identification which treatment modality is associated with pulmonary recovery (binary, yes/no)

Stopping ACE-inhibitors in COVID-19
Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death;Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death

Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)
Level of IFN-gamma after a non-specific stimulation of T lymphocytes

Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19

Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19

Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
Patient with more than 2 points on the ODORATEST

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Number of patients with clinical response

Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability

SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)

Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)

Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection
Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).;Efficacy: Death from any cause;Efficacy: Need for mechanical ventilation;Efficacy: Any of the following analytical data after 72h of randomization.;Efficacy: SOFA scale = 3 after 72 hours of randomization or an increase of 2 points or more from the basal level

Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study
Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study

Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19

C-reactive Protein Levels Among Individuals With COVID-19

Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization

London's Exogenous Surfactant Study for COVID19
Adverse events (patient) - Decrease in oxygenation;Adverse events (patient) - Decrease in hemodynamics;Adverse event (healthcare worker) - Circuit breach;Adverse event (healthcare worker) - COVID-19 symptoms

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
Percentage of patients hospital admission or death by day 30

LDCT in COVID-19 Pneumonia: a Prospective Moscow Study
Evaluate the correlation between standard CT and low-dose CT scans for the detection of community-acquired pneumonia.

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale

Emergency Ventilator Splitting Between Two or More Patients (COVID-19)
Completion of 1-minute test;Completion of 24-hour test;Completion of 24-hour test

Inhaled Ibuprofen to Treat COVID-19
Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen.;Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen.

Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.;Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.

Myeloproliferative Neoplasms (MPN) and COVID-19

Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19

Oral 25-hydroxyvitamin D3 and COVID-19
COVID-19 (SARA-Cov-2) infection;Severity of COVID-19 (SARA-Cov-2) infection;Hospitalization;Disease duration;Death;Oxygen support

Predictors of Severe COVID-19 Outcomes
Performance (discrimination / calibration) of models

Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

Postpartum Sexual Function in Pregnant Women With COVID-19
Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale

Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19
Evaluation of pregnant women diagnosed with COVID-19 with "Post-operative Recovery Index" and "Prenatal Care Satisfaction and Patient Expectations Scale"

Respiratory Decompensation and Model for the Triage of COVID-19 Patients

Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
Mean days of hospital stay;Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead;Mean of oxygenation index delta

Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic
Best Corrected Visual Acuity (BCVA) Per Eye

Serologic Testing of Household Contacts of Confirmed Cases of COVID-19

Impact of COVID-19 Pandemic on Depression and Quality of Life
Sociodemographic information form;Zung Depression Scale;World Health Organization Quality of Life - Bref

Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients
Admission to ICU and/or mechanical ventilation

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Proportion of subjects alive and off of oxygen at day 14

Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic
Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic?;Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism?

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
Humoral responses to peptide antigens derived from SARS-CoV-2 structural proteins and regions of the spike protein not present in vaccines;SARS-CoV-2-specific antibody binding response rate;SARS-CoV-2-specific antibody binding response magnitude;SARS-CoV-2-specific antibody binding response epitope specificity;SARS-CoV-2-specific antibody neutralization response rate;SARS-CoV-2-specific antibody neutralization response magnitude;SARS-CoV-2-specific antibody neutralization response epitope specificity;SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response rate;SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response magnitude;SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response epitope specificity;SARS-CoV-2-specific CD4+ and CD8+ T cell responses;SARS-CoV-2-specific CD4+ and CD8+ T cell response rate;SARS-CoV-2-specific CD4+ and CD8+ T cell response magnitude;SARS-CoV-2-specific CD4+ and CD8+ T cell response functional profiling;SARS-CoV-2-specific memory B cell characterization;SARS-CoV-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants

A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers
Immune responses to components of SARS-Cov-2;Swabs for the presence of SARSCoV-2

Role of Children in Transmission of COVID-19 to Immunocompromised Patients
To define the role of household contact with children or siblings in the transmission of SARS-CoV-2 to immunocompromised patients.

Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients

Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study

Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders
Global symptom load (Anxiety, Somatisation, Depression, Global Symptom Index);Depressive symptoms;Sleep disorders and Sleep Quality

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers
Exercise Benefits and Barriers Scale;Sociodemographic information

Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry
Number of patients undergoing primary angioplasty;Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;;Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission;In-hospital mortality

Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis

Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period
Study of the evolution of pregnancies in the first trimester following MAR management during a COVD-19 pandemic period

PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS
Number of participants who die due to COVID-19 infection;Number of participants who require hospitalization due to COVID-19 infection

Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19

Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease
Quality of life (QoL);Depressive symptoms - Geriatric Depression Scale - 15 item;Physical Activity - International Physical Activity Questionnaires (IPAQ)

Lanadelumab for Treatment of COVID-19 Disease

Fibromyalgia During the COVID-19 Pandemic

COVID 19 Serology in Pulmonologists
covid 19 serology;risk factors for positive serology testing

Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea
Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea

Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia

Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure
Change in the partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio after CytoSorb therapy

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

The Impact of COVID-19 on Dialysis Users
Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours

Endoscopic Interventions in Patients With COVID-19

Telematic Monitoring Through a Mobile Application of Patients With COVID-19

Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19
Serum levels of cytokines and chemokines;Serum levels of cytokines and chemokines;Serum levels of cytokines and chemokines;Viral load;Viral load;Immunophenotype of myeloid cells;Immunophenotype of myeloid cells;Immunophenotype of myeloid cells;RBD-SARS-CoV Protein S- antibodies;RBD-SARS-CoV Protein S- antibodies;RBD-SARS-CoV Protein S- antibodies;Analysis of cellular immune response;Analysis of cellular immune response;Analysis of cellular immune response;Hematopoietic stem cells and progenitor cells populations in peripheral blood;Hematopoietic stem cells and progenitor cells populations in peripheral blood;Hematopoietic stem cells and progenitor cells populations in peripheral blood

COVID-19 Related Health and Infection Control Practices Among Dentists

Efficacy and Safety of Nitazoxanide 600 mg TID for the Treatment of Hospitalized Patients With COVID-19

Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning

MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study
Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.;Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies;Estimate of the prevalence of active infection in Cabarrus County.;Estimate of the prevalence of exposure and potential immunity to COVID-19.

Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers
Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies

External Dead Space in Ventilated COVID-19 Patients
change in carbon dioxide elimination (VCO2) i.e. ml CO2 eliminated/minute

Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia
Number of patients with diagnosis of PTSD.

Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol

Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients
Invasive respiratory support in patients with COVID-19

Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

The Natural History of Hospitalized COVID-19 Patients

Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric
Change from baseline on waist circumference at 4 months of follow-up.

AiM Covid Self Monitoring

Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar
Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)

A 3 Study Evaluating Favipiravir in Treatment of COVID19
Time from randomization to clinical recovery

A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial
Retention of the correct technique for running subcuticular sutures

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

Ivermectin In Treatment of COVID 19 Patients
to evaluate the role of Ivermectin as a line of treatment for COVID 19

MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
Number of Participants Who Experience an Adverse Event (AE);Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE);Change From Baseline to Day 1 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2);Change From Baseline to Day 2 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2);Change From Baseline to Day 3 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2);Change From Baseline to Day 4 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2);Change From Baseline to Day 5 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2);Change From Baseline to Day 6 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2);Change From Baseline to Day 7 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
Change (reduction) in viral load from baseline

Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19

COVID-19 Antibodies Among Healthcare Workers

Efficacy of Convalescent Plasma Therapy in Patients With COVID-19
Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)

Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic - PRO-SERO-COV
Serological immune status to an infection by the SARS-CoV-2 virus

The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries

Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study
Severe Covid-19;Severe Covid-19 with pulmonary embolism

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O )
Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC=1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first

Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19
Identification of genetic factors determining the course of the disease in case of COVID-19

Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants
the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave (from March to August 2020) among patients with IRC under IS.

SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak

Community Health Workers Against COVID19
Change in patient-reported Emotional Support (based on the PROMIS® Emotional Support instrument);Change in patient-reported Social Isolation (based on the PROMIS® Emotional Support instrument);Change in patient-reported Ability to participate in social roles and activities (based on the PROMIS® ability to participate in social roles and activities instrument);Change in patient-reported anxiety (based on the PROMIS® anxiety instrument)

Core Warming of COVID-19 Patients
Viral load measured in tracheal aspirate 72 hours after initiation of core warming

Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Proportion of patients, at each sample timepoint, with a positive detection of IgM and IgG specific antibodies to SARS-CoV-2.

Smell and Taste Disorders in COVID-19 Patients
Identification of demographic and clinical factors in covid19 patients.

Predictive Factors COVID-19 Patients
Identify risk factors for intra-hospital mortality.;Identify risk factors to build a prognostic score.;Identify risk factors to build a prognostic score.

RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population
Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection

Exploring Interventions for Glue Ear During Covid-19

Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI
MACE (major adverse cardiovascular events);all-cause death

Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure

Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.

Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication;The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group;COVID-19 incidence rates in both the study and control groups

Cerebral Compliance Impairment in COVID-19
Detection of cerebral compliance impairment by the B4C sensor;Detection of cerebral hemodynamics impairment by transcranial Doppler

Safety of TY027, a Treatment for COVID-19, in Humans
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia

Donated Antibodies Working Against nCoV
Patients requiring mechanical ventilation or death

COVID-19 prophylaxis with hydroxychloroquine in Front-line Health and Allied-Health Care Workers: The COVID-SHIELD Trial
Incidence of COVID-19 using standard PCR analysis for COVID-19 [Daily during 4 months of intervention period]

A reusable personalised ventilation hood: A phase 1 safety study of a new device (McMonty) in patients with suspected or confirmed COVID-19.
Clinical safety assessment will be performed by collation of technical product complaints forms. The technical product complaint form will capture descriptive information from staff about device malfunction, breakage or incidents related to use of the device. The investigator team will then assess this information and categorise the event against criteria for the following:
Adverse device effect (ADE). Adverse event related to the use of the investigational product.
Adverse event (AE). Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device.
Serious adverse effect (SAE). Any adverse effect that results in any of the following outcomes: death, a life-threatening adverse effect, inpatient hospitalization or prolongation of existing hospitalization, a persistent or injury or permanent impairment to a body structure or a body function.
Unanticipated serious adverse device effect (SADE). Serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report.
This report will then be distributed to an independent data safety monitor team for escalation of regulatory reporting as required.
[Safety assessment data capture can occur at any time throughout clinical use of the device. All staff will be able to submit a technical product complaint form at any time. ]

An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants.
To assess the safety and tolerability of SARS-CoV-2 Sclamp vaccine compared to placebo by evaluating:
- the frequency, duration and intensity of solicited local adverse events (AEs), including pain, redness, induration
- the frequency, duration and intensity of solicited systemic AEs, including fever, nausea, chills, diarrhoea, headache, fatigue, myalgia
- the frequency, duration, intensity, and relatedness of unsolicited AEs through to Day 57.
Solicited AEs will be assessed by severity score, frequency, duration and intensity by FDA toxicity scoring. [Information on solicited AEs (local and systemic) will be collected for the 7 days following each vaccination (at Days 1 and 29)
Information on unsolicited AEs, SAEs and MAAEs will be collected from the time of consent through to study completion, Study completion is anticipated to be 12 months after the first dose of vaccine.
Information on any AEs leading to withdrawal will be collected from time of consent to the time of withdrawal/ study completion. Study completion is anticipated to be 12 months after the first dose of vaccine.
An interim analysis will be conducted after the first vaccination (Day 29), with the final analysis at the conclusion of the active study period (Day 57). Addenda to the study report will be produced for 6-month and 12-month follow-up data.];To assess the total serum antibody immune responses elicited by SARS-CoV-2 Sclamp vaccine compared to placebo.
This will be evaluated by looking at the Geometric mean titre (GMT) of the serum antibody response to the Sclamp antigen compared to placebo by antigen specific Enzyme-linked immunosorbent assay (ELISA).[Blood samples will be collected for analysis at Day 29 (28 days after first dose) and Day 57 (28 days after second dose).
An interim analysis will be conducted after the first vaccination (Day 29) for serum antibody responses by ELISA, with the complete immunogenicity analysis at the conclusion of the active study period (Day 57).];To assess the neutralizing antibody (NAb) immune responses elicited by SARS-CoV-2 Sclamp vaccine compared to placebo.
This will be evaluated by looking at the GMT of the serum NAb titres to SARS-CoV-2 virus compared to placebo by microneutralization (MN) assay
[Blood samples will be collected for analysis at Day 29 (28 days after first dose) and Day 57 (28 days after first dose).
A complete immunogenicity analysis will be performed at the conclusion of the active study period (Day 57).]

Amnion cells for COVID-19 related respiratory failure
ventilator free days score (VFD, composite of mortality and ventilator-free days) at 21 days after randomisation based on patient medical records[21 days after randomisation];daily change in P/F ratio based on patient medical records of ventilator settings[over the first 5 days following intervention]

A phase III study to investigate a vaccine against COVID-19
Virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 12 months

Studying the immune response and long-term morbidity of COVID-19 infection in pregnancy
Lung function for mothers measured by spirometry at 3 months post-discharge (if COVID-19 infection coincides with delivery) or 3 months post-delivery (if COVID-19 infection does not result in or coincide with delivery)

Behavioural Activation in Social IsoLation (BASIL): Benefiting from activities to improve your mood while you are socially isolating
Self-reported depression severity (as measured by the Patient Health Questionnaire 9) at 1 month post-randomisation

To study the treatment of COVID-19 with severe viral pneumonia by using purified stem cell exosomes
1. Safety and adverse events measured using i.v. administration of 0.2mg/kg of placental, mesenchymal stem cell-derived exosome preparations (KTA 100,= XoGlo®) at day 1 and day 3
2. Improved respiration measured using PaO2/FiO2 at day 1, 2, and onwards daily

Does ivermectin cure and/or prevent COVID-19?
Viral RNA load measured using quantitative branched DNA (bDNA), reverse transcriptase-polymerase chain reaction (RT-PCR), and qualitative transcription-mediated amplification at baseline and 1, 2, 4, 7, 10, 12, 14 days

CROWN CORONATION: Chloroquine repurposing to healthworkers for novel coronavirus mitigation
Clinical diagnosis of COVID-19 with laboratory confirmation (i.e. based on viral PCR or serology), with limitation of activities (WHO Severity Scale 2-8) or symptoms of COVID-19 (cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell) over the treatment period of 90 days

Therapeutic plasma exchange (removal of the non-cell portion of blood) in critically ill adult patients with serious SARS CoV-2 disease (COVID-19)
1. 28-day mortality assessed using patient medical records
2. Safety assessed by measuring adverse events and serious adverse events collected as usual for TPE treatment using the Saudi FDA reporting standard during the TPE session and the following 48 h

Evaluation of COVID-19 assessment in emergency departments and ambulance services
Patients who die or require respiratory, cardiovascular or renal support will be defined as having an adverse outcome. If patients survive to 30 days without requiring respiratory, cardiovascular or renal support they will be defined as having no adverse outcome. If a severe pandemic leads to hospital resources being overwhelmed the researchers will categorise patients as having an adverse outcome if they were deemed to have needed respiratory, cardiovascular or renal support but were denied this due to lack of resources; Timepoint(s): 30 days

UKOSS: Pandemic COVID-19 in pregnancy
Incidence of pandemic COVID-19 in pregnancy assessed as proportion of pregnant women hospitalised with confirmed COVID-19 disease per 100,000 maternities during the study period

Inhale work package 3 – rapid versus standard testing to diagnose lung infections in intensive care, including COVID-19 observational sub-study
1. Non-inferiority in clinical cure of pneumonia at 14 days post randomisation. Cure of pneumonia defined as: absence of (i) death where the pneumonia was considered causative or at least contributory, (ii) septic shock (except when associated with a documented non-respiratory infection), or (iii) relapse of pneumonia. Relapse is defined as an infectious pulmonary event, associated with clinical and radiological signs of HAP or VAP, or a worsening of 2 points of the baseline multiple organ dysfunction score (SOFA or PELOD-2).
2. Improvement in antimicrobial stewardship at 24 h post-randomisation. Defined as: Participants on active and proportionate antimicrobial therapy within 24 h of clinical diagnosis, where active therapy is defined as receiving an antimicrobial active against the organism(s) in vitro and proportionate as defined in the prescribing algorithm specific to that site.; Timepoint(s): .

A follow-up study of novel coronavirus pneumonia (COVID-19) patients in Wanzhou District, Chongqing
chest CT;pulmonary function;viral nucleic acid test;Blood routine test;liver and kidney function;

A multicenter clinical study: transmission of COVID-19 and impact on health and developmental outcomes among newborns of mothers with confirmed/suspected COVID-19
SARS-CoV-2 RNA;SARS-CoV-2 antibodies (IgM and IgG);Feeding methods;

Psychological Preparedness towards Novel Coronavirus Precautionary Measures – an online survey

A medical records based study for the influence of novel coronavirus pneumonia (COVID-19) on the symptoms of patients with achalasia
Eckardt score;Hospital Anxiety and Depression Scale;Diet self-evaluation;

Impact of COVID-19 on Laboratory Professionals-Early Evidences from a Survey at a Clinical Chemistry Laboratory in a Developing Country

Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic

Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the standard of care in patients hospitalized with COVID-19.;Secondary Objective: To evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by Clinical Severity, Oxygenation, Ventilation, Hospitalisation.;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):
7. Death.;Timepoint(s) of evaluation of this end point: Day 15

A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection
Main Objective: Time to Clinical Improvement (TTCI);Secondary Objective: - Mortality
- Additional Clinical Endpoints
- To determine the anti-inflammatory and immune effect of selinexor
- To assess safety and tolerability of selinexor [time frame: up to 28 days];Primary end point(s): Absence of fever, oral temperature <38°C x 24 hours without antipyretics (acetaminophen) AND one of the following:
- Respiratory rate =24/minute OR
- Oxygen saturation >94% on room air OR
- Hospital discharge;Timepoint(s) of evaluation of this end point: Throughout the study

Systematic study of the medicine hydroxychloroquine against placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19
Main Objective: Primary objective: Effect of HCQ on in vivo viral clearance. ;Secondary Objective: Exploratory objectives are to assess the effect of infection and HCQ treatment on clinical outcome, cardiac function, mucosal, humoral and cellular immune response including single cell phenotype and RNA expression, effect on anti-viral defense, assessment of chronic symptoms and quality of life. ;Primary end point(s): Primary efficacy endpoint: Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number =100, measured by real time reverse-transcription polymerase chain reaction in throat swabs
;Timepoint(s) of evaluation of this end point: One interim analysis for evaluating the primary efficacy endpoint is planned for this study. The interim analysis will be done when 40% of events have accrued. In case the interim analysis shows a HR > 1.93 (nominal p < 0.0018), efficacy is shown and the trial may be stopped. Final analysis upon completion of the trial and final database lock.

Does subcutaneously(SC) administered of anakinra achieve good penetration in blood and result in reduce inflammation in patients with SARS-CoV-19?
Main Objective: Principal question/objective:
Ascertain if anakinra administered subcutaneously will reach concentrations in the plasma (blood) that is thought to be effective and ascertain its effect on inflammation within the first week of treatment with the drug.
;Primary end point(s): Plasma IL-1Ra levels from Day 1 to Day 7 following administration of SC anakinra in patients with SARS-CoV-2 infection.
Plasma IL-6 levels from Day 1 to Day 7 following administration of SC anakinra in patients with SARS-CoV-2 infection.
;Timepoint(s) of evaluation of this end point: Sampling at baseline, days 1, 3, 5, 7 and end of administration (day 14 or earlier) post-randomisation.
;Secondary Objective: Secondary objectives are:
1. To establish a relationship between concentrations of anakinra and markers of inflammation after SC and IV administration.
2. To determine and compare the pharmacokinetics and pharmacodynamics (amount and action of drug within the body) of SC and IV anakinra.
3. Obtain further safety information on patients with SARS-CoV-2 given SC anakinra.
4. To obtain and compare the feasibility of SC and IV administration.
5. To obtain preliminary data on efficacy and help to decide if a larger study of SC anakinra in COVID-19 patients is justified.

Treatment with Ruxolitinib in Covid-19 patients with severe symptoms
Main Objective: Reversal of hyperinflammation;Secondary Objective: efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy in patients with COVID-19. ;Primary end point(s): Proportion of patients achieving 25% reduction in hyperinflammation score (CIS);Timepoint(s) of evaluation of this end point: Day 7 after start of study treatment

Treatment with Omega-3 polyunsaturated fatty acids in COVID-19 patients.
A single-blind, randomized, placebo-controlled feasibility study.
Secondary Objective: To establish if Omegaven® increases omega-3 index and proresolving mediators.
To establish the feasibility of the study protocol.
;Primary end point(s): Changes in a panel of inflammatory biomarkers measured in blood samples, urine samples and released from ex vivo stimulated leukocytes after 5 days of treatment.;Timepoint(s) of evaluation of this end point: After 5 Days of treatment.;Main Objective: To establish the effects of omega-3 fatty acids (Omegaven®) on inflammatory biomarkers in COVID-19 patients compared to placebo.

A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).
Main Objective: To investigate the effect of Remdesivir and Hydroxychloroquine on allcause
in-hospital mortality compared to standard of care.;Secondary Objective: - To assess the effect of Remdesivir and Hydroxychloroquine treatment
on hospital duration, receipt of ventilation or intensive care, and to
identify any serious adverse reactions.
- To assess the effect of Remdesivir and Hydroxychloroquine treatment
on 28 days mortality, viral clearance, kidney and myocardial failure, coinfections,
organ dysfunction and health-related Quality of Life.
;Primary end point(s): All-cause in-hospital mortality.;Timepoint(s) of evaluation of this end point: During hospitalisation.

Treating COVID-19 infections with inhaled corticosteroids
Main Objective: Evaluate the effect of inhaled corticosteroid (ICS) therapy compared to standard care in participants with early CoVID-19 illness in reducing COVID related emergency department presentations and/or hospital admissions.;Secondary Objective: Evaluate the effect of ICS therapy on body temperature, blood oxygen saturation level, viral load, and symptoms compared to standard care in participants with early CoVID-19 illness.;Primary end point(s): Hospitalisation or emergency department attendance related to COVID-19.;Timepoint(s) of evaluation of this end point: Day 0 to 28

An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301+SOC vs SOC in hospitalized participants with COVID-19 requiring supplemental oxygen
Main Objective: • To evaluate efficacy of RESP301 in preventing progression of hospitalized COVID-19 participants at level 4 in the modified World Health Organization (WHO) ordinal scale into levels >4.;Secondary Objective: • To assess the effect of RESP301 as measured by room air SpO2.
• To assess the effect of RESP301 as measured by the National Early Warning Score (NEWS) 2 symptom score.
• To assess the treatment response on clinical status.;Primary end point(s): • Proportion of participants who progress to level >4 of modified WHO ordinal scale due to COVID-19 by Day 14.;Timepoint(s) of evaluation of this end point: By Day 14.

A Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
Main Objective: The overall objective of the study is to evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19;Secondary Objective: To assess pharmacokinetics of acalabrutinib and its active metabolite in subjects with COVID-19 when administered with BSC
To evaluate the safety of acalabrutinib in
subjects with COVID-19 when
administered with BSC;Timepoint(s) of evaluation of this end point: 14 days
;Primary end point(s): Primary Endpoint is Proportion of subjects alive and free of
respiratory failure at Day 14.
For the purpose of this study, respiratory failure, is defined based on resource utilization of any of the following modalities:
(a) Endotracheal intubation and mechanical ventilation
(b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen =0.5)
(c) Noninvasive positive pressure ventilation or continuous positive airway pressure
(d) Extracorporeal membrane oxygenation

A study to investigate the safety and efficacy of two approved drugs, niclosamide and camostat, administered alone and in combination and compared to placebo in COVID-19 patients
Main Objective: To assess the safety and tolerability of ascending doses of Camostat and of the treatment combination Niclosamide and Camostat in mild to moderately affected Covid-19 patients.;Secondary Objective: ? To assess the preliminary efficacy (“proof of concept”) of Camostat in two ascending doses and of Niclosamide at 2 g QD, each substance alone and both substances in combination in mild to moderately affected Covid-19 patients
? To assess the effect of two ascending doses of Camostat and of Niclosamide at 2000 mg QD, each substance alone and both substances in combination on viral load in mild to moderately affected Covid-19 patients
? To assess the effect of two ascending doses of Camostat and of Niclosamide at 2000 mg QD, each substance alone and both substances in combination on biomarkers in mild to moderately affected Covid-19 patients;Primary end point(s): The primary endpoint of the study is safety which will be evaluated according to the following parameters:
? Adverse event monitoring - AEs and SAEs
? Physical examination
? Vital sign monitoring (blood pressure, pulse rate, temperature, respiratory rate)
? Oxygen saturation
? Safety lab including coagulation;Timepoint(s) of evaluation of this end point: at time of IMP administration until follow-up visit 2 (day 14 after end of treatment)

Treatment with inhalation of Ciclesonide for patients with coronavirus disease: A randomised open study.
Main Objective: Can inhalation treatment with ciclesonide decrease the number of days with oxygen therapy for hospitalized patients with Covid-19?;Secondary Objective: - Can inhalation treatment with ciclesonide decrease the risk for intubation and/or death within 30 days?
- Can inhalation treatment with ciclesonide decrease respiratory symptoms after 1 month and 5-7 months?;Primary end point(s): Number of days with oxygen therapy (30 days follow up after study inclusion). Terminated oxygen therapy is defined as discharge from hospital, without subsequent rehospitalization with oxygen therapy within 2 days, or at least 2 days without oxygen therapy for hospitalized patients.;Timepoint(s) of evaluation of this end point: 30 days after inclusion

A clinical study to evaluate the efficacy of different anti-viral drugs in
SARS-CoV-2 infected patients (COVID-19)
Main Objective: To investigate the effect of Remdesivir on allcause in-hospital mortality compared to standard of care.;Secondary Objective: - To assess the effect of Remdesivir treatment
on hospital duration, receipt of ventilation or intensive care, and to
identify any serious adverse reactions.
- To assess the effect of Remdesivir treatment on 28 days mortality, viral clearance, kidney and myocardial failure, coinfections, organ dysfunction and health-related Quality of Life.
Exploratory:
Assess the effect of Remdesivir on biomarkers and safety.;Primary end point(s): All-cause in-hospital mortality.;Timepoint(s) of evaluation of this end point: During hospitalisation.

A Phase 2 Study for the Treatment of COVID 19 in Hospitalised Patients
Main Objective: •Stage 1: To evaluate the efficacy of candidate agents as add on therapies to Standard of Care (SoC) in patients hospitalised with COVID 19 in a screening stage.
•Stage 2: To confirm the efficacy of identified efficacious candidate agents in patients hospitalised with COVID 19 in an expansion stage.
;Secondary Objective: Secondary
• To evaluate the ability to prevent deterioration according to the ordinal scale by 1, 2, or 3 points
• To evaluate the number of oxygen free days.
• To evaluate ventilator-free days and incidence and duration of any form of new ventilation use.
• To evaluate SARS CoV 2 viral load.
• To evaluate response rate. (see primary endpoint for definition of responder).
• To evaluate time to discharge.
• To evaluate overall mortality.
• Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2/FiO2),
• To evaluate the safety of candidate agents as add on therapy to SoC in patients with COVID-19.
• To evaluate intensive care unit (ICU) and hospitalisation length.
• To evaluate National Early Warning Score 2 (NEWS2).
***********
Additional sub protocol(ACCORD-2-002) secondary objectives
To evaluate the pharmacokinetic exposure to bemcentinib in Covid-19
To evaluate pharmacodynamic response to bemcentinib by circulating biomarkers (GAS6, soluble AXL;Primary end point(s): •Time to sustained clinical improvement of at least 2 points (from randomisation) on a 9 point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale), whichever comes first, by Day 29 (this will also define the “responder” for the response rate analyses).
9-point category ordinal scale:
0. Uninfected, no clinical or virological evidence of infection
1. Ambulatory, no limitation of activities
2. Ambulatory, limitation of activities
3. Hospitalised – mild disease, no oxygen therapy
4. Hospitalised – mild disease, oxygen by mask or nasal prongs
5. Hospitalised – severe disease, noninvasive ventilation or high flow oxygen
6. Hospitalised – severe disease, intubation and mechanical ventilation
7. Hospitalised – severe disease, ventilation and additional organ support – vasopressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)
Sub-protocol-ACCORD-2-002: As defined in Master Protocol.;Timepoint(s) of evaluation of this end point: As defined in Main protocol
Sub-protocol-ACCORD-2-003:
Day 29

Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure
Lower Murray lung injury score;Lower Murray lung injury score

The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
The time to oxygen saturation recovery to normal level (=97%);The proportion of patients with normal level of oxygen saturation(=97%)

Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial

Losartan for Patients With COVID-19 Not Requiring Hospitalization

NO Prevention of COVID-19 for Healthcare Providers

Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection

Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP

National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19

Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients
Proportion of patients remaining free of mechanical ventilation in both groups

Seroprevalence of SARS-Cov-2 Antibodies in Children
Immunoglobulins (G and M) to SARS-Cov2 in plasma

Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died

Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic
Prevalence of burnout among anaesthesiology clinicians during Covid-19;Prevalence of depression risk among anaesthesiology clinicians during Covid-19;Prevalence of self-perceived medical errors among anaesthesiology clinicians during Covid-19;Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19

COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie
Antibodies against the SARS-CoV-2 virus in serum at inclusion;Antibodies against the SARS-CoV-2 virus in serum at 1 month;Antibodies against the SARS-CoV-2 virus in serum at 3 months;Antibodies against the SARS-CoV-2 virus in serum at 6 months

Multi-site Adaptive Trials for COVID-19

Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS
Proportion of patients with altered spleep

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
Mortality;long of hospitalization;Laboratory Treatment Response (Blood cell count);Laboratory Treatment Response (CRP );Dyspnea;Oxygen saturation without supplemental oxygen.;Oxygen therapy

Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
Clinical status during follow-up at 30th day

Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event

Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS
Proportion of patients improving PaO2/FiO2 ratio at 6 hours of APRV

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic
Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection)

Interferon Lambda Therapy for COVID-19
Number of participants with resolution of hypoxia

The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes
Psychological impacts by CoronaVirus Disease 2019(COVID-19)

Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS

A Study of ResCure™ to Treat COVID-19 Infection
The rate of recovery of mild or moderate COVID-19 in patients using ResCure™;Reduction or progression of symptomatic days;Assess the safety of ResCure™ via pulse;Assess the safety of ResCure™ via oxygen saturation;Assess the safety of ResCure™ via EKG;Assess Tolerability of ResCure™

A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
Identify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection.;Determine which SARS-CoV-2 proteins are frequently recognized by T cells in patients with varying HLA types.

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19

EMPOWER - BAME vs COVID
Identify COVID-19 specific host-defence ("protective") or predisposing ("susceptibility") genetic biomarkers

Pulmozyme to Improve COVID-19 ARDS Outcomes

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
Development of Acute Respiratory Distress Syndrome (ARDS) and Other Organ Injuries

COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking
Rate of hospitalization;Duration of hospitalization;Rate of admission to intensive care unit;Length of stay in intensive care unit;Need of mechanical ventilation;Duration of mechanical ventilation;Disease-specific mortality rate

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Proportion of patient alive and free of respiratory failure

Use of PCR-Sars-CoV-2 in Children
Percentage of children screened with a positive PCR result

Cardiac COVID-19 Health Care Workers

Clinical Characteristics of Critically Ill Patients With COVID-19

Online Learning of Veterinary Anatomy During COVID-19 Pandemic
Measure the students' interest in studying anatomy on-line.

Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients

Senior-COVID-Rea Multicentric Survey
Evaluation of the impact of age on mortality at 30 days after admission to intensive care

Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
Number of zones of pulmonary parenchyma corresponding to viral pneumonia detected by chest MRI in comparison with CT scan

HFNC Treatment in COVID-19 Pneumonia

COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach
Number of participants with treatment-TOMEKA® usage as assessed by Education

Obesity and Mortality of Critically Ill Patients With COVID-19

Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)
Antibodies to SARS-CoV2: IgA, IgM, IgG;PCR of nasopharyngeal smears on all IgM +

Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients
Skin thermometry;Hygrometry under costume;Heart rate;Air thermometry;Air hygrometry

Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19

Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?
The presence of SARS-CoV2 in adipose tissue of Covid19 patients

Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia

Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation

Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS
Proportion of subjects free from respiratory failure;Mean change from baseline in clinical status using the NIAID 8-point ordinal scale at Day 7;Percentage of patients with improvement in clinical status;Change in cytokine levels from baseline

Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Viral clearance at day 6;Viral shedding duration;Symptoms clearance time

Health Professional Exposure Assessment to Covid-19

Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19
Percentage of patients with a positive serological test for COVID-19.

COVID-19 Psychological Wellbeing for Healthcare Students
Qualitative Interviews with Healthcare Students;Warwick-Edinburgh Mental Wellbeing Scale

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease
Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.

Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital

Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients

Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#

Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic

Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic

A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19
Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.

CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment
Measure of Anxiety as assessed by the OASIS;Measure of Depression as assessed by the ODSIS;Measure of PTSD as assessed by the PCL-5

Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects

ANTIBODY-LEVEL BASED ANALYSIS OF COVID CONVALESCENT SERUM (ABACCuS)
Avoidance of intubation at 28 days (group A);Mortality (group B)

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
Percentage of Participants Dying or Requiring ICU Admission;Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation

Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.
Association between Covid-19 pandemic and maternal psychological distress

Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia
Bland-Altman estimate of bias and Limits of Agreement (LoA) of patient mean scores obtained with the two instruments

COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising
COVID19 versus H1N1; radiological comparative study

COVID-19 - Implications on Surgeons' Burnout and Career Satisfaction
Change in Burnout before COVID-19 and during COVID-19;Change in Job satisfaction before COVID-19 and during COVID-19

Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection

Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients
Clinical complications and Mortality;Neutrophil-Lymphocyte and Lymphocyte-Platelet ratio

MR-Evaluation of Renal Function In Septic Patients
Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus;Descriptive renal oxygenation and blood flow in critical illness due to sepsis;Descriptive renal oxygenation and blood flow in critical illness in no/low grade AKI or high grade AKI.

Careful Ventilation in COVID-19 -Induced Acute Respiratory Distress Syndrome

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)
Change in lesion proportion (%) of full lung volume from baseline to day 28.

Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic
Perceived Stress Scale;Perceived Stress Scale;Perceived Stress Scale

ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
Composite of hospitalization, invasive mechanical ventilation or death within 30 days

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
Duration of Viral shedding of SARS-CoV-2 by qRT-PCR

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Cause of death or invasive mechanical ventilation

The Role of Resistant Starch in COVID-19 Infection
Rates of hospitalization for a COVID-19 related complication

Convalescent Plasma in the Treatment of COVID 19

A Real-life Experience on Treatment of Patients With COVID 19
Number of patients with decreased viral load

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
Mean change in viral titers of SARS-CoV-2

Dapagliflozin in Respiratory Failure in Patients With COVID-19
Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:

An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease
Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS);Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS);Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)

Modulation of Hyperinflammation in COVID-19
Efficacy of a L-MOD against controls receiving supportive care in ICU.

Asymptomatic COVID-19 Infection Among Healthcare Workers
Number of IGg seropositive health care workers

Efficacy of Tocilizumab on Patients With COVID-19

Measles Vaccine in HCW

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Keto-diet for Intubated Critical Care COVID-19
Change in the partial pressure of carbon dioxide (PaCO2)

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
7-day length of invasive mechanical ventilation (MV);30-day mortality rate

Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19
Composite endpoint with disease progression defined as a NEWS2score = 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.

Collection of Biological Samples With Clinical Characterization of Covid-19 Patients
Phenotype/genotype correlation research modulating the severity of Covid-19 disease

Tocilizumab Treatment in Patients With COVID-19
Hematic biometry;Blood chemistry;Blood gas;Hematic biometry;Blood chemistry;blood gas;Hematic biometry;Blood chemistry;blood gas;Hematic biometry;Blood chemistry;blood gas;Hematic biometry;Blood chemistry;blood gas;thorax radiography;thorax radiography;thorax radiography

Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
Score on the WHO 11-point ordinal scale for clinical improvement at 14 days

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19)
Phase 1: Frequency and Severity of Adverse Events (AE);Phase 1: Rate of clearance of SARS-CoV-2;Phase 1: Rate of clinical improvement;Phase 2: Time to Clearance of SARS-CoV-2;Phase 2: Time to Clinical Improvement by NEWS2 Score

OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome

Thrombosis and Covid-19
thrombotic event (VTE) or arterial thrombosis

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19
Rate of extubation (for intubated patients)

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection.

Outcomes of Covid-19 Protective Measures in Endoscopy
Rate of new Covid infection of patients and staff members

COVID-19 Health Messaging to Underserved Communities
Knowledge Beliefs and Practices related to COVID-19

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
Proportion of participants who have died due to any cause

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19
Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%

Sitagliptin Treatment in Diabetic COVID-19 Positive Patients
Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Clinical parameter of acute lung disease;Death

Covid-19 Triage Using Camera-based AI
Agreement between the new camera based method and reference standard to estimate body temperature;Agreement between the new camera based method and reference standard to estimate heart rate;Agreement between the new camera based method and reference standard to estimate blood oxygen saturation;Agreement between the new camera based method and reference standard to estimate systolic blood pressure;Agreement between the new camera based method and reference standard to estimate diastolic blood pressure;Agreement between the new camera based method and reference standard to estimate respiratory rate

Prone Positioning for Patients on General Medical Wards With COVID19
Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more

Determinants of COVID-19 Pneumonia (MC-19)

COVID-19 Related Lockdown Effects On Chronic Diseases
% adherence to each pharmacological class;number of occurrence of medical events at 1 year

Low Dose Radiation Therapy for Covid-19 Pneumonia
Symptomatic improvement by National Early warning score (NEWS);Symptomatic improvement by National Early warning score (NEWS);Symptomatic improvement by National Early warning score (NEWS);Length of hospital stay;Number of ICU admissions or deaths

EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.

Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19
Levels of senescent CD16+CD8+ T cells prior to COVID-19 disease and time to COVID-19 disease morbidity (antibody positvity).

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
Solicited local and systemic adverse reactions (ARs);Unsolicited adverse events (AEs);Medically-attended adverse events (MAAEs);Serious adverse events (SAEs);Change in the measure of clinical safety laboratory values in Cohort 2 from baseline;The number and percentage of participants with abnormalities in blood pressure, temperature, HR or respiratory rate will be assessed.;The number and percentage of participants with abnormalities in physical examinations will be assessed;Evaluate immunogenicity of mRNA-1273 by titer of SARS-CoV-2-specific binding antibody (bAb) measured by enzyme-linked immunosorbent assay (ELISA)

A Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19
Virologic Efficacy;Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach

The Effect of EIDD-2801 on Viral Shedding of SARS-CoV-2 (COVID-19)
Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801;Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS;Number of Participants With any Adverse Events(AEs) as assessed by DAIDS

COG-UK Project Hospital-Onset COVID-19 Infections Study
Incidence rates of IPC-defined hospital-onset COVID-19 infection (HOCIs);Change in incidence rates of IPC-defined HOCIs with rapid vs standard sequencing

Appendicitis During the National Lockdown During the COVID-19 Pandemic

AKI Biomarkers in Coronavirus(COVID)-19

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28

DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
Safety of inhaled rhDNase1 in non-ventilated COVID-19 patients by reporting of adverse events: rate of all adverse events, rate of serious adverse events, rate of grade 3/4/5 adverse events, drug-related adverse events.

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
Number of subjects not hospitalized or, if hospitalized, free of respiratory failure;Adverse Events

Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19
Incidence of treatment-emergent adverse events (TEAEs)

Bacillus Calmette-guérin Vaccination to Prevent COVID-19
Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3.

COVID19 Clinical Predictors and Outcome
SARS-CoV-2 hospital mortality;SARS-CoV-2 mortality in critical care unit

Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19

RAS and Coagulopathy in COVID19

Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19
World Health Organization (WHO) 9-levels scale (from 0-8);WHO 9-levels scale (from 0-8)

SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study
The prevalence of SARS-COV2 seroconversion in chronic hemodialysis patients

Implications of Covid-19 on the Lifestyle Changes
The ratio of individuals living in the province of Reggio Emilia who completed the survey

Handling Oxygenation Targets in COVID-19

USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients
To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.;To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.;To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.;To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients
Reduction in documented infection with COVID-19 Reduction in infection with COVID-19

Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study

A Study of Immune Responses to the Virus That Causes COVID-19
Response rate of SARS-CoV-2-specific B cells in peripheral blood samples;Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples;Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples;Response rate of SARS-CoV-2-specific antibody binding in serum samples;Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples;Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples;Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples;Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples;Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples;Frequency of leukocyte populations in peripheral blood;Transcriptional profiles of peripheral blood leukocytes;Concentration of serum cytokines and other soluble factors;Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells;Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells;Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells

The Use of Lung Ultrasonography in COVID-19 Patients

Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma
INCIDENCE OF CRITICAL PNEUMONIA;MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS

A Phase 1 Study to Assess BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19)
Incidence of adverse events (AEs);Duration of survival and free of respiratory failure;Percentage of patients reporting each severity rating on an 8-point ordinal scale

Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19

Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study

Natural Language Processing (NLP) Analysis of Free Text Notes to Investigate Coronavirus (COVID-19)
research database of EHR records from COVID-19 patients processed using NLP tools for named entity recognition and linking adapted to CUH EMR data to identify variables of interest

Dornase Alpha for the Treatment of COVID-19

A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
Proportion of participants who test negative for COVID-19

BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19
Measurement of N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer in COVID-19 patients;Cardiac complications in COVID-19 patients associated with more adverse effects

COVID19 and Physical and Emotional Wellbeing of HCP
Presence of anxiety at baseline;Presence of depression at baseline;Proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used.;Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study;Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study

COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units

COPE - COVID-19 in Pregnancy and Early Childhood
Biobank with linkage to registers;Experiences of pregnancy during a pandemic

PB1046, a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
Days alive and free of respiratory failure from initiation of PB1046

The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
to compare presence of fever in patients with and without pancreatic injury;to compare presence of dyspnea in patients with and without pancreatic injury;To compare cRP levels in patients with and without pancreatic injury;To compare d-dimer levels in patients with and without pancreatic injury

COVID-19 in Pediatric Oncology and Hematology Centers in France
Oncologic data;COVID-19 diagnosis;Clinical signs;Biological signs;Radiological signs;COVID-19 management;Potent COVID-19 sequelae

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

Hydroxychloroquine May Reduce Risk of COVID-19 Infection in Rheumatoid Arthritis Patients:
The risk of COVID-19 infection among RA patients

An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Rate of viral elimination by Day 10 [pilot stage, dose selection];Time to viral elimination [pivotal stage];Time to clinical improvement [pivotal stage]

Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2
Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program

Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV
Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.;Evaluation of test accuracy;Interleukin-6 quantification;Interleukin-2 quantification;Interleukin-1 quantification;Tumor Necrosis Factor (TNF) quantification;Interferon gamma quantification

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

Remote-by-Default Care in the COVID-19 Pandemic

Physical Rehabilitation in ICU in ARDS Patients With COVID-19

Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)
Measure the time to weaning from high-flow nasal cannula;Measure the time to breathing ambient (room) air

Covid-19 and Vitamin D in Nursing-home
Number of deaths of any cause in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19

Crizanlizumab for Treating COVID-19 Vasculopathy

Virtual Assistant for COVID-19 PPE
performance of healthcare workers;performance of healthcare workers;performance of healthcare workers;performance of healthcare workers

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study

Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Reduction of Diffusion of Lung CO (DLCO, single breath technique);Reduction of Diffusion of Lung CO (DLCO, single breath technique)

Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19

Cardiovascular Implications of COVID-19

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.

Inhaled Ciclesonide for Outpatients With COVID19

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

A Study of Ad26COVS1 in Adults
Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination

Niclosamide In Moderate COVID-19
The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group

Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece

Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia
Correlation between the Covid-19 pandemic and postpartum depression with EPDS scale (Edinburgh postnatal depression scale)

Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients
Prevention of SARS-CoV-2 infection;Presence of any adverse effects related to HCQ;Incidence of COVID-19 related symptoms

Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling

Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients
Safety and efficacy assessment of infusion associated adverse events;Chest Radiograph or Chest CT Scan

COVIDAR - Arrhythmias in COVID-19

Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test

COVID Screening Strategies in Homeless Shelters

Rehabilitation Needs After COVID-19 Hospital Treatment
number of participants with considerable dyspnea: Medical Research Council (MRC, 0-4, lower score better outcome);number of participants with fatigue;number of participants with anxiety;number of participants with depression

Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection

Brain Health in the Time of COVID-19

A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)
Time from Randomization to Respiratory Improvement

COVID-19 in Patients With Chronic Liver Diseases
All-cause mortality;All-cause mortality;Liver-related mortality;Liver-related mortality;Overall survival;Number of patients with hepatic decompensation

Comparing the user seal check and fit test between two types of N95 respirators - the Halyard N95 Particulate Filter Respirators and the ProShield® N-95 masks
Fit test result - pass or fail.
Pass is defined as a fit factor of >100. The fit factor is calculated by dividing the concentration of the particles in ambient air outside the mask by that inside the mask.
It is assessed by a trained personnel using the PortaCount machine, which will be calibrated at the beginning of each testing day, using a provided HEPA filter. The subject will attach their mask probe to the PortaCount machine via plastic tubing that has been soaked in 99.5% isopropyl alcohol solution. The test will be performed according to United States Occupational Safety and Health Administration protocols the time of fit testing ]

Maintaining the health of people with and without COVID-19 during isolation
Anxiety/ Depression Screening Tool (DASS-21) (Henry et al 2015). [At enrolment and following completion of the intervention.];Participant experience measure:: Participants will be asked to fill in a short questionnaire to report their experiences of the program. The questionnaire has been designed specifically for this study and was based on the NSW Ministry of Health/Agency of Clinical Innovation criteria for evaluating patient reported experience of care.. [Immediately following completion of the intervention]

Atrial Fibrillation in Patients with an Implantable Cardiac Device during the COVID-19 Pandemic
Primary Outcome- the impact of the COVID-19 pandemic on the occurrence of AF.
This outcome will be measured by comparison of the number of AF episodes, and number of patients affected by AF episodes, between the COVID period, and Control periods.
The number of AF episodes, and the number of patients who experience an AF episode will be derived from the PaceMate remote monitoring database.[The primary outcome measure will be assessed daily during in each participant, during the 100-day COVID period, and daily during the 100-day Control period.]

Management of patients with heart failure with preserved ejection fraction: what do patients and providers need and want?
Perspectives on care provided and received since COVID-19, assessed using interview and survey at a single timepoint (baseline)

A Saudi Arabia based study into the impact of coronavirus infection on the nervous system
1. Incidence of neurological manifestations in COVID-19 hospitalized patients measured using neurological examination and other pertinent paraclinical examinations, tests, and questionnaires (i.e., total blood count, biochemistry, screening for systemic disorders and hypercoagulable states, imaging such as brain computed tomography scans and magnetic resonance imaging studies, other tests such as cerebrospinal fluid analysis, electromyography, biopsies, etc.) collected from medical records at baseline, on hospital discharge, and 6 months follow-up
2. Range of symptoms of neurological manifestations in COVID-19 hospitalized patients measured using neurological examination and other pertinent paraclinical examinations, tests, and questionnaires collected from medical records at baseline, on hospital discharge, and 6 months follow-up
3. Severity of neurological manifestations in COVID-19 hospitalized patients neurological examination and other pertinent paraclinical studies such as imaging studies (CT, MRI, etc.) collected from medical records at baseline, on hospital discharge, and 6 months follow-up

PRINCIPLE: A trial evaluating treatments for suspected COVID-19 in people aged 50 years and above with pre-existing conditions and those aged 65 years and above
Current primary outcome measure as of 10/06/2020:
Hospital admission or mortality related to suspected COVID-19 infection assessed using reports of patients’ medical records, from enrolment up to 28 days after completing treatment
_____
Previous primary outcome measure as of 08/06/2020:
Hospital admission or mortality related to suspected COVID-19 infection.
Previous primary outcome measure:
Hospital admission or death, for patients aged =50 years with comorbidity, and aged =65 years with or without comorbidity and suspected COVID-19 infection during time of prevalent COVID-19 infections, measured by hospital admission or mortality related to suspected COVID-19 within 28 days

Enhanced cognitive behavioral therapy for children and adolescents with obsessive compulsive disorder: an open trial
1. Acceptability assessed using Client Satisfaction Questionnaire (CSQ-8), child and parent version post-treatment
2. Feasibility: preterm treatment drop-out measured post-treatment
3. Effectiveness assessed using the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS) administered by a blind rater (blinded for treatment phase) pre- and post-treatment, and at 3 and 6 months follow-up

Understanding cognitive decline after stroke and the impact of COVID-19
Rates of cognitive impairment and dementia up to at least two years after stroke, measured using a seven-level ordered categorical scale compromising cognition (normal, impairment in one domain, impairment in two or more domains), dementia (mild, moderate, severe) and death. The outcome scale is driven by information from the Montreal Cognitive Assessment (MoCA), the Modified Telephone Interview for Cognitive Status (TICS-m), Modified Rankin Scale (MRS), Barthel Index, IQCODE, disposition (need for nursing care), and evidence of dementia (formal diagnosis, taking a cholinesterase inhibitor or memantine) or death. These outcomes are measured at baseline, 4-8 weeks, and annually for a minimum of 4 years.

Trauma Healing Project Based on Chinese Mind-Body Wisdom in the novel coronavirus pneumonia (COVID-19)
Symptom impact score;qualitative interview theme analysis;

A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above

Novel coronavirus pneumonia (COVID-19) loaded autologous dendritic cell trial

A prospective, randomized,open, multi-center clinical trial evaluating the efficiency and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)

Low dose hydrocortisone in patients with COVID-19 and severe oxygen deficiency – the COVID STEROID trial
Main Objective: To assess benefits and harms of low dose IV hydrocortisone versus placebo on patient-important outcome measures in adult patients with COVID-19 and severe hypoxia.;Secondary Objective: Not applicable.;Primary end point(s): Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28.;Timepoint(s) of evaluation of this end point: Day 28.

Hydroxychloroquine for the treatment of mild COVID-19 disease
Main Objective: Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment;Secondary Objective: Difference between hydroxychloroquine- and placebo-treated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)
All-cause mortality within 28 days
;Primary end point(s): The primary endpoint will be the difference in duration from the initiation of treatment until resolution of the clinical signs and symptoms assessed by daily self-assessment in hydroxychloroquine- versus placebo-treated patients.;Timepoint(s) of evaluation of this end point: One interim analysis for evaluating the primary efficacy endpoint is planned for this study. The interim analysis will be done when 40% of events have accrued. A one-sided Hwang-Shih-DeCani spending function with gamma = -4 (alpha-spending) was considered in the sample size calculation to account for multiplicity repeated tests. In case the interim analysis shows a HR > 1.21 (nominal p < 0.0018), efficacy is shown and the trial may be stopped.
Final analysis upon completion of the trial and final database lock

trial comparing different doses of single-dose tocilizumab in adults with severe COVID-19 infection
Main Objective: To determine the safety and efficacy of standard dose versus low
dose tocilizumab in adults with severe, non-critical, PCR-confirmed
COVID-19 infection with evidence of progressive decline in
respiratory function and evolving systemic inflammation on time to
intubation, non-invasive ventilation and/or all-cause mortality.;Secondary Objective: In adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation, to determine if single dose
administration of tocilizumab will:
- be safe, as defined by no difference in all-cause mortality compared to standard of care.
- result in a longer time to intubation and non-invasive ventilation and lower all-cause mortality than
standard of care.
- result in similar time to intubation and noninvasive
ventilation and all-cause mortality than standard of care.;Primary end point(s): Proportion of subjects at day 8 who have reached a
composite primary endpoint of progression to intubation and
ventilation, non-invasive ventilation or death;Timepoint(s) of evaluation of this end point: Day 8

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
Main Objective: The aim of the protocol is to compare the effect of standard care alone and standard care with using one of the four antiviral alternatives.
The primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID-19.
;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.
;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death

Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patients
Main Objective: Primary objective of this trial is to investigate the efficacy of the JAK1/2 inhibitor ruxolitinib in preventing deterioration to the point of requiring mechanical ventilation in COVID19 patients admitted to hospital.;Secondary Objective: To evaluate time to progression free survival and clinical/ laboratory responses to the intervention.;Primary end point(s): Number requiring mechanical ventilation or death in patients with COVID-19 disease [Time Frame: 28 days];Timepoint(s) of evaluation of this end point: 28 days

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)
Main Objective: To determine if chloroquine or hydroxychloroquine prophylaxis prevents symptomatic COVID-19 infection in health care workers or other groups at high risk.
To determine if chloroquine or hydroxychloroquine prophylaxis attenuates COVID-19 infections.;Secondary Objective: To determine if chloroquine or hydroxychloroquine prophylaxis prevents asymptomatic COVID-19 infection.
To determine if chloroquine or hydroxychloroquine prophylaxis prevents all-cause symptomatic acute respiratory illnesses.
To characterise genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity.;Primary end point(s): The number of symptomatic COVID-19 infections will be compared between the chloroquine and placebo groups.
The symptoms severity and duration of COVID-19 illness, in those who become infected during the study will be compared between the two groups using a respiratory severity score.;Timepoint(s) of evaluation of this end point: During the clinical trial

Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety
of several experimental treatments to reduce the risk of hospitalization or death
(COVERAGE trial)
Main Objective: The main objective of this trial is To estimate the efficacy of several specific experimental treatments, compared to standard care, to prevent hospitalization or death at D14 in adults over 65 years of age, with documented SARS-CoV-2 infection, with symptoms lasting less than 72 hours and not meeting any hospitalization criteria.;Secondary Objective: To estimate :
- the effectiveness of experimental treatments against SARS-CoV-2, to prevent death on D28
- the effectiveness of experimental treatments against SARS-CoV-2, to prevent hospitalization on D28
- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent hospitalization in intensive care on D28
- the effectiveness of experimental treatments against SARS-CoV-2 to suppress nasopharyngeal viral carriage, compared to standard care
- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent a loss of autonomy on D14 and D28
- the tolerance of experimental treatments against SARS-CoV-2
- Study the factors associated with the worsening of the disease
- Evaluate the feasibility and acceptability of the trial and the care model implemented
- Assess the relationship between the concentration of each drug and the effectiveness of each treatment;Primary end point(s): Proportion of participants with an occurrence of hospitalization and/or death between D0 and D14 in each arm;Timepoint(s) of evaluation of this end point: day 14 after inclusion

Use of Defibrotide to reduce progression of acute respiratory failure rate in
patients with COVID-19 pneumonia
Main Objective: To demonstrate that the treatment with Defibrotide administered intravenously in addition to the best available therapy according to institutional guidelines is able to reduce the progression of acute respiratory failure, the need of mechanical ventilation, the transfer to the intensive care unit or death, in patients with severe COVID-19 pneumonia;Secondary Objective: • To evaluate the safety of Defibrotide in the cohort of patients treated (incidence of adverse events)
• To evaluate the duration of hospitalization for patients enrolled
• To evaluate the overall survival at day+28 after start treatment with Defibrotide
• To evaluate the change in biological features of systemic inflammation (PCR, LDH, ferritin, IL-10, IL-6, TNF-alpha, IFN-gamma, PTX3) at day +7 and +14 after start of treatment with Defibrotide;Primary end point(s): Respiratory-failure rate (RFR);Timepoint(s) of evaluation of this end point: 14 days from treatment start

PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION
Main Objective: To evaluate the safety and clinical efficacy of sarilumab in adult patients hospitalized due to severe Covid-19 pneumonia based on the proportion of patients who show an improvement of the respiratory function, described as =30% decrease in oxygen requirement compared to baseline.;Secondary Objective: Potenziale efficacia di sarilumab nella polmonite Covid-19:
• Nei pazienti con febbre al basale, valutazione del tempo alla risoluzione della febbre, definita come temperatura corporea =36,6 ° C axilla, =37,8 ° C rettale o timpanica per almeno 48 ore senza antipiretici;
• Valutazione della carica virale, sangue ed espettorato per COVID-19 prima della somministrazione di sarilumab, 48 ore e 96 ore dopo la somministrazione;
• Valutazione della concentrazione plasmatica di Il-6, TNF-a, Il-10 e GM-CSF pre-trattamento e 96 e 120 ore dopo il trattamento;
• Valutazione del tasso di progressione della frazione WBC di granulociti immaturi - IG - (conteggi assoluti e%) e dei parametri morfologici-funzionali definiti da:
- complessità citoplasmatica
- intensità di fluorescenza
- dimensioni
- ampiezza di distribuzione degli eventi su entrambi gli assi del citogramma WDF.;Primary end point(s): Proportion of patients who show an improvement of the respiratory function, described as =30% decrease in oxygen requirement compared to baseline.;Timepoint(s) of evaluation of this end point: Daily until discharge

PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19)
Main Objective: Group 1: Prevention of COVID-19 or related symptoms in SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patients within one month from randomization
Group 2: Efficacy of Hydroxychloroquine in early phase COVID-19 within 14 days from randomization;Secondary Objective: To compare the efficacy of Hydroxychloroquine:
- as prophylaxis, in prevention of COVID-19 infection in a population of SARS-CoV-2-exposed subjects (household members/contacts of COVID-19 pts) respect to observation only
- as prophylaxis, in subgroup population (stratification factors, class of age, gender)
- in early phase COVID-19 pts within 14 days from randomization in subgroup population (stratification factors, class of age, gender)
- in early phase COVID-19 pts within 1 month from randomization in overall population and in subgroup population (stratification factors, class of age, gender)
To evaluate in study groups:
- treatment toxicity
- QoL
To participate in European network for meta analysis of similar studies or in data collection for identifying prediction rule of outcomes.
Explorative: To identify biologic features that correlate with susceptibility or resistance to SARs-CoV2 infection or treatment with Hydroxychloroquine in study subgroups.;Primary end point(s): Group 1: the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization
Group 2: the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization;Timepoint(s) of evaluation of this end point: 4 months

A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia .
Main Objective: To evaluate the efficacy of sarilumab, combined with standard of care, in patients affected by severe COVID-19 pneumonia.;Secondary Objective: To evaluate the effect of sarilumab on survival
To evaluate the effect of sarilumab on clinical evolution
To evaluate the effect of sarilumab on lung function
To evaluate the effect of sarilumab on hyperinflammation parameters
To evaluate the effect of sarilumab on other relevant laboratory parameters
To evaluate the effect of sarilumab on radiological response
To evaluate the effect of sarilumab on virological response
To evaluate the effect of sarilumab on duration of hospitalization
To describe safety profile of sarilumab;Primary end point(s): The primary end point was the time to clinical improvement, defined as the time from receiving the first dose of drug to an improvement of two points (from the status at baseline) on a 7-point category ordinal scale.
The 7-point category ordinal scale consisted of the following categories:
1. not hospitalized with resumption of normal activities;
2. not hospitalized, but unable to resume normal activities;
3. hospitalized, not requiring supplemental oxygen;
4. hospitalized, requiring supplemental oxygen;
5. hospitalized, requiring noninvasive mechanical ventilation (CPAP or NIV);
6. hospitalized, requiring ECMO, invasive mechanical ventilation, or both;
7. death.;Timepoint(s) of evaluation of this end point: Every visit

Investigating a Vaccine Against COVID-19
Main Objective: To assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.
To assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children.
;Secondary Objective: To assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19
To assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19
To assess humoral immunogenicity of ChAdOx1 nCoV-19
To assess cellular immunity of ChAdOx1 nCoV-19 in older adults and in children (groups 1, 2 and 3 only)
To assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)
Exploratory Immunology
Measure exposure to COVID-19
To assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection
Compare safety, reactogenicity and immunogenicity between different manufacturing batches of ChAdOx1 nCoV-19 used in COV001 and COV002
Compare safety, reactogenicity and immunogenicity between different dosing methods (Abs260 and qPCR) of ChAdOx1 nCoV-19
To assess vaccine induced mucosal immunity
To compare viral shedding on stool samples and/or re;Primary end point(s): Virologically confirmed (PCR positive) symptomatic COVID-19 infection;Timepoint(s) of evaluation of this end point: As required

Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals
Main Objective: Evaluation of the effectiveness of therapy in reducing the proportion of subjects with who still have viruses in the upper airways after 7 days of therapy
Evaluation of the effectiveness of therapy in reducing the proportion of hospitalized subjects within 14 days of starting therapy.;Secondary Objective: Evaluation of the effectiveness of therapy in reducing the proportion of subjects with who still have viruses in the upper airways after 14 and 28 days of therapy.
Evaluation of the effectiveness of therapy in reducing the proportion of hospitalized subjects within 7 or 28 days of starting therapy.
7, 14 and 28 day drug safety and tolerability profile
Modeling of blood and biochemical parameters between T0 and T28;Primary end point(s): Virologic outcome. Proportion of participants with undetectable SARS-CoV-2 gene E and gene M at day 7 after randomization.
Clinical outcome. Proportion of participants who need not hospitalization (NEWS = 2) by day 14 after randomization.;Timepoint(s) of evaluation of this end point: 7 days
14 days

PRECOV: a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk
Main Objective: To evaluate the efficacy of the preventive treatment with hydroxychloroquine in reducing the risk of SARS-CoV-2 infection in healthcare workers at risk;Secondary Objective: • To evaluate the efficacy of the preventive treatment with hydroxychloroquine in reducing the severity of COVID-19 clinical manifestations
• To evaluate the safety and tolerability of hydroxychloroquine as a prophylaxis treatment for SARS-CoV-2;Primary end point(s): • Proportion of hydroxychloroquine treated subjects treated with SARS-CoV-2 positive nasopharyngeal swab compared to controls;Timepoint(s) of evaluation of this end point: At days +14 and +28 from the start of the treatment

A phase I/II to determine efficacy, safety and immunogenicity of a candidate COVID-19 vaccine
Secondary Objective: To assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV
To assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19
To assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19
Exploratory Immunology
To assess immunogenicity of ChAdOx1 nCoV-19 given as homologous prime-boost;Main Objective: To assess efficacy of ChAdOx1 nCoV-19 against COVID-19
To assess the safety of the candidate vaccine ChAdOx1 nCoV;Primary end point(s): To assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19:
a)Virologically confirmed (PCR positive) symptomatic cases of COVID-19
To assess the safety of the candidate vaccine ChAdOx1 nCoV:
a)Occurrence of serious adverse events (SAEs) throughout the study duration;Timepoint(s) of evaluation of this end point: Throughout the study duration

Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design.
Main Objective: The primary objective is to assess the hypothesis that an adjunctive therapy with steroids and unfractionated heparin or with steroids and molecular weight heparin (LMWH) are more effective in reducing any-cause mortality in critically-ill patients with pneumonia from COVID- 19 infection compared to low molecular weight heparin (LMWH) alone. Mortality will be measured at 28 days.
The confirmation of the efficacy of this composite treatment in reducing the mortality rate among critically ill patients with pneumonia from COVID-19 infection will lead to a revision of the current clinical approach to this disease.;Secondary Objective: -;Primary end point(s): All-cause mortality at day 28;Timepoint(s) of evaluation of this end point: 28 day

Clinical study aimed to verify the efficacy and safety of mavrilimumab in COVID-19-associated pneumonia in patients who have signs of excessive inflammation
Main Objective: To demonstrate the benefit of mavrilimumab vs placebo added to best standard of care in reducing the dependency on oxygen supplementation in patients with COVID-19 pneumonia and signs of systemic hyperinflammation;Secondary Objective: To evaluate clinical outcomes using the WHO 7-point ordinal scale
To evaluate the time to disappearance of fever if present at baseline
To demonstrate the potential benefit of mavrilimumab in reducing the case fatality rate over 4 weeks in the study cohort regardless of other subsequent clinical interventions
To evaluate the in-hospital outcomes in the study cohort
To evaluate change in laboratory parameters through follow up
To evaluate changes in the National Early Warning Score 2 (NEWS2)
To evaluate the variations in radiological findings in patients that underwent a repeated radiological evaluation (mavrilimumab vs placebo)
To evaluate safety of mavrilimumab in the study cohort
To evaluate the clinical efficacy of mavrilimumab compared to the control arm by clinical severity (i.e. mild vs moderate subgroup)
To measure the time course of the effects of mavrilimumab on biomarkers;Primary end point(s): Time to the absence of need for oxygen supplementation (time to first period of 24 hrs with a SpO2 of 94%) within day 14 of treatment, stated as Kaplan-Mayer estimates of the proportion of patients on room air at day 14 and median time to room air attainment in each arm.;Timepoint(s) of evaluation of this end point: Daily evaluation until day 14

A study with immunotherapy for Moderate COVID-19
Main Objective: The primary objective of this nation-wide randomised trial is to assess whether immunosuppressive agents in addition to hydroxicloroquine can reduce the progression to very severe respiratory failure with PaO2/FiO2 ratio < 200 mmHg (ARDS-range).;Secondary Objective: The secondary objectives are to assess any effects of these immunomodulatory drugs on surrogate markers of COVID-19 severity and course with particular attention towards modelling kinetics of markers of immune response associated with disease evolution. Another secondary objective is to verify the safety of the immunomodulatory agents for during COVID-19. Surrogate markers of COVID-19 course will include:
a) Clinical deterioration, defined as at least one of the following:
• Death
• Need of orotracheal intubation/ECMO
• Increase in NEWS-2 score ¿ 2 from baseline
• Increase in MELD score ¿ 8 from baseline
b) Mortality
c) Need of orotracheal intubation or ECMO
d) Evolution of NEWS-2 and MELD scores
e) Clinical improvement, defined as one of the following
• Discharge
• Absent ventilator support, NEWS-2 score =3 and MELD =13
f) Discharge
g) Defervescence
h) Course of blood tests and PaO2/FiO2;Primary end point(s): Proportion of patients with PaO2/FiO2 <200 mmHg at day 10 in each intervention arm as compared to the control arm
;Timepoint(s) of evaluation of this end point: Day 10

Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial
Main Objective: To evaluate the efficacy of out-of-hospital treatment with HCQ in the reducing viral loads and need for hospitalization in symptomatic SARS-CoV-2 infected patient who are confined at home.;Secondary Objective: NA;Primary end point(s): virological clearance (nasopharyngeal sample negative for SARS-CoV-2 virus) at the sample taken on days 8. Co-primary end-point: Hospital admission over the time-interval between day 0 (randomization) and day 15.;Timepoint(s) of evaluation of this end point: 7-15 days

Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection -A Tertiary Hospital based study
Infected Non infectedTimepoint: Time to clinical improvement

Screening for symptoms of COVID-19
To identify suspected cases of COVID-19Timepoint: Weekly follow-up will be done

Knowledge, attitude and fear of COVID-19 in Bangladesh
Knowledge, attitude, practice, fear to COVID 19Timepoint: during answering the questionnaire

Viral Infection and Respiratory illness Universal Study
To create a real time COVID-19 registry of current ICU/hospital care patterns to allow evaluations of safety and observational effectiveness of COVID-19 practices
To determine the variations in practice across hospitals
Hypothesis: The registry will be essential for near-real time observational comparative effectiveness studies to learn effective treatment strategies and/or provide meaningful hypotheses for clinical trialsTimepoint: 04/30/2021

Study of the effect of Chloroquine in addition to standard therapy in COVID-19 patients
number of days of hospitalizationTimepoint: discharge

Assessment of Objective clinical scoring system to rule out COVID-19 with high sensitivity
100% sensitivity in ruling out COVID-19 cases through ORTIS system.Timepoint: 100% sensitivity in ruling out COVID-19 cases through ORTIS system.

Study of Shreepad Shree Vallabh SSV Formulation to improve immunity in quarantine patients of COVID-19
Improvement in ambulatory patients who are assessed daily for symptoms which include cough, fever with or without chills and difficulty in breathing for the period they are in quarantine.
Timepoint: Baseline, telephonically everyday and day 15.

Effect of convalescent plasma in COVID-19 patients
Proportion of patients remaining free of mechanical ventilation in both groupsTimepoint: day 7

COVID-19 Data-bank Project
A single source of patient-level clinical data for researchers to access so that clinical and analytics tools can be created to fight COVID-19 during the epidemic phase in India.Timepoint: NA

Study to Evaluate Preventive Effect of Ayurveda and Homeopathy Treatment in COVID 19
Episodes and severity of symptoms of respiratory tract infection (cold, sore throat, dry cough, breathlessness) in subjects who may get direct or indirect exposure to COVID 19 during lockdown in March and April 2020Timepoint: From Baseline till the end of 15 days

Topical Chloroquine Nasal Drops in Early Stage Covid 19-
Impact on Viral load and cure rates
1) The Ct values on Day 0, 3, 7, 10 shall be plotted on a graph for all patients.
2) The rate of decline for each patient shall be calculated.
The time to cure (Covid 19 RT PCR -ve.) shall be determined
3) The two groups shall be compared for
a. Rate of decline of Ct values
b. Time to Cure
c. Rate of Cure or alternate outcome
Timepoint: 1) The Ct values on Day 0, 3, 7, 10 shall be plotted on a graph for all patients.

Comparison of suspected or negative cases with confirmed cases of COVID-19 at Max Hospital
Seropositivity in the collected samplesTimepoint: 6 weeks

EFFECTIVENESS TO MANAGE COVID 19 PANDEMIC BY TEACHING VENTILATORY MANAGEMENT TO NON-ANAESTHESIOLOGY RESIDENTS
1. To prepare a module for non anesthesiology trainees to handle ventilators in management of COVID 19 patients.Timepoint: 1. To prepare a module for non anesthesiology trainees to handle ventilators in management of COVID 19 patients.

Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease.
The primary outcome is a composite measure of the avoidance of -
1. Progression to severe ARDS (P/F ratio 100) or
2. All-cause Mortality at 28 days
Timepoint: 28 days from intervention

A clinical trial to study the effects of additional treatments for patients hospitalized and receiving treatment due to COVID -19.
All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the studyTimepoint: Throughout the study

Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects
1.Number of subjects with laboratory confirmed COVID-19 infection among HCWs
2.Number of subjects with laboratory confirmed COVID-19 infection among other high-risk subjects
3.Number of laboratory confirmed COVID-19 infection with severe, critical or life-threatening disease as assessed by Investigator among HCWs
4.Number of laboratory confirmed COVID-19 infection with severe, critical or life-threatening disease as assessed by Investigator among other high-risk subjectsTimepoint: up to 6 months (180 days) following vaccine administration

Imatinib in COVID-19 infection
1. Proportion of patients with negative viral titre in the intervention arm in comparison with those in standard arm on D-7
2. Proportion of patients with negative viral titre in the intervention arm in comparison with those in standard arm on D-14Timepoint: d-7 & d-14

Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients
Safety, efficacy.
Side effects measured by Chest Radiograph.
Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing, and diarrhea within 3 days of the convalescent plasma transfusion.
Oxygen Saturation, Pao2/Fio2.
Decrease in viral load as detected by PCR, serum antibody titer.
Routine blood biochemical parameters including renal and liver function tests.
Sequential Organ Failure Assessment (SOFA)Timepoint: Viral load (RT-PCR)- Day -2, Day 1, Day 3, Day 7, Day 14
Eg. CT chest- Day -2, Day 3, Day 7 and Day 14
Pao2/Fio2 and Sequential Organ Failure assessment (SOFA)- Day 0, Day 1, Day 3, Day 7 and Day 14
Remaining parameters will be checked on Day 0, Day 1, Day 3, Day 7, Day 14 and Day 28

Novel Artificial Intelligence Algorithm to screen COVID-19 Patients from X-Ray , CT-Scan of Thorax and Voice Sampling through Android App and storage through Cloud
To asess sensitivity and specificity of screening based on Artificial Intelligence module by performing Chest X-Ray, CT -Thorax and Voice Sampling in COVID +VE patients.Timepoint: 8 Weeks - Data collection
10 Weeks - Validation through Artificial Intelligence Modules

ANXIETY AND DEPRESSION DURING COVID-19 IN INDIA
To understand the prevalence (magnitude) of depression and anxiety of general adult population during COVID-19 using Generalized Anxiety Disorder Scale (GAD-7) and Patient Health Questionnaire (PHQ-9). Rise in Anxiety and Depression will be noted.
Timepoint: 1 month during the period of COVID-19 pandemic.

Impact of Covid-19 pandemic on practice pattern of Indian urologists
Reduction in outpatients after Covid outbreak
Reduction in surgeries after Covid outbreakTimepoint: % Reduction in outpatients after Covid outbreak
% Reduction in surgeries after Covid outbreak

BCG-Denmark versus no-BCG for COVID 19 prevention
Proportion of HCW with symptomatic COVID 19 disease 6 months after randomization. Symptomatic COVID 19 will be defined as self-reported fever or cough, or shortness of breath, or respiratory distress, or runny or blocked nose plus a positive PCR test and/or antibody testTimepoint: Six months after randomisation

A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
To evaluate the efficacy of Mw by measuring the improvement in organ dysfunction (or occurrence of new organ dysfunction) based on Change in Sequential Organ Failure Assessment (SOFA) score and Ordinal scale.Timepoint: From baseline to day 3, 7, 14, 21 and 28 and day of transfer from ICU, if earlier than 28 days.

Proving the efficacy of Homeopathic treatment in prevention and cure of COVID-19.
Lesser percentage of admissions to critical care.Timepoint: At 4 weeks and 8 weeks.

To Study the Clinical characteristics and treatment Outcome of COVID-19 Patients admitted in hospitals of Max Healthcare (SCOPe Study)
To study clinical profile and outcome of hospitalized COVID-19 patients.Timepoint: Till discharge or death of subject

â??To study the effectiveness of Ivermectin with standard of care treatment
versus standard of care treatment for COVID 19 cases. A Pilot Study
This study aims to confirm the antivirus effectiveness of Ivermectin on coronavirus i.e COVID 19
then to explore its potential use in the combating to the COVID 19 pandemics.Timepoint: Viral load will be monitored at 1, 3 & 5 days from beginning of trial drug (48 hours interval) Until the report comes negative. Drug will be delivered on daily basis upto eradication of virus or completion of
the trial

A study to assess the effectiveness of Ayurvedic formulation in addition to standard of care in COVID-19 positive patients in a tertiary hospital.
Percentage of patients progressing to serious/critical stage of disease
Progress of disease as per clinical severity score (COCSS)
No. of days of treatment, hospitalisation, type of care and site of treatment at hospital, oxygen support requirement, days of ventilation required, period of convalescence and return to normal life activity
No. of days taken to test negative for COVID, total days to discharge frm hospital
Profiling acc to tridosha
Defining the disease according to AyurvedaTimepoint: Observed and recorded on all days of the treatment as relevant
Recorded on the days when the investigation is done
Recorded on the days when the medication is changed in type or dose
Recorded as average of pO2 in a day
Recorded as volume of O2 supplied etc

Treatment of COVID19 : A randomised controlled trial
COVID Ordinal Outcomes Scale is defined as:
2. Hospitalised on invasive mechanical ventilation or extracorporeal mechanical ventilation ( ECMO)
3. Hospitalised on non-invasive ventilation or high-flow nasal cannula oxygen therapy
4. Hospitalised on supplemental oxygen
5. Hospitalised not on supplemental oxygen
6. Not hospitalised with limitation of activity (due to continued symptoms)
7. Not hospitalised without limitation in activity (no symptoms)Timepoint: D14

Clinical research on safety and efficacy of ZingiVir-H as an add on therapy in COVID-19 patients.
The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 15 [Time Frame: Day 15 from the day of study inclusion]. The odds ratio represents the odds of improvement in the ordinal scale between the treatment groups. The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded.
Timepoint: Baseline ,Day 7 and Day 15

Characteristics of seriously ill COVID-19 patients admitted to a tertiary care centre
To assess ICU mortality in COVID-19 patients admitted to the intensive care unit of AIIMS, New DelhiTimepoint: Till ICU stay/ or upto 4 weeks

A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
The primary outcome is a composite measure of the avoidance of -
1. Progression to severe ARDS (P/F ratio 100) and
2. All-cause Mortality at 28 daysTimepoint: one year

A clinical Trial to Study the Effects of Hydroxychloroquine, Ciclesonide and Ivermectin in treatment of moderate COVID-19 illness
Proportion of patients having virologic cure on Day 6 in each of the groupsTimepoint: Day 6 of treatment initiation

A study to evaluate the effect of Oral Niclosamide in mild and very mild COVID-19 cases
Proportion of patients having virologic cure on Day 6 in both the groupsTimepoint: Day 6 of treatment initiation

Clinical trial on effects of homeopathic medicine made from cadamba on COVID-19
with refrance to time scale T1-T4 --
from 5-7 weeks we expect complete recovery of patient who presented with initial symptoms.
1 patient should be asymptomatic with gental recovery (with serologically negative blood test) within 7-14 days after administration of 1st dose of medicine.
2 asymptomatic patient (serologically positive) will remain asymptomatic and should be serologically negative after 7-14 days of treatment.Timepoint: with refrance to time scale T1-T4 --
from 5-8 weeks we expect complete recovery of patient who presented with initial symptoms.

Clinical trial on Immunity and antiviral for quarantine patients of COVID-19
i. Improvement in Immunity and anti viral properties in patients who are assessed daily for
symptoms which include cough, fever with or without chills and difficulty in breathing for the period they are in quarantine..
Timepoint: Day 1,Day 14 and Day 21

Efficacy and Safety of Itolizumab in COVID-19 Complications
One-month mortality rate between the two arms
1-month mortality is defined as the ratio of patients who will live after 1month from
study start out of those registered at baseline
Timepoint: One-month

Homoeopathy as adjuvant in management of Covid-19 infection
Clinical outcome in terms of recovery of patient or requirement of life support (ventilator)/ death.Timepoint: Ever 24 hr.

The use of topical Povidone Iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic as a potential measure to reduce viral transmission
comparing the reduction in the progression, transmission of disease in 48 participants taking oropharyngeal gargles and intranasal application of PVP-I in comparison to the control group not doing the same for which patients in both the group will be tested for viral load on 7 th and 21 st day. Spread of the disease can be checked by confirming if the nasal / oropharyngeryngel swabs turn negative and no contacts turn covid-19 positiveTimepoint: The study group will be tested for covid-19 to check for negativity on & 7th and 21st day following intervention

Clinical study on Dabur Chyawanprash as a preventive remedy in pandemic of Covid-19.
1.Comparative assessment of incidence of COVID-19 in subjects taking DCP and those not taking it over a period of 3 months (90 days)
2. Comparative assessment of incidence of other non COVID-19 infections in subjects taking DCP and those not taking it over a period of 3 months (90 days)

Effects of using hydroxychloroquine and azithromycin in the treatment of confirmed COVID-19 positive patients

Usage of topical lignocaine to decrease the gag reflex
while sampling for Covid-19: Does it affect the yield of
specimen?
The sensitivity of nasal and throat swabs for RT-PCR of Covid-19 after topical lignocaine useTimepoint: none

How has the spread of COVID 19 disease affected the teaching and training of postgraduate students who are studying anaesthesiology
Analysis of responses obtained from the 20 point questionnaire sent online to the respondentsTimepoint: One week after the survey has been sent, the responses will be analyzed

Hydroxychloroquine prophylaxis in Covid 19 infection
The proportion of healthcare workers who likely contracted COVID-19 infection from a nosocomial source in the 12-week period during which they were under HCQ prophylaxisTimepoint: Every week for 12 weeks

Mechanism of Covid 19 infection in Humans
-Identification of variants in host factors ACE2 receptor and Serine protease in COVID 19 patients in India
-Mechanism of action of identified variant proteins in viral entry into host cell employing Bioinformatic tools and in vitro testing
Timepoint: one year

HOMOEOPATHY IN PREVENTION OF COVID-19
Confirmation of diagnosis for COVID-19 infection / end of quarantine period as per standard protocol.Timepoint: Every 7th day.

Evaluation of BCG as potential therapy for COVID-19
Primary Outcome Measures:
1.Total duration of Hospitalization with COVID-19 symptoms such as febrile respiratory distress [Time Frame: from admission until discharge]
2.Decrease in Viral Titer [Time Frame: Measured on day of enrolment, on day 7 and 15 after intervention]
3.Duration of COVID-19 symptoms [Time Frame: At time of admission, following enrollment until discharge]Timepoint: Primary Outcome Measures:
3.Duration of COVID-19 symptoms [Time Frame: At time of admission, following enrollment until discharge]

Hydroxychloroquine in patients with mild COVID-19 illness with risk factors for severe disease
Progression to moderate- severe diseaseTimepoint: 6 month

A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19
Proportion of laboratory confirmed symptomatic COVID-19 cases between the groups at the end of 6 monthsTimepoint: Proportion of laboratory confirmed symptomatic COVID-19 cases between the groups at the end of 6 months

Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study
1.Determine the radiographic findings in chest X-ray of COVID-19 positive patients.Timepoint: At Baseline

A CLINICAL TRIAL TO STUDY THE EFFICACY OF HOMOEOPATHIC MEDICINE IN PREVENTION AND CURE OF CORONA VIRUS DISEASE 19
Primary endpoint of this trial will be measured in terms of clinically recovered cases (covid 19 negative)or deathTimepoint: 1 MONTH

Ayurvedic Interventions in prevention of COVID-19 infection-A survey study
Incidence of COVID 19 positive cases (as confirmed by hospital by standard investigation (real-time polymerase chain reaction test) among Ayurveda usersTimepoint: 3) After enrolment on day one, assessment will be done on day 7, 15, 22 and 30 by telephonic communication or as convenient to the participant.

An Observational study to identify the issues and challenges in cancer patients on active treatment during the COVID-19 Pandemic and the resulting Lockdown
Our study aims to identify the challenges faced by oncology patients during the pandemic.Timepoint: 09-05-2020 to 30-06-2020

Can a medicine help in curing viral infection
To study if Ivermectin can reduce the viral load in patients with hematological illnesses who are admitted with COVD19 infectionTimepoint: Day 7

Clinical trial evaluating two ventilator settings in Corona virus related severe lung diseases ( known as ARDS)
Difference in the area under the curve (adjusted to survival time) for Murrayâ??s lung injury score between the two groups in the first 4 days.Timepoint: The first 4 days during ICU stay and mechanical ventilation

Study of GUDUCHI TABLET on healthy individuals to prevent covid 19.
1. Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 15th day, 30th day, 45th day

Effect of Hydroxychloroquine on QTc Interval
Change in QTc intervalTimepoint: Before and after HCQ prophylaxis

Study of effect of Yashtimadhu tablet for the prevention of COVID -19 on healthy individuals.
1.Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 15,30 and 45th day

Outcomes of viral infection in hematology patients
To study the clinical profile and outcomes of COVID 19 infection in patients with
Hematological disordersTimepoint: DAY 8

Knowledge status of public about COVID 19 disease prevention and control in Tamil Nadu
Estimate awareness regarding COVID-19 prevention, control and promotive measures among population Estimate practices regarding COVID-19 prevention, control and promotive measures among populationTimepoint: 90 days

A Clinical Study on Favipiravir Compared to Standard Supportive Care in Patients With Mild to Moderate COVID-19.
Time until cessation of oral shedding of SARS-CoV-2 virus [ Time Frame: Up to 28 days ] (Time in days from randomization to a negative SARS-CoV2 RT-PCR result of both oropharyngeal swab and nasopharyngeal swab).Timepoint: Up to 28 days

Effect of Ayurveda intervention AYUSH-64 add-on therapy for patients with COVID-19 infection (Stage I)
1.Clinical cure rate: Time to negative conversion of severe acute respiratory syndrome corona-virus 2.Timepoint: At baseline, 4 weeks

Surgery Outcomes in COVID patients
30-day mortality
To determine 30-day mortality in patients with COVID-19 infection who undergo surgery. This will inform future risk stratification, decision making, and patient consent.Timepoint: 30 days (4 weeks)

Outcomes Of Cancer Surgery During COVID-19 Pandemic
30-day postoperative COVID-19 infection rateTimepoint: 30-day postoperative COVID-19 infection rate

Effect of pranayama and meditation on psychological well-being of healthcare workers during COVID-19 pandemic.
Pittsburgh Sleep Quality Index (PSQI) for sleep qualityTimepoint: 0, 2 weeks

To study the Effectiveness of herbal formulation - Aayudh Advance as a supplementary treatment for the Corona Virus 2019 (Covid-19) infected patients
1) Rate of Recovery
2) Symptom Resolution: Fever
3) Symptom Resolution: Cough
4) Symptom Resolution: Shortness of breath
Timepoint: Every 3-4 days from patient enrollment till recovery of patient and discharged from hospital

Study of ASHWAGANDHA TABLET on healthy individuals to prevent covid 19
Primary outcome parameter:
1. Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic Care
Timepoint: 15th day , 30th day and 45th day

Evaluation of the Immuno-Stimulatory Potential (Shareera Bala) of an Ayurveda Management Protocol in Cohort of Quarantined Delhi Police under Covid-19 Care Centers- An Exploratory Clinical Study
Improvement in Bala of an individual
Immuno-stimulation leading to non-development of symptoms of CoVID-19 in risk population exposed to infected individuals. (Bala will be assessed by using specialised proforma including dashavidha pareeksha and other questionnaires which will reveal the physical and mental health of an individual.)Timepoint: Baseline, 15th day, 30th day, 45th day, 60th day and 90th day

Evaluation of Efficacy and Safety of Thymoquinone compared to Best supportive care in Patients with COVID-19
To characterize virologic and clinical response of Thymoquinone in patients diagnosed with COVID-19
Timepoint: 1. Virologic outcome
a. Change in positive COVID-19 status on day 8 and day 15
2. Clinical outcomes
a. Proportion of Patients on WHO progression scale 0 to 10 on day 8 and day 15.

Ayurveda protocol & COVID-19 exposed individuals: Clinical trial of an Ayurveda Intervention
Improvement in Bala of an individual
Immuno-stimulation leading to non-development of symptoms of CoVID-19 in risk population exposed to infected individuals.
(Bala will be assessed by using specialized proforma including dasvidha pareeksha and other questionnaires which will revel the physical and mental health of an individuals)Timepoint: 8 week

Psychological impact of COVID â?? 19 Pandemic
Distress Scores (GHQ-12 Scores)Timepoint: Distress Scores (GHQ-12 Scores) at Baseline only is taken for the study (cross sectional study)

Mental status of public during lockdown COVID-19
The results obtained will give the psychosocial emotions created by the lockdown which will be the primary objective of the analysis and secondary objectives like the rate of impact of lockdown on existing lifestyle disorders may also get evaluated. This survey helps in developing new aspects/concepts on quarantine in futureTimepoint: 0th day, 15th day, 30th day, 45th day

Siddha interventions prevention to front line workers
The results obtained will give the benefit of prevention offered among the front line workers who take these interventions as prophylaxis .By comparing the back ground data from health workers who have not exposed to prophylaxis the benefit can be calculated. This survey helps in establishing prophylaxis on quarantine in future .Timepoint: 0th day, 15th day, 45th day and 60th day

Ayurveda formulation for COVID-19 prevention
Incidence of COVID 19 positive cases as confirmed by hospital by standard investigation, real time polymerase chain reaction test among Ayurveda users.Timepoint: At baseline,1 week, 2 weeks, 3 weeks, 4 weeks

Arsenicum album â?? 30 as prophylactic for Covid-19
1. Confirmation of diagnosis for COVID-19 infection based on RT-PCR / end of quarantine period as per standard protocol.Timepoint: Every third day till 21st day.

To observe the effect of Ayurvedic medicine for the treatment of COVID-19
a) Mean time (days) for clinical recovery [Day of randomization to the day of clinical recovery
b) Proportion of patients showing â??clinical recoveryâ??.
Timepoint: On 7th day, 15th day, 23rd day and 30th day

Questionnaire based study of drugs taken by healthcare workers to prevent COVID 19
In HCW working in hospitals caring for COVID 19 patients, we will understand the rates of and types of drugs used, doses taken for prophylaxis, concomitant illness, concomitant medications, adverse reactions if any and the COVID-19 status at the end of the prophylaxis period. We will also understand the reasons why HCW did not take prophylaxis or discontinued.Timepoint: To be studied at the end of 12 weeks of prophylaxis or later if the recommendations change

Assessing Stress levels among the Health Care Workers during and after Outbreak of
COVID-19
To study anxiety, depression and post-traumatic stress disorder among the HCW
in the radiation oncology department during the COVID-19 outbreak.Timepoint: 1 year

A clinical trial for validating therapeutic efficacy of convalescent plasma in severe COVID-19 disease
2. To compare â??all causeâ?? mortality
3. To identify the immune correlates for response to plasma therapy.
Timepoint: 1. Discharge
2. Discharge/death
3. Day 0, Day 3, Day 7 after admission

HCQ POCKET ECG Ambulatory Telemetry Study
No of patients with QT prolongation by 25 percentage of baseline
No of patients with QT prolongation greater than 500 ms
No of patients with ventricular arrhythmias
Syncope
Sudden cardiac DeathTimepoint: 7 days

Effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of Mild COVID 19 patients.
Reduction in incidence of clinical symptoms of COVID 19
Negative conversion of SARS-CoV-2
Reduction in Viral load of SARS-CoV-2 at the end of treatment
Examine the levels immune markers and inflammatory markersTimepoint: 14 days

COVID-19 and cancer chemotherapy
To describe change in cancer treatment patterns as a result of the pandemicTimepoint: 6 months from start of enrollment

To study the effect of COVID-19 pandemic and Psychological Well-being of Healthcare Professionals and Support Staff in Max Super Speciality Hospital, Saket in New Delhi, India.
Specific to the sub-scale domain assessed, individual psychotherapy sessions would
be provided to the identified healthcare professionals reporting severity of psychological
distress and if the individual is in need of further management or somatic symptom
related treatment, they will be guided for pharmacotherapy.Timepoint: 3months

To find out what has happened to the treatment and care of children suffering with cancer in India during the lockdown from the COVID-19 pandemic
% change in number of children registered, % of chemotherapy given behind schedule or not givenTimepoint: 10 week time period

Create registry of Childhood Cancer patients in India with COVID 19 to provide guidelines for prevention and treatment
Mortality rate at 30 days from diagnosis of COVID-19 Treatment abandonment rates at 90 days from diagnosis of COVID-19
Timepoint: Day 30
Day 90

A survey for challenges faced by the Investigators during COVID-19 pandemic in the conduct of Clinical Trials at Tata Memorial Centre.
Challenges faced by the investigators in conducting trials during COVID-19.Timepoint: 6 months

Efficacy of Tablet AOIM - Z in Prevention of COVID - 19 in High Risk Healthy Police Personnel
Prevention of Incidence of COVID â?? 19 infection in study participantsTimepoint: 6 weeks(45 days) and 12 weeks (90 days)

Study to efficacy of Ivermectin in patients of COVID-19
Effect of Ivermectin on eradication of virus.
Test for virus at 1, 3 and 5 days from beginning of trial drug started for the patient in the hospital
Timepoint: 3 months

Hydroxychloroquine of pharmacokinetics in healthcare workers
The modelling will help assess which of the variables including the presence of comorbidities (if any) would have the greatest impact on the drug concentrations in an Indian population. It would also help us understand if COVID-19 infection alters the pharmacokinetics of HCQ.Timepoint: 2-8 weeks

A study on salivary samples and nasopharyngeal samples in diagnosis of COVID-19 Disease Patients
To compare the sensitivity and specificity of paired salivary samples and nasopharyngeal samples in diagnosis of COVID-19 infectionTimepoint: Day 0,7 and 14

Emotional Impact of Isolation during COVID 19 among college students and staff
The outcome measures include scores on the three rating instruments, namely, Connor-Davidson Resilience Scale, Distress Tolerance Scale, and Mindful Attention Awareness ScaleTimepoint: Cross sectional one point response

A study to assess the efficacy of Homoeopathic medicine in the prevention of Covid-19
To assess in quarantined persons related to Covid-19 in Palakkad District
1)the incidence of symptoms of flu like illness/Covid- 19 infection
2)the relative risk of flu like illness/Covid-19 infection among persons under Homoeopathic prophylactic intervention when compared to the control population
Timepoint: 28th and 56 th day

To Study effectiveness and outcomes of Unani Medicine prophylactic interventions on population at risk of COVID-19
Incidence of COVID-19 cases in control as well in interventional group
2.Improvement in immune status using Immune Status Questionnaire (ISQ)
Timepoint: 20days

effect of Ayurvedic intervention in COVID-19 positive cases
1. Time taken and number of patients progressing from asymptomatic to symptomatic condition.
Timepoint: baseline
Daily
14 days

Impact of effect of Ayurvedic treatment on novel Corona virus disease
Virological Clearance as measured by RT PCR of nasopharyngeal swabTimepoint: Baseline, 3 Days, 7 Days, 14 Days

Role of Chyawanprash in the prevention of COVID-19 in health care workers
Percentage of participants with SARS- Cov-2 positivity as estimated by RT-PCR of nasopharyngeal swabTimepoint: baseline
Day 30

Impact of remote audio-visual surveillance of doffing process during COVID 19 pandemic on the safety of health care workers
To study the incidence of error or breech in the safety during doffing process of health care workers by remote audio visual monitoring using camerasTimepoint: during the process of doffing

Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill
Number of patients with increased disease severityTimepoint: From baseline to at any time during the study till 28 days post first dosing.

COVID-19 telephonic counseling model for addressing mental health concerns in different populations during corona outbreak in India
Primary outcome is Anxiety (assessed as a continuous variable on HADS).Timepoint: Pre and Post intervention ( 14 days)

To Study Clinical Characteristics, Treatment Outcome of Coronavirus (COVID-19) Patients
A. Clinical status of subject
B. Clinical status of subject at discharge
3. Death;
Timepoint: During Hospitalization Baseline to till Discharge

Difficulties faced by pregnant women during the Covid 19 Pandemic and lockdown
To assess the number of pregnant women who could not avail Antenatal services during the lock down and pandemicTimepoint: baseline

Corona virus in tears
Proportion of positive results for SARS-CoV-2 RNA from tears will be compared with those from naso/oropharyngeal swabs.Timepoint: within 48 hours of collection of naso/oropharyngeal swab

Spectrum of injuries during COVID-19 Lock down at a major trauma centre in Central India
volume of patients and the causes of injuryTimepoint: During lockdown for COVID-19 and before lockdown

Psychological distress among health care workers due to COVID-19 outbreak
Psychological distress among health care workers during COVID-19 pandemic.Timepoint: Will be compile at end of the study.

Clinical Trial of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
No. of subjects acquiring COVID-19 infectionTimepoint: From first dosing till 8 week post first dosing.

Convalescent Plasma treatment trial in COVID 19 patients
Avoidance of progression to severe ARDSTimepoint: day 28

Siddha Intervention Population Study.
1. Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 1stweek 2ndweek 3rd week and 4th week

Effect of Yoga & Naturopathy in patients with COVID-19
Time to progress to next stage of severity i.e., from asymptomatic/uncomplicated/mild pneumonia to moderate/severe stagesTimepoint: At 15 days

SURVEY OF MOUTH-DISSOLVING TURMERIC LOZENGES IN HEALTHCARE WORKERS
Clinical acceptability of turmeric lozenges in COVID-19 healthcare teamsTimepoint: DAY 15 (follow up 1) and DAY 30 (end of study) are evaluation time points.

Trial of antihypertensive losartan for additional benefit in treating COVID 19 infection.
Percentage of patient with treatment failure:
Treatment failure defined as any of following after 48 hours of randomization
i) A Fall in 1 score in Respiratory SOFA score
ii) New requirement of respiratory assist devices (HFNC, NIV)
iii) New requirement of mechanical ventilation
iv) MortalityTimepoint: Percentage of patient with treatment failure:
iv) Mortality

Home based prehabilitation via telemedicine in lung cancer patients during COVID 19
change in emotional functioning by DASS 21, physical functioning by change in performance score (Karnofsky Performance Scale) score and change in respiratory functional parameters from baseline to 3 weeks of home based prehabilitationTimepoint: at Baseline and 3 weeks

To study some blood tests which would help predict severity and outcome in children with cancers having the novel corona virus infection.
For every child with febrile illness, the following outcomes will be measured: (1) clinical outcomes of infections (if any) including severity (pneumonia, multi-organ failure, death) and time to recover.Timepoint: Outcomes will be measured at baseline, week1, week2, week3 and at week4. Antibody response will be measured at week 4 and at 3 months.

Study to Assess the Safety and Efficacy of Convalescent Plasma on outcome of COVID-19 Associated Complications
The primary outcome is a composite measure of the
i. All-cause Mortality at 28 days
ii. Improvement of SOFA score Post transfusion
Timepoint: 28 days from intervention

Evaluation of Efficacy and Safety of Ayurveda Intervention (Ayush -64) in the management of COVID-19 infection (Asymptomatic &Mild to Moderate symptoms
a) Mean time (days) for clinical recovery as per clinical recovery criteria defined below.
b) Number of patients showing â??clinical recoveryâ??.
Timepoint: a) Mean time (days) for clinical recovery as per clinical recovery criteria defined below. [Time frame: Daily]
b) Number of patients showing â??clinical recoveryâ??. [Time frame: Daily]

mask use in covid in medical personnel - a survey
To assess the awareness about the use of mask and its disposalTimepoint: 1 month

Randomized Controlled Trial Of Resveretrol-Copper Or Sodium-Copper-Chlorophyllin Vs Standard Treatment In Mild Covid-19 infection
Proportion of patients who suffer clinical deterioration OR viral
persistence at Day 10 from the date of randomization (excluding the date of randomization)
Clinical deterioration will be defined as defined as a 2-point or greater deterioration on a 7-point ordinal scale in every patient measured on each day, until Day 10 from the date of randomization.Timepoint: Day 10

Randomized Controlled Trial Of Resveretrol-Copper OR Sodium-Copper-Chlorophyllin Versus Standard Treatment In Severe Covid-19
The time to clinical improvement, defined as a 2-point improvement on a 7-point ordinal scale will be the primary endpoint.Timepoint: Day 28

Efficacy of AYUSH-64 (a polyherbal formulation) in COVID - 19 Cases
a) Mean time (days) for clinical recovery as per clinical recovery criteria defined below
b) Number of patients showing â??clinical recoveryâ??
Timepoint: Baseline

A study to know the effect of Ayurvedic Kwath(Kiratiktadi Kwath) & Ashwagandha Churna along with yoga exercises in the treatment of COVID-19 Positive patients.
Efficacy of Kiratiktadi Kwath & Ashwagandha Churna with yoga modalities in the management of mild and asymptomatic cases of COVID-19 PatientsTimepoint: approx 12 weeks

Psychological impact of COVID-19 pandemic on health care workers
To study the psychological impact in terms of insomnia, depression, anxiety, and stress experienced by the health care workers in India.Timepoint: outcomes will be assessed only at baseline, at a given point of time

Medical students preference and perspective for online teaching during lockdown period
Student perceptions and preference for Online teaching for medical students - Mean attitude scores will be measured for the feedback items reported on five-point Likert scale. A thematic analysis will be undertaken for open ended questions asked in the survey.Timepoint: One time response

Effects of the corona virus disease on mental health of Anaesthesiologists working at different parts of India.
To study the psychological impact of COVID-19 pandemic on Anaesthesiologists working at different parts of India during the COVID -19 pandemic.Timepoint: After completion of the survey.

A Clinical Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.
To prevent progression to severe ARDS (P/F ratio 100) and all-cause Mortality at 1 month.
Timepoint: Improvement of clinical symptoms and investigations will be monitored daily for first 3 days, and on day 7, 14, 21, 28, once a month till 3 months.

Study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19
Clinical improvement, as defined by live discharge from the hospital, a decrease of at least 2 points from baseline on a modified ordinal scale (as recommended by the WHO R&D Blueprint Group)
Conversion of Covid19 status to negativeTimepoint: 28 days

Evaluation of Role of Ayurvedic Drug- Guduchi Ghan Vati in the treatment of COVID-19 related illness
1. Clinical cure rate: Time to get a negative status of Covid-19. (defined as viral load of respiratory specimen negative for two consecutive times when tested in an interval of two days) [Time frame 1 month]Timepoint: [Time frame 1 month]

Research study to evaluate the impact of Selected Ayurvedic interventions in containment zone
Comparative assessment of occurrence of COVID-19 infection in Clinically stable participants in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 0, two weeks, 4 weeks, 6 weeks.

A study on treatment of COVID-19 patients with study drug along with standard of care
Proportion of subjects showing progressive COVID 19 disease from moderate to severe, or from severe disease to deathTimepoint: Up to Day 14

Retrospective Assessment of Treatments of Hospitalized COVID19 Patients.
Time to recovery/ discharge or death in hospitalized COVID-19 patients.Timepoint: At recovery/ discharge or death.

Ayurvedic intervention (Chyawanprash) in the prevention of COVID-19 pandemic among Health Care Personnel
1. Percentage of participants with SARS- Cov-2 positivity as estimated by RT-PCR of nasopharyngeal swab.Timepoint: Assessment on baseline and at the end of study that is 30th day

Clinical features and outcome of COVID-19 and non-COVID respiratory infection
Mode of oxygen therapy. Other interventions needed. Outcome from illnes- recovery or deathTimepoint: Baseline, 3rd day, 5th day and at dischargefrom hospital.

Pregnancy and COVID-19 Registry
1. Incidence of COVID-19 in pregnancy
2. Socio-demographic, epidemiological and clinical characteristics of pregnant women with COVID-19
3. Pregnancy outcomes in women with COVID-19
4. Neonatal outcomes in women with COVID-19
5. Response to treatment
6. Modes of transmission of COVID-19 from mother to child
Timepoint: at the end of 24 months

effect of Ashwagandha (Withania somnifera) as a prophylactic measure among high risk population (Health Care Workers/Containment Zone Population) exposed to COVID-19
1. Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 0 15 30 45 day

EFFECT OF AYURVEDA IMMUNO-MODULATOR DRUGS on HEALTH OF CORONA WARRIORS
To boost immunity of engaged person in care of COVID-19 infected/ suscpected casesTimepoint: 15 days

A study to find our proportion of Covid 19 cases, need for hospital beds and utility of lockdown at Aurangabad
Percentage of households with Covid 19 infectionTimepoint: At 4 weeks

Clinical Characteristics and Outcomes of Patients Admitted with Severe Acute Respiratory Illness
13. Clinical outcomes (discharged from ICU, still in ICU, died, still in hospital)
14. Ventilation days, ICU days
Timepoint: Final follow-up planned in September 2020

A clinical trial to evaluate the Medicinal effects of ZingiVir-H as Anti-Viral therapy in COVID-19 patients.
The odds of ratio for improvement on a 7 point ordinal scale on Day 15 and clearance of medically attended lung infection due to RT-PCR confirmed COVID19 infection , in Zingivir H treated group to the placebo group.
Timepoint: base line , 7 th day, 15 th day

A study to estimate drug levels in health care workers on COVID infection prophylaxis
To determine the peak and trough values achieved in blood over the course of the prophylactic drug administration.Timepoint: The estimated concentration for the sampling time points (hr) 0.00, 4.00, 168.00, 336.00,
descriptive statistical analysis.

Respiratory emergencies during the COVID-19 Pandemic.
Disease burden of respiratory emergencies reporting to the emergency department.
outcome and mortality of Respiratory emergencies.Timepoint: Data collection will go on for a period of 6 months from the date of CTRI approval.
Data collection will stop on or before 11.01.2021 if 6 months of data collection is complete. If it is not then a request for an IEC extension amendment will be requested.
All the outcome variables will be assessed after 6 months of data collection-anticipated January 2021.

the effect of Guduchi (Tinospora cordifolia) as a prophylactic measure among high risk population (Health Care Workers/Containment Zone Population) exposed to COVID-19
1. Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 0 15 30 45 days

study on the effect of Chyavanprash Lehyam as a prophylactic measure among high risk population (Health Care Workers/Containment Zone Population) exposed to COVID-19
1. Comparative assessment of occurrence of COVID-19 infection in healthy volunteers in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 0 15 30 45 day

Dental studentsâ?? perceptions and concerns regarding the current COVID-19 pandemics
perceived stress due to COVID-19Timepoint: at baseline

Development of Smell based test for identifying COVID-19 infection.
Economical, rapid, Make in India, a five-minute odor test that can present the identification, discrimination and thresholds of odor perceptions as a detection of suspected cases of COVID 19.
Sensory capabilities of COVID positive patients get damaged and thus can be used as tool of diagnosing infected / symptomatic COVID subjectsTimepoint: The new diagnosed COVID positive cases will be tested will our odour test. Whereas those quarantined shall be monitored only after confirmation of their corona test report.
The odour test may be repeated on the recovered COVID patients either immediately or later.

A Clinical trial to study the efficacy of pH based Integrated SARS Cov-2 Immunity in Human Subjects.
Full(100%) protection from Covid-19 infection and Disease.Timepoint: 5 weeks

Clinical study on Guduchi Ghana Vati as a preventive remedy in pandemic of COVID-19
Comparative assessment of incidence of COVID-19 in subjects taking GUDUCHI GHANA VATI and those not taking it over a period of 45 daysTimepoint: (day-5, day 0, day-15, day-30, day-45)

The efficacy of Homeopathic medicines in the prevention of COVID-19 in Quarantined or Exposed Individuals
a. Number of people turning symptomatic
Number of people turning Covid19 positive
c. Number of people recovering after turning positive
d. Number of deaths, if any, if get infectionTimepoint: Baseline, week 2 and week 4

Impact of tele-consultation for following up newborns during COVID-19 pandemic
Need for emergency room visit or re-hospitalizationTimepoint: At 28 days of life for term neonates and at 4 weeks corrected age for late preterm neonates

Effect of Ayurvedic medicine in the Prophylaxis for COVID-19 of Police personnel Dept of AYUSH, TS & CCRAS- NIIMH, Hyderabad.
Comparative assessment of occurrence of COVID-19 infection in healthy volunteers vis Police personal in community having at least 1 confirmed case already identified with control arm of Standard Prophylactic CareTimepoint: 3 months

Mental impact of SARS Covid-19 disease outbreaks among suspects coming to AIIMS Rishikesh, their close contacts, and associated healthcare providers
To estimate the fear, stress, and depression levels according to PSS 10 and DASS 21 questionnaires and according to the Likert scaleTimepoint: base line, and 14 days interval

Study to observe safety of CNV01 homeopathy preparation in healthy volunteers
Safety measure in terms of investigations (PCR) blood parametersTimepoint: at baseline, 17th day and follow-up at 30th day

Screening of healthcare workers, Doctors and Nurses working in Covid-19 wards using a continous wearable watch device
Fortis will distribute the wearable device Watch called ( Empatica E4 ) provided by TCS to consenting volunteers. The volunteer will wear the watch continously for 2 weeks , wherein the following metadata will be recorded. Heart rate, Spo2, Body temperature, height, weight, Blood pressure( recorded manually ), will be recorded against the USER ID provided to TCS.Timepoint: Data to be analysed at Baseline, at 2 weeks, at 4 weeks and at 6 weeks

Knowledge, attitudes, and practices towards COVID-19 among Indian residents during the period of the COVID-19 outbreak
To assess Knowledge, attitudes, and practices towards COVID-19Timepoint: AT BASELINE

To observe the impact of Ayurveda Kwath in Healthy and Suspected persons for COVID-19
To prevent the spread of infection in healthy persons residing in containment zone and / or other areas.Timepoint: One Month

Clinical trial on Immunity and antiviral for quarantine patients of COVID-19
i. Improvement in Immunity and anti viral
properties in patients who are assessed daily for
symptoms which include cough, fever with or
without chills and difficulty in breathing for the
period they are in quarantineTimepoint: Day 0 to Day 14

A clinical study of Ayurvedic formulations in the treatment of Mild to Moderate COVID-19 patients
a) Mean time (days) for clinical recovery [Day of randomization to the day of clinical recovery (see criteria below)]
b) Proportion of patients showing clinical recoveryâ??
Timepoint: Baseline, Daily assessment during symptomatic phase or hospitalization phase till complete recovery, WEEK 4, week 8, and study completion week 12

A clinical trial to know the effect of VirulinaÂ® along with standard treatment in covid 19 positive patients.
Time until cessation of oral shedding of SAARS-CoV- 2 virus (Time in days from randomization to a negative SAARS-Cov-2 RT-PCR result of both oropharyngeal swab and nasopharyngeal swab).
Time point-Up to 14 days
- Clinical cure based on Clinicianâ??s assessment of symptoms which include cough relief, recovery from fever and difficulty in breathing for the period they are in quarantine. (For those patients who presented with clinical signs and symptoms at baseline).Timepoint: Day 1, Day 7 and Day 14

Homoeopathic Medicines Bryonia alba 30C as a Prophylaxis for COVID-19
The results of the study will be able to determine the prophylactic effect of Homoeopathic Medicines in COVId-19 cases. If found effective, this could prove to be a Vital contribution in public health care for this Global Crisis of COVID-19.Timepoint: 1 week

Knowledge, Practice and mental health status of Spinal injured people
Knowledge attitude and Practice towards COVID 19Timepoint: 14 days

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised control trial
1. Time to Clinical recovery (TTCR)
TTCR is defined as the time (in hours) from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours.
2. Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimenTimepoint: 72hrly

A clinical trial to evaluate safety and efficacy of polyherbal capsule Astha-15 used as an add on therapy with standard care of therapy as an immunity booster in the suspected and COVID-19 diagnosed patients.
1. Changes in scores of the St. George Respiratory Questionnaire from baseline to EOT visit.
2. Changes in scores of the Leicester Cough Questionnaire from baseline to EOT visit.Timepoint: Day -2 to -1, Day 1, Day 14, Day 28 (End of Treatment), Day 35 (Follow-up)

Effect of Ayurvedic medicine in the Prophylaxis for COVID-19 of AYUSH healthcare workers , Dept of AYUSH, TS & CCRAS- NIIMH, Hyderabad.
Comparative assessment of occurrence of
COVID-19 infection in healthy volunteers vis
Police personal in community having at least 1
confirmed case already identified with control
arm of Standard Prophylactic CareTimepoint: 0 day and
40th day
COVID-19 infection in healthy
volunteers vis
AYUSH personal in community having at least 1
arm of Standard Prophylactic Care

Melatonin Immune Boost COVID 19 Study
SARS-CoV 2 infection rate : Number of confirmed (positive CRP) symptomatic infections in each treatment group
Timepoint: 8 weeks

A study to determine relative efficacy of hydroxy-chloroquine prophylaxis to healthcare-professionals for Covid-19 mitigation
(1) Incidence of Symptomatic COVID-19 in each one of 4 arms;
Clinical diagnosis of COVID-19 with virology confirmation, with limitation of activities (WHO Severity Scale 2-8) over the study enrolment period.
(2) Incidence of Peak severity of COVID-19 over the study period in COVID-19 positive MPs
Timepoint: at multiple intervals over 3months

As the present outbreak of novel coronavirus in Indian scenario we want to study about the prophylactic study in Distric Hospital, Vidisha.
Parameter will test :Complete blood picture,Serum ferritin,C-reactive protein,LDH,Troponin, Nucleic acid amplification test and RT-PCRTimepoint: every 3 day with baseline up to 8 week

Study of the effect of Siddha Treatment in addition to standard therapy in COVID-19 patients
Proportion of patients confirmed as negative for SARS-CoV-2 in 2 consecutive throat/nasal swabs (taken 24 hours apart) at Day 15/Day16.Timepoint: To compare the efficacy of Siddha drug regimen plus Standard of Care (SoC) with SoC alone in the treatment of Covid-19 positive patients.

To assess the postoperative outcomes after implementation of the protocol in patients undergoing surgery for gynaecological malignancies in the COVID-19 pandemic
The primary endpoint will be assessment of Length of Hospital Stay (LOS) with the
implementation of an enhanced recovery after surgery pathway. LOS was defined as
the number of days from the day of surgery to discharge.Timepoint: 8 Months

To assess the safety and outcome of herbal medicine in prevention of COVID-19 infection among high risk population
1. Incidence of COVID-19 cases in control as well in interventional group
2. Improvement in immune status using Immune Status Questionnaire (ISQ)Timepoint: 0th Day, 10th Day, 20th Day and 35th Day

A study on association between tobacco and COVID 19 to help policy makers
Summary of stakeholder survey findings
Report outlining findings from the rapid evidence review
Policy and practice briefings for stakeholders
Webinars for stakeholders involved in tobacco control and COVID 19 management
Timepoint: Summary of stakeholder survey findings -4 weeks
Report outlining findings from the rapid evidence review-6 months
Policy and practice briefings for stakeholders-6 months
Webinars for stakeholders involved in tobacco control and COVID 19 management-6months

To evaluate the effect of herbal medicine in prevention and management of COVID-19
The outcome will be focused on decrease severity of parameters:
â?? Fever
â?? Sore Throat, Cough with sputum, Cough with haemoptysis, Dyspnoea (Shortness of breath), Wheezing, Chest pain, Runny nose, Fatigue, Headache, Arthralgia, Irritability/confusion, Seizures, Nausea/Vomiting, Diarrhoea, Abdominal pain, skin rashesTimepoint: 0th Day, 14th Day and 21st Day

A clinical trial to evaluate the medicinal efficacy of Ayurvedic Tablet Bhoumya and Tablet Saathmya in COVID-19 positive Patients.
1.Time in days for Clinical cure:Stable normal clinical temperature and vitals in 3-5-7-10-14 days.
2.Time in days till RT-PCR is negative .
3.Rate of improvement of IL-6 levels at 0-7-14 days as compared to baseline.
Timepoint: From the baseline till the end of 15 days.

This study has been conducted to collect the Cough and breathing sound of COVID-19 positive and COVID-19 negative patients for analysis of early indication of COVID-19 in humans.
The primary objective of this research study is to utilize the data that is being collected and process it to build and train an AI model and work towards achieving a baseline accuracy that helps in compiling a software tool that can be used as a preliminary diagnosis tool on a mass scale with less time consumption and very limited resources.Timepoint: Screening/Baseline Visit

Oral Fluid Sars-CoV-2 Ab Rapid test
There is a significant positive correlation between presence or absence of (blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease after onset of symptoms. It is expected to initially observe this relationship most strongly in individuals who have specific disease (RT-PCR confirmed COVID-19 disease) within 7 days of onset, and these antibodies continue to remain positive in recovery period, 21 days and much later for many more weeks.Timepoint: June 16-July 31, 2020

Knowledge, Attitude, Feelings and Behavior in Adolescents during COVID-19
To understand the knowledge, attitude, feeling, coping and behavior of adolescents during the COVID-19 pandemic. Predominant emergent patterns of lifestyle, feeling and behavior will be noted.Timepoint: 1 month during the period of COVID-19 pandemic.

Ulinastatin for COVID-19 in patients with breathlessness
1. Number of days of use of Mechanical Ventilation
2. Change from baseline in PF ratio (PaO2/FiO2)
Timepoint: 1. Number of days of use of Mechanical Ventilation

A Randomized controlled Clinical Trial to determine the efficacy of Siddha drugs in COVID 19 patients
Primary Outcome would be measured through Reduction of symptoms and
Recovery of patients from COVID 19 disease in a time bound manner.Conversion of RT PCR negative within first week of accelerated recoveryTimepoint: 6 months

Assessment of depression, anxiety and coping strategies among Health care workers working in dedicated COVID-19 hospitals
There will be increased level of depression and anxiety among healthcare workersTimepoint: 3 months

A study of 254nm UVC ray therapy in pharynx for asymptomatic to mild cases of Corona Virus Disease
Proportion of patients virologicaly cured on (asymptomatic and mild cases)
Proportion of patients clinically cured (mild cases)Timepoint: Day 1, 3, and 5

A clinical trial to study the effect of drug named Sofosbuvir in hospitalized patients with COVID 19.
mortality of the study subjectsTimepoint: during hospitalisation

An open label Randomized Controlled Clinical trial to Evaluate the Safety and Efficacy of selected Siddha formulations in patients diagnosed with COVID-19
Primary Outcome would be measured through Resolution of symptoms and Recovery of patients from COVID 19 disease compared to patients taking only standard of care treatment at specific time points. RT PCR conversion within first week with accelerated recovery as compared to control groupTimepoint: 6 months

Population based cross sectional study for COVID 19 prophylaxis with
Polyherbal Siddha formulation Kabasura Kudineer / Nilavembu kudineer in containment zones and non
containment zones during 2020 pandemic in Tamil Nadu, South India
COVID-19 Test Positivity / Negativity upto 31 days follow up.Timepoint: COVID-19 Test Positivity / Negativity upto 31 days follow up.

An Open-Label Randomized Controlled, Proof-of-Concept (PoC) Study to
Evaluate the Safety and Efficacy of selected Siddha formulations in patients
diagnosed with COVID-19
Outcome would be measured through Reduction of symptoms and Recovery of patients from COVID 19 disease compared to patients taking only standard of care treatment at specific time points.Timepoint: 6 months

A prophylactic interventional study to determine the possible protective effect of Siddha Polyherbal formulation Kabasura Kudineer / Nilavembu kudineer against the COVID 19 on
intermittent, month-long consumption by Highrisk population and frontline workers in Tamil Nadu, India
Percentage of participants protected during the outbreak of COVID 19 compared between the Kabasura Kudineer taken and Standard of Care taken groupsTimepoint: Assessment will be done at Baseline and 30th day from the start of Prophylactic intervention.

Role of Herbal Immunomodulators in mild COVID-19 confirmed cases
Time to Clinical Recovery
No. & Percentage (%) of subjects converting into severe cases.
Time to convert 2019 nCoV RT PCR in negative in upper respiratory tract specimen
Lenth of Hospital stay
Proportion of clinical failure -ICU admission, mechanical ventilation or death
Number & Percentage (%) of subjects converting into positive test for COVID-19
Protection as defined by various laboratory parameters related to inflammation and immunity
Overall well-beingTimepoint: Visit-1 Baseline
Visit-2 Date of discharge
Visit-3(Telephonic) 7 days from the date of dischargeÂ±1day
Visit-4 14 days from the date of discharge Â±3day
(EOS)

Effect of aragwadhadi kwath (kadha in Hindi) in treatment of mild corona virus disease
Proportion of Clinically and Virologically cured patientsTimepoint: at Day 5, 10 and 14

Study of AYUSH KWATH in quarantine persons
Percentage of participants with SARS- Cov-2 positivity and Number/ percentage of participants not developing any Covid-19 like sign & symptoms (Time line 30 days)Timepoint: Percentage of participants with SARS- Cov-2 positivity and Number/ percentage of participants not developing any Covid-19 like sign & symptoms (Time line 30 days)

COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study
â?¢ Prevalence of liver injury in patients infected with SARS-CoV-2 virus.
â?¢ Prevalence of new liver injury in patients having COVD-19 infection over underlying liver dis-eases.
Timepoint: 4 weeks

A study of Favipiravir in patients with mild to moderate coronavirus disease (COVID-19)
Time from randomization to negativity in RT-PCR nucleic acid test. [defined as the presence of two consecutive negative results with RT-PCR detection over an interval of 24 hour]Timepoint: Up to 28 days

Role of Ayurveda in Covid 19 management.
To reduce Virus Clearance Time.
To improve General Quality of Life.
To minimise the chances of Disease progression in terms of Severity.
To assess role of Ayurveda medicines in the COVID 19 Pandemic management.
To establish Ayurvedic drugs role in National programme for COVID managementTimepoint: 5 days and 10 days

Quality of Life During COVID-19 Lockdown
To Evaluate the Quality of Life in Cancer Patients on Palliative Care during Lockdown in the COVID-19 PandemicTimepoint: From 25th March 2020 to 8thJune 2020

Effectiveness of lying face down in improving the outcome of COVID-19 patients
Primary outcomes (Phase 1 study):
1. Oxygen saturation measured using by pulse oximeter at 0, 10, 20, 30, 40 minutes
Primary Outcomes (Phase 2 study):
1. Need for endotracheal intubation and mechanical ventilation measured at discharge or death
2. Mortality up to 30 days after enrolmentTimepoint: Primary outcomes (Phase 1 study):
2. Mortality up to 30 days after enrolment

Effect of convalescent plasma in COVID-19 patients
efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)
Timepoint: Day 28

Clinical Analysis of Patients Hospitalized Due To Covid-19
All Covid -19 Patients will be stratified according to demographic parameters, clinical symptoms, co-morbidities, clinical course, laboratory, and radiological features, treatment given, ICU care, complications, and outcome (discharge or death). We aimed to compare the above parameters in different clinical outcomes.Timepoint: Death Or Discharge

Study to Evaluate the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in COVID-19 Patients
Change from baseline in mean viral load (determined by rRT-PCR on a nasopharyngeal/ oropharyngeal swab)Timepoint: Day 14 or at discharge from hospital, whichever is earlier

RNB in UPUMS SAIFAI
1)Clinical improvement of symptoms which was their at the time of admission
2)microbiological: microbiological clearance of virus by nasal swab and throat swab by RTPCRTimepoint: after 10 day of intervetion

Mental Health of children during Covid-19 Pandemic
Prevalence of psychosocial problems among the Indian school going children during the pandemic covid-19Timepoint: 10 days

Studying tobacco use and quitting behaviour due to the coronavirus lockdown in India.
1) Tobacco Use (Prevalence, Type, Frequency)
2) Tobacco Cessation BehaviourTimepoint: Baseline

BCG vaccination against COVID-19
Proportion of patients with Severe COVID disease based on COVID Severity Scale and proportion of death due to Covid 19 disease
Timepoint: 6 months post vaccination

Evaluation of siddha regimen in the management of covid 19
Primary Outcome would be measured through Resolution of symptoms and Recovery of patients from COVID 19 disease compared to patients taking only standard of care treatment at 4 weeks.Timepoint: Primary Outcome would be measured through Resolution of symptoms and Recovery of patients from COVID 19 disease compared to patients taking only standard of care treatment at 4 weeks.

Effect of AYUSH 64 in COVID 19
Ordinal scale for Clinical improvement as per WHO
Duration on mechanical ventilator
All cause mortality
Timepoint: 0 7 14 and 28th day

Observational study on suspected COVID 19 patients admitted to ICU
To study the epidemiology and clinical characteristics of patients admitted with SARI possibly due to COVID19 and their outcome
Timepoint: ICU mortality
at 4 weeks

Follow-up of COVID-19 Positive Patients
Socio-demographics, Symptom presentation, Co-morbidity, Quality of life, Physical Activity, Functional limitationsTimepoint: 30 days

Scientific evaluation of Immuno-modulatory effects of AYUSH INTERVENTIONS on normal healthy and high-risk individuals in context with COVID-19 pandemic: An open level study
i. Clinical, psychological and Quality of life assessment
ii. Comparative analysis of occurrence of COVID-19 in subjects taking Ayurvedic Interventions and those not taking Ayurvedic Intervention
iii. Comparative analysis of occurrence of conclusive symptoms of COVID-19 (as per ordinal scale of clinical improvement published by WHO).
iv. Comparative analysis of occurrence of conclusive symptoms of other than non-COVID-19Timepoint: From baseline assessment, 1 week, 2 week and 4 week

Low Dose Radiation Therapy for COVID-19
Symptomatic improvement or deterioration by comparing baseline NEWS score with post LDRT NEWS score on day 3, day 7 and day 14.Timepoint: NEWS score on day 3, day 7 and day 14.

To observe the effect of Siddha formulation Kabasura kudineer in COVID 19 patients
1.Reduction in incidence of clinical symptoms like fever, cough and breathlessness.
2.Negative conversion of SARS-CoV-2 by 14 days
3.Reduction in Viral load of SARS-CoV-2 at the end of treatment (0, 7, 14 days)
4.Examine the levels of immune markers and inflammatory markers (IgG, IgM, IgA, Th1 (TNF-Alfa, IFN-gamma, IL2) Th2 (IL6, IL10) at the end of treatment (0, 7, 14 days)
Timepoint: 14 days

Local application of Povidone Iodine solution in nose and oral gargle for house hold contacts of COVID19 cases
The Decrease in the attack rate of Primary and Secondary contacts of COVID19 patients and reduction of the Viral Load (Using cycle threshold values of RT PCR at different timelines)Timepoint: 7th day

Psychological assessment of the health care-workers amid COVID-19 working at a tertiary care teaching hospital of the central India and impact of tele-counselling on their psychological problems
Change in scores DASS21 (Depression, Anxiety, Stress) and IES-R (Impact of Scale revised)Timepoint: 10 days, 24 days and 38 days after commencement of Tele-counselling, which is the intervention.

A Clinical Study on Favipiravir and Umifenovir Compared to Favipiravir alone in Hospitalized Patients with Moderate COVID-19.
Time from randomization to clinical cure (defined as resolution of baseline clinical signs and symptoms of COVID-19 infection and at least 2 point improvement on WHO Ordinal Scale for Clinical Improvement) (Time frame-28 days).Timepoint: Upto 28 days

Clinical Study to Study Safety and Efficacy of herbal formulation - Aayudh Advance
To compare the safety and efficacy of the Supplemental herbal formulation - Aayudh Advance with Standard treatment.
Establish if the preventive administration of herbal formulation - Aayudh Advance attenuates the clinical manifestations of COVID-19 in people who become infected.
Timepoint: every visit

Giloy Gomutra Capsule, Asthi churna aur Kamdhenu Asava ka vaishvik mahamari Covid-19 par Chikitsakiya parinam ka Ankalan karne ke liye Adhyayan
Investigations of Covid-19 will be done before and After the treatment.Timepoint: Investigations of Covid-19 will be done before and After the treatment. All the symptoms will be graded and before and after the treatment symptoms will be measured on first day, 7th day and at 15 day.

Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients
Micro-biologically becoming RT-PCR negative for SARS-CoV-2Timepoint: Micro-biologically RT-PCR results for SARS-CoV-2 shall be evaluated at baseline, day 6 and day 12

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor
Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response

Acute Encephalopathy in Critically Ill Patients With COVID-19

Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.

Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
Change in Oxygen Saturation by Pulse Oximetry

Awake Prone Position for Early Hypoxemia in COVID-19

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients
Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation

The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment
Number of patients with virological cure

Camostat Mesylate in COVID-19 Outpatients

The United Kingdom Multiple Sclerosis Register Covid-19 Substudy
Incidence of COVID-19 Infections within an MS Cohort in the UK;Hospitalisations in MS Patients with COVID-19;Mortality

Convalescent Plasma Trial in COVID -19 Patients

Liver Injury in Patients With COVID-19

A Randomized Trial of Anticoagulation Strategies in COVID-19
Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock

Covid-19 Associated Coagulopathy

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)
Days to resolution of cough, fever and shortness of breath

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
Evaluate the effect of RBT-9 versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale

Management of Covid-19 Patients During Home Isolation
Arterial Blood Gases (ABG): Partial Pressure of Oxygen and Carbon Dioxide;Arterial Blood Gases (ABG): Acidity Potential Hydrogen (pH)

MSCs in COVID-19 ARDS

Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation

Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients
Global Prevalence of COVID-19 TX;Hospitalization rate in COVID-19 TX

Favipiravir vs Hydroxychloroquine in COVID -19
Primary outcome measure will be time to viral clearance

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
Proportion of subjects that are alive without respiratory failure at Day 29.

The COvid-19 Symptom MOntelukast Trial

FAvipiravir and HydroxyChloroquine Combination Therapy

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
7-Point National Institute of Health Clinical Health Score

Sleep Quality in Healthcare Personnel During COVID-19
measure sleep quality in healthcare worker

hCT-MSCs for COVID19 ARDS
Safety of the Investigational Product;Safety of the Investigational Product;Safety of the Investigational Product

COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via "Quit to Win" Contest 2020
Biochemical validated quit rate;Biochemical validated quit rate

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons
Inflammatory responses of cells in lung and circulation

Adaptive COVID-19 Treatment Trial 2 (ACTT-II)

Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
Clinical recovery at day-14, from the start of treatment.

Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women
Serum zinc, vitamin d vitamin b12 deficiency levels

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC=1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first

Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

A Study of Baricitinib (LY3009104) in Participants With COVID-19
Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19
Illness development;Reduction of need ICU admission;Reduction of mortality rate

Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic
Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)

Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients

Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children

Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection
To highlight the perceptions, representations and experiences of septic isolation of patients hospitalized for COVID-19 infection

A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection
Adverse event rates;Efficacy for shortening duration of SAR-CoV2 detection by PCR

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19
Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days;Number of Participants With Adverse Events

Immune Biomarkers of Outcome From COVID-19

Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic

An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19
The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days;Number of Participants With Adverse Events

Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
Time to Resolution of Symptoms;SAEs within 24 hours of plasma infusion

Evaluation of Immune Response in COVID-19 Patients
COVID-19 associated immune disorder;COVID-19 associated inflammation;Oxygenation;Diagnostic of COVID disease composite

COVidIVERmectin: Ivermectin for Treatment of Covid-19

Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19

Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic
Analysis of the effect of prone position in patients with covid-19 in intensive care

Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels

Glucocorticoids in COVID-19 (CORTIVID)
Proportion of patients developing treatment failure;Proportion of patients developing treatment failure;Proportion of patients developing treatment failure;Proportion of patients developing treatment failure

The COVID-19 Disease and CARdiac Events Study
Cardiac abnormalities in COVID-19 disease in-patients

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Proportion of patients who require artificial ventilation;Death

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology
Loneliness as evaluated by the UCLA loneliness scale;Alcohol Use as evaluated by the AUDIT;Drug Use as evaluated by the DAST-10;Anxiety as evaluated by GAD-7;Depression as assessed by CES-D-10

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Proportion of patients developing severe ARDS.

Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients

Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
Death versus survival of treated patients

Assessment of Lung Inflammation With FDG PET/CT in COVID-19

Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic

Effect of Positive Attitudes on Behavior and Wellness
Teamwork climate, as measured by selected items from the validated Safety Attitude Questionnaire (SAQ);Resiliency, as measured by the validated Brief Resilience Scale (BRS);Burnout, as validated by the single-item burnout scale inventory

Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)
Presence of specific SARS-CoV2 antibodies in the serum in the 3 groups of subjects studied, at the inclusion visit (D0).

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
Correlation of adverse events with the investigational product

Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity

Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants
Gender division of caregiving/domestic tasks;Couple communication;Couple conflict;Men's alcohol use;Household economic situation;Stress and frustration

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )
Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC=1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first

Convalescent Plasma as a Possible Treatment for COVID-19

Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic
Patient Health Questionnaire 9;Generalized Anxiety Disorder 7

Factors Associated With Adherence to Hygiene-related Behaviors and Viral Mitigation Protocols During the COVID-19 Pandemic
Adherence to WHO-advised hygiene-related;Adherence to viral mitigation protocols

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
Proportion of patients with clinical worsening

Difficulties in Emotion-regulation and Interpersonal Problems During and After the COVID-19 Pandemic
Patient Health Questionnaire 9 (PHQ-9);The Generalized Anxiety Disorder - 7;Difficulties in Emotion Regulation Scale;Interpersonal problems

The Impact of Information Sources on Mental Health During the COVID-19 Pandemic
Patient Health Questionnaire 9;Generalized Anxiety Disorder 7

Parental Burnout During the COVID-19 Pandemic: Risk Factors and Predictors

Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress
Gut microbiome composition of exposed group;Gut microbiome composition of exposed group;Gut microbiome composition of exposed group;Gut microbiome composition of non-exposed group;The Impact of Event Scale-Revised (IES-R) of exposed group;The Impact of Event Scale-Revised (IES-R) of exposed group;The Impact of Event Scale-Revised (IES-R) of exposed group;The Impact of Event Scale-Revised (IES-R) of non-exposed group

Glycine Supplement for Severe COVID-19

Predictors of Mental Well-being During the COVID-19 Pandemic
The Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)

Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program

Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
Treatment success, defined as number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.;Number of patients not requiring mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.;Time to mechanical ventilation to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.;Time to oxygen saturation normalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.;Stay in ICU and hospitalization to assess the effect of anakinra in addition to standard treatment on the need for mechanical ventilation in patients with severe COVID-19 and CSS pneumonia.

Loneliness During Strict and Lifted Social Distancing Protocols Against the COVID-19 Pandemic
UCLA Loneliness Scale-8 (ULS-8);Patient Health Questionnaire-9 (PHQ-9);Generalized Anxiety Disorder-7 (GAD-7)

Antibody Responses in Contacts of COVID-19 Patients
Measure level of Abs in asymptomatic close contacts of COVID 19 patients.

Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols?
Patient Health Questionnaire-9 (PHQ-9);Cognitive-Attentional Syndrome-1 (CAS-1)

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

Ivermectin in Treatment of COVID-19

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia

Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention
Study 1- Clinical and virological outcome in exposed contacts;Study 1- Transmission of SARS-CoV-2 in exposed contacts;Study 2- Virological outcome in index cases;Study 2- Clinical outcome in index cases

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Incidence of COVID19 Disease among those who are asymptomatic at baseline;Overall change in disease severity over 14 days among those who are symptomatic at baseline

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

Losartan for Patients With COVID-19 Requiring Hospitalization
Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days

Mechanisms for Covid-19 Disease Complications
Number of participants with ICU admission or death

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Clinical Status Assessed Using a 7-Category Ordinal Scale

Risk Factors for Community- and Workplace Transmission of COVID-19

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)

Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28;In-hospital Death Within 28 Days;Admission to Intensive Care Unit (ICU);Endotracheal Intubation (Invasive Mechanical Ventilation)

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
Number patients developing severe infection or death

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

Convalescent Plasma to Stem Coronavirus (CSSC-001)
Cumulative incidence of composite outcome of disease severity

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Outpatient trial - Colchicine vs. control and Aspirin vs. control;Inpatient trial - Interferon-ß vs. control and Colchicine vs. control;Inpatient trial - Aspirin and rivaroxaban vs. control

COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III

Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)

Coronavirus (COVID-19) ACEi/ARB Investigation
Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)

Impact of the Coronavirus (COVID-19) on Patients With Cancer
Number of participants who fill out the survey and participate in the semi-structured interviews.

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
Efficacy of Interventions as assessed by all-cause mortality

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

A Study of Quintuple Therapy to Treat COVID-19 Infection
The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy;Reduction or Progression of Symptomatic Days;Assess the safety of Quintuple Therapy;Assess the safety of Quintuple Therapy via pulse;Assess the safety of Quintuple Therapy via oxygen saturation;Assess the safety of Quintuple Therapy via EKG;Assess Tolerability of Quintuple Therapy

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
Prevention of COVID-19 symptoms as recorded in a daily diary;Safety as determined by presence or absence of Adverse Events and Serious Adverse Events

Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0

Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection
Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19;Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19

Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers
NIMH COVID Study survey - adult responses

Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients

A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic
• Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)

A Study of LY3127804 in Participants With COVID-19

Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19
Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them

Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19

Pegylated Interferon Lambda Treatment for COVID-19

Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation

Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis
Describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 PSI required;Describe patient safety incidents (types, severity, contributing and correcting factors) - 100 PSI required

Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)
Ventilation Mode;Tidal volume set;Expiratory tidal volume;Positive end-expiratory pressure;Maximum airway pressure or plateau pressure (P plateau) or peak pressure (P peak) (cm H2O);;Level of pressure support above positive end-expiratory pressure (PEEP);Inspired fraction of oxygen;Set and measured respiratory rate;Inspiration to expiration ratio

Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
To evaluate efficacy of vazegepant (BHV-3500) compared with placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a six-point rating scale at Day 15. .

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
Time until cessation of oral shedding of SARS-CoV-2 virus

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)

Hydrocortisone for COVID-19 and Severe Hypoxia
Days alive without life support at day 28

Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study
Describe patient safety incidents (types, severity, contributing and correcting factors) - 1000 PSI required;Describe patient safety incidents (types, severity, contributing and correcting factors) - 100 PSI required

Efficacy and Safety of Favipiravir in Management of COVID-19

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE).

Immunological Profiling of Patients With COVID-19 in Respiratory Distress
Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled);Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).;Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).;Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled);Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled);Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled);Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled);Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled);Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)

Efficacay of Chloroquine in COVID-19 Treatment
Number of patients with virological cure

Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women

Administration of Chlorpromazine as a Treatment for COVID-19

Use of UC-MSCs for COVID-19 Patients
Incidence of pre-specified infusion associated adverse events;Incidence of Severe Adverse Events

Gut Microbiota, "Spark and Flame" of COVID-19 Disease
Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.

Convalescent Plasma in Outpatients With COVID-19
Number of patients with disease progression

Analysis of the Coagulopathy Developed by COVID-19 Infected Patients
28-day survival rate;Absolute thrombin generation test latent period;Relative thrombin generation test latent period compared to reference plasma;Absolute thrombin generation test initial velocity;Relative thrombin generation test initial velocity compared to reference plasma;Relative thrombin generation test peak thrombin compared to reference plasma;Absolute thrombin generation test peak thrombin;Absolute thrombin generation test peak thrombin time;Relative thrombin generation test peak thrombin time compared to reference plasma;Absolute thrombin generation test total thrombin generation time;Relative thrombin generation test total thrombin generation time compared to reference plasma;Absolute thrombin generation test endogenous thrombin potential;Relative thrombin generation test endogenous thrombin potential compared to reference plasma

Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives

Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )
Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
Proportion of participants who died from any cause or were hospitalized

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

COVID-19 Patient Positioning Pragmatic Trial

Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19

Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients
Assessment of the presence of the SARS-COV-2 virus at T4

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection
Vertical transmission;Neonatal protection due to maternal antibodies

A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19
Change in mean clinical status score in each treatment arm

Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress
Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ;Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ;Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ;Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ;Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ;Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ;Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ;Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ

Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection

Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
Median days alive and out of the hospital

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first.

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

International Registry of Coronavirus (COVID-19) Exposure in Pregnancy

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
Percentage of participants reporting local reactions;Percentage of participants reporting systemic events;Percentage of participants reporting adverse events;Percentage of participants reporting serious adverse events;Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values;Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values;Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values;Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments;Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
Hospital-free days to Day 28 [ Time Frame: 28 days];1. Severity of Disease

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Survival (based on all-cause mortality) at Day 29

Treating COVID-19 With Hydroxychloroquine (TEACH)
Cumulative incidence of SAEs through day 30;Cumulative incidence of grade 3 or 4 AEs through day 30;Incidence of discontinuation of therapy (for any reason);Severe disease progression composite outcome

Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry
Comparison of sleep quality during COVID-19 containment between children usually followed in child psychiatry and children without follow-up

Tocilizumab for Patients With Cancer and COVID-19 Disease
Clinical outcome as evaluated by the 7-category Clinical Status Ordinal Scale

Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.
Self-rated measure of Resilience;Self-rated measure of Loneliness

Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
Characteristics and outcomes of acute respiratory infections due to COVID-19 in children.;Clinical risk factors of acute respiratory infection due to COVID-19 in children.

Genetics of COVID-19 Susceptibility and Manifestations
Molecular etiology of host susceptibility to severe COVID-19

Covid-19 Pandemic Triage Score

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
Modified COVID Ordinal Outcomes Scale: Study Day 15

Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
Testing Immunity to SARS-CoV-2 over time

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
Cumulative incidence of hospitalization or death prior to hospitalization;Cumulative incidence of treatment-related serious adverse events;Cumulative incidence of treatment-related grade 3 or higher adverse events

Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19

Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe
Time to improvement by two points on a seven-category ordinal scale

Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs

A Study of N-acetylcysteine in Patients With COVID-19 Infection
Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement;Arm B: number of patients who are discharged from the hospital due to clinical improvement

Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)
Change from Baseline Snap and Sniff Threshold Test at 3 months;Change from baseline Smell Identification Test (SIT) at 3 months;Change from Baseline Snap and Sniff Threshold Test at 6 months;Change from baseline Smell Identification Test (SIT) at 6 months

Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Percentage of Participants Alive and Without Respiratory Failure

COVID-19: Human Epidemiology and Response to SARS-CoV-2
Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
Proportion of participants alive and free of respiratory failure at Day 28

Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses
Patterns of neural connectivity as predictors

Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)

Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children

Spread and Course of COVID-19 Infections
seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations
Calculate the Medication Risk Score of de-identified participants from Medicare/Medicaid and commercial health insurance plans using their current drug regimen via our proprietary risk stratification process.;Simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen via our proprietary risk stratification process.;Compare the impact (change) on the Medication Risk Score using the calculate before score and simulated after score following the addition of repurposed drugs for COVID-19 to the drug regimens of patients enrolled in the study.;Measure the effects of various repurposed drugs for COVID-19 on each of the five factors computed by algorithms to derive the Medication Risk Score will be calculated via our proprietary risk stratification process.

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Proportion of patients without any need* for INV until end-of-study (EoS)

Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients
Incidence of adverse events (AEs);Reduction of progression of infection requiring hospitalization;Reduction of acute respiratory distress syndrome (ARDS);30-day mortality

Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.
Anxiety and Depression;Quality of Life and overall health;Pain Intensity

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier)

Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
Frequency of occurrence of Neutropenia = grade 3;Frequency of occurrence of Thrombocytopenia = grade 3;Frequency of occurrence of Anemia = grade 3;Frequency of occurrence of Lymphopenia = grade 3;Frequency of occurrence of CPK increase = grade 3;Frequency of occurrence of Increase ALT and / or AST = grade 3;Frequency of occurrence of Increase total bilirubin or direct bilirubin = grade 3;Frequency of occurrence of Neurotoxicity = grade 3;Frequency of occurrence of QT-QTc interval extension = grade 3;Frequency of occurrence of Other adverse events = grade 3;Percentage of patients in whom treatment cannot be completed.;Percentage of patients with adverse events.;Percentage of patients with serious adverse events.;Percentage of patients with ECG abnormalities.

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
Respiratory failure-free survival rate at day 28

Study of Efficacy and Safety of MAS825 in Patients With COVID-19
APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)

Surveillance of Individuals Following SARS-CoV-2 Exposure
Results of SARS-CoV-2 RT- PCR testing, antibody assay, and culture

Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers

Predicting Outcomes for Covid-19 Using Sonography
Number of Patients Experiencing Death, ICU Admission, Mechanical Ventilation, or Use of High-Flow Nasal Cannula

Organicell Flow for Patients With COVID-19
Incidence of any infusion associated adverse events;Incidence of Severe Adverse Events

Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic

Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults

Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19

Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
Proportion of cases who during 14 exhibit one of the following conditions

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
Clinical Status, Assessed Using a 7-Category Ordinal Scale

COVID-19 Pandemic and Academic Performance of Veterinary Students
Measure the effect of COVID-19 pandemic on the academic performance of veterinary medical students;Measure the average studying time;Evaluate on-line education during COVID-19 pandemic lockdown;Evaluate on-line education in practical lessons during COVID-19 pandemic lockdown

NCI COVID-19 in Cancer Patients, NCCAPS Study
Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity;Effects of COVID-19 on cancer therapy and association with clinical outcomes

Convalescent Plasma for the Treatment of COVID-19
Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Proportion of participants who are alive and free of invasive mechanical ventilation

IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)

COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
Safety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1): Adverse Events;Safety and Tolerability of Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events;Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax

Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

Lung Irradiation for COVID-19 Pneumonia
Phase 1: Feasibility and safety of treating hospitalized patients with SARS-CoV-2 pneumonia with single or bilateral whole lung irradiation;Phase 2: Proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization

Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial
Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.

Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms
Rate reduction in Depressive symptoms;Rate reduction in Anxiety symptoms;Rate reduction in Post traumatic Stress symptoms;Rate reduction in Perceived stress level

Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)
To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.

Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic

Effectiveness of Basic Body Awareness Therapy in Post-traumatic Stress Disorders: A Randomized Clinical Trial

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
Incidence of the Solicited AE in all groups;Incidence of Unsolicited AE in all groups;Incidence of Serious adverse events (SAE) in all groups

The Efficacy Comparing Daily and After-each-case Room Disinfection.
Qualified rate of room disinfection;The number of colony-forming units (CFU)

Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19

Flow Controlled Ventilation in ARDS Associated With COVID-19

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Stabilization or Improvement in Clinical Status

Investigating a Vaccine Against COVID-19
Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.;Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Evaluation of lymphocyte subsets in patients with COVID-19 at various stages of disease, including recovery.

TD-0903 for ALI Associated With COVID-19
Part 2: SaO2/FiO2 ratio;Part 2: Ventilator-free Days (VFDs)

SCB-2019 as COVID-19 Vaccine
Incidence of solicited adverse events (AEs) after vaccination;Incidence of unsolicited AEs after vaccination;Immunogenicity(Anti-SCB-2019 Antibody Titers);Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)

Study of the Spread of COVID-19 in Saint Petersburg, Russia
Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia

COVID-19: Respiratory and Sleep Follow-up
Diffusion Capacity for Carbon Monoxide (CO) 3 months after COVID diagnosis

Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.
Virological clearance;Remission of fever;Remission of cough

Convalescent Plasma Therapy in Patients With COVID-19
Plaque reduction neutralization test (PNRT);D-dimer;C-Reactive Protein (CRP);International Normalized Ratio (INR);Oxygenation Index;Chest X-ray

Testing the Accuracy of a Digital Test to Diagnose Covid-19

Prognosis in Pregnant With COVID-19
the factors affecting prognosis in pregnant women diagnosed with COVID-19

Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
The incidence of tracheal intubation or death prior to tracheal intubation

Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients

A Longitudinal Study of COVID-19 Sequelae and Immunity
Medical Sequelae in COVID- 19 Survivors;Risk Factors for Medical Sequelae in COVID-19 Survivors;Antibody and cell-mediated immune responses to SARSCoV-2;Antibody and cell-mediated immune responses to SARSCoV-2 over time;Incidence of reinfection with COVID-19;Incidence of clinical silent infection;Mental health status in COVID-19 survivors and contacts

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study

Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19

COVID-19 Convalescent Plasma (CCP) Transfusion
Change in PaO2/FiO2 after CCP transfusion.;Change in pulse oximetry status after CCP transfusion.;Change in aO2 after CCP transfusion.;Change in respiratory rate after CCP transfusion.;Change in intubation status after CCP transfusion.

Cyclosporine in Patients With Moderate COVID-19
Safety-oxygen, ICU transfer and ventilation;Safety-changes in absolute lymphocyte count;Safety-changes in creatinine clearance;Safety-secondary bacterial infections

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Evaluation of the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (L/min) over 14 days

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival
Hospital Mortality;Ventilator-Free Days;ICU-Free Days;Participant Quality of Life at 3 and 12 months after discharge

Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment

Study of LAU-7b for the Treatment of COVID-19 Disease in Adults
Health status of the patient on the 7-point ordinal scale (World Health Organization) compared to placebo

Living With Sickle Cell Disease in the COVID-19 Pandemic
Stress;Anxiety;Depressive symptomology;Pain episodes, and severity;Healthcare utilization (primary care, emergency department, telehealth other)

Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
The proportion of subjects who died or had respiratory failure

Registry of Patients With Hematologic Disease and COVID-19 in Russia

Prophylactic Ivermectin in COVID-19 Contacts
appearance of symptoms ( fever ,cough, sore throat, myalgia,diarrhea, shortness of breath)

Saliva/Nares as Source of Detection for SARS-CoV-2 at NIH
Saliva and nasal swab SARSCoV-2 RT-PCR test results

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19
Proportion of patients with treatment-emergent serious adverse events (SAEs);Proportion of patients with infusion-related reactions;Proportion of patients with hypersensitivity reactions;Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples;Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in saliva samples;Proportion of patients with at least one COVID-19 related medically attended visit

Use of Remote Monitoring for COVID-19 Patient
Monitored versus Non-Monitored in-patient admission;Emergency Department Visits;Length of stay;patient satisfaction;the incidence of mechanical ventilation and ECMO;serious adverse events

Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population
sociodemopraphic factors;perceived stress;level of anxiety;self-reported health state;number of complaints;strategies in coping with stressful situations;psychological effects of the coronavirus pandemic on the participants' mood and ways of coping with difficulties arising from the pandemic;level of depression

COVID-19 and the Healthy Minds Program for Educators
Change from baseline on an aggregate measure of Psychological distress that averages the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depressive Measures and the NIH Perceived Stress Scale

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
Proportion of patients with treatment-emergent Serious Adverse Events (SAEs);Proportion of patients with infusion-related reactions;Proportion of patients with hypersensitivity reactions;Time-weighted average change from baseline viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples;Time-weighted average change from baseline viral shedding as measured by RT-qPCR in saliva samples;Proportion of patients with at least 1-point improvement on a 7-Point Ordinal Scale in clinical status

Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).
Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of tolerance;Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of compatibility with technical gestures.

A Study of LY3819253 (LY-CoV555) in Participants With Early Mild to Moderate COVID-19 Illness
Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) Viral Load

Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
Mortality rate of subjects treated with whole lung low-dose radiation

Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method
Sensitivity of the method by SARS-CoV2 ELISA compared

Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf
The impact of COVID-19 on cardiovascular patient

Impact of COVID-19 Lockdown on Obesity and Eating Behaviors
Comparison of the BMI (kg/m²) evolution between the two groups;Score comparison of the Dutch Eating Behavior Questionnaire

In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers
Rates of intestinal atresias and limb abnormalities;Rates of preterm labor, fetal growth restriction and spontaneous abortions;Rates of maternal SARS-CoV-2 infection among mothers to infants born with intestinal atresias or limb anomalies

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease
Proportion of subjects who never received mechanical ventilation and/or ECMO and alive

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death

Impact of Cancellation of Non-urgent Surgical Cases on Patients During the COVID-19 Pandemic

Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
Number of days with severe respiratory disease at hospital and/or at home

Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19
Proportion of subjects alive and free of respiratory failure at Day 14

FOUND - Ancillary Study to Smile Protocol NCT03654105
Temporal variations in the frequency and morphology of SSNs according to the COVID-19 epidemic;Geographical variations in the frequency and morphology of SSNs according to the COVID-19 epidemic;Correlation between sub-solid lesions and individual risk;Correlation between sub-solid lesions and incidence of acute events

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
The rate of "flu-like illness" which includes:

Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique
COVID-19 disease incidence rate (symptomatic infections per month);COVID-19 related hospitalization rate due to SARS-CoV-2;Case (disease) fatality risk (percent) due to SARS-CoV-2;Proportion asymptomatic infections, by age group;SARS-CoV-2 infection annual attack rate (percent);SARS-CoV-2 infection fatality risk;Infection fatality of SARS-CoV-2 infection.;Serial interval number of SARS-CoV-2 infection;Reproduction number of SARS-CoV-2 infection

PTSD Symptoms Among Health Workers and Public Service Providers After the COVID-19 Outbreak: A 3 Month Follow up

Parental Stress After the Covid-19 Pandemic

Effectiveness of Convalescent Immune Plasma Therapy
Plasma ferritin level;Lymphocyte count;D-Dimer level;C-Reactive protein level;Plasma procalcitonin level;Plasma fibrinogen level

Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?

Brain Imaging in Babies Study

Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients
Negative Polymerase Chain Reaction assay at day 0;Polymerase Chain Reaction assay at day 60

Insomnia After the COVID-19 Pandemic

Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19

Status and Predictors of Mental Health Symptoms Among Migrants and Refugees During the COVID-19 Pandemic
Patient Health Questionnaire 9;Generalized Anxiety Disorder 7;Health Anxiety Symptoms

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection
To Measure the efficacy of NORS compared to saline placebo in the hospitalization of participants with mild COVID-19 infection

Mesenchymal Stem Cell Infusion for COVID-19 Infection

Information Sources and Their Relationship to Depressive and Anxiety Symptoms During the COVID-19 Pandemic: A Network Study
The Patient Health Questionnaire 9;Generalized Anxiety Disorder 7

Registry on NEN Patients and COVID-19
Correlation between clinical parameters and SARS-CoV-2 infection;Clinical outcome of SARS-CoV-2 Infection

Clinical Improvement and COVID-19 Pneumonia

Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study

Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19

PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
Anti-viral cytokine levels in blood samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection;Anti-viral cytokines profiles within sputum samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection;Anti-viral cytokine profiles within nasal lavage samples in chronic respiratory disease associated with susceptibility to severe COVID-19 infection associated with susceptibility to severe COVID-19 infection;Expression of inflammatory gene expression in upper respiratory epithelial airway cells using nasal brush specimens in chronic respiratory disease associated with susceptibility to severe COVID-19 infection

Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise

COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-negative adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety);Determine if there is a reduction of severe and non-severe COVID-19 disease in HIV-negative adults who receive candidate vaccine ChAdOx1 nCoV-19 compared to placebo recipients (efficacy);Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-positive adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety);Assess cellular Immunogenicity of ChAdOx1 nCoV-19 in people living with HIV (immunogenicity);Assess humoral immunogenicity of ChAdOx1 nCoV-19 in people living with HIV

COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?

A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to COVID-19 Pandemic

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine
The number of adverse events after intramuscular injection

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy
Safety and tolerability as measured by incidence of IP-related serious adverse events

COVID-19 Household Transmission Study
Secondary household infection rate;Secondary household infection rate - risk factors

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury
Incidence of any stage of acute kidney injury

Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
To calulate the time of intubation;To calculate the time with oxygen therapy;To calculate the time with Non-invasive mechanical ventilation;To evaluate mortality rate

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Mortality at 28 days;Systemic Therapeutic Response

Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19
Assessment of patients' current status : recovery (personal recovery);Assessment of patients' current status : citizenship (personal recovery);Assessment of patients' current status : COVID-19 Stress Scales

Stellate Ganglion Blockade in COVID-19 Positive Patients
Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS

Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults
Incidence of solicited adverse events;Incidence of unsolicited adverse events;Incidence of serious adverse events

Pediatrics HOT COVID-19 Database in NY Tristate
Number of tristate area pediatric HOT patients tested for COVID-19 that completed 1 year follow-up

Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers
diagnostic value of COVID-19 antibodies testing;Role of COVID -19 Antibodies testing in treatment of Patients;Assement of COVID -19 prevalence among healthcare workers

OPV as Potential Protection Against COVID
Mortality or infectious disease causing consultation or admission (Composite outcome)

An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso

Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection
To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia;To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia;To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia;To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia

An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection

EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )
Prevalence of COVID-19 infection in suspected stroke population;Quality head pulse recordings

Short Term Corticosteroids in SARS-CoV2 Patients
Effect on transfers to ICU and escalation of care needing mechanical ventilation

Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19
Prevalence of SARS-CoV-2 in the sampled tissue

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Prasugrel in Severe COVID-19 Pneumonia

Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study

Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure
Optimum positive end-expiratory pressure (PEEP) level;Optimum positive end-expiratory pressure (PEEP) level;Number of patients with recruitable lung;Number of patients with recruitable lung

Protection of Health Workers Against COVID-19
Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR

A Preventive Treatment for Migrant Workers at High-risk of Covid-19
Incidence of acute respiratory illness in treatment arms (hydroxycholorquine, ivermectin, zinc and povidone iodine)

COVID-19 (SARS-CoV-2) in Urine and Semen
SARS-CoV 2 presence in semen;SARS-CoV 2 presence in urine;Inflammation in Semen;Semen quantitative and qualitative analysis

Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19
Effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19

Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre

A Study of LAM-002A for the Prevention of Progression of COVID-19

Anti-Androgen Treatment for COVID-19

Effect of COVID-19 on Platelet Aggregation

Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome
Western versus Mediterranean diet in COVID-19 outcome;Gut- Lung axis in COVID-19;Protective role of minerals and vitamins in COVID-19 patients;non-communicable diseases and COVID-19

Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study
Minimal Dietary Diversity (MDD) of more than 5 food groups in 24 hours;Height;Weight;Meal frequencies in past 24 hours

Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors
Coronavirus disease-2019 (COVID19)-specific psychological distress;The extent to which COVID-19 experiences are associated with COVID-19 specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and health-related quality of life (HRQoL);Resiliency factors;Group differences in the outcomes assessed in the protocol relative to prior group assignment in the behavioral clinical trials;Health-related quality of life (HRQOL);General quality of life (QOL);Sleep disturbances;Depression;Changes in anxiety;Perceived availability of social support;Elements of mindfulness;Non-judgmental physical and emotional sensations associated with eating;The degree to which participants exercise compassion towards themselves under difficult circumstances and how this impacts their emotions;Physical activity;Intrusive thoughts, or the tendency to ruminate on or avoid thoughts about stressors;Basic fruit/vegetable intake;Usual intake of percentage energy from fat;Engagement in the core mind-body practices that the patients learned

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Incidence of severe complications due COVID-19 infection

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Cohort 1: Proportion of Participants Alive and Without Respiratory Failure at Day 15;Cohort 2: Mortality Rate at Day 15

Self-sampling for the Study of COVID-19

Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Percutaneous Tracheostomy With COVID-19
Complications observed in the cases in which we applied percutaneous tracheostomy with aerosol box

Control of COVID-19 Outbreaks in Long Term Care

Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence
Duration of SARS-CoV-2 viral persistence in naso/oropharyngeal samples;Duration of SARS-CoV-2 viral persistence in stool or rectal swab samples;Duration of SARS-CoV-2 viral persistence in semen samples;Duration of SARS-CoV-2 viral persistence in breast milk samples;Prevalence of cell immune responses;Duration of COVID-19 Symptoms;Prevalence of post-viral sequelae;Prevalence of SARS-CoV-2 persistence and bacterial/viral community structures

Covid-19 Lockdown and Deviant Sexual Fantasies
Impact of confinement on deviant fantasies

The Impact of COVID-19 Outbreak on Trans-population's Health in Italy
Assessment of the specific health need of the transpopulation during the COVID-19 pandemic in Italy;Assessment of risk factors for COVID-19 infection in the traspopulation

Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak

Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children
Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies;Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies;Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies

Role of Microparticles in Covid-19 Infection
Western blot measurement of ACE2 receptor expression in porcine cells

M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia
Percentage of Participants Alive and not Requiring Supplemental Oxygenation;Occurrence of Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious AEs (SAEs);Number of Participants With Clinically Significant Changes in Laboratory Parameters and Electrocardiogram Findings

Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19)

Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation
Incidence and pattern of presentation of Reverse triggering in COVID-19 patients under invasive mechanical ventilation

The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry

Knowledge, Attitude and Practice of Dental Students About COVID-19
Knowledge, Attitude, Practice of dental students towards COVID-19

Emergence of the COVID 19 Epidemic in the City of Nice

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults
Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination;Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination;Number of Participants with Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Duration of Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Number of Participants with Unsolicited Adverse Events;Intensity of Unsolicited Adverse Events Assessed by the Investigator;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse events (SAEs);Number of Participants with One or More Serious Adverse events (SAEs) Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients
Time to negative conversion of SARS-CoV-2 nasopharyngeal swab

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline;28-day all-cause mortality rate

Psychological Impact of Admission With Covid-19 During the SARS-CoV-2 Pandemic: Clinical Trial of a Digital Intervention to Improve Wellbeing
Anxiety as measured by generalised anxiety disorder score (GAD-7) scale

Vitamin D Supplementation in Patients With COVID-19

Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int)
Adherence to the Mediterranean diet before and during the COVID-19 confinement;Eating behaviours

Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery

Povidone-Iodine Rinses in the Management of COVID-19
Change in SARS-CoV-2 positivity in the saliva;Change in the SAR-CoV-2 viral load in the saliva

TARGet Kids! COVID-19 Study of Children and Families

Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
Immediate adverse event (AEs);Solicited local and systemic adverse events (AEs);Unsolicited adverse events (AEs);Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths;Safety labs;Neutralizing antibody (Nab assay) response;Specific Th1 cell-mediated immunity (CMI) response;Specific Th2 cell-mediated immunity (CMI) response

Clinical Features of Severe Patients With COVID-19
Mechanical ventilation duration;Non-invasive Mechanical ventilation duration;Mortality

Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic
Surgical morbidity in patients with COVID-19 infection and general surgical conditions

Early Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia
Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation or All-cause Death by Day 28

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
Number of ventilator free days following infusion of decidual stromal cells

Changes in Physical and Sports Activity, Anxiety and Sleep Patterns Following the Containment Period Imposed by the COVID-19 Pandemic in Patients With Chronic Medical Conditions and in Healthy Athletes.

Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection
Clinical response to COVID-19;Immunological response to COVID-19;Genetic predisposition to COVID-19;Microbiome-related response to COVID-19

Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19

Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients
Number of COVID-19 Participants With Notable Differences in the pCLE images in comparison with the pCLE images of non-COVID-19 Participants

COVID-19 and Rare Skin Diseases European Observational Study During an Epidemic
Analysis of the impact of COVID-19 infection on rare skin diseases: complications;Analysis of the impact of COVID-19 infection on rare skin diseases: potential comorbidity factors;Analysis of the impact of COVID-19 infection on rare skin diseases: impact on the management of chronic conditions (change in treatment)

Physical Activity Level in Patients With OSAS During Covid-19 Pandemic

Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
Incidence of infusion-related adverse events;Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology
Number of cumulated deep venous thrombosis among the hospitalization

Safety and Efficacy of C21 in Subjects With COVID-19
Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.)

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category

Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments (COVID-19-LAT)
decisions of limitations and therapeutic stops

NA-83, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (NATADEX)

Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Clinical prognostic factors for infection with COVID-19;Biological prognostic factors for infection with COVID-19;Medical care of Coronavirus infection

Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19
occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death

Cardiovascular Consequences After COVID-19
Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel
Incidence of subjects with COVID-19;Severity of COVID-19

VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation
Reduction in Respiratory Failure;Reduction in cardiac/circulatory Failure

The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice
The ICU admission with associated Pneumonia;Impact of COVID-19 on the different presentation of vascular surgery at the emergency

Acceptability of Telehealth Triage Using Robotic Systems in COVID-19
Acceptance of robotic telehealth system;Willingness to interact with robotic telehealth system;Satisfaction of interacting with a robotic telehealth system

HFNC and NIV for COVID-19 Complicated by Respiratory Failure
detection of viral RNA from one or more participants' air samples

Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers
Documented cumulative incidence of SARS-CoV-2 infection

Hesperidin and Diosmin for Treatment of COVID-19

Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19

Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
Changes on eicosanoid lipid mediators;Changes on plasma levels of a panel of 40 human cytokines and chemokines

Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)
Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the categories of cured patients.

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)
P/F (PaO2/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV.

Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
Phase 2a: XAV-19 antibody titers;Phase 2a: Adverse events of XAV-19;Phase 2b: Time to weaning of supplemental oxygen.

Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS- COV-2 Infection in Healthcare Workers
Documented cumulative incidence of SARS-CoV-2 infection

Anti Infective Agents Impact in COVID-19 Pneumonia

Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic
Number of participants enrolled over 3 months;Number of participants enrolled per week over 3 months;Proportion of participants who enroll in the study over 3 months;Proportion of participants who complete the study over 3 months;Proportion of missing data over 3 months;Proportion of participants who complete the 45-minute video over 3 months

The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19
Complement Activation;Leukotrienes Measure;Coagulation Measure;Hyperinflammation Measure;Cell Count;Cytokines and Chemokine Measure;Endothelial dysfunction measures:

FilmArray and Management of ICU Patients With Pneumonia in the Covid-19 Context

CICERO- A Care Home Study of COVID-19

Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.
Sociodemographic information and training characteristics;The Beck Anxiety Inventory (BAI);The Visual Analogue Scale (VAS);Perceived Stress Scale (PSS);Satisfaction with Life Scale;Brunel mood scale (BRUMS)

Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health

Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid Coronavirus Disease of 2019 (COVID-19)
Change in Perceived Level of Stress as assessed by the Perceived Stress Scale;Change in Perceived Level of Informational Support as assessed by the PROMIS Informational Support Short Form;Change in Awareness of the Maryland Early Childhood Family Engagement Framework and Toolkit as assessed by a survey question;Change in Social, Emotional, and Behavior Functioning in Children as assessed by the Social Competence and Behavior Evaluation for Children

Neuropathology in Adults Intensive Care Unit Patients With COVID 19
detection of severe acute respiratory syndrome related to coronavirus-2 in brain tissues;quantification of inflammation, necrosis and hemorrhage in different brain areas

The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications

RLF-100 (Aviptadil) Individual Patient Expanded Access

Hexoskin Feasibility Study With COVID-19 Patients
Qualitative assessment of the feasibility of the Hexoskin Platform and Virtual Recruitment Process via three subjective feedback questionnaires provided to all patients enrolled in the study.;Ensure the collection of high-quality data during wake and sleep activities, registered as overall > 90% good quality cardiac data and overall > 90% good quality respiratory data per recording.;Ensure adequate patient compliance, qualified as > 75% of total recording hours completed, and > 75% of daily questionnaires completed.;Investigate the predictive power of Hexoskin physiological data, patient information and symptoms information to correctly classify patient disease progression quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.70).

Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a
SARS-CoV-2 in breastmilk;SARS-CoV-2 antibody in breastmilk

Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b
SARS-CoV-2 in breastmilk;SARS-CoV-2 antibody in breastmilk

Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients

COVID-19 in Pain Perspective
Numeric Rating Scale for Pain;Hospital Anxiety and Depression Scale (HADS);SF-12 Health assesment Questionaire

Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

Study to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19
Incidence of treatment-emergent adverse events (safety and tolerability of STI-1499)

The New Silicone N99 Half-Piece Respirator

Inflammatory Regulation Effect of NAC on COVID-19 Treatment

COVID-19 and Chilblains
Level of viral exposure in "case family" compared to "comparator family"

Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked
Imaging data at Baseline;Imagine data at Follow-up

Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial
Feasibility of recruitment, intervention adherence, incidence of treatment related adverse events and trial completion to final assessment timepoints

German Covid-19 ICU Registry

A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home
Number of participants who require hospital admission and require supplemental oxygen.

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

COVID-19 in ART: Perception and Experience
Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation

Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care
Change from pre-COVID-19 condition in ADL independence on the mod. Rankin scale score at the enrolment (T0) assessment, at 3, 6 and 12 months;Change from pre-COVID-19 condition in walking performance on the Walking Handicap scale (WHS) at 3, 6 and 12 months;Patient-reported health-related well-being perception on the 36-Item Short Form Survey - SF-36 at 3, 6 12 months follow-up

Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19

Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic

Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients

Atovaquone for Treatment of COVID-19

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection

Characteristics of Patients and Healthcare Workers With COVID-19 in Meta State, Colombia

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation
Incidence and severity of adverse events

Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19)
Combined Endophthalmitis and Orbital Cellulitis in patients with Novel Coronavirus Disease (COVID-19)

Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals
Incidence of COVID-19 cases after two-doses immunization schedule;Frequency of adverse events up to seven days after immunization

A Placebo-Controlled Study to Evaluate the effect of the recombinant Bacillus Calmette–Guérin (BCG) vaccine VPM1002 on the Incidence or Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Participants in Australia
Evaluate the incidence SARS CoV-2/COVID-19 infection associated with acute respiratory symptoms between VPM1002 vaccinated participants compared with placebo as determined through the detection of COVID-19 infection in participants using validated laboratory methods within approved testing facilities. The types of test methods will be determined based on testing procedures in place[Participants will provide data relating to acute respiratory symptoms monthly for up to 6 months (180 days) post-vaccine administration];Evaluate the incidence of laboratory confirmed SARS CoV-2/COVID-19 infection with severe, critical or life-threatening disease severity based on medical records for VPM1002 vaccinated participants compared with participants who receive placebo[Outcomes assessed for each occurrence for up to 6 months (180 days) post-vaccine administration]

Fit testing of N95 filtering facepieces for anaesthetists and nurses treating COVID-19 patients
The primary aim is to evaluate the failure rate of N95 FFP in a group of anaesthetists and anaesthesia nurses. The outcome will be defined as a positive leak being detected using a Portacount Respirator Fit Testing unit. In this situation, the machine performing the measurement will display the word "fail". The outcome is binary i.e pass or fail.[The fit testing takes 15 minutes. The timepoint for completion of the test will be immediately after the test has been completed.]

Lifestyle modification of adolescents from different countries during confinement by Covid-19
1. Lifestyle of adolescents during confinement by COVID-19 measured using novel online survey at a single timepoint
2. Changes in dietary and physical activity habits measured using novel online survey at a single timepoint

Can the COVID-19 virus be detected in the smoke generated in minimally invasive surgery in patients with confirmed coronavirus infection?
Correct detection of the presence of SARS-CoV-2 virus particles collected in surgical smoke during laparoscopic surgery through highly efficient Biosamplers and RT-PCR test when compared to the presence of SARS-CoV-2 RNA detected in plasma using RT-PCR in the same cohort prior to the procedure

Psychological intervention to improve the mental health of patients with COVID-19
Psychological health level of the patient with COVID-19, assessed using the Chinese Version of
Depression Anxiety and Stress Scale-21 (DASS-21) for all participants at baseline and post-
intervention (1 day later)

A diagnostic study comparing different tests for the diagnosis of COVID-19
Current primary outcome measure as of 25/06/2020:
Test accuracy for the diagnosis of SARS-CoV-2 infection assessed through comparison against a patient classification made using all the molecular tests and selected clinical variables, using the statistical technique of Latent Class Analysis (LCA) and with clinical reassessment of uncertain cases; the standard molecular test is performed at baseline (upon patient recruitment), while the six serological and two additional molecular (Rt-PCR) tests will be performed on cryopreserved swabs (Rt PCR) and serum specimens (serological tests), after completion of patient recruitment.
Previous primary outcome measure:
Test accuracy for the diagnosis of SARS-CoV-2 infection assessed through comparison against a patient classification using the standard molecular test, performed at baseline (upon patient recruitment) and with clinical reassessment of uncertain cases; and the six serological and three molecular (Rt-PCR) tests, performed on cryopreserved swabs (Rt PCR) and serum specimens (serological tests), after completion of patient recruitment (within 1 h)

DIAMONDS-SEARCH study: Designing new tests that can diagnose the causes of fever, including COVID-19
Gene expression measured using RNA sequencing at presentation in children and adults with different infectious and inflammatory conditions
RNA biomarker signature with a sensitivity of 95% and specificity of 95% based on groups of at least 50 patients in each diagnostic category, which would allow capture of the effect sizes between the different comparator groups of as little as 1.5 fold change.

Evaluation of a COVID-19 antibody test: What is the performance of the Panbio™ COVID-19 IgG/IgM rapid test device in fingerstick blood, venous whole blood, serum and plasma in adult participants?
User’s test result interpretation of the Panbio™ COVID-19 IgG/IgM rapid test device at 10 minutes and at 20 minutes after sample application, using fingerstick whole blood, venous whole blood and venous serum, in comparison with venous plasma

Could prone positioning increase lung function for patients with severe COVID-19 infection?
Rate of intubation for mechanical ventilation support, recorded in EHR at inclusion and once if applied. Timeframe 30 days after inclusion.

Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women
1. Solicited local injection site reactions (pain, tenderness, erythema, swelling), collected via symptom diaries and immunisation eCRFs, within 7 days of administration of each vaccine
2. Solicited systemic and laboratory reactions (pyrexia, fatigue, myalgia, headache, chills, arthralgia) collected via symptom diaries and immunisation eCRFs, within 7 days of administration of each vaccine
3. Unsolicited adverse reactions (ARs, including serious ARs) collected via the eDC system throughout the study period (52 weeks)
4. Serious Adverse Events collected via the eDC system throughout the study period (52 weeks)
5. Unsolicited adverse events collected via the eDC system throughout the study period (52 weeks)
6. The titre of serum neutralising antibodies measured using SARS-CoV-2 pseudovirus-based neutralization assay, data received by statisticians directly from the laboratory, at 2 weeks after the second vaccination
7. The titre of vaccine-induced serum IgG binding antibody responses to the SARS-CoV-2 S glycoprotein, data received by statisticians directly from the laboratory, at 2 weeks after the first and second vaccinations

Best available treatment study for inflammatory conditions associated with COVID-19
1. Comparative effectiveness of different anti-inflammatory and immunomodulatory drugs in treating the inflammatory syndrome as measured by:
1.1. Fall in blood inflammatory markers (CRP, pro-calcitonin, ferritin)
1.2. Prevention of cardiac dysfunction (left ventricular function on echocardiogram) and coronary artery aneurysms (z-scores of coronary arteries on echocardiogram)
1.3. Other long-term complications (any long-term disability not present on admission)
Data collected using an online case report form. Clinical data entered onto the online database will span the duration of each patient's hospital stay for that episode of illness.

Peer support training for adolescents during the COVID-19 outbreak
1. Motivation to provide peer support, perceived support giving skills, and frequency of support provided, measured using Adolescent Social Connection & Coping During COVID Scale Items at 1 week post-randomisation
2. Compassion towards others, measured using Compassionate Engagement and Action Scale-Compassion for Others Scale at 1 week post-randomisation
3. Connectedness to peers, measured using Inclusion of Other in the Self Scale at 1 week post-randomisation

Investigating a vaccine against COVID-19
1. Efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older measured by virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 6 months
2. Safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children measured by recording the occurrence of serious adverse events (SAEs) over the course of 6 months

A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers
1. Efficacy of candidate vaccine measured by virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 6 months
2. Safety of candidate vaccine measured by the occurrence of serious adverse events (SAEs) over the course of 6 months

A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)
Current primary outcome measure as of 07/05/2020:
All-cause mortality at 28 days after randomisation. Data collected via a secure web-based case report form wherever possible, or otherwise via linkage to electronic health records.
Previous primary outcome measure:
Number of hospitalised patients who died within 28 days of randomisation, data collected via a secure web-based case report form

The experiences of nurses hospitalized with novel coronavirus pneumonia (COVID-19) in China: a qualitative study Summary

Novel coronavirus pneumonia (COVID-19) Prevention and Control Strategy - Development of multi-layer Network Early Warning System

Survey for Surgery status of a designated Hospital for COVID-19 management in Guangzhou

Qualitative Study on Self-protection Experience of Medical Staff in the Isolation Area of Novel Coronavirus Pneumonia (COVID-19)

Follow up study of convalescent patients of novel coronavirus pneumonia (COVID-19)
Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;

Neurological Manifestations of COVID-19 and Indications of an Association with Respiratory Failure

The use of ACE2 receptor increasing medication at hospital admission and
mortality rates in COVID-19 patiënts
mortality and end of mechanical respiratory support.

Covid High-intensity Immunosuppression in Cytokine release syndrome
1. Time to clinical improvement: defined as the time from start of immunosuppressive treatment to improvement of at least 2 points on an ordinal scale 1-7 or hospital discharge, whichever comes first. This endpoint is recommended by WHO and used as the primary endpoint in the Lopinavir-Ritonavir trial. (17) The ordinal scale categories are: 1) non-hospitalized, able to resume normal activities; 2) non-hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring oxygen therapy; 4) hospitalized, requiring additional oxygen therapy; 5) hospitalized, requiring high-flow nasal oxygen therapy, non-invasive mechanical ventilation, or both; 6) hospitalized, requiring ECMO, mechanical ventilation, or both; and 7) death.

Using eHealth to support COVID-19 education, self-assessment and symptom tracking.
Number of people that download the app and choose to check their health, perform the self-assessment and use the 7 day self-reported symptoms diary for one or more days.

The Digital Doc in the Emergency Department: The solution for patient care in the Covid-19 pandemic?

Volatile Anaesthetics in COVID-19 – a pilot study
Change in PaO2/FiO2 (P/F) ratio, oxygenation index, and ventilation parameters

Bioelectric Impedance Analysis in COVID-19 positive patients. A prospective prevalence study
To measure body composition and specifically fat percentage and localisation in SARS-CoV-2 positive patients

Patient’s knowledge And behavior oN the COVID-19 disease and as DEterMInants of Contamination

COVID-19 infections in health care workers
The primary outcome measure is the number of healthcare workers with and without specific COVID-19 antibodies.

General practice cooperative COVID-19 centre Urmond

Prevalence of asymptomatic deep vein thrombosis in admitted COVID-19 patients

Effect van COVID-19 op kwaliteit van leven bij astma
- mental health status before and during a pandemic
- number of respiratory tract infections and asthma exacerbations before and during a pandemic

Continuous positive airway pressure in severe Covid-19 pneumonia
A change in the two-dimensional variable (SpO2, RR), the combination of oxygen saturation and respiratory rate.
SpO2 is measured with a pulse oximeter and RR is derived from the pressure changes in the mouth compartment of the mask.

Metabolic syndrome And Severity of Covid-19
? - BMI
? - Hip- waist ratio
? - Covid-19 laboratory test (Ferritin, triglycerides, HDL-cholesterol, CRP, procalcitonin, ALAT, ASAT, GGT, AF, glucose, LDH, sodium, potassium
? - CT-scan; CO-RADS and severity score
? - Medication use (statins, inhalation corticosteroids, antihypertension medication etc.)
? - Severity of covid-19 infection defined by hospitalization, oxygen suppletion and intubation and ventilation at the intensive care.
? - Outcome after 30 days (complete recovery, rest abnormality, deceased)

Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)

Digital Cardiac Counseling Trial: DCC Trial
-What is the effect of an interactive Digital Cardiac Counseling platform with E-consulting on cumulative incidence of major adverse cardiovascular events (MACE) at 1 year after the cardiac surgery compared to the control condition (no interactive Digital Cardiac Counseling)?

Quality of life in COVID-19 survivors
Generic quality of life, measured with the 5-level EQ-5D questionnaire

Biomarker-based Early Anti-inflammatory Therapy for severe COVID-19
Biomarker profiles or signature which correlate with future clinical progression of patients infected with SARS-CoV-2 to multi-organ failure and acute severe lung injury requiring mechanical ventilation.

Control of COVID-19 in hospitals

Functional status and health status in COVID-19 patients pre and post rehabilitation
- Functional status, assessed with Short Physical Performance Battery (SPPB), hand grip strength, Medical Research Council, Medical Research Council for muscle strenght, lower-limb muscle function using a hand-held dynamometer
- Health status, assessed with Nijmegen Clinical Screening Instrument (NCSI), Hospital Anxiety and Depression Scale (HADS), Care Dependency Scale (CDS), European Health Literacy Survey (HLS_EU_Q16), COPD Assessment Test (CAT), Patient Activation Measure (PAM)

Sleep position related to hospital length of stay in admitted COVID-19 patients

COVID-19 in rheumatic patients: a prospective cohort study
Our primary study parameter is the percentage of participants with a positive IgM or IgG response admitted to the hospital.

Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS)
The main study parameter is the fold-increase in production of pro-inflammatory cytokines by PBMCs/monocytes following vaccination.

Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort; MaastrICCht.
Clinical data, laboratory results, EIT measurements and vital parameters will be collected within the MaastrICCht cohort. As multiple hypotheses can be investigated within the observational cohort, no predefined primary outcome for the whole cohort will be defined.
Rather, investigators have to submit a data request including a predefined analysis plan according to reporting guidelines appropriate for the type of study (i.e., STROBE for observational studies, STARD for diagnostic studies, TRIPOD for prognostic studies; see the Enhancing the QUAlity and Transparency Of health Research network at www.equator-network.org for detailed information). All external researchers submitting a data request will be required to produce a statistical analysis plan that will be reviewed by the cohort steering committee.

COVID19 ultrasound triage

Hocus POCUS: a tool for increasing the efficiency of diagnosing venous thromboembolic disease in critically ill COVID-19 patients?
The percentage of preventable CTPA in the work up of suspected PE in COVID-19 positive patients.

REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL

Association of BMI with COVID-19 incidence and severity
Incidence of COVID-19 (association with BMI)

A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infections
Ordinal outcome at day 14 of all cause mortality, mechanical ventilation, ICU admission and long duration of hospital stay (6 days or more), with less than 6 hospitalized days as reference category.

Sero-surveillance SARS-CoV-2
prevalence and time to SARS-CoV-2 seroconversion (IgG and/or IgM) compared between groups. We will test for differences between groups (dichotomous & survival data), assuming a 10% minimally relevant difference. If groups are not statistically different we will use non-inferiority analysis methods to test whether the difference between groups is within the non-inferiority margin of 10%.

Lifestyle of pregnant women during COVID-19 pandemic
Health behaviour:
- Physical activity behaviour
- Dietary behaviour
- Following courses online (sports, meditation, courses preparing for labour)
- Experiences with and appreciation of online tools to improve lifestyle
- Experienced stress

Immunity against SARS-CoV-2 in Dutch population
To assess achieved immunity against COVID-19 across the different age groups in The Netherlands by testing a representative part of
the Dutch population for the presence of SARS-Cov-2 specific antibodies in serum

An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19
- Composite endpoint with disease progression defined as a NEWS2score = 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.

Neuroinvasion in COVID-19

COVID-19 in professional soccer players (COPROS study)
• To determine the cumulative incidence of SARS-CoV-2 (re)infection, measured by semi-quantitative real-time reverse transcriptase PCR (sqRT-PCR) in PSPs with self-reported symptoms suspected for COVID-19 during follow-up.

Prospective diagnosis of Covid-19 ïnfectionusing exhaled breath analysis by electronic nose
Primary Objectives:
To determine the diagnostic accuracy of exhaled breath analysis by eNose at point of care
for discrimination between healthy controls and individuals with respiratory symptoms with
and without a Covid-19 infection.

Extracorporeal membrane oxygenation in patients with coronavirus disease 2019
To quantify patient and ECLS characteristics of patients on ECLS due to COVID-19.

Quality of life in patients with suspected COVID-19
general Quality of life (5-level EQ-5D version; EQ-5D-5L)

COVID-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: a combined rehabilitation, pulmonary, and intensive care perspective
Pulmonary function, fitness, mobility, physical activity, cognitive function, psychological function

The impact of COVID-19 among illiterate people and people with a mild intellectual disabilities: preventative measures, (mental) health and support needs

Primary care Research on Outcomes of COVID-19

Risk of infection with SARS-CoV-2 amongst physicians
Incidence of doctors with positive PCR test for COVID-19

Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study

A weapon against COVID-19: (Social) media and influencers
Elevation of proper hygiene behaviour (behavioural change)

COVID-19 during pregnancy: a prospective observational cohort
-To describe the clinical presentation (symptoms) of pregnant women who tested positive on SARS-CoV-2
-To describe the clinical course of COVID-19 infection during pregnancy

Countering Lung Damage in COVID-19 infection (CounterCovid) study
time to liberation from ventilation and supplemental oxygen and alive during a 28day period after randomization

Lung ultrasound vs CT scan in COVID-19 disease
Diagnostic accuracyof LUSand CT in COVID-19 patients

Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients
Patients will receive regular care as indicated by the treating physician. LUS is performed immediately in the Emergency Department or after admissionto the hospital. SARS-CoV-2 PCR testing will be performed along with standard laboratory testing and other microbiological tests to detect pathogens that cause respiratory tract infection.CT-scan during admission is only performed if this is clinically indicated or protocol during COVID outbreak.

Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial

COVID-19 associated brainstem encephalitis - is SARS-CoV-2 a neurotropic agent?
Predictive value of the clinical symptoms ageusia and anosmia for a negative outcome of COVID-19 disease and for the detection of changes in the brain, meninges and cerebrospinal fluid in the instrumental diagnostics.

Feasibility and usability of video-based physical therapy for older people in the context of the COVID-19 pandemic
Feasibility: The feasibility of videotherapy during the COVID-19 pandemic in elderly people measured by the number and type of treatments provided.
subjective perception: subjective evaluation of the feasibility of videotherapy and identification of barriers and supportive factors using a self-developed telephone questionnaire

CytoResc - CytoSorb Rescue for COVID-19 Cytokine Storm
time to resolution of vasoplegic shock (defined as no need for vasopressors for at least 8 hours in order to sustain a MAD = 65mmHg) in days

SARS-CoV-2 in tears in patients with COVID-19

Observational clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients
Equivalence of the method measured by correlation of the smear result

Explorative Study of the Association of Oropharyngeal Microbiota Profiles with SARS-CoV-2 Infection and COVID-19 disease
The main outcome is the association of oropharyngeal microbial diversity and composition with the detection of SARS-CoV-2 in volunteers who have a medical indication for testing for this viral infection.

Limitations of social life in the context of the COVID-19 pandemic - Effects on physical performance and health-related quality of life of older people
The primary outcome of the study is the difference in the product of training weight and number of repetitions at the Milon-circuit leg extension machine. The product is measured at the last week of training before and the first week of training after the restrictions due to the COVID-19 pandemic.

Exploring immunological control mechanisms of SARS-CoV-2 (COVID-19)
- Prevalence (ELISA) (Baseline)
- Risk factors (Questionnaire) (Baseline)
- Antibody response (ELISA, neutralization assays) (Baseline, every 6-12 weeks)
- Cellular response (cytokine assays)

Prospective gas chromatographic and spectrometric analysis of the exhalation of healthy test persons and of SARS-CoV2 infected patients as well as of patients suffering from COVID-19 at the Klinikum Dortmund
identification of a characteristic index of SARS-CoV2 in the gas chromatography / ionic motility spectrometer

The effects of the COVID-19 pandemic on mental health
The primary goal criterion is the qualitative description of effects of the COVID-19 pandemic on mental health in the phenomenological interview. The interviews will take place during the pandemic while patients are admitted for psychological diseases. For employees, the interviews take place during the pandemic, outside working hours, the interview time is registered as overtime.

Dysosmia and Dysgeusia in COVID-19 patients
The aim of the study is to include 100 patients with fully completed questionnaires, 50 patients with fully completed questionnaires and completely completed odor and taste tests in order to be able to make a valid statement about the incidence of smell and taste disorders

Prevalence of COVID-19 in Children in Baden-Württemberg
Part A:
What is the rate of SARS-CoV2 RNA positive children aged 1-10 years and one parent in a population-based sample in Baden-Württemberg?
What is the seroprevalence of SARS-CoV-2 antibodies in the collective mentioned under 1.
Are there age subgroups within the children of 1 and 10 years of age regarding infection rate?
Part B:
A nasal/pharyngeal swab and a blood sample (2-3 ml blood) are taken from the child and the accompanying parent to determine SARS-CoV2 RNA in the nasal/pharyngeal swab and SARS-CoV2 antibodies in the blood. The result will be communicated to the participants afterwards.
The participants will receive a questionnaire in which, among other things, their living situation, occupation, age and chronic illness will be assessed. Parents' chronic illnesses will be asked. Concerning the children, chronic illnesses, attendance of day-care centers, kindergarten, elementary school, since when the children have been in home care, or whether they have continued to attend KITAs or kindergartens or after-school care as part of emergency care, and whether there has been contact with a person with proven COVID-19 infection or whether SARS-CoV2 has already been detected in the participants themselves. Health problems (fever, cough, "cold", diarrhoea) current or in the last 4 weeks are asked for children and the participating parent.
What is the seroprevalence of SARS-CoV-2 antibodies in children and adolescents compared to adults from the same household with at least one index patient with a proven SARS-CoV-2 infection (positive PCR test) with or without COVID-19 disease?
Are there age-dependent subgroups within the children and adolescents aged 0 and 17 years with regard to the infection and disease rate?
Is the circulating ACE2 serum concentration as a biomarker associated with SARS-CoV-2 infection with or without COVID-19 disease or its severity?

The influence of proton pump inhibitor therapy on the clinical course of COVID-19
1. Prevalence of bacterial superinfection in patienst with and without proton pump inhibitor (PPI) treatment.
2. Development of ARDS in patients with and without PPI treatment.

Local and systemic markers of inflammation and circadian rhythmicity in COVID-19 disease and their role in the prediction of clinical outcome
Contingency table: mRS categories vs. inflammation high / inflammation low categories

Evaluation of online support during the coronavirus (COVID-19) pandemic: a group chat program in the psychiatric outpatient clinic of the Leipzig University Hospital
feasibility and acceptance of the group chats, assessed via log-in data of the participants and questionnaires: Questionnaire on Patient Satisfaction, adapted (ZUF-8) and Credibility/Expectancy Questionnaire (CEQ) at end of intervention

Registry of hospitalized pediatric Patients mit SARS-CoV-2 infection (COVID-19)
Goals:
Prospective surveillance of all hospitalized pediatric COVID-19 Patients in Germany
Analysis of clinical courses, needed interventions, risk factors
real-time updates via the DGPI Homepage

Database for diagnosis and therapy of COVID-19 infected patients
The aim of this study is the prospective registration and characterisation of all outpatients and inpatients with COVID-19 detection in the Lung Clinic Cologne-Merheim from initial diagnosis to hospital discharge or death by
influencing factors which could be used in the further course of the project for possible recommendations for action.

Investigation of the predictive value of coagulation parameters for the course of disease in COVID-19 patients
Blood sampling (6 ml Plasma) at day 1 and 7 of hospitalization: determination of Quick, PTT, fibrinogen, D-dimer, antithrombin, hs-troponin, coagulation factors und VWF-antigen, Protein C und Protein S, thrombin generation, plasminogen-activator inhibitor-Type 1

Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19
Evaluation of the effect of the proton-pump Inhibitor (PPI) pantoprazole on the absorption of HCQ in healthy volunteers

Covid-19 HOspitalized patients RegisTry
Prognosis and epidemiology of COVID-19 in hospitalized patients in Mid-Germany

Validation of new detection methods for SARS CoV-2 in suspected COVID-19
Validation of a new detection method for SARS CoV2

Long term Analysis and Evaluation of morphologic and clinical Parameters in COVID-19 Patients: prospective development of a practical risk score
Severity levels of COVID pneumonia and mortality factor in computer tomography in the acute phase of the disease.
Chronic lung damage according to the criteria of computer tomography in aftercare (at least 4 weeks after discharge).

Lung Ultrasound in Covid-19 Pneumonia
Cohen`s kappa regarding the binary outcome pulmonary opacities/infiltrations yes/no by both Methods.

Naturalistic evaluation of an Internet-based psychological training program for mental strain associated with the coronavirus / COVID-19 pandemic
Depressive Symptoms, Patient Health Questionnaire 8-item version (PHQ-8; Kroenke, Spitzer, Williams, 2001), Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks (Post-assessment)

Alterations in inflammatory and coagulation variables in COVID-19 patients
Association between coagulation alterations and course of COVID-19-disease

A short, animated video to improve COVID-19 hygiene uptake: an online randomized experiment with 20,000 participants
The primary outcome Behavioral intent to uptake COVID-19 hygiene in the "next week". Behavioral intent will be measured using a list experiment in each of the three arms.
We will analyze the binary endpoints of the list experiments using modified Poisson regression.
Another primary outcome is knowledge of COVID-19 hygiene. We will measure knowledge using True/False items in the questionnaire.
We will analyze the binary endpoints of the knowledge items using modified Poisson regression.
As secondary analysis, we will repeat all of the analyses described above, controlling for baseline covariates (i.e., age, sex, and educational attainment).
We will also measure bias between the intervention items that appear in the list experiments and as standalone items.

Identification of predictive biomarkers for severe progression of COVID-19
Invasive or non-invasive ventilation within 30 days of onset of COVID-19 related symptoms

COVID-19 Registry Freiburg
Association of biomarkers with incidence and course of COVID 19 disease.

COVID-19 related obstetric and neonatal outcome study (CRONOS)
Trying to identify the risk/risk factors for bad outcome of Covid-19 infection during pregnancy for mother and baby until the end of the puerperium (6 weeks postpartum).

Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease
Frequency of hospitalization with a continuous oxygen requirement of at least 24 hours.
Control calls are scheduled for week 0, week 2, week 4 and week 6. In UKSH patients, as part of the Global Consent residual materials serum and stool are preserved for exploratory analyzes of the serum levels of tryptophan, tryptophan metabolites and neopterin and the composition of the stool microbiome.

Point-of-care coagulation testing in patients suffering from COVID-19
Correlation of the cumulative 7-day amplitude of the thrombelastometric measurements of native blood (NATEM) and the 30-day mortality. The maximum amplitudes (MCF, maximum clot firmness) of the daily thromlastometric measurements of the native blood (NATEM) are summed up. In the case of a homogeneous distribution, a correlation with the 30-day mortality is carried out. In the case of a multi-peak distribution, groups should be defined and their survival times analyzed.

Investigation of the influence of the new coronavirus pandemic (COVID-19) on pain, mood and everyday life of patients with painful polyneuropathy
Pain development during the corona crisis.
End: as soon as the measures are cancelled and daily life can take place again as before
with which: the assessment is carried out using the questionnaires mentioned

PROTEGO: PRospective Observational cohort Trial Evaluating correlation of clinical findings, symptoms and disease development of German in- or Outpatients infected with SARS-CoV-2 - a CHIR-Net Student-Initiated German Medical Audit trial COVID-19 study (CHIR-Net SIGMA study group)
1. SARS-CoV-2 infection associated symptoms
2. COVID-19 associated complications
3. Health-related quality of life according to EQ-5D
4. Depression and anxiety measured via the HADS-D
5. In case of hospital admission:
a. Rate of hospital admissions
b. Rate of Intensive Care Unit admissions
c. Length of hospital stay in days
d. Imaging results
e. Need of mechanical ventilation
f. Need of cardiovascular support
g. SARS-CoV-2 associated lab parameters
6. Health economic outcome measures:
a. Time to recovery,
b. Influence on work
7. Overall mortality
8. SARS-CoV-2 associated mortality

COVID-19 Registry of the LMU Hospital Munich
The aim of this project is to characterize the etiology and clinical course of COVID-19 infections and identify biomarkers to predict morbidity and mortality of those patients.

Evaluation of the performance of novel rapid diagnostics for COVID-19 at point-of-care
Point estimates of sensitivity and specificity of index test, with 95% confidence intervals, using an RT-PCR reference standard

Accompanying monitoring of primary care in GP practices during the COVID-19 pandemic
The aim of this project is to conduct a regular survey among Austrian and German general practitioners working in GP practices during the Covid-19 pandemic regarding their role in this pandemic, their specific challenges in this setting and their strategies developed during the pandemic.

Development of a test to measure the immune response in patients with Covid-19
The study determines if the test identifies persons with previous infection by comparing with a gold standard test

Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course
The primary endpoints are composed of admission to an intensive care unit (ICU), tracheal intubation or death.

Psychological distress of the COVID-19 pandemic: A comparison between cancer patients and healthy controls
Psychological distress and behavioural changes of oncology patients and matched healthy controls in the context of the COVID-19 pandemic

Lean European Open Survey on
SARS-CoV-2 (COVID-19)
To identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2.

COVID-19 Contact Study - Immunoreaction after possible SARS-CoV-2 / COVID-19 contact

get.calm and move.on – tackling worries and finding strength for the crisis (COVID-19) in 10 steps
Worry: Penn State Worry Questionnaire: Meyer, T. J., Miller, M. L., Metzger, R. L. & Borkovec, T. D. (1990). Development and validation of the Penn State Worry Questionnaire. Behaviour Research and Therapy, 28, 487-495. (t1, t2, t3, t4)

prospective observational study to evaluate transpulmonary pressure, end expiratory lung volume and intraabdominal pressure in mechanical ventilated patients with Covid-19
measurement of transpulmonary pressure, end expiratory lung volume and intraabdominal pressure at a PEEP Level of 15, 10 an 5 cm of water in mechanical ventilated intensive care patients

An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic: CoPE It
The primary outcome is psychological distress measured with the German Version of the Perceived Stress Questionnaire [PSQ] (Fliege et al., 2001) at measurement time T1.

Cytokine adsorption in severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation
IL-6 at 72 hours after initiation of vv-ECMO

COVID-19 Symptom Tracker
Aim of the study: Symptom progression and detection of new symptoms

Covid-19 Case-Cluster-Study
The primary endpoint is the prevalence of SARS/CoV-2 positive individuals in the study population, defined as the number of individuals with positive laboratory findings (from at least one of the sample media collected in the study) divided by the total number of study participants.

Study on SARS-CoV-2-Serology (COVID-19) in Bremen's public sector
The aim of the study is to identify the number of seropositive persons (SARS-CoV-2 serology) in public sector persons. For this, 100 study participants (laboratory results and questionnaires) are needed for this purpose.

Clinical characteristics of renal patients with COVID-19 infection
It is an explorative study to get better understanding of the disease in order to provide preventive and therapeutic Options in future.

Clinical and immunological predictors of SARS-CoV-2 infection and Covid-19 diseases in patients with renal diseases and healthy persons
incidence of a severe COVID-19 infection (hospitalized in an intensive care unit)

VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic
Primary Outcome will be the psychological distress (Depression/anxiety) and will be assessed at the following 3 measurement points: April 2020, November/June 2020, April 2021

Dynamics of regional lung aeration non-invasive determined by electrical impedance tomography in patients with COVID 19

Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in Germany
How many employees develop a COVID-19 positive test and how many develop antibodies in the sense of a seroconversion?

Effects of digital home exercise programs on physical and mental well-being during the COVID-19 pandemic: a multi-center trial
Physical and mental well-being assessed with questionnaire battery
- Nordic Physical Activity Questionnaire, short-form
- WHO5-questionniare
- Graded Chronic Pain Scale
- MOS sleep scale
- Generalized Anxiety Scale 7

Analytical study of the profile of pro-inflammatory and pro-resolution factors in non-obese males with pulmonary symptomatology resulting from SARS Covid-19 verified with PCR blood analysis.
Evaluation of the plasma and serum parameters of the inflammation and resolution factors of SARS Covi-19 positive males and measurement the ratio of these parameters

Serological screening and metabolic analysis for evaluation of the immune response to SARS-CoV2 (COVID-19)
The primary outcome is the level of IgM- and IgG antibodies against SARS-CoV2. The titers will be measured up to 3x within one year. In one part of the experiments we will also study the virus-specific Tcells.

Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection (COVID-19)

Traumatological emergency consultations during the COVID-19 pandemic 2020
Total number of emergency consultations in the traumatological emergency department

CovidCare 1 – Surveillance and care for confirmed and suspected patients with COVID-19 in general practice: an observational study

An intensive longitudinal study on habit formation of hand washing behavior during the COVID-19 pandemic
Increases in automaticity of hand washing in participant-chosen situations (up to 86 days following baseline). Automaticity is measured daily across 86 days using the Self-Report Behavioral Automaticity Index (SRBAI; Gardner et al., 2012; Thurn et al., 2014).

COVID-19 in inpatient care facilities (nursing homes) in Thuringia - it hit us hard! A structured retrospective review of primary care, the work of nurses and the course of infections
The primary study objective of this observational study is to record the cases of Covid-19 and the course of infections among residents in different geriatric care facilities in Thuringia.

Study on the Evaluation of the Infectious Process of SARS-CoV-2 in Teachers and Students in Saxony (COVID-19)
Infection with Sars-CoV-2 (RT-PCR tasts of throat swab), presence of antibodies (IgG) in the blood sample

Psychosocial functioning and stress factors of psychiatric patients during the COVID-19 pandemic: Telephone survey of patients in the psychiatric outpatient clinic of the Leipzig University Hospital
Opinions and personal situation of patients during the COVID-19 pandemic as well as psychosocial consequences of the COVID-19 pandemic, assessed via one-time telephone survey. Several adapted questionnaires are used for this survey (Brief-Symptom-Checklist, BSCL-53; 32 items on opinions to and personal situation during the COVID-19 pandemic).

Evaluation of three commercially available rapid assays for detection of IgG and/or IGM antibodies to SARS-CoV-2 (COVID-19) for assessment of contact persons’ immune status and termination of quarantine and self-isolation – a prospective pilot study
Sensitivity and specificity of 3 commercially available SARS-CoV-2 antibody tests against the golden standard (ELISA)

Effects of COVID-19 on lung function and gas exchange
Comparison of TLCO after recovery from COVID-19 after 12 weeks.

Prevalence of SARS-CoV-2 (COVID-19) in pregnancy and at delivery in Franconia, Germany
Rate of seropositive pregnant women in pregnancy in three cohorts (1st month, 2nd month, 3rd month)

Ambulatory healthcare models and processes during the ongoing SARS-CoV-2 pandemic (COVID-19)
(1) Which ambulatory health care models and process have been implemented to ensure medical care for patients with COVID-19 infection or potential COVID-19 infection in Baden-Wuerttemberg? To what extent are this models/processes used? How are they organised? -> paper-based Survey (June - July 2020)
(2) What experiences have healthcare professionals and patients gained regarding the different ambulatory health care models and processes? -> paper-based Survey (July - August 2020)
(3) How has medical care for patients without COVID-19 infection been secured? -> paper-based Survey (July - August 2020)

Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled study
1. Proportion of clinical recovery (composite) within 14 & 21 days (Normalization of fever (=37.2 °C oral), Respiratory rate (=24/minute on room air), Oxygen saturation (=94% on room air)), sustained for at least 24 hours (using Exact test with Boot-Strapping).
2. Time to clinical recovery (composite) [Time frame: 21 days after randomization (using Kaplan Meier curve and Cox-regression).
3. Time to viral negativity assessed twice 48 hours apart (log10 viral load assessed by reverse transcription-PCR) during hospital stay (Kaplan Meier curve and Cox-regression).
4. Mean change in Clinical status using 8 point ordinal scale [Day 3 through Day 14, 21 (using Repeated measure Factorial ANOVA test]: 1) Death; 2) Hospitalized, on invasive ventilation or ECMO; 3) Hospitalized, on NIV or HFO2; 4) Hospitalized with oxygen supplement; 5) Hospitalized, not requiring oxygen but need medical care; 6) Hospitalized, not requiring supplemental oxygen or ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized with normal activity.

Data evaluation of an online symptom and risk detection application for Covid 19 research
Recording of the currently expected Covid 19 disease frequency by region for capacity planning of the health facilities (crisis teams, hospitals, doctors, smear centers, health authorities)

Influence of the Covid-19 pandemic on the patient mix in German emergency departments
Frequency of different presenting complaints in German emergency departments during the Covid-19 pandemic in comparison to the period 12 months before the pandemic and 12 months after

Scientific guidance for risk-control and prevention of COVID-19 in professional soccer-players in Austria
Occurrence of COVID-19 infection during the course of the study. The players will be subjected to regular tests. COVID-19 RT-PCR tests are repeated weekly as part of the Bundesliga's internal standard protocol with a nasopharyngeal swab.

Antibody assesement for COVID-19 prevalence two months after outbreak in the hot spot Region of Tirschenreuth / Bavaria
Seroprevalence of antibodies vs COVID-19 in medical and non-medical working population.

Investigation of the immune status against SARS-CoV-2 of medical professionals in Doctor's Practices in Thuringia (COVID-19 research project)
Period prevalence of infection with SARS-CoV-2 and of the resulting immune status (proof of IgG-antibodies against SARS-CoV-2 with a Lateral-Flow-Test plus ELISA) over four points of time

Survival and risk factors in Covid-19 and influenza, a retrospective analysis
Mortality from Covid-19 and influenza in hospital patients

The role of immune-reactions in patients with COVID-19
Analysis of immune reactions in combination with clinical parameters.
Blood-, stool-, and urine samples are taken at the day of admission and at day 7, 10, 13 (counted after symptom onset) and eyery further third day, and in addition on days of deterioration.

Prevalence of SARS-CoV2 in scholars: Comparison of boarding and private school (COVID-19)

Pulmonary embolism and/or deep vein thrombosis in COVID-19 patients.
Pulmonary embolism and/or deep vein thrombosis in COVID-19 patients

COVID-19 in an academic teaching hospital in Konstanz/Germany - evaluation of the "double rule out - single rule in" concept (DURO-SIN)
Descriptive evaluation of the DURO-SIN concept regarding SARS-CoV-2 detection in naso-pharyngeal swabs and positive radiological features

Hypernatremia in critically ill patients with Covid-19
absolute numbers and dynamic of sodium levels

CORRECT: COvid (Covid-19) Registry REChts der Isar intensive care Trial
1. Support of clinical research (e.g. prognostic marker, laboratory parameters hemodynamic monitoring, use and effectiveness of extracorporeal organ support, incidence and prognostic value of superinfections, radiologic data)
2. Description of epidemiologic correlations and differences.
3. Support of quality management.
4. Evaluation and monitoring of patient safety.

Retrospective analysis of the relationship between invasive ventilation (considering COVID-19) and a Comprehensive Geriatric Assessment (CGA)

SARS-CoV-2 exposure and psychological well-being of health care workers in a German Department of Anesthesiology during the COVID-19 pandemic
Depression, anxiety, and burn-out dependent of resilience and self-management capabilities

Retrospective examination of the course of a Covid-19 infection
in patients with inflammatory bowel disease
Retrospective observation of the course of a Covid-19 infection in patients with inflammatory bowel diseases

A Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing
ICU admission, Morbidity and Mortality in Adult Patients With COVID-19
The proportion of subjects admitted to the intensive care unit from day 1 to day 30, based on at least one of the following criteria
1. rapid progression over hours
2. lack of improvement in oxygen with high flow >40L/min or non-invasive ventilation with a proportion of inhaled oxygen (FiO2) > 0.6
3. developing hypercapnea or increased work of breathing that does not respond to increased oxygen despite maximum standard therapy available outside the ICU
4. haemodynamic instability or multi-organ failure with maximum standard care available outside the ICU

Detection of a delayed Treatment of urgent ophthalmologic Treatment during the SARS-CoV-2 pandemic (COVID-19)
Rate of patients indicating a delay in Treatment due to COVID-19 pandemic.

Analysis of the Pathophysiology and Pathology of Corona Virus Disease 2019 (Pa-COVID-19)
WHO scale for clinical improvement on day 15

Quality assurance of cochlear implant rehabilitation in times of the COVID-19 pandemic (Corona)
Comparison of different aspects of rehabilitation between pre-Corona and under the special circumstances of the Corona pandemic by questionnaire.

lnfluence of the COVID-19-pandemic on the treatment of ENT patients
Analysis of ressources in the ENT departement prior to/during and after the COVID-19 pandemic. We will evaluate number of cases in our in- and outpatient departement, available doctors and workload in the ENT departement quantitatively. Furthermore we will analyze how different meassures like cancelation and resumption of elective procedures will affect these factors.

Prospective COVID-19 Cohort Munich
sero-prevalence and -incidence of SARS-CoV-2 antibodies in a representative household sample of the Munich population

Incidence and risk factors for acute kidney injury in COVID-19

Influence of COVID-19 Infection on sensory organs in othorynolaryngology
A COVID-19 infection leads to functional changes of the sensory organs in the ENT area.

Sorting the wheat form the chaff – COVID-19 in the Emergency department
Are there parameters to discriminate between proven COVID-19 and without before?

COVID-19 associated neuropathy and myopathy in Germany.
Prevalence of neuromuscular symptoms after COVID-19 (based on the initial online or telephone interview and in the course of up to 12 months)

Communication in times of the corona virus pandemic (COVID-19)
Assessment of the mental stress caused by visitation restrictions in the context of the corona virus pandemic in hospitalised patients

Neuroendocrine mechanisms Social isolation and psychobiological stress during the Covid-19 pandemic
Subjective well-being, psychological and physical symptoms (SCL-K9, CTQ, UCLA Loneliness) perceived stress (PSS-10), anxiety and depressiveness (HADS), social relationships (PFB, SCORE-15, F-SozU, SNI), trust.
Once during the current pandemic and one after the pandemic.

Incidence and long-term course of subclinical and clinical myocardial damage as well as pulmonary vascular and structural changes in patients with COVID-19
Left and right ventricular ejection fraction (echo and MRI) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months

A prospective trial on the prevalence and the variation over time of SARS-CoV-2 antibodies in hospital health care workers (COVID-19)
Determination of SARS-CoV-2 antibodies in HCW with and without former positive SARS-CoV-2 PCR at time of inclusion in our study. Determination of the respective prevalence.

Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial
combined clinical improvement (7-category ordinal scale of clinical Status or Hospital discharge), daily assessment

Evaluation of online support during the coronavirus (COVID-19) pandemic: Online cognitive behavioral therapy for obsessive-compulsive disorder (OCD NET program)
Feasibility and acceptance of the program, assessed via log-in data of the participants and questionnaires: Questionnaire on Patient Satisfaction, adapted (ZUF-8) and Credibility/Expectancy Questionnaire (CEQ) at end of intervention

Serial cross-sectional seroprevalence study of SARS-CoV-2 infection during and after the COVID-19 epidemic in Heidelberg and the Rhein-Neckar region
Age-group specific prevalence of antibodies to SARS-CoV-2 among the general population of Heidelberg and the Rhein-Neckar region.

Impact of the COVID-19 Pandemic on Symptoms of Obessive Compulsive Disorder
Exploration of the impact of the COVID-19 pandemic on patients with OCD using a questionnaire

Influence of the Corona regulation on the physical activity of hospital staff - COVID-19
Physical activity questionnaire in minutes per week.
Measurement with an online version of the Freiburg physical activity questionnaire. During the survey period, the questionnaire can be called up at any time via a link. The survey period is 2 weeks.

Covid-19 related Obstetric Anaesthesia Longitudinal Assessment-Registry
Outcome of mother and child after SARS-CoV-2 infection during pregnancy and childbirth

COVID-19 treatment outcomes at the University Medical Center Freiburg

CoViD-19 imaging register study Aachen
Analysis of the presentation form of the SARS-CoV-2 infection and the different stages and manifestations or organ manifestations of the COVID-19 disease in imaging procedures (X-ray diagnostics, CT, ultrasound, MRT).
As this is a register, this endpoint will be examined regularly and at regular intervals.

Study platform ArcHIV - Substudy on SARS-CoV-2 (COVID-19) IgG antibody prevalence in an HIV cohort
The primary goal of the ArcHIV substudy is to evaluate the presence of IgG antibodies against SARS-CoV-2 - as a prevalence estimate of previous infections - in an HIV population.

Collection of clinical data in patients with inflammatory rheumatic disease during the pandemic with the SARS-CoV-2 virus - COVID-19
Prevalence of Covid-19 infection (positive PCR for SARS-CoV-2 or antibody detection) in patients with inflammatory rheumatic disease

The Impact of quarantine and social distancing on mental health in the context of the Covid-19 pandemic
Change in psychopathology (PHQ-D, PCL-5, PSQI) during Covid-19 measures, at a time when measurements are fully enforced, relaxed protection measures and abolished measures depending on physical activity

HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d’aggravation secondaire : étude prospective multicentrique randomisée en double aveugle
Main Objective: L’objectif principal est d’évaluer l’efficacité de l’hydroxychloroquine versus placebo sur le taux de décès ou de recours à une ventilation invasive chez les patients ayant une infection COVID-19 à haut risque d’aggravation.;Secondary Objective: Les objectifs secondaires sont :
1) Évaluer l’efficacité de l’hydroxychloroquine versus placebo chez les patients COVID-19 sur :
a- l’évolution clinique via l’échelle OSCI (Ordinal Scale for Clinical Improvement) pour COVID-19 de l’OMS
b- la mortalité toute cause
c- le portage viral
d- l’incidence des accidents thrombo-emboliques veineux
2) Évaluer l’efficacité de l’hydroxychloroquine versus placebo dans le sous-groupe des personnes âgées de 75 ans ou plus sur :
a- l’évolution clinique via l’échelle OSCI pour COVID-19 de l’OMS
3) Évaluer la tolérance de l’hydroxychloroquine versus placebo sur la survenue d’évènements indésirables graves
Objectifs ancillaires
Évaluer, dans un sous-groupe de patients COVID-19, l’impact de l’hydroxychloroquine versus placebo sur l’évolution des cytokines et des marqueurs biologiques de l’immunité, de l’inflammation et de l’hémostase
;Primary end point(s): Le critère de jugement principal est le décès quelle qu’en soit la cause ou le recours à une intubation et ventilation invasive dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J0).;Timepoint(s) of evaluation of this end point: Le critère de jugement principal est le décès quelle qu’en soit la cause ou le recours à une intubation et ventilation invasive dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J0).

COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA
Main Objective: To evaluate the clinical efficacy of colchicine relative to the control arm in adult patients hospitalized for COVID-19 with pneumonia and clinically stable conditions;Secondary Objective: - Clinical efficacy of colchicine compared to the control arm by clinical severity
- Duration of predefined symptoms and signs (if applicable)
- Duration of supplemental oxygen dependency (if applicable)
- Incidence of new mechanical ventilation use during the study
- Duration of new mechanical ventilation use during the Study
- Need for admission into intensive care unit (ICU)
- Evaluate duration of hospitalization (days)
- Evaluate the 28-day mortality rate
;Primary end point(s): Time to clinical improvement: defined as time from randomization to an improvement of two points from the status at randomization on a seven-category ordinary scale (cfr 7.5.2) or live discharge from the hospital (whatever comes first) as recommended by Coronavirus Disease (COVID – 2019) R&D Geneva World Health Organization http://www.who.int/;Timepoint(s) of evaluation of this end point: 28 days

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY
Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm among hospitalized adult patients who have COVID-19.
;Secondary Objective: Not applicable;Primary end point(s): improvement of the clinical status on the ordinal 7-point severity-scale at day 15:
1. Not hospitalized, no limitations on activities;
5. Hospitalized, on non-invasive ventilation or high flow oxygen
devices;
7. Death;Timepoint(s) of evaluation of this end point: daily

A clinical study in a community setting to see whether use of camostat reduces the worsening of COVID-19.
Main Objective: To evaluate the efficacy of camostat to prevent respiratory deterioration in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.;Secondary Objective: 1. To assess the ability of camostat to reduce the requirement for COVID-19 related hospital admission in patients with SARS-CoV-2 infection.
2. To evaluate the requirement for supplementary oxygen (non-invasive or mechanical invasive) in patients who have received camostat as treatment for SARS-CoV-2 infection.
3. To evaluate the requirement for ventilation in patients who have received camostat as treatment for SARS-CoV-2 infection.
4. To evaluate overall mortality.
5. To evaluate efficacy of camostat by effect on clinical improvement.;Primary end point(s): Hospital admission requiring supplemental oxygen;Timepoint(s) of evaluation of this end point: Days 1-28

A study to investigate whether the experimental medication IMU-838 is safe and effective when it is given to Covid-19 patients in addition to their normal treatment
Secondary Objective: - To evaluate the efficacy of IMU-838 (+SoC) vs placebo (+SoC) in the treatment of COVID-19 based on the duration of hospitalization in intensive care unit (ICU) and all-cause mortality up to 28 days
- To evaluate the efficacy of IMU-838 (+SoC) vs placebo (+SoC) in the treatment of COVID-19 based on a variety of further variables and time points (e.g., clinical status, renal impairment, oxygenation, hospitalization, concomitant vasoactive treatments, clinical recovery)
- To evaluate trough plasma levels of IMU-838
- To evaluate safety and tolerability of IMU-838
- To explore blood levels of disease markers
- To explore viral titers, measures of viral virulence and inflammatory markers;Primary end point(s): Proportion of patients without any need for INV until end-of-study (EoS);Timepoint(s) of evaluation of this end point: Day 0 to day 28;Main Objective: To evaluate the efficacy of IMU-838 plus investigator’s choice of standard of care therapy (SoC) vs placebo plus SoC in the treatment of coronavirus disease 2019 (COVID-19) based on the need for invasive ventilation (INV) up to 28 days

Phase 2/3 study of ABX464, once daily oral capsule, in high risk patients infected by SARS-CoV-2 prior to respiratory distress.
Main Objective: The primary objective of the study is to determine the efficacy of ABX464 50mg to prevent respiratory failure or death in study patients.;Secondary Objective: Evaluate the proportion of patients requiring hospitalization compared to the {Standard of care + placebo} group
Assess the proportion of patients reporting each severity rating on a 7-point ordinal scale
Assess the time to an improvement of one category of the a 7-point on an ordinal scale from baseline
To evaluate and compare the effect of ABX464 on oxygen saturation before hospitalization
To evaluate and compare the effect of ABX464 on oxygen saturation level at the end of the study treatment
Evaluate and compare the effect of ABX464 on immunophenotyping and cytokines levels
Evaluate the proportion of patient requiring oxygen supplementation
Assess the time to hospitalization
Evaluate the time to application of invasive and non-invasive mechanical ventilation or high flow oxygen therapy
Assess the IMV and/or NIV duration
Please refer to the study protocol for further objections
;Primary end point(s): Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive at the end of the 28 days period.;Timepoint(s) of evaluation of this end point: Day 28

Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19
Main Objective: To evaluate the safety and tolerability of remdesivir (RDV ) in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years
To evaluate the pharmacokinetics (PK) of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years
;Secondary Objective: The secondary objectives of this study are as follows:
To evaluate the efficacy of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years
To determine the antiviral activity of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years
Change from baseline in oxygenation use
Change from baseline in the use of mechanical ventilation or extra corporeal membrane oxygenation (ECMO)
To evaluate clinical improvement using the PEWS scale in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years
Determine sulfobutylether ß-cyclodextrin sodium (SBECD) exposures (where possible)
To provide data on use of medications other than RDV for treatment of COVID-19
;Primary end point(s): The proportion of participants with treatment-emergent adverse events (TEAEs)
The proportion of participants with treatment-emergent graded laboratory abnormalities
PK assessed by plasma concentrations of RDV and metabolites;Timepoint(s) of evaluation of this end point: Summary of descriptive statistics for each endpoint

Investigating potential new therapies for COVID-19.
Main Objective: To evaluate the safety of candidate agents as add-on therapy to standard of care in patients with COVID-19. Safety will be assessed using:
• Haematological and biochemical safety laboratory investigations (blood tests).
• Physical examination
• Vital signs (blood pressure/heart rate/temperature and respiratory rate)
• Daily electrocardiogram (ECG) readings
• Adverse events
;Secondary Objective: 1) To determine what the drugs does to the body (pharmacodynamics) and what the body does to the drug (pharmacokinetics) of the proposed trial treatments in COVID-19 patients.
2) Assess the response of key exploratory biomarkers/pathways during treatment period.
3)To evaluate the improvement or deteroriation of patients in each treatment arm.
4) To evaluate the number of oxygen-free days.
5) To evaluate ventilator-free days and incidence and duration of any form of new ventilation use.
6) To evaluate the amount of virus in the patient using saliva/oropharyngeal/nose samples
To evaluate time to discharge
7) Duration of total hospital stay
8) To evaluate the use of renal dialysis or haemofiltration for each treatment arm.
;Primary end point(s): Safety will be assessed using:
• Haematological and biochemical safety laboratory investigations.
;Timepoint(s) of evaluation of this end point: Daily assessments

BCG VACCINATION TO PREVENT COVID-19
Main Objective: The aim of the study is to demonstrate in a double-blind, placebo-controlled approach if vaccination of participants susceptible to COVID-19 with BCG vaccine may modulate their disease susceptibility for COVID-19. This will be validated using both clinical and immunological criteria. A sub-study will run in order to assess the mechanism of benefit from BCG vaccination on vascular endothelial function and on mononuclear blood cells.;Secondary Objective: Not applicable;Primary end point(s): The two groups of vaccination are compared for the primary endpoints which is composite. Patients who meet any of the following will be considered to meet the primary endpoint:
• Positive for the respiratory questionnaire endpoint when at least one of the following combination is met either at visit 2 and/or at visit 3:
-One situation definitively related to COVID-19
-All four questions of symptoms possibly related to COVID-19 answered YES
-At least two questions of symptoms possibly related to COVID-19 answered YES + need for admission at the emergency department of any hospital and/or need for intake of antibiotics answered YES
-At least four questions of symptoms probably related to COVID-19 answered YES one of which is “need for admission at the emergency department of any hospital and/or need for intake of antibiotics”
• Positive IgG or IgM antibodies against SARS-CoV-2
;Timepoint(s) of evaluation of this end point: 90 +/- 5 days

A study of an antibiotic called Azithromycin for those who come to hospital with COVID-19 symptoms who are not admitted to hospital (otherwise known as Ambulatory COVID-19) – ATOMIC2
Main Objective: Can a course of antibiotics reduce the number of people with COVID-19 symptoms who go to hospital but who doctors decide do not need to be admitted from getting worse?
(There is where worse is considered being admitted to hospital or dying).
Another more scientific way of describing this is:
Does giving patients who have a clinical diagnosis of COVID-19 who go to hospital with their symptoms, but who doctors decide to not need to be admitted and and are sent home, does giving these patients 14 days of an antibiotic called Azithromycin result in reducing the number of patients who then either die or get admitted to hospital with respiratory failure requiring help with their breathing either by Non-Invasive Mechanical Ventilation (NIV) or Invasive Mechanical Ventilation (IMV) in the period of 28 days from randomisation. ;Secondary Objective: -Are there differences in those that die in each group in the trial
-Are there differences in those that die or are admitted to hospital for help with their breathing (when those that take part are split into those that a test called a PCR confirms that the patient does indeed have COVID-19 or not
- Are there differences in those that progress to having pneumonia in each group
- Are there differences in those that progress to have severe pneumonia in each group
- Are there differences in the peak severity of illness scores in each group
- Are these differences in the number of severe adverse events in each group;Primary end point(s): To compare the effect of Azithromycin in participants with a clinical diagnosis of COVID-19 in reducing the proportion with either death or hospital admission with respiratory failure requiring Non-Invasive Mechanical Ventilation (NIV) or Invasive Mechanical Ventilation (IMV) over the 28 days from randomisation. ;Timepoint(s) of evaluation of this end point: 28 days after randomisation

Early intervention with Tocilizumab in patients with COVID-19 and hypoxia
Main Objective: To assess in a randomized comparison the effect of pre-emptive Tocilizumab in patients with hypoxia due to COVID-19 on 30-day mortality (from randomization);Secondary Objective: To asses in a randomized comparison:
- days in hospital (calculated from randomization)
- the percentage of patients who need ICU care.
- the percentage of patients who develop respiratory failure and need mechanical ventilation
- the days on a ventilator.
- normalization of HRCT after resolution of disease
- seroconversion 14 days after randomization
- To identify potential biomarkers predictive of response (blood: cytokines (including Il-6 and IL-18), lymphopenia, CRP, ferritin, LDH, sCD25; nasal epithelial brushes: epithelial transcriptome immune response by bulk and single-cell RNA seq; faeces: microbiome, viral load), gender, age, co-morbidity and plasma levels tocilizumab by exploratory analysis.
- To assess safety and feasibility of pre-emptive use of tocilizumab (AE grade 4, increase in dyspnea according to CRS scale)
- OS after 3 months (after randomization)
- quality of life and pulmonary function after 3 months (after randomization);Primary end point(s): ? 30-day mortality (from randomization);Timepoint(s) of evaluation of this end point: 30 days after randomization